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Abstract 
Part I of this thesis describes the development of bioactive small molecules of relevance to 
the study of the apicomlexan parasite Toxoplasma gondii into useful chemical tools. The 
research includes the target identification and validation studies, using both chemical and 
biological methods. 
Chapter 1 provides an overview of chemical genetics with a particular emphasis on methods 
for the identification of the protein targets of bioactive small molecules. The concept of 
biochemical protein target identification techniques was introduced with a detailed 
discussion of interesting applications from the literature.  
Chapter 2 focuses on the development of a tetrahydro-β-carboline based lead molecule into a 
chemical tool through target identification studies. The structure activity relationship (SAR) 
data associated with this core structure, the design of a chemical inducer of dimerisation 
(CID) and the synthesis of this CID are discussed in detail.  
Chapter 3 described work done to identify the potential protein target(s) of Conoidin A. 
Experiments to assess whether Conoidin A can inhibit a proposed target in vitro are also 
included. Further optimisation of this structural class to develop more potent inhibitors is 
discussed in the second part of this chapter.  
Part II of this thesis describes the development of methods for the synthesis of 
medium-sized ring containing compounds using oxidative fragmentation and rearrangement 
strategies.  
Chapter 5 provides an overview of the existing oxidative fragmentation methodology, with 
an emphasis on the use of oxidative fragmentation reactions for the synthesis of 
medium-sized ring systems (8-11 ring atoms).  
Chapter 6 focuses on using the established oxidative fragmentation method in the oxizino 
carbazolone system to investigate the diasteroselectivity of this reaction. Possible 
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mechanisms for this transformation are investigated and discussed using both chemical and 
computational methods. An interesting rearrangement reaction has also been observed during 
this study.   
Chapter 7 focuses on developing an asymmetric oxidative fragmentation method, for use in 
the diazabenz[e]aceathrylenes system. Asymmetric oxidative fragmentation reactions using 
[Ru(pybox)(pydic)] catalysts are discussed. Attempts to optimise the enantiomeric excesses 
of the reaction by varying reaction conditions and substituents in the substrate are also 
included.  
Acknowledgements 
                                                                                                     
III
Acknowledgements 
First, I would like to thank Dr Nick Westwood for the opportunity to work in his lab and for 
his guidance and discussion throughout my Ph.D. I would also like to thank all the members 
of the Westwood group, past and present, for their support and advice. In particular, I would 
like to thank Dr Jeff Walton for his kind help. I would also like to thank Fede, Lisa, Magali, 
Craig and Alan for proof-reading this thesis.  
I would also like to thank the staff at St Andrews University. I particular, I would like to 
thank: Dr Tomas Lebl for advice about NMR experiments and computational calculation; 
Mrs Melanja Smith for assistance with NMR facility; Prof. Alex Slawin for X-ray 
crystallography analysis; Dr Catherine Botting and Mrs Caroline Horsburgh for assistance 
with mass spectrometry; Mrs Sylvia Williamson for elemental analysis; and Dr Guogang Xu 
for helping with molecular modelling.  
Outwith St Andrews University, I would like to thank Prof. Gary Ward and Prof Sylke 
Müller for their advice and collaborations.  
I also would like to thank Alan for his care and support that helped me get to this point. 
我要特别感谢我的爸爸妈妈，感谢他们一直以来对我的支持和鼓励。还有关心我和帮
助过我的亲人和朋友们。  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                      
IV
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   谨以此献给我爱的人和爱我的人 
最衷心的希望你们永远幸福快乐 
 
 
 
 
 
 
 
 
Abbreviations 
                                                                                                     
V
Abbreviations 
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Ac acetyl 
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Da Dalton  
DBD DNA binding domain 
DCM dichloromethane 
DDQ 2,3-dichloro-5,6-dicyanobenzoquinone 
dec. decomposition 
DEAD diethyl azodicarboxylate 
DEPT distortionless enhancement by polarization transfer 
DET Diethyl tartrate 
DHFR dihydrofolate reductase 
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DIPEA N,N-diisopropylethylamine 
DIPT diisopropyltryptamine  
DMDO dimethyldioxirane 
DMF N,N-dimethylformamide 
DMSO dimethylsulfoxide 
DNA Deoxyribonucleic acid 
DTT Dithiothreitol 
EDG electron donating group 
e.e. enantiomeric excess 
EI electron impact 
eq. equivalents 
ERK extracellular signal-regulated kinase 
ESI Electrospray Ionisation 
Et ethyl 
et al. et alia (Latin) and others 
ES+ electrospray ionisation, operating in positive mode 
ES– electrospray ionisation, operating in negative mode 
EWG electron withdrawing group 
FCG forward chemical genetics 
FKBP FK506 binding protein 
g gram(s) 
GR glucocorticoid receptor 
GSK glycogen synthase kinase 
HDAC histone deacetylase 
HIV Human immunodeficiency virus 
hrs hour(s) 
HMBC Heteronuclear Multiple Bond Correlation 
HOBt 1-hydroxybenzotriazole 
HOMO highest occupied molecular orbital 
HPLC high-performance liquid chromatography 
HRMS high-resolution mass spectrometry 
HSQC Heteronuclear Single Quantum Coherence 
Hz Hertz 
IC50 inhibition concentration affecting 50% of specimens 
IHB Internal hydrogen bonding 
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IR infrared 
J coupling constant (in NMR spectroscopy) 
LBD Ligand binding domain 
lit. literature 
μ micro 
m multiplet (spectral); metre(s); milli 
M molar (moles per litre) 
M+ parent molecular ion 
MALDI Matrix-assisted laser desorption/ionization 
MAO monoamine oxidase 
MDH malate dehydrogenase 
Me methyl 
MHz megahertz 
MIC minimum inhibitory concentration 
min minute(s); minimum 
mol mole(s) 
mmol millimole(s) 
Mp melting point 
MS mass spectrometry 
MTX methotrexate 
m/z mass-to-charge ratio 
NF-κB nuclear factor kB 
NOE nuclear Overhauser effect 
Nu nucleophile 
OAT ornithine δ-amino transferase 
PDE phosphodiesterase 
PDXK Pyridoxal kinase 
PEG Polyethylene glycol 
PGAM glycolytic enzyme phosphoglycerate mutase 
Ph phenyl 
ppm part(s) per million 
i-Pr isopropyl 
Prx peroxiredoxin  
Py pyridine 
q quartet (spectral) 
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qt quintet (spectral) 
RCG reverse chemical genetics 
RNS reactive nitrogen species 
ROS reactive oxygen species 
rt room temperature 
s singlet (spectral); second(s) 
SAE Sharpless asymmetric epoxidation 
SAR structure activity relationship 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
SN1 unimolecular nucleophilic substitution 
SN2 bimolecular nucleophilic substitution 
t triplet (spectral) 
TBHP tert-butyl hydroperoxide 
TFA Trifluoroacetic acid 
T. gondii Toxoplasma gondii 
THF tetrahydrofuran 
TLC thin layer chromatography 
TOF time of flight 
t½ half life 
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UV ultraviolet 
ν wavenumber, cm-1 
Y3H yeast three hybrid 
Y2H yeast two hybrid 
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Chapter 1: Introduction  
1.0 Introduction 
The aim of this chapter is to provide an overview of chemical genetics, with an emphasis on 
methods for the identification of the protein targets of potential small molecule tools. The 
concept of biochemical protein target identification techniques will be introduced and the 
advantages and disadvantages of each technique will be reviewed. Finally, interesting 
applications of these techniques will be provided.  
Chemical genetics (Figure 1.1) is an approach that uses small molecule tools to assist in 
understanding biological systems.1-12 Chemical genetics is different from classical genetics 
because it directly targets proteins, which are the products of genes, rather than mutating the 
organism’s genetic material. This approach has similar overall logic and principles to 
classical genetics; however, it is complementary to the use of genetic analysis because the 
use of small molecules provide in many cases temporal control over the study of the 
functional mechanisms of biological systems.1-11 
Small molecules, which are generally of low molecular weight (<500 Da) and composed of 
C, N, H, O, and other heteroatoms, have played important roles in many studies in science 
and have provided many useful treatments for diseases. There are several advantages of 
using small molecules with complex biological systems. These advantages include in 
addition to the temporal control discussed above, the ability to offer reversible modification, 
the possibility of using more than one modulator and the function of disrupting 
protein-protein interactions. Unlike most mutagenic methods, both gain and loss of 
individual protein functions can also be studied by using small molecule tools. 1-11  
Analogously to classical genetics, there are two types of chemical genetic approaches 
(Figure 1.1): forward chemical genetics (FCG)2-4 and reverse chemical genetics (RCG)13. 
Forward chemical genetics proceeds from an interesting biological question to the selection 
of bio-active small molecules.2-4 It is normally considered a three-step process: firstly, a 
phenotypic assay which allows for the measurement of the selected biological property or 
mechanism needs to be developed. Then an active small molecule needs to be identified, 
usually by the high throughput screening of small molecule libraries in the phenotypic assay. 
The final step is often considered the most challenging step: the identification of the protein 
target for the active small molecule.2-4,12 The FCG process allows us to observe the effect of 
a biologically active small molecule interacting with a functional pathway without knowing 
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its protein target or mechanism of action. On the other hand, reverse chemical genetics 
begins with a protein of interest, and then uses this protein to screen for compounds that 
affect the function of this protein. Confirmation that the compound can alter the function of 
the target protein in cells is required later on in the process.13 The main focus of Part I of this 
thesis is the target identification challenge in forward chemical genetics.  
 
Figure 1.1 General overview of the discovery phase of the chemical genetic approach.11 An example of using 
forward and reverse chemical genetics methods to identify the possible protein target(s) in zebrafish was shown 
to explain the differnces between the two appraoches.  
1.1 Target identification in chemical genetics 
One of the most important aspects of forward chemical genetics, and the most challenging, is 
the identification of the biological target(s) of the small molecule that induces the desired 
phenotype.2-4 To approach target identification, various genetic and biochemical methods 
have been employed and reviewed extensively in the literature. These methods include: gene 
knockdown and knockout or comparing the effect of bioactive small molecules with or 
without overexpression of the gene of interest,14,15 comparison of the overlap of genetic 
interactions of the results from the chemical genetic sensitivity screens16-20, microarrays 
(nucleic acid, protein, tissue and cell),21 zinc-finger proteins,22,23 haplotype analysis24 and 
chemical-driven random mutagenesis25. In this chapter, the main focus is to review target 
Chapter 1 
                                                                                                     
9
identification methods that can be used directly to study small molecule-protein interactions. 
These include affinity chromatography, radio/photoaffinity labelling, small molecule 
microarrays, activity based probes and the yeast three-hybrid approach.  
 
Figure 1.2 Chemical structures of cyclosporine A (1) and FK506 (2).  
Several examples in which a small molecule’s protein target(s) has been identified exist in 
forward chemical genetics.11,26-32 Arguably, the most successful case in target identification 
history is the discovery of the common targets of the immunosuppressant drugs cyclosporine 
A (CsA, 1, Figure 1.2) and FK506 (2, Figure 1.2) published by Schreiber and colleagues.33,34 
Prior to their study, CsA (1) was established as an inhibitor of the production of a 
T-cell-derived cytokine, IL-2, which can mediate the immune response to reject transplanted 
organs. However, the mechanism of this process remained unknown. FK506 (2), which was 
isolated from the fermentation broth of Streptomyces tsukubaensis for the purpose of 
development of new immunosuppressants, was also found to block IL-2 secretion with 
increased potency compared to CsA (1). Identification of the cellular receptors/targets of 
both of these two natural products interested scientists, and soon after, cyclophilin was 
identified as the binding partner for CsA (1), and FK506 (2) binding protein-12 (FKBP12), 
the target of FK506 (2), were discovered by affinity chromatography. The inhibition of the 
Ca2+ and calmodulin-dependent phosphatase, calcineurin, was found to be the working 
mechanisms of the complexes of cyclophilin-CsA and FKBP12-FK506 after further 
investigations using affinity chromatography. The importance of calcineurin was recognised 
soon after these discoveries, as it acts as a mediator of the T-cell signal transduction pathway 
and regulator of the central nervous system (CNS) and cardiovascular systems.  
Chapter 1 
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1.1.1 Affinity chromatography 
Traditionally, this technique involves covalently attaching the small molecule ligand to a 
solid support matrix via a suitable functional group, followed by incubation with a cellular 
extract. Several washing step are required to remove unspecific binding. The proteins which 
have high affinity for the small molecule are retained on the affinity matrix and are then 
eluted off through denaturation or competition with free ligand. Mass spectrometry 
techniques are normally required to identify the eluted proteins. In this approach, the 
synthesis of active analogues of the small molecule which can be rapidly functionalised to 
couple to the supporting matrix is needed. The development of a linker which can be 
positioned in between the small molecule and the matrix is also required to supply the 
necessary accessibility of the protein extract to the small molecule.35 A series of examples in 
which affinity chromatography has been used to identify the potential target(s) of small 
molecules are listed in Table 1.1.  
Small molecule Activity Proposed Target protein Author 
Aloisine A Anti-infective agent CDK/GSK-3/PDXK Carbel36 
JTP-70902 Anti-cancer (human colon cancer) MEK1/2 Yamaguchi
37 
Reloxifene Formation of quinoids in the uterus Uterine peroxidases Liu
38 
Melanogenin (TVG28) Pigmentation modulators F1F10-adenotriphosphatase Li39 
Nitazoxanide 
activities against a wide 
variety of helminths, 
protozoa, and enteric 
bacteria 
 
Nitroreductase G1NR1 Muller40 
Seliciclib Anti-tumor CDK1/CDK2, ERK1, ERK2, CDK7, CDK9, CK1ε Iurisci
41 
NS5A-p58-i NS5A hyper-phosphorylation NS5A (p58) CKI-α Quintavalle
42 
CAC-1098 
CBI-0997 
KRIBB3 
Migration of 
MDA-MB-231 cells HSP27 Shin
43 
FR177391 Anti-hyperlipidemic Protein phosphatase 2A (PP2A) Yamaoka44 
Roscovitine (CYC202) Cell-cycle regulator CDKs pyridoxal kinase Bach45 
PPA/ADA/PPA06 Pigmentation of early stage zebrafish embryos F1F0-ATP synthase Jung
46 
EGCG 
Regulation of proteins 
involved in signal 
transduction 
CDK2, cAMP-dependent protein 
kinase/vimentin Ermakova
47 
NGL127A443 (S)-1 Anti-infective DHFR Annis48 
Resveratrol Anti prostate cancer RTP-22, NQO2 Wang49 
Bisindolylmaleimide Potent inhibitor of PKC 
CDK2, Ste20-related kinase, 
adenosine kinase and quinone 
reductase type 2 
Brehmer50 
Gwennpaullone Anti-cancer GSK-3α/3β, mitochondrial MDH Knockaert
51 
Purvalanol B Parasite proliferation CK1  Knockaert
52 
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Leflunomide Immunoregulatory Anti-inflammatory 
glyceraldehyde 3-phosphate 
dehydrogenase, pyruvate kinase 
and lactic dehydrogenase 
Mangold53 
Aminopurvalanol (AP) 
Mitosis in xenopus egg 
extracts, cell cycle 
regulatory pathway 
CDK1 Rosania54 
ZLLLal 
responsible for neurite 
outgrowth induced by a 
tripeptide aldehyde in 
PC12H cells 
LLLal-binding protein (33KDa 
& 35 KDa) Saito
55 
Encephalazine 
Suppresses eye/brain 
development of zebrafish 
embryos 
Ribosomal subunit proteins (S5, 
S13, S18, L28) Khersonsky
56 
SFK1 Suppressor of FK506 calcineurin Por1p Butcher
57 
Myoseverin Induce formation of myotubes Tublin Rosania
58 
MPC11 
Correct for albinism in 
albino type2 murine 
melanocytes 
Mitochondrial F1F0-ATPase Williams59 
Tws119 Control stem cell fate GSK-3β Ding60 
PNRI-299 
Human lung epithelial A 
549/ activator protein 
(AP-1) 
REF-1 Nguyen61 
Trapoxin B Inhibit deacetylation of histone  
HDAC1 and protein homology 
to yeast Rpd3p Taunton
62,63 
QS11 Wnt/β-catenin signaling pathway ARFGAP I Zhang
64 
azithromycin Anti Pseudomonas aeruginosa infection Ribosomal-related protein Glansdorp
65 
Taxol Anti-tumor Β-tublin, Hsps, Hsp90 Byrd66 
Diazoamide A antimitotic OAT Wang67 
Table 1.1. Examples using affinity chromatography to identify the potential protein target(s) for bioactive small 
molecules. Keyword: affinity chromatography, target identification.  
A key example of the application of this approach is the identification of the targets for 
trapoxin B (Figure 1.3, 3).68 Prior to this study, trapoxin B (3) was known to inhibit 
deacetylation of histone HDAC and causes reversion of oncogene-transformed fibroblast 
cells.69 It has been proved by several groups70-72 that the epoxide in 3 is essential for the 
biological activity as hydrolysis or reduction of this functional group leads to complete loss 
of activity. This suggested that trapoxin B acts as an irreversible covalent inhibitor of its 
receptors.70-72 However, the reason of how it was connected with the deacetylation of histone 
remained unclear. To solve this problem and understand the mechanism, affinity 
chromatography was employed. However, due to the structure of this natural product, it was 
difficult to modify the molecule to link to the affinity matrix.68 K-trap (4, Figure 1.3), an 
analogue of trapoxin B (3) was therefore synthesised, and directly attached to an affinity 
matrix to give 5 (Figure 1.3) after removal of the Alloc protecting group.63 This matrix 5 was 
then treated with mammalian cell extract, followed by washing and denaturation. Two major 
proteins were isolated from this process.62 The histone deacetylase catalytic subunit 1 
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(HDAC1) was identified through peptide microsequencing as well as a protein homologous 
(60% similarity) to a putative yeast protein named Rpd3p, which is known as a 
transcriptional regulator.62 The success of this study enabled the first molecular 
characterisation of histone deacetylase.  
K-trap (4)
NH
NO
HN
O
HN
O
O
trapoxin B (3)
O
H
N
O
N
H
O
O
K-trap affinity matrix (5)
(i, ii)
O
O
NH
NO
HN
O
HN
O
O
O
O
NHAlloc
NH
NO
HN
O
HN
O
O
O
O
N
H
 
Figure 1.3 Chemical structure of trapoxin B (3) and its analogue K-trap (4). Schematic process of loading 
K-trap (4) onto affinity resin. Reaction conditions: (i) Pd(Ph3P)4, dimedone, 35 °C; (ii) Affi-gel 10, Et3N, 
DMSO, rt.  
The example described above clearly showed that affinity chromatography can be a useful 
method for protein target identification. However, there is an associated problem of 
non-specific binding of background protein to the resin and linker unit. Several approaches 
have been employed to reduce or detect the level of non-specific binding. Using an inactive 
structural analogue of the active compound as a negative control is often considered an ideal 
method. In this approach, relevant targets can be identified by comparing eluted proteins 
from both active and inactive resins. For example, in the case of a small molecule used to 
study the Wnt/β-catenin signalling pathway, an active purine derivative, QS11 (6, Figure 1.4), 
was discovered to synergize with Wnt-3a ligand to activate selectively Wnt/β-catenin.64 The 
protein target of QS11 (6), the GTPase activating protein of ADP-ribosylation factor I 
(ARFGAP I), was identified via affinity chromatography studies in which an inactive 
analogue (7, Figure 1.4) was used as a negative control.64  
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Figure 1.4 Chemical structure of QS11 (6) and its inactive analog (7). 
The use of an inactive control is often difficult to obtain for such studies. Therefore, a 
method using two batches of resins with the same protein lysate has been developed (Figure 
1.5). Ideally, both resins should bind to the same amount of non-specific proteins, however, 
the specific binding target will be enriched in the first part of this experiment.73 Alternatively, 
a competition approach can be employed (Figure 1.5). The bioactive small molecule is 
preincubated with the cell lysate, and then the same batch of lysate is treated with the small 
molecule attached affinity resin. The amount of a specific binding partner of this small 
molecule significantly decrease in amount compared to other non-specific binding proteins.73 
 
Figure 1.5 Schematic approach of optimised affinity chromatography methods.73 Competition method: A1: 
affinity resins were added to the cell lysate, and bound both specific and nonspecific proteins; A2: the affinity 
resins and free ligand were added to the cell lysate, most of specific binding protein x was bond to free ligand. 
By comparison of the A1 and A2 protein profile, protein x can be identified. Serial affinity chromatography 
method: B1: the first batch of resins was added to the cell lysate, and bound both specific binding protein x and 
some nonspecific protein; B2: only nonspecific binding protein remained on the resins. By comparison of the 
B1 and B2 protein profile the protein x can be identified.  
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In addition to the problem of non-specific binding, another issue for affinity chromatography 
approach is the synthesis of resins for different small molecules. A more convenient 
approach is to use biotinylated small molecules with avidin columns. Small molecule can be 
loaded onto the resin through the strong non-covalent interaction between biotin (8, Figure 
1.6) and avidin. A successful example of the application of this approach can be seen in the 
attempts to identify the possible targets for the marine toxin diazoamide A (9, Figure 1.6), 
which was known to inhibit mitotic spindle assembly.67 Biotinylated toxin (10, Figure 1.6) 
was treated with both HeLa cell and Xenopus egg extract, followed by fishing with avidin 
resin. As a result, ornithine δ-amino transferase (OAT) was identified in both systems for the 
first time as a potential target for chemotherapy as it is essential for proper spindle assembly 
in both human cancer cells and Xenopus egg extracts.67  
 
Figure 1.6 Chemical structure of diazonamide A (9), the biotinylated analog (10) and biotin (8).  
1.1.2 Radio and photoaffinity labelling  
Radiolabelling involves the preparation of radiolabelled derivatives of the bioactive small 
molecule and the identification of the protein target(s) by using these radioactive probes. 
Once a radioactive analogue has been synthesised several options are available for 
identifying its protein target(s). These methods include separating the target protein(s) from a 
crude protein mixture with the use of gels or chromatography and using the radioactive 
decay of the isotopically labelled compound to highlight the protein fractions of interest. 
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After mass spectrometric analysis the target protein(s) can be identified.74,75 Ideally these 
radioactive small molecule probes bind to their protein target(s) covalently as denaturing 
conditions of sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), or 
mass spectrometry analysis are normally required to determine the identity of the protein 
target(s).76 However, the radioactive atom should be added as late as possible in the synthesis 
due to cost and safety issues.  
Another useful method for target identification that also raises the issue of covalent binding 
between a small molecule and its protein target(s) is photoaffinity labelling, which is often 
used with radiolabelling method in many cases. Photoaffinity labelling,77-81 which has been 
developed by Westheimer et al. almost fifty years ago,82 requires the synthesis of a 
photoactivatable but chemically inert analogues of the bioactive small molecule. These 
analogues contain photoactive functional groups which can form irreversible covalent bonds 
to the biological receptor at the site of interaction by the action of light. The functional 
groups that are often involved in photoaffinity labelling experiments are azido, diazo, azo 
groups, diazirines and diazomium salts. These functional groups can release nitrogen, which 
is an inert gas, to afford reactive species such as nitrenes, carbenes, radicals and 
carbocations.80 Aryl azides are the most frequently used photoaffinity labels due to their 
stability in the dark and well established synthetic methods.80 Interesting examples of using 
radio and photoaffinity labeling to identify protein targets are listed in Table 1.2.  
Small molecule Activity Proposed target protein Author 
1-BP 
3-BP 
Anti FRDA & 
Huntington’s disease HDAC Xu
83 
HUN-7293 Inhibitor of VCAM expression Sec61α Mackinnon
84 
Pladienolide B, D Antitumor 140-KDa protein in splicing factor SF3b Kotake
85 
5,6-dimethylxanthenone 
-4-acetic acid Vascular disrupting agent NF-κB Palmer
86 
Pyridazin Inhibit human and rat T lymphocyte proliferation
Monocarboxylate 
transporter MCT1 
(SLC16A1) 
Murray87 
5-(3-chlorothiophene-2-yl) 
-3-(4-trifluromethylphenyl) 
-1,2,4-oxadiazole 
Apoptosis inducer (breast 
cancer & coloreactal 
cancer) 
TIP47 (IGF II receptor 
binding protein) Zhang
64 
3,5-diaryl-oxadiazoles 
MX-126374 Apoptosis inducer 
Tail-interacting protein 47 
growth factor II receptor 
binding protein 
Jessen88  
Ezetimide Inhibitor of intestinal cholesterol absorption Aminopeptidase N (CD13) Kramer
89 
Dantrolene Suppresses intracellular Ca2+ release Ryanodine receptor (RyR1) Paul-Pletzer
90,91 
Tamoxifen Anti-estrogen agent 
Microsomal epoxide 
hydrolase carboxylesterase 
L-FABP 
 
Mesange92 
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HDCS 
Induce differentiation & 
consequent cessation of 
proliferation of 
transformed cells 
 
40 S ribosomal protein S3 Webb93 
Ceramide Lipid signaling c-Raf & protein kinase C isoenzymes Pfeilshifter
94 
LY303366 Antifungal activity 40 KDa & 18 KDa protein Radding95 
α-Trinositol Anti-inflammatory 55 KDa &43 KDa putative protein Chaudhary
96 
(S)-Thalidomide Sedative & tetratogenic effects α1-acid glycoprotein (AGP) Turk
97 
Pyridiryl-imidazole Inhibit interleukin-1 & tumor recrosis factor CSBPs kinase Lee
98 
MK-886 Leukotriene synthesis in human leukocytes FLAP Evens
99,100 
Iodomycin 
Daunomycin 
Anthracyclines  
multidrug nesistant P-glycoprotein Busche
101 
Cyclopamine (11) Teratogenic & Antitumor
“smoothened” 
seven-transmembrane 
protein 
Chen102 
Table 1.2 Examples using radio and photoaffinity labelling to identify the potential protein target(s) for 
bioactive small molecules.  
An interesting example of this approach has been published by Chen and colleagues.102 
Steroidal alkaloid cyclopamine (11) had been known to have both teratogenic and antitumor 
activities. It has also been shown to be an inhibitor of the hedgehog signalling pathway. 
However, the mechanism of action of 11 was unknown. In order to solve this problem, azido, 
125iodine-labelled derivative 12 was synthesised. As a reactive of the azido group in 12, the 
photoaffinity labelling approach could be used, enabling 12 when covalently linked to its 
target protein to survive SDS-PAGE analysis. In brief it was possible to detect the 
radioactive small molecule 12 bonded to the protein “smoothened”, a seven-transmembrane 
protein, expressed in COS-1 cells following exposure to light. This result was also supported 
by using a fluorescent derivative of this small molecule that was also suitable for affinity 
chromatography experiments.102  
 
Figure 1.7 Chemical structure of cyclopamine (11) and its radiolabelled analogue 12. 102  
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1.1.3 Activity-based protein profiling (ABPP) 
There are some issues that always worry scientists, one of which is that certain small 
molecule-protein interactions are only present in the living system, and cannot be observed 
within cell lysates. In addition visualisation tags, such as biotin or fluorophores, can affect 
the affinity of small molecule probes, as well as their performances in living cell systems.103 
To overcome this problem, the Staudinger ligation104 and “click chemistry”105-107 have been 
employed in a number of target identification studies (Figure 1.8). By introducing these 
reactions, it has enabled the small molecule probe to react with its protein target(s) first, and 
then the detective tags are installed afterwards. Applying this kind of approach through 
Staudinger ligation, an alkyl/aryl azide functional group (for example in structure 14) is 
needed to react with methyl ester-modified triphenylphosphines (13).104 On the other hand, 
alkyl/aryl azide functional group (for example in structure 14, 18) can also undergo 
Cu(I)-catalysed [3+2] cycloadditions with primary alkynes (16, 19) to form triazole products 
(17, 20).105-107 Both of these reactions perform well under aqueous conditions and have 
relatively low reactivity with nucleic acids and proteins.108 Because this approach can 
increase the ability of the small molecule to label its protein target(s) in living cells, it has 
become more and more important in the target identification field (examples of using ABPP 
to identify small molecule protein target(s) are listed in Table 1.3).  
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Figure 1.8 Schematic approach of the Staudinger ligation and click chemistry.103 A Staudinger ligation. B 
Cu1-catalysed click chemistry. Reaction conditions: TCEP, potassium phosphate buffer pH 8.0, t-BuOH, CuSO4, 
4 °C. C Two-step labelling approach using ABPP allows the visualisation and identification of target proteins. 
 
 
Small molecule Activity Proposed protein target(s) Author 
4-hydroxynonenal 
Mediate cell signalling, 
alter gene expression 
pathway induce oxygenase 
& apoptosis in colon cancer
Glucose-regulated protein Vila109 
1-BP 
3-BP 
Neurodegenerative diseases 
FRDA 
HDAC3 
HDAC1/2 Xu
83 
(R)-lacosamide Anticonvulsants Putative (R)-lacosamide target protein Cotten
110 
HUN-7293 
Inhibitor of vascular cell 
adhesion molecule 
expression 
Sec61α Mackinnon84 
Acromelic acid 
GIF-0448 
Neuroexcitatory activity in 
the mammalian CNS HMG-CoA reductase Sun
111 
Photovastatin CAA1 Neuroexcitatory activity in the mammalian CNS HMG-CoA reductase Hosoya
112 
β-lactones Anti-infectives  Antibiotics Serine & cysteine hydrolases Bottcher
113 
Chapter 1 
                                                                                                     
19
Azido-E-64 Bacterial virulence Cat B Hang114 
FMK-pa 
Inhibit Ser386 
phosphorylation & 
downstream signalling in 
response to phorbol ester 
stimulation 
C-terminal kinase domain of 
P90 ribosomal protein S6 
kinases 
Cohen115 
SAHA-BPyne Regulation of gene expression 
HDACs & multiple HDA 
associated proteins Salisbury
116,117 
MJE3 Breast cancer proliferation Glycolytic enzyme phosphoglycerate mutase 1 Evens
118 
Table 1.3 Examples using ABPP to identify the potential protein target(s) for bioactive small molecules.  
One of the interesting examples using ABPP is to identify the protein target(s) for MJE3 
(Figure 1.9, 21).118 In this study, a synthetic small molecule library was screened for 
antiproliferation activity against the invasive human breast cancer cell line MDA-MB-231 
via XTT assay. One of the library members, MJE3 (21), was found to inhibit 60% 
proliferation while other members cannot inhibit more than 30%. The spiroepoxide 
functional group in MJE3 was shown to be essential as replacing it led to complete loss of 
activity. The authors then compared the in situ proteome reactivity profiles between MJE3 
(21) and other library members to identify proteins that were specifically labeled by MJE3 
(21). A 26 KDa protein was identified under “click chemistry” conditions using an 
azide-derivatised rhodamine tag (22) with MJE3 (21) treated MDA-MB-231 cells. The 
26KDa protein was also enriched with a trifunctional “click chemistry” tag (azide, 
rhodamine, and biotin groups, 23), followed by avidin chromatography. The resulting 
mixture was then submitted to SDS-PAGE, followed by tryptic digestion and LC-MS 
analysis to identify that the 26 KDa protein is brain-type phosphoglycerate mutase 1 
(PGAM1), which is an essential enzyme in glycolysis, promoting the reaction from 
3-phosphoglycerate to 2-phosphoglycerate.118 These results suggest that cancer cells 
proliferation depends on glycolysis, and PGAM1 can be a potential drug target.  
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Figure 1.9 Chemical structure of MJE3 (21), Rhodamine azide (22), and a trifunctional rhodamine-biotin-azide 
(23).  
1.1.4 Microarray technologies 
There are two different approaches which can be used with microarray technologies to 
identify protein target(s) for small molecules, protein microarrays and chemical array assays 
(Figure 1.10).35 In the protein microarrays approach (Figure 1.10 A), recombinant proteins 
are installed onto the surface in a high-density format. A small molecule, labeled with 
detectable tag is then added to determine the level of interaction between the small molecule 
and the proteins.119 The most important advantage of this approach is to monitor the 
interaction between the small molecule and many proteins at the same time. However, to 
obtain thousands of purified and active proteins is laborious.35 Another drawback of this 
approach is that this type of assay only studies single protein-compound interactions without 
any real biological context.35 In the chemical array assay approach (Figure 1.10 B), instead 
of proteins, small molecules are coupled onto the surface.120 Due to the lack of a direct 
method of coupling different chemical structures to the chip surface, the installation of small 
molecules becomes a rate determining process in this approach. The small 
molecule-containing chips are then treated with cell lysate to identify potential protein 
targets for each small molecule.120  
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Figure 1.10 Microarray techniques. A. protein microarray; B. small molecule microarray.35 
The small molecule microarray approach has been applied by Molnar and colleagues to 
identify specific protein targets in an anticancer study.120 Ligand chips, which contain 
numerous small molecules that are linked by a common 6-carbon spacer to the surface, were 
used to screen protein extracts from both healthy and tumor cell lines. This was followed by 
treatment with non-specific fluorescent dyes to label the proteins. Different binding levels 
across the chip were identified.  
1.1.5 Yeast three-hybrid approach (Y3H)   
The yeast three-hybrid (Y3H, Figure 1.11) system, which is based on the well-established 
yeast two-hybrid (Y2H) system, is designed for identifying and characterising small 
molecule-protein interaction in host cells, normally in budding yeast, Saccharomyces 
cerevisiae.121 Both Y2H and Y3H approaches require fusion proteins containing a 
DNA-binding domain (DBD) and fusion proteins containing a transcription activation 
domain (AD) to be expressed in the same host cells. In the Y2H system, direct interactions of 
fusion proteins are studied.122-125 In the Y3H approach (Figure 1.11), the interactions between 
DBD- and AD- fused proteins are mediated by a third hybrid molecule.121 This hybrid 
molecule is a covalently linked heterodimer of two small molecules, sometimes also referred 
to as a chemical inducer of dimerisation (CID) or “dimerizer”.126 The CID is made up of a 
known small molecule with known binding affinity for a ligand-binding domain (LBD) 
which is fused to the DBD.126 Recruitment of an AD-fusion protein to the promoter region of 
a reporter gene is induced by its interaction with the small molecule under test and that is 
incorporated in the CID. A positive interaction promotes the transcriptional activation of the 
reporter gene.126  
A B 
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Figure 1.11 Schematic representation of the Y3H system.14 DNA-binding domain (DBD) and fusion proteins 
containing a transcription activation domain (AD) to be expressed in the same host cells. The interactions 
between DBD- and AD- fused proteins are mediated by a third hybrid molecule. AD-fusion protein to the 
promoter region of a reporter gene is induced by its interaction with the small molecule under test and that is 
incorporated in the CID. A positive interaction promotes the transcriptional activation of the reporter gene. 
The first successful example of this approach was by Liu and colleagues.121 A CID 24 was 
synthesised from the immunosuppressant FK506 (2) and the steroid hormone agonist 
dexamethasome. Both of these two compounds have the known protein binding partner, 
FKBP12 protein and the glucocorticoid hormone receptor, respectively. The host cells were 
engineered with the cDNA vectors that encoded two hybrid protein molecules, LexA-DBD 
fused to the rat glucocorticoid receptor hormone-binding domain (GRhbd) and B42-human 
FKBP12 protein fusion, as well as the reporter gene lacZ. The yeast strain was then grown 
on media which contained the synthetic CID 24. The expression of the reporter gene lacZ 
indicated that both proteins had bound to 24 to activate reporter gene expression. This study 
was repeated using a B42-fusion cDNA library instead of the B42-FKBP12 protein. 
Overlapping clones of human FKBP12 were isolated, demonstrating that the Y3H technique 
can potentially be used to screen unknown small molecule-protein interactions.121  
LBD 
LBD 
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Figure 1.12 chemical structure of FK506-dexamethasome CID 19.  
Optimisation of Y3H systems to create a more stable and consistent read-out by 
chromosomally integrating the fusion has been attempted by Baker and co-workers.127 In this 
study, LexA-DBD was fused to dihydrofolate reductase (DHFR) to create DBD-DHFR, and 
the B42 activation domain was fused to the glucocorticoid receptor (AD-GR). CID 25 was 
synthesised using dexamethasone and methotrexate (MTX, (26)) which can bind to the 
glucocorticoid receptor and DHFR respectively. Comparing the results from the integrated 
fusion with the original plasmid based fusions, the new method was more stable and 
reproducible.127 This optimization brought the Y3H system into a high throughput format 
that enabled the screening of small molecules with unknown protein target by replacing the 
dexamethasone with small molecules for example in CID 27 and the glucocorticoid receptor 
with a library of potential protein binding partners.127  
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Figure 1.13 dexamethasone-methotrexate CID 25, small molecule-MTX CID 27, Methotrexate (MTX, 26).127 
To achieve success in Y3H screens, the choice of the known small molecule in the CIDs is 
important. MTX (26), as described above, is the most promising option.126 MTX (26) has 
high affinity for the monomeric form of DHFR, which is a small protein, the expression of 
which as a fusion protein in yeast cells is easily achieved.128 Furthermore, MTX (26) exhibits 
the ability to improve the cell permeability of hybrid CID molecules by improving the water 
solubility.128 The choice of linker is another important factor for the success of Y3H 
approach. Kley and his co-workers found that, MTX-based CID 27, which uses a 
polyethylene glycol (PEG) as a linker unit showed the most success. Variable lengths of PEG 
linkers have been used, however, generally PEG repeats of 3 to 6 subunits appear to be the 
most suitable length.126  
Since the Y3H approach provides a rapid method to screen complex collections of candidate 
target proteins which are encoded by cDNA libraries, and enables efficient secondary 
validation experiments without prior knowledge of the biochemical activity of the candidate 
target proteins, it has been employed in several target identification and characterisation 
studies. Applications of the Y3H approach are listed in Table 1.4. 
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CID Purpose of study Proposed target protein Author  
TMP-SLF 
Small molecule active against 
modulating transcription in yeast 
& glycosylation in mammalian 
cells 
DHFR Czlapinski129 
DMOG S956711 Mammalian HIF-regulatory EGLN enzymes Alcaide-German130
RGB-286147 
RGB-286156 
RGB-286580 
Cell cycle arrest 
Induction of apoptosis 
CDK/CRK specific kinase 
inhibitor Caligiur
131i 
Purvalanol B-MFC Prove generally usefulness of technique 
CDK1, CDK5, CDK6 
(previously known target) 
CLK3, PCTK1, PCTK2, 
PAK4, RSK3, FYN, YES, 
EPHB2, FLT4  
(unknown targets) 
Becker126 
MTX-SLF 
Investigate the relationship 
between the binding affinity of a 
ligand-receptor pair and the 
transcription readout  
FKBP12 de Felipe132 
Estrone 
oximes-biotin 
Identify target for natural 
product ERs 
Muddana133 
Hussey134 
MTX-Cephem-Dex 
Demonstrate the possibility 
using well studied enzyme 
catalysed reaction in Y3H 
DHFR, GR Baker135 
MTX-DEX Charactrise system DHFR Abida128 
DEX-MTX 
FK506-DEX Demonstrate GAL4 promoter 
DHFR 
FKBP12 Henthorn
136 
PD173955 
ABL tryosin kinase inhibitor 
Demonstrate mammalian 
three-hybrid (M3Y) system 
Cyclin G-associated kinases, 
ephrin receptor, tyrosine 
kinases, FGFR1 & SRC 
kinases FYN & LYN 
Caligiur137 
Table 1.4 Examples of application of yeast three hybrid system. 
As with any approach, the Y3H approach has its limitations. Until now, it is unclear with 
what affinity the small molecule has to bind to the protein target for the interaction to be 
observed by this technique.138 In addition, the fused proteins may not accurately represent 
proteins in their native environments, some of which may even have lost their normal 
functions and therefore be missed out in the screens.138 
1.2 Background to the projects 
Toxoplasmosis is an infection caused by the apicomplexan parasite Toxoplasma gondii. It is 
estimated that 10-25% of the world’s population carry this parasite.139 In most humans 
infected by T. gondii, the disease is asymptomatic. In healthy individuals, a primary infection 
causes relatively mild flu-like symptoms, swollen lymph glands or muscle aches and pains 
that last for one month or more.140 However, toxoplasmosis can give people with weak 
immune systems, such as infants, those with HIV/AIDS, those who are undergoing certain 
types of chemotherapy or those who have recently received an organ transplant, serious 
pathology including blindness, hepatitis, pneumonis, and neurological disorders.140-146 
Toxoplasmosis can also be transmitted transplacentally resulting in a spontaneous abortion, a 
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still birth or a child that is severely handicapped mentally and/or physically.142,147 The 
diagnosis of toxoplasmosis can be difficult, because other illnesses such as lymphoma can 
cause similar markings or lesions on the brain.141,146,148 The main way to single out the 
presence of T. gondii is to test for the antibody IgG that is induced by parasite.141,146,148 The 
standard treatment is a combination of the drugs pyrimethamine and sulfadiazine that are 
also used against malaria. Other drugs are being used experimentally such as atovaquone.146 
It is not clear whether new combination anti-HIV treatments can improve the immune system 
enough to stop toxoplasmosis from establishing a serious infection.145 The main side effects 
from toxoplasmosis treatment are allergies to the sulfa drugs. A process of building up the 
dose of the sulfa drug solely, known as desensitization, can sometimes avoid these 
reactions.149  
Toxoplama gondii is a protozoan parasite of the apicomplexa phylum. This parasite is an 
obligate intracellular parasite.140 The life cycle of T. gondii is complex and several reviews 
and articles that discuss it in detail are present in the literature (Figure 1.14).150-153 In brief, 
the life cycle consists of two stages: 1) the asexual stage, which takes place in the 
intermediate host (normally mammals or birds); 2) the sexual stage that takes place in the 
definitive host. T. gondii parasites are only able to grow and replicate within the cells of their 
hosts. The process of host cell invasion by T. gondii and the other apicomplexans is therefore 
both a key step in the life cycle of the parasite and a potential point for therapeutic 
intervention. The mechanism of host cell invasion by apicomplexan parasites has been 
previously studied in some detail,154 in part through the use of pharmacological inhibitors 
whose targets have been well characterized in other system. However, little progress has 
been made towards the development of anti-parasitic drugs that target the process of 
invasion.  
 
Figure 1.14 Cartoon overview of the life cycle of T. gondii. The life cycle consists of host cell invasion, 
parasite replication, and host cell lysis.  
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1.2.1 Chemical genetic approach to study T. gondii host cell invasion.  
It is a real challenge to study the parasite-host system to understand how parasites function 
by classical genetic methods although the situation is improving. However by using a 
chemical genetics approach it may be possible to identify small molecules that help advance 
our understanding of this complex process. This can be achieved, for example, by using 
small molecules to identify parasite proteins that mediate invasion.  
A high throughput screen of 12,160 structurally diverse small molecules was carried out with 
the aim of identifying small molecules that perturb the invasion of the host cells by T. 
gondii.155 The screen (Figure 1.15) consisted of host cells in 384 wells plates with each well 
containing a test compound. To each well was added yellow fluorescent protein expressing 
parasites. The plates were incubated at 23 °C for 15 minutes then at 37 °C for 60 minutes. 
After washing, any remaining extracellular parasites were labeled with an Alexa 546 
conjugated antibody to the major surface protein, SAG1. Images were collected using a 
fluorescent microscope and pseudo-coloured red and green. The number of invaded parasites 
per field was then calculated by automated computer analysis. A hit was defined as a 
compound that led to a significant change in the number of invaded parasites compared to 
the control. As a result of the screen, a total of 24 non-cytotoxic invasion inhibitors were 
identified as well as 6 enhancers.155  
 
Figure 1.15 The high-throughput invasion assay. See text for details.155 
To determine whether the observed effect of each of these “hits” was reversible, the small 
molecules were washed out after the initial 15 minute incubation time.155 These results 
classified five small molecules as irreversible inhibitors. For these five inhibitors, target cell 
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identification was attempt by independent pretreatment of host cells and parasites with or 
without the inhibitors. After washing, all four combinations were tested for invasion. Three 
inhibitors (28, 29, 30, Figure 1.16) were found to target selectively the parasite.155 
 
Figure 1.16 Chemical structure of irriversable inhibitors 28, 29, 30, which selectively target the parasites.  
1.2.2 Project aim 1: developing tetrahydro-β-carboline (28) as a chemical tool. 
Dose-response assays determined that the minimum effective inhibitory concentration (MIC) 
of irreversible inhibitor 28 was 12.5 μM.155 Inhibitor 28 is also a known inhibitor of the 
mitotic kinesin Eg5,156-158 and this led us to consider whether its inhibitory activity on 
parasite invasion results from inhibition of a T.gondii kinesin. Furthermore, 28 is also 
structurally related to tadalafil (31, Figure 1.17), a clinically used inhibitor of the mammalian 
cGMP-specific 3’, 5’-cyclic nucleotide phosphodiesterase PDE5,159 raising the possibility 
that 28 may target a parasite PDE activity. However, results gained from further 
chemoinformatics and bioinformatics studies are in contrast with this possibility, suggest that 
the inhibition of T. gondii invasion by 28 probably occurs through a different target class or 
through a parasite kinesin with unique characteristics (for a detailed discussion see Section 
2.1.2). To investigate the mechanism by which 28 inhibits T. gondii invasion, 28 needs to be 
developed into a chemical tool which can be used in target identification studies.  
 
Figure 1.17 Chemical structure of tadalifil (31) which is structurally related to 28. 
As discussed above (Section 1.1.5), the Y3H approach is a useful method to investigate the 
protein targets of small molecules in intact cells. It was therefore chosen as the target 
identification method used in this study. One of the aims of this thesis is to synthesis a 
complex CID for use in the Y3H approach based on 28 as the small molecule and possibly to 
use this tool to determine the protein target(s).  
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1.2.3 Project aim 2: developing 2,3-bis(bromoethyl)-quinoxaline 1,4-dioxide (29) as a 
chemical tool 
To probe key steps in the invasion process, secondary assays were performed on all 30 hits 
from the high throughput screen.155 One of the three parasite specific, irreversible inhibitors, 
2,3-bis(bromoethyl)-quinoxaline 1,4-dioxide (29), was observed to inhibit Ca2+ 
ionophore-induced conoid extension.155 Although the exact function of the conoid and its 
cycles of extension/retraction during invasion remains unclear, it is widely thought that the 
conoid plays some role in the invasion process.139,160,161 Further investigations have shown 
that 29 efficiently blocked Ca2+ ionophore induced conoid extension in a similar manner to 
cytochalasin D (32).155 In addition, 29 was shown to have no effect on either constitutive or 
induced microneme secretion.155 Both of these two processes are dependent on calcium 
levels. Furthermore, 29 had no detectable effect on parasite intracellular calcium levels. It is 
therefore believed that 29 acts through a different mechanism from the known calcium 
binding agent, BAPTA/AM (33).162  
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Figure 1.18 Chemical structure of cytochalasin D (32), BAPTA/AM (33), and 34.  
Dose-response assays determined that the MIC of 29 was 12.5 μM. An analogue of 29 in 
which, the two bromine groups were replaced by hydroxyl groups (34), showed no inhibition 
of invasion or conoid extension in T. gondii, which suggests that 29 acts as a covalent 
inhibitor by alkylation of its protein target(s).155 This observation was consistent with 29 
being an irreversible inhibitor of parasite invasion.  
In summary, 29 selectively inhibits parasite invasion by acting on the parasite rather than the 
host cells. 29 selectively inhibits conoid extension over other parasite processes and also acts 
as a covalent inhibitor. This raises the possibility of developing 29 as a useful tool to 
understand the complex process of host cell invasion which is essential in the parasite’s life 
cycle. The mechanism and reactivity of 29 has been chemically addressed previously within 
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the group.163-165 The aim of this project was to identify the protein target(s) for 29. The 
studies presented in this thesis will focus on how potential protein targets of 29 were 
identified. In particular, once potential protein targets had been identified, studies showing 
that 29 could inhibit these proteins in vitro will be discussed in detail. It was envisaged that 
the chemical and biological knowledge gained through these studies could be combined to 
develop second generation tools based on 29.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
                                                                                                     
31
Chapter 2: The Synthesis of a Chemical Inducer of Dimerisation and 
Preliminary Biological Evaluation  
2.1 Introduction 
One of the inhibitors in the parasite invasion assay (see Chapter 1) was the 
tetrahydro-β-carboline 28. The trans-(5R, 11aS) 28a, which is one of the four stereoisomers 
of compound 28, is an irreversible inhibitor of T. gondii and has a minimum effective 
inhibitory concentration (MIC) of 12.5 μM.  
 
Figure 2.1 Tetrahydro-β-carboline 28.  
This chapter focuses on developing 28 from an active hit to a chemical tool which can be 
used in target identification studies. The structure activity relationship (SAR) data associated 
with this core structure, the design of a chemical inducer of dimerisation (CID) and the 
synthesis of this CID will be discussed in detail. The majority of the biological component of 
the research presented in this chapter was carried out in collaboration with Prof. Gary Ward 
at the University of Vermont. Aspects of this work have recently been published in Organic 
and Biomolecular Chemistry.166  
2.1.1 Preliminary SAR studies. 
As a number of analogues of 28 are commercially available, initial studies focused on the 
biological assessment of three racemic compounds that can be viewed as truncated versions 
of 28, compounds 35, 36 and 37 (Figure 2.2). All three analogues were inactive in the 
invasion assay (no inhibition of invasion at the final concentration of 100 μM) and it was 
therefore concluded that the fused tetracyclic core structure of 28 represents the minimum 
bioactive pharmacophore. 
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Figure 2.2 Tetrahydro-β-carboline analogues of 28. 
Previous work in the group had shown that all four stereoisomers of 28 can be prepared by 
reacting either (D)-(38a) or (L)-tryptophan (38b) with m-hydroxybenzaldehyde under 
Pictet-Spengler reaction conditions. This led to formation of the corresponding cis-acid 35a 
and its enantiomer 35b respectively (Scheme 2.1).167 The major isomer formed in the 
Pictet-Spengler reaction had the cis-C1-C3 relative stereochemistry.167 Subsequent reaction 
of cis-35a or 35b with n-butylisocyanate gave cis-39a and 39b, respectively in good yield. 
The relative configuration of 39b has been confirmed by a (1H, 1H)-NOESY NMR 
spectroscopy experiment in which an nOe correlation between the C11a (4.49 ppm) and 
C5-H (6.12 ppm) was observed (Appendix 1).166 This assignment was also consistent with a 
previous literature investigation into the formation of a hydantoin ring in this heterocyclic 
system.167 In order to synthesise the corresponding trans-isomers 28a and 28b, the C11a 
protons in cis-39a and cis-39b were epimerised by treatment with potassium carbonate in 
refluxing acetonitrile. X-ray crystallographic analysis of trans-28a confirmed the relative 
stereochemical assignment at C5 and C11a (Scheme 2.1).166 
  
Scheme 2.1. Synthesis of analogues of 28. Reaction conditions: (i) H2SO4, H2O, 100 °C, 3-hydroxy 
benzylaldehyde, 8 h; 35a, 70%; 35b, 50%; (ii) DMSO/Acetone, R1NCO, 56 °C, 2-4 hrs; 39a, 65%; 39b, 92%; 
(iii) K2CO3, MeCN, 82 °C, 30 min.; 28a, 80%; 28b, 99%; Crystal structure of 28a.166  
Interestingly, the trans-(5R, 11aS)-isomer 28a156-158 proved to be the most potent inhibitor of 
T. gondii invasion with a MIC of 12.5 μM (Table 2.1, entry 1).  Its enantiomer trans-28b 
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did not inhibit T. gondii invasion even at the highest concentration tested (100 μM) (Table 
2.1, entry 2). The other enantiomeric pair in this series, cis-39a and cis-39b, both exhibited 
less potent inhibition of T. gondii invasion compared to trans-28a with MICs of 50 μM 
(Table 2.1, entries 3 and 4).  
Entry # Cpd # C5 C11a R1 R2 MIC (μM) 
1 trans-28a R S n-Butyl OH 12.5 
2 trans-28b S R n-Butyl OH >100 
3 cis-39a R R n-Butyl OH 50 
4 cis-39b S S n-Butyl OH 50 
5 trans-43 R S n-Butyl OCH3 12.5 
Table 2.1. MIC in the T. gondii cell invasion assay for analogues of 28.  
2.1.2 Potential biological targets generated using chemoinformatics and bioinformatics. 
Substructure searches using the core structure of 28 revealed that compounds of this class 
exhibit a wide range of biological activities, although no link to anti-parasitic activity has 
been reported. For example, the reported inhibition of the mitotic kinesin Eg5156-158 by 
trans-28a led our collaborator to consider whether its inhibitory activity on parasite invasion 
results from inhibition of a T. gondii kinesin. 28 is also structurally related to tadalafil (31) 
(Figure 2.3), a clinically-used inhibitor of the mammalian cGMP-specific 3’, 5’-cyclic 
nucleotide phosphodiesterase PDE5,159 raising the possibility that 28 may target a parasite 
PDE activity.  To determine whether T. gondii encodes a kinesin(s) or a cGMP-specific 
PDE(s) with similarity to mammalian Eg5 or PDE5, respectively, a bioinformatic analysis of 
the T. gondii genome has been performed by our collaborator. Although the comparison 
based on inhibitor-binding region were inconclusive, there are four kinesins encoded by T. 
gondii (TgME49_097110, TgME49_006570, TgME49_024880, TgME49_119710) that 
appear to have reasonable similarity to human Eg5.166 
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Figure 2.3 Known inhibitors of cGMP-specific 3’,5’-cyclic nucleotide phosphodiesterase and 
kinesins.159,168,169 
This bioinformatic analysis suggested that a T.gondii family-5 kinesin may be a possible 
target. Therefore, we compared our SAR data (Table 2.1) with the existing literature. The 
observation that trans-28a is the most active isomer for both inhibition of Eg5 and inhibition 
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of T. gondii invasion (Table 2.1) is consistent with the hypothesis that trans-28a acts on a T. 
gondii Eg5 homologue. However, assay results obtained with other close structural 
analogues did not support this hypothesis. For both trans 28a and monastrol (40) (Figure 2.3), 
inhibition of Eg5 involves an important hydrogen bond between the phenol functional group 
and the backbone carbonyl oxygen of either Trp127 or Glu118 in Eg5.168,169 In contrast, we 
observed that the phenolic hydroxyl group in 28a was not essential for inhibition of T. gondii 
invasion. The methyl ether analogue 43, which was synthesised via a Mitsunobu reaction of 
28a and methanol (Scheme 2.2) was as potent in the T. gondii invasion assay as 28a (Table 
2.1, entry 5 vs 1). Furthermore, previous studies on structurally related 
4-aryl-tetrahydroisoquinoline inhibitors (e.g. 41, Figure 2.3), which bind at the same site on 
human Eg5 as 28a and 40, have demonstrated that analogues containing a para-phenol are 
inactive, whereas those containing the phenolic hydroxyl group in the meta-position are 
active.168 This is in contrast to our observations that para-phenol analogue retained the 
activity (data not shown).166 Finally, the replacement of the C3 carbonyl in both trans-28a 
and 28b with a thiocarbonyl was attempted previously within the group and a significant 
effect on the biological activity in our system was observed,166 whereas an identical change 
has previously been reported to have no impact on Eg5 inhibition.156 In the light of these 
observations and the fact that the known Eg5 inhibitors monastrol (40) and 
S-trityl-L-cysteine (42) (Figure 2.3) had no effect on parasite invasion (data not shown), it 
was concluded that the inhibition of T. gondii invasion by 28a probably occurs through a 
different target class or through a parasite kinesin with unique characteristics. 
 
Scheme 2.2. Synthesis of O-substituted analogues of trans-28a.  Reaction conditions. (i) PPh3, DEAD, 
methanol, anhydrous toluene, 85%.  
2.1.3 Genome/proteome-wide target identification techniques.   
As no clear leads to a potential target of 28a in T. gondii could be reached from the 
chemo/bioinformatic analyses and initial SAR studies, it was decided to synthesise analogues 
of trans-28a that could be used for more general target identification techniques. In particular, 
we decided to prepare reagents that were applicable to the yeast-3-hybrid (Y3H) 
approach126,127,131,170-172 (see Chapter 1). This relatively new technique shows considerable 
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promise for identifying protein binding partners of small molecules. Distinguishing itself 
from other methods used in target identification studies, in the Y3H system the interaction 
between a small molecule and a target protein occurs in intact cells rather than in vitro. Liu 
and co–workers first reported its application in screening of cDNA libraries for target 
discovery.121 Laterly, several studies126,127,131,170-172 with small molecules and their known 
binding partners have shown the success of the technique. Baker and co-workers optimised 
the Y3H system to give a more stable and consistent cellular read-out using a small molecule 
(MTX 46)-protein (DHFR) pair. This is amenable to a high throughput format and can 
potentially be used to screen protein libraries for target identification studies.127 These results 
have inspired us to use this new technique in this study to identify potential targets of small 
molecule 28a.  
Amongst many challenges in the Y3H approach is the synthesis of a key compound referred 
to as a chemical inducer of dimerisation (CID). This requires linkage of a protein binding 
partner to the molecule under study in a manner that preserves its ability to bind to its 
target(s). Confidence that an appropriate position for protein binding partner attachment has 
been chosen was derived from the SAR studies.  
2.1.4 Extended SAR studies to identify a suitable position(s) for linker attachment.  
Entry # Cpd # C5 C11a R1 R2 MIC (μM)
1 trans-28a R S n-Butyl OH 12.5 
2 trans-28k R S n-Octyl OH 50 
3 trans-28l R S CH2CH2CO2Et OH >100 
4 trans-28m R S p-C6H4-CO2Et OH 50 
Table 2.2. MIC in the T. gondii cell invasion assay for analogues. For details of structure see Scheme 2.1. 
Variation of the N2-substituent of the hydantoin ring in trans-28a as a possible linker 
attachment site was decided from prior studies within the group. Exchange of the n-butyl 
substituent for an n-octyl group was achieved by reaction of 35a with n-octylisocyanate 
followed by epimerisation at C11a to afford trans-28k (Scheme 2.1). This analogue retained 
the desired biological activity, albeit at a reduced level (Table 2.2, entry 2). This result 
suggested that the N2-position could be a suitable point of attachment for a linker unit and 
led to the synthesis and testing of trans-28l, an analogue containing a shorter alkyl chain 
terminating with an ester functionality (Scheme 2.1). It was envisaged that hydrolysis of the 
ester would provide a carboxylic acid functional group that could be used to attach the linker 
unit using a standard amide bond-forming reaction. Unfortunately, 28l proved inactive in the 
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parasite invasion assay. Before abandoning this approach, an alternative ester analogue, 
trans-28m, was prepared that contained an aryl spacer between N2 (Scheme 2.1) and the 
required ester functionality. 28m did inhibit T. gondii invasion (Table 2.2, entry 4), thereby 
providing a suitable precursor for the desired synthetic transformation to the CID 44 (Figure 
2.5). The different activities of 28l and 28m may be due to differences in the levels to which 
the esters are hydrolysed under the assay conditions in live parasites although no data to 
support this is currently available. 28m could be hydrolysed and a linker unit, required for 
the yeast three hybrid construct, could be attached using amide bond formation. The amide 
bond would be expected to be sufficiently stable under the assay conditions of the Y3H 
approach.  
 
Figure 2.5 Chemical structure of CID 44 and the proposed retrosynthetic analysis.  
2.2 Synthesis of CID 44 
The required CID 44 has similar components to all the previously prepared yeast-3-hybrid 
constructs,126,127,131,170-172 which contain a known compound which has a known protein 
binding partner (Figure 2.5 blue, 46), a PEG linker (green, 45), and the small molecule (red, 
28m) for which the protein target is to be identified. The known compound used in this 
project was methotrexate (MTX, 46, Figure 2.5) which has the protein binding partner 
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dihydrofolate reductase (DHFR). Therefore the synthesis of CID 44 can be divided into four 
main parts: i) small molecule 28m synthesis, ii) PEG6 linker 45 synthesis, iii) methotrexate 
(46) synthesis, and iv) coupling of all the components to give the final CID 44.  
2.2.1 The synthesis of the small molecule 28m. 
Following a literature protocol, the key step in the synthesis of 28m was the Pictet-Spengler 
reaction using the amino acid from the (D)-tryptophan (38a) chiral pool (Scheme 2.3).157 The 
reaction was refluxed at 120 °C in 0.1 N H2SO4 with 3-hydroxybenzaldehyde (48) for 6 
hours to furnish 35a as a white precipitate in 70% yield.  
1H NMR spectroscopic analysis of 35a showed that the C2 indole proton that was present in 
the 1H NMR spectrum of the starting material 38a (7.18 ppm) had disappeared and a new 
singlet corresponding to the hydrogen at the C1 position in 35a was present (5.29 ppm). The 
previous literature corroborated the stereochemistry of 35a.156 In the Pictet-Spengler reaction, 
the ratio between the cis and trans products was reported to be 4:1, but only the cis product 
crystallised from the reaction mixture. The 1H NMR spectroscopic analysis and melting point 
of 35a matched the available literature.156  
 
Scheme 2.3 Synthesis of 2a via the Pictet-Spengler reaction. Reaction conditions (i): 0.1 N H2SO4 
3-hydroxybenzaldehyde (48), reflux, 6 h, 70%. 
Although the Pictet-Spengler reaction was discovered in 1911, the cis-specific 
Pictet-Spengler reaction was not reported until the early 1990’s.173,174 Waldmann et al. have 
discussed this mechanism in detail.173,174 Figure 2.6 shows the Pictet-Spengler cyclisation 
and the steric interactions for the four possible intermediates 49a, 49b, 49c and 49d. Except 
intermediate 49a, unfavourable 1,3-interactions can be observed in all other intermediates 
(Figure 2.6). Therefore, the Pictet-Spengler cyclisation most probably proceeded via the 
iminium intermediate 49a.  
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Figure 2.6 The proposed mechanism of the Pictet-Spengler reaction.173,174 
Compound 35a was then refluxed with 4-(ethoxycarbonyl)phenyl isocyanate in anhydrous 
DMSO and acetone to give 51 (Scheme 2.4).156,167,175 1H NMR analysis clearly showed that 
the peak corresponding to the hydrogen on N2 in 35a disappeared and additional peaks in the 
aromatic region were observed corresponding to the phenyl ring connected to N2 in 51. 13C 
NMR analysis also showed there were two additional peaks corresponding to the two 
additional carbonyl quaternary carbons present in 51. IR spectroscopic analysis of 19 showed 
a stretch at 3440 cm-1, which confirmed the presence of a phenolic hydroxyl group. The 
literature precedent for the synthesis of 28a and its N2-functionalised analogues indicated 
that this step would form the C11a, C5 cis isomer as drawn in 51 rather than the trans 
isomer.156 However, the trans isomer 28m could be obtained by epimerisation of the C11a 
proton which implied that cis isomer 51 is the kinetic product.156  
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Scheme 2.4 Synthesis of 52. Reaction conditions: (i) 4-(ethoxycarbonyl)phenyl isocyanate, DMSO/acetone 
(anhydrous), reflux, 5 hrs. Yield 65%; (ii) K2CO3, MeCN, reflux, 5 hrs. Yield 63%. (iii) LiOH, THF/H2O, rt 
overnight, 65% 
Epimerisation of 51 under basic conditions to furnish 28m occurred in reasonable yield as 
expected (Scheme 2.4).156,175 The 1H NMR spectrum of 28m indicated that the chemical 
shifts of the C11-methylene protons and the C11a proton had moved downfield compared to 
52 which is analogous to previously reported observation.156  
There are numerous methods to attach a linker unit to 28m, however, it must be remembered 
that inside a living cell an amide group is more stable to hydrolysis than an ester functional 
group. In order to form the amide bonding between a linker unit and 28m, it was necessary 
to hydrolyse the ester in 28m to the acid, and then couple the linker to the acid by forming an 
amide bond. The hydrolysis reaction (Scheme 2.4) was attempted under standard hydrolysis 
conditions. The ester 28m was treated with LiOH in THF/H2O to give the acid 52 as a 
yellow solid. 
2.2.2 Synthesis of PEG6 linker (45) 
A linker is required to attach the small molecule 28m to the known protein binding partner 
methotrexate (46). However, the length and type of linker employed is critical for the success 
of the Y3H construct. A PEG6 linker was chosen following the example that was reported by 
Kley.126 Kley suggested that using a PEG-spacer can improve the water solubility properties 
of the CIDs, especially PEG-spacers containing more than three ethyleneglycol subunits, 
which were found necessary for good performance in Y3H system.126 
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The plan for the CID synthesis involved the assembly of the three components using amide 
bond coupling, therefore, this would require modification of hexaethylene glycol 53. It was 
decided to modify the terminus of the linker from an alcohol to an amine group to enable 
amide bond formation. 
The synthesis of linker 45 has been previously reported via a route that converted both 
terminal alcohols to amine at the same time in 5 steps. However, the overall yield was poor 
(14%).176 Previous studies within the group confirmed that converting both hydroxyl groups 
to amino groups at the same time and then selectively protecting one of the amino groups 
was inefficient. Therefore, the terminal amines were introduced in a stepwise manner as 
shown in Scheme 2.5 in 7 steps with a much improved overall yield of 40%.  
 
Scheme 2.5 The synthesis of PEG6 linker (45). Reaction conditions: (i) tosyl chloride, KI, Ag2O, DCM, 0 ºC, 1 
hr, then rt, 20 mins, 84%; (ii) NaN3, DMF, reflux, 6 hrs, 93%; (iii) PPh3, H2O, THF, rt, o/n, 98%; (iv) Boc 
anhydride, DCM, rt, o/n, 89%; (v) tosyl chloride, pyridine, rt, o/n, 47%; (vi) NaN3, DMF, reflux, 4 hrs, 89%; 
( vii) PS-PPh3, H2O, THF, rt, o/n, 85%.  
 
Hexaethylene glycol (53) was treated with tosyl chloride with the assistance of Ag2O and KI 
to afford the monotosylate 54. The mechanism has been speculated to involve coordination 
of the silver cation Ag+ with the multiple ether oxygen atoms in the hexaethylene glycol 
(53).177 This has the effect of making the two hydroxyl groups closer together to favour an 
internal hydrogen bonding (IHB). The hydrogen atom Ha involved in the IHB becomes less 
acidic than Hb, which is in contrast more activated by this chelation, and therefore, Hb will be 
deprotonated by Ag2O. Then the oxygen anion will attack the tosyl chloride to form the 
mono-tosylated compound.177  
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Figure 2.7. The silver complex 60 proposed to be formed during mono tosylation 177 
Compound 54 was subsequently converted into azide 55 in 93% yield by substitution of the 
tosylate group by sodium azide. The azide functionality was then reduced under Staudinger 
conditions178,179 to generate the amine 56 in 98% yield. With the consideration that some of 
the following steps required basic conditions, 56 was protected using Boc anhydride to 
afford 57 in 89% yield.  
With the protected amine 57 in hand, the remaining alcohol was converted into amine 45 
using a similar methodology to that used to convert 53 to 54. The only difference being that 
silver oxide was no longer required in the tosylation reaction, since only one hydroxyl group 
remained. The reaction was therefore carried out in pyridine to afford 58 although this 
reaction proceeded in modest yield (47%). An attempt to optimise this reaction using a mesyl 
group instead of the tosyl group to give compound 61 was performed (Scheme 2.6). As 
mesylate group is less sterically bulky than a tosylate group, it is therefore more reactive as a 
leaving group in SN2 reaction than tosylate. We therefore hoped that this would improve the 
yield. Also the base used in this reaction was changed to the more basic triethylamine from 
pyridine. These modification led to a significant improvement in the yield giving 61 in 75% 
yield (compared to 47% for 58).  
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Scheme 2.6 Mesylation of compound 57 to generate compound 61. Reaction condition: (i) DIPEA, anhydrous 
DCM, 0 °C to rt, 75%.  
Compound 61 was then carried through azide formation and Staudinger reduction steps to 
afford the free amine 45 in 65% yield over the two steps. As 45 was no longer water-soluble, 
simple aqueous extraction could not be performed as a method of separating the amine 45 
from triphenyl phosphine oxide, as had been the case for 56. Due to the high polarity of 45 
column chromatography purification was also not successful. Solid supported triphenyl 
phosphine was therefore employed in this step, to afford 45 in 85% yield after filtration. 
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2.5.3 Synthesis of t-butyl methotrexate (47)170,180  
The known protein binding partner chosen in this project is Methotrexate (MTX, 46), which 
has high affinity for the enzyme DHFR (Chapter 1). As the structure of MTX (46) contains 
two acid functional groups, both the selective coupling with the linker unit and the selective 
protection were considered as problematic. Thus, the t-butyl protecting group needs to be 
introduced in the early stages of the synthesis. Following a literature protocol, 47 was 
obtained in three chemical steps. The first step which began with commercially available 
2,4-diamino-6-(hydroxymethyl)pteridine (62) involved treatment with triphenylphosphine 
dibromide to afford the bromide 63 followed by reaction with 4-(methylamino)benzoic acid 
to furnish 64 (Scheme 2.7). 170,180  
 
Scheme 2.7 Formation of t-butyl methotrexate (47). Reaction conditions: (i) Ph3PBr2, DMA, rt, 24 hrs; (ii) 
4-(methylamino)benzoic acid, Et3N, rt, 4 days. The crude acid 27 was used directly in the next step without 
purification; (iii) TPTU, Et3N, α-tbutyl-glutamate, rt, 2 days, 83%.  
Carboxylic acid 64 was then treated with TPTU (65, Scheme 2.8), Et3N and commercially 
available α-t-butyl-glutamate to yield the t-butyl-methotrexate 47 in 83% yield after 
trituration of the crude reaction residue with ethyl acetate.180 
As the polarities of both 64 and 47 were very high, they could not be purified by column 
chromatography. In addition 47 resisted recrystallisation from all solvent systems that were 
attempted. The only purification method that can be used was washing the solid with 
different solvents. The first time this reaction was performed, the 1H NMR spectrum showed 
there were extra peaks suggesting that there was some impurity present in the product. 
Therefore, an extra wash step was performed with chloroform and ethyl acetate. However, 
the purity of the product was not improved. From the 1H NMR spectroscopy analysis of the 
crude mixture, it was found that one of the impurities was unreacted α-t-butyl-glutamate. 
Thus, by reducing the number of equivalents of α-t-butyl-glutamate used in the reaction, the 
impurities were removed and 47 was successfully synthesised in sufficiently pure form.  
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2.5.4 CID 44 assembly  
After hydrolysis of 28m to afford 52, the amide coupling reaction between 52 and amine 45 
was attempted with the coupling reagent EDC (66). However, without the assistance of 
hydroxybenzotriazole (HOBt, 67), 1H NMR and mass spectroscopic analysis confirmed that 
the desired compound had not been synthesized. Based on our limited spectroscopic analysis 
of the product, a possible structure, 68, of the major product has been proposed (Figure 2.8). 
This may suggest that the reactivity of the PEG6 linker 45 used in this reaction is relatively 
low since 45 might fold up to hinder reaction with the activated intermediate 69. Therefore, 
the well documented rearrangement181 of the O-acylisourea 69 intermediate to the stable 
N-acylurea 68 was observed. 
 
Figure 2.8 Mechanismsof the rearrangement of the O-acylisourea 69 to form the stable N-acylurea 68.  
This result suggested that without HOBt (67), EDC (66) was not suitable for this reaction. In 
addition because the PEG6 linker 45 is laborious to make, the reaction with Boc-TOTA (70) 
(Scheme 2.8), which is commercially available, was performed as a model reaction. TPTU 
(65) was used instead of EDC (66) as a coupling reagent since it could not lead to do the 
observed rearrangement. This reaction was sufficient with the desired model product 71 
being synthesised (Scheme 2.8) in satisfactory yield (63%). Therefore, this method was 
applied to the PEG6 linker 45 to afford the 72 in 45% yield. (Scheme 2.8) 
Chapter 2 
                                                                                                     
44
 
Scheme 2.8 Coupling of the small molecule to linker unit. Reaction conditions: (i) Boc-TOTA linker (70), 
TPTU (65), Et3N, DMF, rt, 3 days, 71 63%, (ii) PEG6 linker (45), TPTU (65), Et3N, DMF, rt, 3 days, 72 45%. 
In order to couple the t-butyl-methotrexate 47 to the other end of the linker unit in 72, Boc 
deprotection of 72 with trifluoroacetic acid (TFA) was required before amide bond coupling 
to afford the amine 73 as the TFA salt (Scheme 2.9). 1H NMR spectroscopy analysis of 73 
showed that the proton signals corresponding to the Boc group in 72 had disappeared, which 
confirmed the success of the deprotection reaction. 73 was then coupled to 47 using TPTU 
(65) and excess DIPEA to give 74. The last step in the synthesis of 44 was hydrolysis of the 
t-butyl ester in 74. TFA: DCM 1:6 was used as the reaction conditions. Pleasingly, this 
enabled the synthesis of 70 mg of the desired CID 44 in 55% yield. (Scheme 2.9) 
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Scheme 2.9 Attaching tbutyl-MTX (47) to the other end of PEG6 linker (45). Reaction conditions: (i) TFA, r.t., 
5 min; (ii) TPTU (65), DIPEA, DCM/DMF, r.t., 3 days; (iii) TFA/DCM, r.t., 5 hrs. 
Signals in the 1H NMR spectrum of 74 associated with all the three components of the CID 
were clearly observed (Figure 2.9). For example, the peak at 4.65 ppm corresponding to the 
C11a proton of 74 was used to set the integration. The peak at 4.19 ppm corresponding to the 
α-proton of the MTX component also integrated to 1 proton. In the aromatic region, there 
were three doublet of doublet peaks (7.03-7.26 ppm) with each peak integrating to 1 proton. 
These signals were assigned to the three aromatic proton at C8, C9 and C5”. The singlet at 
8.55 ppm corresponds to the proton at C34’. Signals corresponding to the linker unit were 
also clear in the 1H NMR spectrum between 3.28-3.65 ppm occurring as a mutiplet. The 
peaks corresponding to the C11syn proton is present under the multiplet assigned to the 
linker as judged by a (1H, 1H)-COSY NMR spectroscopy analysis. The methyl group 
attached to the nitrogen in the MTX portion (C25’) was assigned to a singlet at 3.20 ppm and 
a peak corresponding to the t-butyl group of MTX appeared at 1.40 ppm integrating to 9 
protons. All these signals are consistent with the formation of 74. In addition, the 13C NMR 
spectroscopy analysis of 74 shows 62 carbons and these have all been assigned (see 
experimental). The LRMS of 74 was also consistent with the expected mass of 1207. Since 
74 is laborious to make and it can only be dissolved in DMSO, the optical rotation value was 
not determined.  
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Figure 2.9 1H NMR spectrum of t-butyl construct 74.  
 
The NMR spectra of final CID 44 has also been fully assigned (Table 2.3) using (1H, 
1H)-COSY NMR spectroscopy analysis, (1H, 13C)-HSQC NMR spectroscopy analysis and 
(1H, 13C)-HMBC NMR spectroscopy analysis.  
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Assign  Int. 1H J value /Hz 
13C Assign Int. 1H 13C 
1    171.6 4'   165.5 
3    153.1 5'   166.2 
5 1 6.23  51.7 8’, 9’ x 10, 10’ 24 3.26-3.66 68.8-69.7
5a    131.1 12'   173.8 
6a    134.4 13' 2 2.18-2.24 32.1 
7 1 7.53-7.60  118.3 14' 2 1.87-2.09 26.6 
8 1 7.03 7.5, 8.0 118.6 15' 1 4.26-4.33 52.9 
9 1 7.13 7.5, 8.0 121.7 35'   171.4 
10 1 7.31 8.0 111.5 17'   171.8 
10a    125.8 18'   133.7 
10b    106.1 19', 23’ 2 7.53-7.60 127.7 
11 2 3.09,3.26-3.66   22.6 20', 22’ 2 6.72-6.84 111.1 
11a 1 4.72 5.5, 10.5 52.3 21'   121.2 
1"    141.2 25' 3 3.22 38.5 
2" 1 6.72-6.84  115.2 26' 2 4.79 54.9 
3"    162.8 27'   136.8 
4" 1 6.72-6.84  115.1 34' 1 8.56 149.2 
5" 1 7.17 7.5, 7.5 129.8 32a'   157.7 
6" 1 6.72-6.84  118.9 31'   162.9 
1'    151.1 29'   164.1 
2', 7’ 2 7.74 9.0 126.3 28a'   155.2 
3', 6’ 2 7.96 9.0 128.9     
 
Table 2.3. NMR assignment of 44 
 
2.6 Synthesis of alternative CID (75) 
As the position of linker attachment affects the CID efficiency in the Y3H system, an 
alternative CID 75 has been synthesised within the group. Early studies had demonstrated 
that substitution of the phenolic oxygen in trans-28a with a methyl group led to an analogue 
Chapter 2 
                                                                                                     
48
281 that retained the desired biological activity. This suggested that this position could be 
used as a potential position to attach the linker unit. Further SAR investigation166 confirmed 
this hypothesis. Mitsunobu reaction of trans-28a with the previously prepared linker unit 57 
gave the phenolic ether 76, which was converted to the desired CID 75 via the t-butyl ester 
77 in 26% yield over 3 steps.  
 
Scheme 2.9 Synthesis of alternative CID 75 (i) DEAD, PPh3, THF, 62%; (ii) TFA, DCM; (iii) 57, EDC, HOBT, 
DIPEA, DCM,DMF, 63% over 2 steps; (iv) TFA, DCM, 66%. 
 
2.6 Preliminary biological test of CID 44 and CID 75 in the Y3H system. 
In order to perform an Y3H screen, it is a prerequisite that the synthesised CIDs are 
cell-permeable and can gain access to the yeast nucleus, the location of the transcription 
factor fusion proteins that allow selection of positive small molecule-target interactions. The 
cell- and nuclear-permeability of 44 and 75, the two CIDs based on 28, was assessed by a 
competition assay using a positive control strain of yeast, V1019Y. This strain has previously 
been used to validate other CIDs in a similar manner to the one described here.127 V1019Y is 
a leucine (Leu) auxotroph and, in the absence of any CID, is only able to grow in medium 
containing leucine. However, V1019Y is engineered to activate expression of a LEU2 
reporter when there is a positive interaction between a control CID, Dex-Mtx 78 (Mtx (46) 
linked to dexamethasone, Table 2.4), and a control target fusion protein (the rat 
glucocorticoid receptor fused to the B42 activation domain) resulting in CID-dependent 
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leucine prototrophy and restoration of growth in the absence of exogenous leucine. 
 
Entry Medium CID Competitor  OD600 (48 hrs) 
1 + Leu - - 1.30a 
2 - Leu - - 0.04a 
3 - Leu 10 μM 78 - 0.93 
4 - Leu 10 μM 78 100μM Mtx 46 0.05 
5 - Leu 10 μM 78 100μM 44 0.00 
6 - Leu 10 μM 78 100μM 75 0.00 
7 + Leu - 100μM 44 1.31 
8 + Leu - 100μM 75 1.31 
9 - Leu - 100μM 44 0.03 
10 - Leu - 100μM 75 0.05 
Table 2.4 Structure of control CID Dex-Mtx 78. Strain V1019Y was incubated for 48 hrs at 30 ºC in medium 
with and without leucine, in the presence of the CID and competitors indicated. Entry 3 confirms that Dex-Mtx 
78 can support the growth of V1019Y in selective medium (compare to entry 2). This growth was competitively 
inhibited by methotrexate (46) (entry 4), 44 and 75 (entries 5-6). a average of three experiments. 
 
Strain V1019Y was inoculated into a 96-well plate and growth was assessed under a variety 
of conditions by measuring the OD600 after incubation for 48 hours at 30 ºC. As expected, in 
the absence of any CID, strain V1019Y only grew when leucine was provided exogenously 
(Table 2.4, entry 1; compare to no growth in the absence of leucine, entry 2). In agreement 
with previous reports,127 we showed that incubation of V1019Y with Dex-Mtx 78 (10 μM) 
was sufficient to induce a transcriptional response and supported growth in the absence of 
leucine (Table 2.4, entry 3). Also as previously reported,127 the addition of excess Mtx (46) to 
the medium was found to abrogate the transcriptional activation of the LEU2 reporter 
through competition with Dex-Mtx 78 for binding to the dihydrofolate reductase 
(DHFR)-containing fusion protein present in V1019Y (see Table 2.4, entry 4). 44 and 75 
were then tested to see if they could compete with Dex-Mtx 78 in an analogous manner. 
 
Like Mtx (46), both 44 and 75 (100 μM) were able to inhibit the CID-dependent growth of 
V1019Y in the presence of Dex-Mtx 78, indicating that they do indeed compete for binding 
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to DHFR (Table 2.4, entry 5-6). Further control experiments demonstrated that the observed 
growth inhibition is not due to cytotoxicity associated with 44 or 75 (Table 2.4, entry 7 and 8) 
and that neither 44 nor 75 was able to autoactivate the LEU2 reporter in the absence of the 
rat glucocorticoid receptor-B42 activation domain fusion (Table 2.4, entries 9 and 10).  
These data strongly suggest that both 44 and 75 are cell- and nuclear-permeable and are 
therefore suitable for Y3H screening experiments. 
2.7 Conclusion 
This chapter focused on developing compound 28 from an active hit in the invasion assay to 
a chemical tool that can be used in target identification studies. Based on the SAR data that 
had been generated in the group, a suitable site to join the small molecule, linker unit and 
methotrexate was determined. The complicated CID 44 has been synthesised and the 
structure has been confirmed using various spectroscopic techniques. The CID 44 has the 
properties necessary to access the nucleus of yeast cells which is an absolute requirement for 
its use in the Y3H approach.  
Apart the Y3H approach, there are multiple other methods that can be used in target 
identification studies (Chapter 1). In the next chapter of this thesis, another example of a 
chemical tool used in an alternative method will be discussed.  
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Chapter 3: Identification and Optimisation of Conoidin A as a Covalent 
Inhibitor of Peroxiredoxin II 
3.1 Introduction 
From the original high throughput screen (see Chapter 1) it was found that the 
bis(bromomethyl)quinoxaline di-N-oxide 29 (Conoidin A) also inhibited the parasite 
invasion process.155 Conoidin A is an irreversible inhibitor of host cell invasion by the human 
pathogen T. gondii and has a minimum effective inhibitory concentration (MIC) of 12.5 
μM.155 Interestingly it is the only inhibitor which has been shown in secondary assay to 
inhibit parasite conoid extension.155  
 
Figure 3.1 Conoidin A (29).  
The first part of this chapter describes work done to identify the potential protein target(s) of 
Conoidin A (29). Theses studies will be discussed in detail. Experiments to assess whether 
Conoidin A (29) can inhibit its potential protein target in vitro are also included. The majority 
of the biological research described in this part was carried out in collaboration with Prof. 
Gary Ward at the University of Vermont, however, the in vitro validation studies were 
conducted in St Andrews. This part of the work has recently been published in Organic and 
Biomolecular Chemistry182 as a “Hot Article”. Further optimisation of 29 to develop more 
potent inhibitors will also be discussed in the second part of this chapter. The optimisation of 
29 has also been published recently in the journal ChemMedChem.183  
3.1.1 Identification of Conoidin A (29) as a covalent inhibitor  
Previous studies within the group showed that replacement of the C2 and C3 bromine groups 
in 29 with hydroxyl groups led to a loss of activity.155 Further investigations of the reaction 
of 29 with model thiol and amine nucleophiles indicated that Conoidin A (29) may act via a 
process of covalent modification of its target protein(s) through reaction of the activated 
bromine groups (Scheme 3.1) .163,164  
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Scheme 3.1 Reaction between 29 and a model thiol or amine nucleophile. Reaction conditions: (i) triethylamine, 
methyl mercaptoacetate (2 eq), r.t. 30 min, 93% of 80; (ii) n-butylamine, r.t, 90% of 82.163,164 
Small molecules that covalently modify their target protein(s) are of considerable clinical 
importance. A recent review lists 19 prescribed drugs, that act through irreversible covalent 
protein modification.184 An important example is the β–lactam class of antibiotics (83, Figure 
3.2), which acylate the active site serine of bacterial carboxypeptidases. The formal 
acyl-enzyme intermediate can resist hydrolysis, therefore it effectively eliminates all 
transpeptidase activity in the bacteria.184 As well as drugs, specific covalent modifiers of 
protein function can be useful tools for studying fundamental cell biological processes.185-190 
MJE3 (21, Figure 3.2 was identified by Evans et. al. using a cell-based assay) inhibits cancer 
cell proliferation. It has been discovered that MJE3 (21, see Chapter 1) inhibits the glycolytic 
enzyme phosphoglycerate mutase 1 (PGAM1) activity by covalent labeling through the 
epoxide motif (see Chapter 1, Section 1.1.3). These results suggested that cancer cells are 
dependent on glycolysis for viability and therefore glycolysis is a potential target for cancer 
treatment.185 Another interesting example published by Macpherson et al. showed SC alkyne 
(84, Figure 3.2) can covalently inhibit transient receptor potential family protein (TPRA1) by 
reaction with its activated cysteine residue. SCA (84) therefore is a tool to enable regulation 
in stimuli studies.187 
 
Figure 3.2 Examples of successful small molecules that covalently modify their protein targets. 
Broad specificity small molecules have also recently been used in chemical proteomics to 
modify sub-proteomes covalently.165,191 Perturbation of protein function by covalent 
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modification relies on the ability of a small molecule containing an electrophilic functional 
group to form an irreversible, covalent bond with a nucleophile that is conserved across the 
target protein family. In many examples, it is the sulfur atom in an activated cysteine residue 
that acts as the nucleophile, although carboxylic acids (aspartic/glutamic acid or the 
C-terminus of the protein), alcohols (e.g., activated serine) and amino-containing groups 
(histidine, lysine, arginine or the N-terminus) can all react with electrophiles, depending on 
the effect of the protein microenvironment on the nucleophile protonation state.192      
 
3.1.2 Attempts to identify targets using a biotinylated analogue of 29. 
To identify potential targets of 29 in T. gondii, a biotinylated analogue, 85 has previously 
been prepared within the group (Figure 3.3).163 Although 85 was found to be inactive in 
cell-based T. gondii invasion assays (data not shown), structure-activity relationship (SAR) 
data showed that other analogues of 29 with modifications at the same position retained 
biological activity,163 suggesting that the biotin group either renders 85 
membrane-impermeable or by some unknown mechanism is prevented from reaching its 
cellular target(s) within the parasite. To circumvent this problem, 85 was initially incubated 
with parasite lysates by our collaborator in an attempt to identify the protein target(s). Due to 
the labelling of large number of proteins by 85, the question remained inconclusive. 
Attempts to improve the specificity of labelling by varying the extraction or labelling 
conditions were unsuccessful.182 However, in these experiments 85 appeared to compete 
with iodoacetamide for protein labelling. This therefore suggested that 85 could at least react 
with a protein thiol as a nucleophile.182  
3.1.3 Identification of potential target proteins by “in vivo blocking” 
Previous work has shown that 29 exhibits a highly selective activity profile across a series of 
secondary assays related to T. gondii invasion.155 It inhibits the ionomycin-induced extension 
of a cytoskeletal structure of the parasite known as the conoid,193 but has no effect on 
parasite motility or secretion.155  The large number of proteins labelled by 85 in parasite 
extracts was inconsistent with this apparent biological specificity of 29, suggesting that, in 
extracts, 85 has access to a variety of proteins that are normally inaccessible to 29 within live 
parasites. Our collaborator therefore developed an alternative “in vivo blocking” approach to 
identify potential target(s) of 29 (Fig. 3.3A). Live parasites were pre-incubated with the 
unlabelled compound, 29, in order to bind/block its in vivo target(s). A control sample was 
incubated with an inactive analogue, 86.155 Parasites were then washed to remove unbound 
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29 or 86 and lysed with detergent to make a total protein extract that was subsequently 
incubated with 85. Although it was anticipated that 85 would label many proteins in the 
extract, as described above, the physiologically relevant target(s) would have already been 
bound by 29 in live parasites and should, therefore, remain un-biotinylated or experience a 
considerable reduction in the extent of biotinylation compared to the control.  
  
Figure 3.3 In vivo blocking approach to target identification. (A) Schematic of the in vivo blocking approach. 
(B) Unlabelled compound, 29, or a control inactive analogue, 86, was added to live parasites prior to extraction 
with detergent. The biotinylated analogue, 85, was then incubated with the resulting protein lysates. Total 
parasite proteins were resolved by 2D gel electrophoresis (first dimension isoelectric focusing on pH 3-10 IPG 
strips) and biotinylated proteins were visualised on western blots probed with streptavidin-HRP. Candidate 
target proteins are indicated by the red circle.  
Parasite proteins labelled by the in vivo blocking approach were subjected to 2D gel 
electrophoresis, transferred to nitrocellulose and probed with streptavidin-HRP. In 
comparison with the control (Fig. 3.3B, left panel), the labelling of several biotinylated 
proteins decreased in samples pre-incubated with 29 (Fig. 3.3B, right panel).  While 
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different changes were observed from experiment to experiment, one triad of proteins at 
~25-30 kDa showed a consistent and reproducible decrease in labelling following 
pre-treatment with 29 (Fig. 3.3B, red circle). These three proteins were excised from gels and 
analysed by mass spectrometry. The two lower molecular weight spots were identified as 
two isoforms of peroxiredoxin (Prx) II (TgPrxII: ToxoDB 583.m00002, 24.4 kDa, predicted 
pI 6.51), a protein previously demonstrated to participate in the parasite’s oxidative stress 
response.194 The two isoforms likely represent different oxidation and/or phosphorylation 
states of TgPrxII.25, 26 The third spot corresponded to a conserved hypothetical protein 
(ToxoDB 57.m00038, 25.7 kDa, predicted pI 6.95). In a further study, it was confirmed that 
the labelling of these three protein by 85 could be competed out with iodoactetamide 
indicated that these proteins are very likely to be labelled by 85 on thiols.182 Both TgPrxII 
and the hypothetical protein have multiple cysteine residues that could potentially react with 
29 and 85: TgPrxII contains 5 cysteines194 and the hypothetical protein 57.m00038 contains 
4 cysteines.164 It was decided to test the hypothesis that 29 inhibited conoid extension and 
invasion through an effect on the TgPrxII protein signal transduction roles it has shown in 
some biological systems.  
3.1.4 Peroxiredoxin II 
Peroxiredoxins are ubiquitous enzymes that function in intracellular signaling and defense 
against oxidative stress. Prxs are divided into three classes: “typical” 2-Cys Prxs, “atypical” 
2-Cys Prxs and 1-Cys Prxs.195 While all Prxs use a reactive, peroxidatic cysteine residue to 
reduce reactive oxygen species (ROS), resulting in the formation of a cysteine sulfenic acid 
(Cys-SOH), the three classes of Prxs differ in the mechanism by which the peroxidatic 
Cys-SOH is subsequently reduced during the catalytic cycle. Typical 2-Cys Prxs are obligate 
homodimers. In these enzymes, the Cys-SOH of the peroxidatic cysteine in one subunit is 
attacked by a resolving cysteine in the other subunit, generating an intersubunit disulfide 
bond.  Oxidation of typical 2-Cys Prxs influences structural transitions between dimer, 
decamer and other oligomeric forms.196 In the atypical 2-Cys Prxs, the peroxidatic and 
resolving cysteines are contained within a single polypeptide, and reduction of the 
peroxidatic cysteine occurs via an intramolecular disulfide bond. 1-Cys Prxs do not contain a 
resolving cysteine. In these enzymes, recycling is mediated by other thiol-containing electron 
donors such as glutathione. TgPrxII is unusual, in that it shows homology to 1-Cys Prxs at 
the primary sequence level, but is reported to funtion like a typical 2-Cys Prx.197 
Two models have been proposed to explain how oxidation of the peroxidatic cysteine 
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functions in redox signaling.  The “floodgate” model proposes that Prxs serve to buffer 
fluctuations in ROS levels; hyperoxidation of Prx (i.e., the further oxidation of Cys-SOH to 
sulfinic acid [Cys-SO2H] or sulfonic acid [Cys-SO3H] by locally high concentrations of 
H2O2) leads to Prx inactivation, local accumulation of H2O2 and activation of redox signaling 
pathways.198  Alternatively, the “smoke alarm” model proposes that oxidation of a Prx 
alters its structure and oligomerisation state, in turn affecting its ability to interact with and 
regulate the function of other signaling proteins including kinases, phosphatases and 
transcription factors.196  
The stage-dependent high proliferation rates of many protozoal parasites increase the 
demand for reducing equivalents to form deoxyribonucleoside diphosphates, which are 
essential for DNA synthesis. In proliferating parasites, high metabolic fluxes are also thought 
to have an effect on increasing endogenous formation of reactive oxygen and nitrogen 
species (ROS, RNS) in addition to redox active by-products.199 The intracellular parasites 
also suffer from the immune defence of the host cells, which is considered to exert a large 
oxidative burden. Redox metabolism of many protozoal parasites, including Toxoplasma 
gondii, has therefore been considered as a target for chemotherapy.199,200 The peroxiredoxin 
system is particularly important since together with catalase and glutathione peroxidase, it 
forms the antioxidant network to protect cells against ROS.194 Furthermore, overexpression 
of peroxiredoxin increase the protection to H2O2 treatment.194 It therefore provides a 
potential for the development of urgently required drugs.201 Recently, a homology model of 
TgPrxII from T. gondii was developed. It was also confirmed by mutation that Cys47 in the 
active site of TgPrxII is the peroxidatic cysteine, and the possible interaction with nearby 
Arg130195 or His39197 activates the thiol group of the Cys47 residue in the oxidation 
reaction.201  
3.2 Conoidin A (29) inhibits TgPrxII activity in vitro 
Given the importance of Prx proteins in intracellular signaling pathways in other systems, we 
tested whether the binding of 29 to TgPrxII affects its enzymatic activity. The activity of 
recombinant TgPrxII (rTgPrxII) was assessed using the previously reported glutamine 
synthetase protection assay (summarised in Figure 3.4).202 Glutamine synthetase can convert 
glutamine into glutamate in the presence of ADP, manganese, and arsenic. Glutamate can be 
further converted into a complex with iron and hydroxylamine. This complex has a red 
colour which is detectable by UV spectrometry. The formation of the complex can indicate 
how much glutamate has been formed in the reaction.202 However, glutamine synthetase can 
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be oxidised by hydrogen peroxide, which was generated by the presence of DTT and iron, 
and therefore is inactive in the assay. Prx protein has the ability to reduce hydrogen peroxide 
to water, therefore it can protect the glutamine synthetase from being oxidised by hydrogen 
peroxide to allow the red complex to form in the reaction.202,203 However, when Prx enzyme 
is inhibited, the hydrogen peroxide that is generated in the assay will prevent the complex 
being formed and the red colour being detected. Thus, if 29 can inhibit TgPrxII in vitro, 
glutamine synthetase will be oxidised in the assay and glutamate cannot be formed. UV 
spectrometry, will therefore not detect a colour change in the assay. 
 
Figure 3.4 Schematic process of glutamine synthetase protection assay using TgPrxII.  
Given the nature of the protection assay, the calculated IC50 value is highly dependent on 
factors such as the preincubation time of 29 with rTgPrxII. This is because if 29 is a covalent 
inhibitor of TgPrxII, as the incubation time increases, the IC50 value will reduce until one of 
the reactants (protein or inhibitor) has completely reacted. A five minute preincubation was 
selected in order to provide consistency between this assay and the electrospray mass 
spectrometric analysis (described in Section 3.3). After the 5 minute-preincubation, a large 
amount of DTT, which contains a thiol nucleophile, was added to the reaction. It is believed 
that the excess of DTT quenches the excess 29 to prevent further inhibition of TgPrxII by 29 
the reaction developing further. Using this short preincubation time, the effect of varying 
concentrations of 29 on enzyme activity was determined. 29 shows clear, dose-dependent 
inhibition of rTgPrxII, with an IC50 value of 25.1 ± 0.8 μM (Fig. 3.5).  
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Figure 3.5 1 IC50 curve for TgPrxII inhibition by 29. The mean of the data from 2 independent assays is shown.  
3.3 Conoidin A (29) binds covalently to Cys47, the peroxidatic cysteine of TgPrxII 
Previous studies have implicated Cys47 of TgPrxII as the key nucleophilic residue involved 
in catalysis by this enzyme.198 The thiol functional group of Cys47 is proposed to attack one 
of the oxygen atoms present in hydrogen peroxide resulting in cleavage of the 
oxygen-oxygen bond and in the initial formation of an enzyme-based sulfenic acid.204 
Mutation of Cys47 in rTgPrxII to alanine leads to a loss of activity of the protein in the 
glutamine synthetase protection assay.197 To assess whether 29 reacts with Cys47 of rTgPrxII, 
thereby implicating this residue in the mechanism of inhibition of rTgPrxII by 29, a series of 
mass spectrometry (MS) experiments were carried out in collaboration with Dr Botting.  
 
Figure 3.6 ESI MS analysis of the reaction of TgPrxII with 29 and BnSH; (i) rTgPrxII (Mr = 26924.7 Da); (ii) 
MS analysis of TgPrxII treated with 29 for 5 min.; * unreacted TgPrxII (Mr = 26924.3 Da); (iii) MS analysis of 
TgPrxII and 29 complex treated with BnSH; ++ BnSH adduct of unreacted rTgPrxII; + BnSH adduct of 
rTgPrxII:29:BnSH complex. 
i 
ii
++ +   
iii   
*
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Analysis of rTgPrxII using electrospray ionisation (ESI) methods gave one main species with 
an observed molecular weight (Mr) of 26924.7 Da (Fig. 3.6(i), theoretical Mr (rTgPrxII) = 
26924.8 Da). Following a five minute preincubation of rTgPrxII with 29, in a manner 
analogous to that used for IC50 determination, MS analysis supported the formation of a 
rTgPrxII:29 complex (Fig. 3.6(ii)) although a relatively large signal corresponding to 
unmodified rTgPrxII was also present at this time point. As the analysis was carried out 
under conditions where only covalently linked complexes would survive, the formation of a 
rTgPrxII:29 complex must result from covalent modification of rTgPrxII by 29. In addition, 
the observed mass shift of 267.1 Da was consistent with addition of 29 to rTgPrxII 
accompanied by the loss of one of the two bromine atoms (theoretical mass shift for 
formation of this rTgPrxII:29 complex = 267.0 Da).  
An extensive time course experiment was also attempted to further investigate the reaction 
between 29 and rTgPrxII (Appendix 2). Incubation of 29 with rTgPrxII for 5 minutes gave 
the most reproducible result and it was clear that extended incubation times had a detrimental 
effect on the quality of the protein signals. It is likely that deterioration of the signal results 
from the initial reaction of only one of the two bromine atoms present in 29 with rTgPrxII 
(as judged by the observed mass shift) followed at increased time periods by reactions 
involving the second bromo-methylene functional group in 29 (for a schematic 
representation of possible processes, see Scheme 3.2). Due to the complexity of the data, 
detailed understanding of this experiment remained difficult. However, for incubation times 
of under 10 minutes, only the formation of rTgPrxII:29 complex with the loss of one of the 
two bromine atoms was observed.  
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Scheme 3.2 Schematic representation of possible processes. (i) rTgprxII labeled once by 29; (ii) extra 
alkylation could happen with another molecule of protein or with another nucleophile within the active site; (iii) 
rTgPrxII:29 complex reacted with benzyl mercaptan to form a new complex rTgPrxII:29:BnSH. 
The observed displacement of only one of the two bromine atoms in 29 led to the proposal 
that addition of a thiol-containing compound (for example benzyl mercaptan, BnSH) after 
the initial preincubation with 29 could lead to the formation of a new enzyme-inhibitor 
complex (Scheme 3.2). This newly formed complex will block the second reactive site in 29 
prior to trypsin digestion. Addition of excess benzyl mercaptan to the rTgPrxII:29 complex 
gave a mass shift of 312.1 Da with respect to rTgPrxII (45.4 Da with respect to the 
rTgPrxII:29 complex, Fig. 3.4B(iii)). This second complex corresponds to the displacement 
of both bromine atoms in 29; one by a nucleophile in rTgPrxII and the second by benzyl 
mercaptan (Scheme 3.2(iii), theoretical mass shift for formation of rTgPrxII:29:BnSH 
complex = 310.4 Da with respect to rTgPrxII; 44.6 Da with respect to the initially formed 
rTgPrxII:29 complex). These results, using a model thiol nucleophile (Scheme 3.2), indicate 
that it is chemically possible for reaction at both electrophilic sites in 29 to occur. In addition, 
the observed reaction of the rTgPrxII:29 complex with benzyl mercaptan (Fig. 3.6) provides 
direct evidence that the second electrophilic site present in 29 is highly reactive in the 
presence of a suitable nucleophile. It was therefore concluded that the observed “partial 
reaction” of 29 with rTgPrxII results from a lack of other suitably reactive residues in the 
vicinity of Cys47 (see modeling studies, Section 3.4.5). Interestingly, this observation also 
implies that there is no suitable nucleophile from a second molecule of rTgPrxII available for 
reaction with the rTgPrxII:29 complex, as formation of rTgPrxII dimers cross-linked by 29 
would be predicted to occur. The lack of cross-linked dimer formation in the presence of 29, 
together with the previously reported inability of glutathione, lipoic acid, thioredoxin and 
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glutaredoxin to reduce the protein203 casts same doubt on the model that TgPrxII functions as 
a 2-Cys peroxiredoxin.197  
The plans then turned towards identification of which amino acid residue in TgPrxII reacts 
with 29. In contrast to the rTgPrxII:29 complex, the rTgPrxII:29:BnSH complex was found 
to be stable over extended time periods. It was therefore decided to perform tryptic digestion 
coupled with MALDI MS and MS/MS analysis using the rTgPrxII:29:BnSH complex to 
identify the protein residue involved in reaction with 29.  
 
Figure 3.7 MS/MS analysis of the Cys47 containing tryptic peptide (LYDFLG DSWGLLMSHP 
HDFTPVCTTE LAQAAR) (A) in the absence of treatment with 29 and BnSH; (B) after preincubation of 
rTgPrxII with 29 followed by BnSH, MS/MS fragmentation of the modified tryptic peptide which has lost 2x16 
Da. (C) MS/MS fragmentation of the modified tryptic peptide which has lost 1x16 Da. 
TgPrxII contains five cysteine residues, only 3 of which (Cys47, Cys73 and Cys129) are 
expected to be within tryptic peptides of sufficient size to be observed during MS analysis of 
the digest (Figure 3.7). All three of the expected peptides were observed upon MALDI MS 
analysis of a tryptic digest of rTgPrxII and MS/MS analysis confirmed their sequences (Fig. 
3.6 for Cys47-containing peptide). When the analysis was repeated using the 
rTgPrxII:29:BnSH complex, evidence was obtained to support the reaction of 29 at Cys47. 
MS/MS fragmentation of both the modified and unmodified Cys47-containing peptide gave 
a partial series of y ion fragments corresponding to the predicted sequence. Comparison of 
the ions obtained for the modified and unmodified peptide showed signals of the same mass 
up until y9, the last fragment that does not contain Cys47 (Fig. 3.7). The three spectra are 
then shifted relative to each other at the next y ion observed, y12.  These data demonstrate 
that the modification occurs either on Cys47, Val46, or Pro45. While it is not possible from 
these data to prove definitively that 29 covalently modifies Cys47 of rTgPrxII, the only 
alternative explanation involves reaction of the backbone amides in the Cys47/Val46/Pro45 
region. Given the observed reaction of 29 with model thiols described above (Section 3.1.1), 
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this makes significantly less chemical sense than the proposed reaction of 29 with Cys47. 
The observed mass shift (278.1 Da in spectrum 3.7B) for the modified Cys47-containing 
peptide differs from the theoretical mass shift (310.4 Da) expected for reaction of 29 at 
Cys47 followed by reaction with BnSH by a mass of 32Da. This difference has been 
assigned to the loss of both the oxygen atoms present in the N-oxide functional groups of 29 
(when bound to rTgPrxII) during MS analysis. Interestingly the loss of one oxygen atom 
present in the N-oxide functional groups of 29 was also observed (294.3 Da in spectrum 
3.7C). The reason for the observed fragmentation is currently unclear.  
 
Figure 3.8. Sequence of rTgPrxII. The cysteine-containing tryptic peptides expected from MALDI-MS analysis 
are highlighted in blue. The predicted tryptic peptides containing Cys66 and Cys209 are too small for 
observation using this technique and are highlighted in red.  
The results of MS/MS experiments are consistent with the view that Cys47 of TgPrxII is the 
peroxidatic cysteine, as shown previously, and that in vivo labeling and inhibition of TgPrxII 
results from covalent modification of Cys47 by 29.  
3.4 Optimisation of Conoidin A (29) 
In the first half of this chapter, TgPrxII has been identified as one of the potential targets for 
29. To the best of our knowledge, 29 is the first reported inhibitor of TgPrxII. As was 
mentioned before, the TgPrx family of proteins is considered to play an important role in 
parasite antioxidant regulation and a potential drug target for chemotherapy. It was therefore 
decided to further develop this inhibitor to aid future inhibitor design and optimisation.  
3.4.1 Synthesis of Conoidin B (87) 
It was clear that in Conoidin A (29) only one of the two available alkylating groups (bromine) 
present in 29 reacts with rTgPrxII, and in order to obtain decent tryptic digest data, the other 
alkylating group needs to be reacted using a second nucleophile. These results led to the 
preparation of conoidin B (87) (Scheme 3.3), a mono-bromo-analogue of 29.  
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Scheme 3.3. Synthetic route used to prepare Conoidin B (87). (i) CuBr2, 18-crown-6, CHCl3, reflux, 60 h, 37%; 
(ii) 1,2-phenylene diamine, THF, 0 ° C to rt, 17 h, 37%; (iii) m-CPBA (2 equiv.), DCM, rt, 20 h, 50%. 
87 was prepared using an established approach in the group, that was analogous to that used 
for 29.205 Conversion of butane-2,3-dione (88) to the brominated diketone 89 was achieved 
by treatment with copper(II) bromide using a modification of a literature procedure.9 
Subsequent condensation of 89 with 1,2-phenylenediamine gave high yields of the 
mono-bromo quinoxaline 90 that was readily oxidised using 2 equivalents of m-CPBA to 
give the desired compound 87.  
3.4.2 Inhibition of TgPrxII by 87 
Using the glutamine synthetase assay described previously with a 5 minute pre-incubation 
time of 87 with enzyme, 87 was shown to inhibit rTgPrxII in vitro with an IC50 = 42.3 ± 2.5 
μM (Figure 3.9A). 87 is therefore approximately half as active as 29 (IC50 = 25.1 ± 0.8 μM) 1 
presumably due to the fact that 87 contains only one functional group capable of alkylating a 
nucleophilic residue in rTgPrxII compared to twice that number present in 29. Analysis of 
the incubation of rTgPrxII with 87 using electrospray ionisation mass spectrometry, under 
analogous conditions to those used in the in vitro assay, led to an observed increase in 
molecular weight of rTgPrxII of 187.9 Da corresponding to the addition of one molecule of 
87 accompanied by loss of a bromine atom (Figure 3.9B, theoretical mass shift for formation 
of rTgPrxII:87 complex with loss of bromine = 188.0 Da).  
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Figure 3.9. A IC50 curve for rTgPrxII inhibition by 87, the error bars reflect the mean of percentage inhibition 
of duplicate protection assays; B ESI MS analysis of the reaction of rTgPrxII with 87; rTgPrxII (Mr = 26925.40 
Da); + impurity present in rTgprxII; MS analysis of rTgPrxII treated with 87 for 5 min. (Mr = 27113.30 Da); C 
MS/MS analysis of the Cys47 containing tryptic peptide (i) in the absence of treatment with 87; (ii) after 
incubation with 87. The y ion series is shifted by an average of 187.9 Da after the CVP motif resulting from 
modification of the CVP motif by 87. Theoretical mass shift for formation of rTgPrxII:87 complex with loss of 
bromine = 188.0 Da). 
In an analogous manner to previous studies with 29,182 evidence from tryptic digest and 
MALDI MS/MS experiments supported the view that 87 almost certainly inhibits rTgPrxII 
by covalent modification of the active site Cys47 (Figure 3.9C). The tryptic peptide 
containing Cys47 fragments under MS/MS conditions in such a way that fragmentation 
occurs either side of the CVP tripeptide (see analysis of untreated rTgPrxII, Figure 3.9C (i)). 
When this analysis was repeated using a sample of rTgPrxII that had been incubated with 87, 
the major difference, compared to the untreated rTgPrxII sample, was observed in the CVP 
region where a significant increase in the molecular weight of the peptide fragments 
containing this region was observed (Figure 3.9C (ii)). The observed increase corresponded 
to the addition of 87 to this tripeptide region of rTgPrxII almost certainly due to nucleophilic 
substitution of the bromine group in 87 by the sulfhydryl group present in residue Cys47. 
Interestingly, as for 29, the observed mass shift of this peptide was 32 Da less than expected 
in this experiment.  
(i) 
(ii) 
y6 
y7 y8 y9 y12 y14 y17 y25 
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3.4.3 The synthesis of Conoidin B (87) analogous  
In order to discuss the importance of the two N-oxide groups in conoidin B (87), mono 
N-oxide analogues were synthesised in a similar manner as conoidin B (87) but using limited 
amounts of m-CPBA.  
 
Scheme 3.4 Synthesis of mono N-oxide analogues. Reaction conditions: (i) m-CPBA (1 equiv.), DCM, rt, 20 h, 
75%; 91:92 formed in ratio 6:1 
When the mono-bromo quinoxaline 90 was treated with one equivalent of m-CPBA, the 1H 
NMR analysis of the crude reaction mixture indicated that 91 and 92 were formed in a 6:1 
ratio with oxidation preferentially occurring on N4 in 90 to give 91 as the major product. The 
observed selectivity presumably results from the reduction of electron density at the 
N1-position as a result of the electron-withdrawing nature of the nearby bromine. Separation 
of 91 and 92 by standard chromatographic techniques proved difficult, however a pure 
sample of 91 was obtained following recrystallisation from ethyl acetate/hexane. Comparing 
the 1H NMR spectrum of 91 with starting material 90, the singlet assigned to the CH3 group 
at 2.80 ppm in 90 was shifted to 2.92 ppm in 91, however, the singlet assigned to the CH2 
group at 4.56 ppm in 90 was not shifted in 91. It was therefore believed that the N-oxide 
group was adjacent to the CH3 group and the structure was assigned as 91.  
In addition, an alternative route to isomer 92 was devised which relied on the selective 
bromination of mono-N-oxide quinoxaline 94 that had been readily accessed from 88 via 
condensation with 1,2-phenylenediamine to give 93 followed by N-oxidation of 93 using 1 
equivalent of m-CPBA. The structural assignment of 92 was based on X-ray crystallographic 
analysis (see Scheme 3.5). No evidence for the formation of 91 in this reaction was obtained. 
The bromination presumably occurs adjacent to the N-oxide through reaction of bromine 
with the likely most abundant tautomer 94a (Scheme 3.5), in which the N-hydroxy enamine 
functionality has increased reactivity towards electrophiles compared to the enamine present 
in the alternative tautomer 94b. The expected increased reactivity of the enamine in 94a 
compared to 94b can be rationalised in an analogous manner to the well-known 
alpha-effect,206,207 the interaction of the two lone pairs on the adjacent oxygen and nitrogen 
atoms raises the energy of the HOMO in this system, and makes it a better and softer 
nucleophile, which is more reactive in the displacement of the bromine.  
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Scheme 3.5 Synthesis of 92. Reaction conditions: (i) 1,2-phenylenediamine, AcOH, reflux, 1.5 hrs, 90%; (ii) 
mCPBA (1 equiv.), DCM, rt, 20 h, 65%; (iii) Br2 (0.9 equiv.), DCM, reflux, 2 h, 75%. A representation of the 
X-ray crystal structure obtained on analysis of 92 is also shown.  
3.4.4 Inhibition of rTgPrxII by analogues 90, 91 and 92 
The glutamine synthetase protection assay was also used to determine the IC50 values of 
analogues 90, 91 and 92 (Table 3.1, column 4). Under the same conditions that were used in 
testing 29 and 87, the IC50 value of 90 was 32.9 ± 1.5 μM (entry 2), the IC50 value of 91 was 
105.6 ± 5.2 (entry 3), and the IC50 value of 92 was 16.6 ± 0.9 (entry 4). The greater than six 
fold difference in potency associated with the two mono-N-oxide analogues 91 and conoidin 
C (92) was of considerable interest. In order to rationalise these observations, competition 
experiments with a model thiol, methyl mercaptoacetate (Table 3.1, column 5), were carried 
out to assess the differences in the inherent reactivity of the various analogues. It has 
previously been shown that, under these conditions, Conoidin A (29) reacts with the 
incorporation of two equivalents of methyl mercaptoacetate as both bromines in 29 are 
displaced (Section 3.1). In the competition experiments, each reaction included two 
inhibitors with one equivalent each and, only one equivalent of methyl mercaptoacetate was 
used in all cases. The amounts of remaining unreacted starting material, were assessed by 
integration of the 1H NMR spectrum to work out the relative reactivity of the two analogues 
(for spectra, see Appendix 3).  
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Compound N1 N4 IC50  (μM) Model thiol competition experiment [b] 
87 N+O- N+O- 42.3 ± 2.5 1 = 
90 N N 32.9 ± 1.5 3 
91 N N+O- 105.6 ± 5.2 2 
92 N+O- N 16.6 ± 0.9 1 = 
Table 3.1 IC50s for conoidin B (87) analogues against rTgPrxII and relative reactivity of the analogues with a 
model thiol, methyl mercaptoacetate. Preincubation time of inhibitor with enzyme = 5 minutes in all cases. For 
inhibition curves see Appendix 4. Order of reactivity 1, fastest; 3, slowest, 1H NMR spectra for competition 
experiments with model thiol, please see Appendix 3. 
Comparison of the IC50 values for 90 and its di-N-oxide analogue 87 showed that 
incorporation of the two N-oxide functional groups in 87 led to a slight reduction in activity 
against rTgPrxII. This is of particular interest when it is considered that, as shown by the 
competition experiments (Table 3.1, column 5, 1H NMR spectrum, please see Appendix 3), 
the ratio between the methylene proton signed for 87 at 4.83 ppm and the methylene proton 
signed for 90 at 4.69 ppm, changed from 1:1 to 1:18, which means after 30 minutes reaction, 
the ratio between unreated 90 and unreacted 87 is 17:1; in other words, 87 reacts 
significantly faster with a model thiol than does 90. In addition, removal of the N4-oxide in 
87 to give conoidin C (92) led to a further increase in potency against the enzyme compared 
to 87 (Table 3.1, column 4 entry 4 vs entry 1), despite the fact that 92 reacts at a very similar 
rate to 87 with a model thiol (Table 3.1, column 5, after 30 minutes reaction, the ratio 
between the methylene proton signed for unreacted 87 at 4.83 ppm and the methylene proton 
of unreacted 92 at 4.77 ppm remained 1:1, for 1H NMR spectrum, see Appendix 3). A direct 
comparison of 90 and 92 is complicated by the fact that 92 is inherently more reactive than 
90. However, the relative potency of 87 and 92 suggests that there may be a detrimental 
interaction of the N4-oxide with the protein. This effect can also be seen when the potency of 
90 and 92 are compared. These compounds differ only in the presence in 91 of the N4-oxide, 
but 90 is a significantly more potent inhibitor of rTgPrxII than 91 despite the fact that 90 is 
less reactive than 91 towards a model thiol (The competition experiments between 87 and 90, 
87 and 91 were done under identical conditions with the same amount of 87, therefore, by 
comparing the integration value in the two resulting spectra, a conclusion that 91 (1:11) is 
slightly more reactive than 90 (1:18) can be made).183 A preference for 91 to adopt an 
unproductive binding mode may also explain the relative potency of 90 and 91. These studies 
Chapter 3 
                                                                                                     
68
clearly indicated that the potency of the various analogues could not be explained 
exclusively based on their chemical reactivity and that, as expected, the details of their 
interaction with the active site of the protein are important. It was therefore decided to use 
computational modeling techniques to provide some insights into the nature of these 
interactions. 
3.4.5 Molecular modelling of TgPrxII 
Whilst no crystal structure of TgPrxII exists, two computational models of TgPrxII in the 
“closed” and “open” state have been reported in the literature.197 Regeneration of the 
“closed” model for monomeric TgPrxII based on the crystal structure of human PrxVI (PDB 
code: 1PRX) was carried out using the SWISS-MODEL server in collaboration with Dr Xu. 
Overall the model of TgPrxII was very similar to human PrxVI with a superimposition of the 
two structures showing a root mean square deviation (rmsd) of 0.54 Å over 221 Cα atoms 
(Figure 3.10). 
 
Figure 3.10. Sequence alignment of T. gondii PrxII (TOXGO Prx-2) and human Prx-6. The identical and 
positively similar residues were highlighted with red boxes and red letters respectively. The secondary structure 
elements of human Prx-6 (PDB code: 1PRX) was shown on top of the sequences.  
Figure 3.11A shows a view of the model emphasising the position of the active site 
containing the key residue Cys47. The program GOLD was then used to dock the conoidin 
analogues in the proposed active site of TgPrxII. In brief, a 10 Å radius sphere around the 
Cys47 residue was defined as the ligand binding pocket and the sulfur atom of Cys47 was 
specified as the covalent linking atom. For each analogue, a bromine atom in the inhibitor 
was replaced by the sulfur atom of Cys47. Ten independent optimisation runs were then 
carried out and yielded ten GOLD docking solutions, which were ranked according to their 
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GOLD score. For all the analogues assessed, the highest scoring poses were found to be very 
similar to that shown in Figure 3.8B obtained using conoidin B (87). The inhibitor is oriented 
in such a way that the N1-oxide group is placed in a shallow pocket close to the active site 
Cys47 residue. The model suggests that the N1-oxygen may accept two hydrogen bonds 
from the hydroxyl group of Thr44 and the backbone NH of Val46. In the case of 91, if the 
N4-oxide oxygen atom is positioned in this pocket, the reactive alkylating group is forced to 
be remote from the active site Cys47 sulfhydryl group. In addition the C3-methyl group may 
reside inside the active site, with the C6 and C7-carbon atoms pointing out into solution. It is 
interesting that the model also predicts that the N4-oxide is positioned in a hydrophobic 
region of the protein consisting of the residues Ile125 and Val127 (Figure 3.11B). An 
inability to stabilise the highly electron-rich N4-oxide oxygen atom or the inability of the 
protein to accommodate, for example, water molecules that may be hydrogen bonded to this 
functional group in bulk solvent, may explain why the presence of the N4-oxide was found to 
be detrimental to activity (c.f. activity of conoidin B (87) vs conoidin C (92), Table 3.1). 
 
Figure 3.11. A Molecular model of TgPrxII; B Docking of Conoidin B (87) in the active site of TgPrxII model; 
C Docking of Conoidin A (29) in the active site of TgPrxII model; D Docking of Conoidin D (98) in the active 
site of TgPrxII model.  
Analogous results were obtained when the docking was repeated using our original inhibitor, 
Conoidin A (29). Interestingly, the modelling studies suggest that the TgPrxII active site can 
accommodate the additional large bromine atom in 29 (Figure 3.11C). It has been shown 
previously that when 29 reacts with TgPrxII, only one of the two bromine atoms is displaced. 
A possible rationalisation of this result is that in the proposed binding mode there are no 
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nucleophilic residues positioned correctly for a second SN2 reaction. Previous studies with 29 
also showed that the initially formed TgPrxII:29 complex could react rapidly with an 
externally added thiol nucleophile. At present, it is difficult to rationalise this experimental 
observation with the proposed binding mode unless the protein undergoes a significant 
conformational change after reaction occurs at Cys 47. A conformational change of this type 
has been proposed previously for TgPrxII. 195 
3.4.6 Inhibition of TgPrxII by C6/C7 substituted analogues of Conoidin A (29) 
Whilst the proposed binding modes must be viewed with some caution, additional modeling 
studies led to two interesting predictions that could be addressed experimentally. First, 
previously studies within the group using a model thiol nucleophile had shown that in 
analogue 95 the initial substitution reaction occurs at the C2-bromine atom adjacent to the 
N1-oxide functional group rather than at the methylene bromide substitutent at C3. It would 
therefore seem likely that 95 should fit well with the predicted binding mode due to the 
presence of the N1-oxide and absence of this functional group at N4. Interestingly, this 
prediction turned out to be correct as analysis of 95 in the glutamine synthetase protection 
assay showed that 95 was twice as active as 29 despite the fact that it has one strongly 
activated and one weakly activated alkylating function group compared to the two strongly 
activated alkylating groups present in 29 (IC50 (95) = 10.3 ± 1.7 μM vs IC50 (29) = 23.1 ± 0.8 
μM, Table 3.2). In addition, it was observed that the absence of both N-oxide functional 
groups in 96 was detrimental to activity probably reflecting both the reduced chemical 
reactivity and the lack of a N-oxide functionality that helps correctly orientate the inhibitor. 
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Compound N1 N4 R IC50 (μM) Model thiol competition experiment 
29 N+O- N+O- H 23.1 ± 0.8 3 
95 N+O- N H 10.3 ± 1.7 4 
96 N N H 41.4 ± 0.6 n.d. 
97 N+O- N+O- NHBoc 8.1 ± 0.1 2 
98 N+O- N+O- Br 19.9 ± 0.2 1 
Table 3.2 IC50s for Conoidin A (29) analogues against rTgPrxII and relative reactivity of the analogues with a 
model thiol, methyl mercaptoacetate. preincubation time of inhibitor with enzyme = 5 minutes in all cases. 
order of reactivity: 1, fastest; 4, slowest; n.d. not determined.  
The second prediction was that if the proposed binding mode is correct then it may be 
possible to prepare C6/C7-substituted analogues of Conoidin A (29) that have increased 
activity resulting from additional interactions with residues remote from the active site. 97 
and 98, the C6/C7-NHBoc and -bromine substituted analogues of 29 respectively were 
prepared in the goup.163 Whilst there was little difference in the biological activity of 98 
compared to 29, the incorporation of the NHBoc functionality did indeed lead to an increase 
in potency (IC50 (97) = 8.1 ± 0.1 μM vs IC50 (29) = 23.1 ± 0.8 μM,1 Table 3.1), making 97 
(conoidin D) the most potent analogue prepared in this series to date. This result can be 
rationalised by the potential for 97 to form an additional hydrogen bond with the hydroxy 
group in Thr150 that cannot be achieved by 29 (Figure 3.11D). Interestingly, competition 
studies with model thiols again showed that there was little correlation between inherent 
reactivity with a model thiol and observed activity against TgPrxII as 98 was found to be 
slightly more reactive towards methyl mercaptoacetate than 97 (Table 3.2, for spectrum, see 
Appendix 3).  
3.5 Further in vivo biological studies.  
The identification of TgPrxII as a potential target of 29 raised the intriguing possibility that 
redox signaling plays a previously unrecognised role in host cell invasion by T. gondii. To 
test directly whether binding of 29 to TgPrxII underlies the invasion-inhibitory effect of 29, 
our collaborator generated a transgenic parasite line in which the single TgPrxII gene was 
disrupted by homologous recombination.182 The knockout parasites were viable, and showed 
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no obvious growth defects in culture. No differences in the sensitivity of wild type and 
TgPrxII knockout parasites to various concentrations of 29 were observed in either the host 
cell invasion or conoid extension assays.182 These results strongly suggest that inhibition of 
TgPrxII is not responsible for the invasion defect observed upon treatment of parasites with 
29. One caveat to this set of experiments is that T. gondii tachyzoites express four putative 
Prx proteins, TgPrxI-III and TgAOP (Genbank accession #FJ356079), a homologue of the P. 
falciparum protein PfAOP208, and it is possible that 29 targets one or more of these other Prx 
proteins in addition to TgPrxII. If the different Prx proteins serve redundant functions with 
respect to conoid extension and invasion, the disruption of any one Prx might not be 
sufficient to confer resistance to 29. It should be noted that while TgPrxI and TgPrxII are 
cytosolic enzymes,194 epitope-tagged TgPrxIII and TgAOP localise to the parasite 
mitochondra and endoplasmic reticulum, respectively.209 It is therefore unlikely that either 
TgPrxIII or TgAOP plays a role in invasion or conoid extension. Further work will be 
required to determine if 29 inhibits TgPrxI, TgPrxIII and/or TgAOP, and whether a parasite 
in which multiple Prx proteins have been disrupted shows any reduction in sensitivity to the 
compound. Our collaborators are also currently attempting to generate a parasite line in 
which the other potential target identified by in vivo labeling, 57.m00038, has been disrupted. 
While the predicted sequence of 57.m00038 contains no motifs or homologies that provide 
insights into its potential function, it is intriguing that this protein was recently identified in a 
conoid-enriched protein fraction during an analysis of the T. gondii conoid proteome.193 
3.6 Conclusions   
This chapter focused on identification of possible protein targets for Conoidin A (29), which 
was one of the active hits from the invasion assay. Peroxiredoxin II and another potential 
target 57.m00038 were identified in the in vivo blocking process by our collaborator. 
Although the knockout experiment of TgPrxII proved that inhibition of this protein is very 
unlikely to be responsible for inhibition of invasion or conoid extension by the parasite, 
respecting the important role the peroxiredoxin family of protein play in many biological 
systems, further investigations of how 29 inhibits this protein were attempted and proved 
successful. As a result of developing additional SAR data relating to 29, further optimisation 
of 29 was possible and provided a better view of the TgPrxII protein’s active site which is 
particularly useful for future drug design and development.   
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Chapter 4: Experimental 
4.1 General procedures 
Chemicals and reagents were obtained from either Aldrich or Alfa-Aesar and were used as 
received unless otherwise stated. All reactions involving moisture sensitive reagents were 
performed in oven dried glassware under a positive pressure of argon. Tetrahydrofuran 
(THF), dichloromethane (DCM) and toluene were obtained dry from a solvent purification 
system (MBraun, SPS-800). Thin-layer chromatography was performed using glassplates 
coated with silica gel (with fluorescent indicator UV254) (Aldrich). Developed plates were 
air-dried and analysed under a UV lamp. Flash column chromatography210 was performed 
using silica gel (40-63 μm) (Fluorochem). 
Melting points were recorded in open capillaries using an Electrothermal 9100 melting point 
apparatus. Values are quoted to the nearest 1 oC and are uncorrected. 
Elemental microanalyses were performed on a Carlo Erba CHNS analyser within the School 
of Chemistry at the University of St Andrews. 
Infrared spectra were recorded on a Perkin Elmer Spectrum GX FT-IR spectrometer using 
either thin films on NaCl plates (NaCl) or KBr discs (KBr) as stated. Absorption maxima are 
reported as wavenumbers (cm-1) and intensities are quoted as strong (s), medium (m), weak 
(w) and broad (br). 
Low resolution (LR) and high resolution (HR) electrospray mass spectral (ES-MS) analyses 
were acquired by electrospray ionisation (ESI), electron impact (EI) or chemical ionisation 
(CI) within the School of Chemistry, University of St Andrews. Low and high resolution ESI 
MS were carried out on a Micromass LCT spectrometer and low and high resolution CI MS 
were carried out on a Micromass GCT spectrometer recorded on a high performance 
orthogonal acceleration reflecting TOF mass spectrometer, coupled to a Waters 2975 HPLC. 
Only the major peaks are reported and intensities are quoted as percentages of the base peak. 
Nuclear magnetic resonance (NMR) spectra were acquired on either a Bruker Avance 300 
(1H, 300.1 MHz; 13C, 75.5 MHz), Bruker Avance 400 (1H, 400 MHz; 13C, 100.1 MHz) or a 
Bruker Avance 500 (1H, 500 MHz; 13C, 125 MHz) spectrometer and in the deuterated solvent 
stated. 13C NMR spectra were acquired using the PENDANT or DEPTQ pulse sequences. All 
NMR spectra were acquired using the deuterated solvent as the lock. Coupling constants (J) 
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are quoted in Hz and are recorded to the nearest 0.1 Hz. The following abbreviations are 
used; s, singlet; d, doublet; dd, doublet of doublets; ddd, doublet of doublets of doublets; dt, 
doublet of triplets; t, triplet; m, multiplet; q, quartet; qt, quintet; and br, broad.  
4.2 Preparation of individual compouns and characterisation data 
(1R,3R)-1-(3-Hydroxy-phenyl)-2,3,4,9-tetrahydro-1H-carboline-3-carboxylic acid 
(35a)156 
 
(D)-tryptophan (38a) (6.0 g, 29.30 mmol, 1.0 eq) was suspended in 0.05 M H2SO4 (42 mL) 
and the desired aldehyde (6.98 g, 57.20 mmol, 2.0 eq) was added. The reaction mixture was 
stirred at reflux for 6 hours and the solid product collected by filtration and thoroughly rinsed 
with diethyl ether to obtain 35a as a yellow solid(6.32 g, 20.51 mmol, 70%). Mp:. 265-266 
ºC (lit 265-266 ºC); 1H NMR (400 MHz, DMSO-d6) δ 7.44 (d, 1H, 3J= 8.0 Hz, H5), 
7.15-7.26 (m, 2H, H5’, H8), 7.03-7.01 (m, 1H, H6), 7.01-6.90 (m, 1H, H7), 6.86 (d, 1H, 3J= 
7.6 Hz, H6’), 6.81-6.73 (m, 2H, H4’, H2’), 5.29 (s, 1H, H1), 3.75 (dd, 1H, 3J= 11.4 4.2 Hz, 
H3), 3.10 (dd, 1H, 3J= 13.6 4.2 Hz, H4syn), 2.84 (dd, 1H, 3J= 13.6 12.5 Hz, H4anti); LRMS 
(ES-) m/z(%) 307.20 (100) [M-H]-; [α]20D = +147.2 (c = 0.0075, MeOH). 
(5R,11aR)-2-(4-benzoic acid ethyl ester)-5-(3-hydroxyphenyl)-6H-1,2,3,5,11,11a- 
hexahydro-imidazo[1,5-b]-β-carboline-1,3-dione (51) 
 
35a (0.5 g, 1.62 mmol, 1.0 eq) and 4-(ethoxycarbonyl)phenyl isocyanate (0.47 g 2.44 mmol, 
1.5 eq) were stirred at reflux for 3 hours in anhydrous DMSO (0.5 mL) and anhydrous 
acetone (2 mL). The solution was diluted with water (5 mL) and extracted into EtOAc (3 x 5 
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mL). The combined organic layers were dried (Na2SO4) and reduced in vacuo. Purification 
of the residue by chromatography on silica gel (EtOAc:Hex 20:80) afforded title compound 
51 as a yellow solid (0.51 g, 1.05 mmol, 65%). Mp: 176 -177ºC; 1H NMR (400 MHz, 
DMSO-d4) δ 7.99 (d, 2H, 3J= 9.0 Hz, H3’ H5’), 7.52 (d, 1H, 3J= 7.0 Hz, H10), 7.47 (d, 2H, 
3J= 9.0 Hz, H2’ H6’), 7.18-7.06 (m, 4H, H7, H5”, H9, H8), 6.82 (d, 1H, 3 J= 8.0 Hz, H6”), 
6.70 (s, 1H, H2”), 6.63 (d, 1H, 3J= 8.5 Hz, H4”), 5.73 (s, 1H, H5), 4.50 (dd, 1H, 3J= 11.5 5.0 
Hz, H11a), 4.30 (q, 2H, 3J= 7.0 Hz, H9’), 3.45 (dd, 1H, 2J= 15.5 Hz, 3J= 5.0 Hz, H11syn), 
3.12 (dd, 1H, 2J= 15.5 Hz, 3J=11.5 Hz, H11anti), 1.31 (t, 3H, 3J= 7.0 Hz, H10’); 13C NMR 
(100 MHz, DMSO-d6) δ 170.0 (C1), 165.9 (C7’), 156.2 (C3”), 153.2 (C3), 140.1 (C1”), 
137.3 (C6a), 136.8 (C1’, C5’), 135.4 (C4’), 133.0 (C5a), 130.3 (C5”), 130.2 (C3’), 126.1 
(C10a), 125.4 (C2’, C6’), 122.9 (C9), 120.3 (C8), 119.9 (C6”), 118.5 (C10), 115.9 (C4”), 
114.7 (C2”), 111.3 (C7), 106.6 (C10b), 61.2 (C9’), 57.8 (C11a), 56.8 (C5), 22.6 (C11), 14.3 
(C10’). IR (KBr) νmax= 3349 (s) (OH), 2981 (s) (CH2, CH3), 1773, 1729 (s) (-CO-N-CO-) 
cm-1; LRMS (ES+) m/z (%) 482.30 (100) [M+H]+; HRMS (ES+): m/z calcd for C28H24N3O5 
[M+H]+: 482.1716; found 482.1733; [α]20D = + 0.8 (c = 0.007, EtOAc). 
(5R, 11aS)-2-(4-benzoic acid ethyl ester)-5-(3-hydroxyphenyl)-6H-1,2,3,5,11,11a- 
hexahydro-imidazo[1,5-b]-β-carboline-1,3-dione (28m) 
 
The cis-isomer 51 (0.49 g, 1.01 mmol, 1 eq) was then dissolved in anhydrous MeCN (12 mL) 
and K2CO3 (0.182 g, 1.32 mmol, 1.3 eq) was added. After stirring at reflux for 5 hours, the 
mixture was filtered and the solvent was removed in vacuo. Purification of the residue by 
chromatography on silica gel (EtOAC:Hex 20:80) gave 28m as a yellow solid (0.31 g, 0.64 
mmol, 63%). Mp: 178.2-179.1ºC; 1H NMR (400 MHz, DMSO-d6) δ 10.90 (s, 1H, NH), 9.50 
(s, 1H, OH), 8.05 (d, 2H, 3J= 8.5 Hz, H3’, H5’), 7.85 (d, 2H, 3J= 8.5 Hz, H2’, H6’), 7.57 (d, 
1H, 3J= 8.0 Hz, H10), 7.31 (d, 1H, 3J= 8.0 Hz, H7), 7.18 (dd, 1H, 3J= 8.0 7.5 Hz, H5”), 
7.13-7.08 (dd, 1H, 3J= 8.0 7.5 Hz, H9), 7.06-7.00 (dd, 1H, 3J= 8.0 7.5 Hz, H8), 6.82 (d, 1H, 
3J= 8.0 Hz, H6”), 6.78 (s, 1H, H2”), 6.73 (d, 1H, 3J= 7.5 Hz, H4”), 6.21 (s, 1H, H5), 4.60 
(dd, 1H, 3J= 11.0 5.5 Hz, H11a), 4.33 (q, 2H, 3J= 7.0 Hz, H9’), 3.42 (dd, 1H, 2J= 15.0 Hz, 
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3J= 11.0 Hz, H11syn), 3.08 (dd, 1H, 2J= 15.0 Hz, 3J= 5.5 Hz, H11anti), 1.31 (t, 3H, 3J= 7.0 Hz, 
H10’); 13C NMR (100 MHz, DMSO-d6) δ 171.7 (C1), 165.8 (C3), 165.5 (C7’), 158.1 (C4’), 
156.1 (C3”), 144.4 (C1”), 136.8 (C1’), 136.5 (C6a), 131.4 (C5a), 130.8 (C2’, C6’), 130.2 
(C5”), 129.9 (C3’, C5’), 126.1 (C10a), 122.9 (C9), 119.3 (C8), 118.6 (C10), 117.9 (C6”), 
115.6 (C4”), 115.4 (C2”), 111.8 (C7), 106.5 (C10b), 61.3 (C9’), 53.2 (C11a), 52.1 (C5), 22.9 
(C11),14.7 (C10’); IR (KBr) νmax= 3349 (s) (OH), 2981 (s) (CH2, CH3), 1773, 1729 (s) 
(-CO-N-CO-) cm-1; LRMS (ES+) m/z (%): 482.29 [M+H]+; HRMS (ES+) [M+H]+ m/z 
expected for C28H24N3O5 482.1716 found 482.1709 [α]20D  = -258.0 (c = 0.003, EtOAc). 
(5R,11aS)-2-(4-benzoic acid)-5-(3-hydroxyphenyl)-6H-1,2,3,5,11,11a-hexahydro- 
imidazo[1,5-b]-β-carboline-1,3-dione (52) 
 
To a solution of 28m (0.20 g, 0.42 mmol, 1.0 eq) in THF (10 mL) was added LiOH (0.10g, 
0.42 mmol, 1.0 eq) in H2O (5 mL), and left to stir overnight. The solvent was reduced, and 
the residue was partitioned between EtOAc (10 mL) and H2O (10 mL). The aqueous layer 
was separated, adjusted to pH 4 with 2M HCl, and extracted with EtOAc (3 x 10 mL). These 
combined extracts were washed with brine, dried (Na2SO4) and reduced in vacuo. 
Purification of the residue by chromatography on silica gel (DCM:MeOH 98:2) afforded 52 
as a yellow solid (0.13 g, 0.29 mmol, 65%). Mp: 155.7-158.3 ºC; IR (KBr) νmax= 3352 (s) 
(OH), 1726 (s) (C=O), 1245 (m) (C-O), 1123 (m) (C-O) cm-1; 1H NMR (400 MHz, 
DMSO-d6) δ 10.97 (s, 1H, NH), 9.49 (s, 1H, OH), 8.03 (d, 2H, 3J= 8.5 Hz, H3’, H5’), 
7.62-7.55 (m, 3H, H7, H2’, H6’), 7.31 (d, 1H, 3J= 8.0 Hz, H10), 7.20-7.15 (m, 1H, H5”), 
7.13-7.08 (m, 1H, H9), 7.06-7.00 (m, 1H, H8), 6.82 (d, 1H, 3J= 7.8 Hz, H6”), 6.77 (s, 1H, 
H2”), 6.74 (d, 1H, 3J= 8.0 Hz, H4”), 6.22 (s, 1H, H5), 4.60 (dd, 1H, 3J= 10.0, 6.0 Hz, H11a), 
4.05 (s, 1H, OH), 3.41 (dd, 1H, 2J= 15.0, 6.0 Hz, H11syn), 3.12-3.05 (m, 1H, H11anti); 13C 
NMR (100 MHz, DMSO-d4) δ 171.7 (C1), 167.1 (C7’), 158.1 (C3”), 153.2 (C3), 141.5 
(C1”), 136.8 (C1’), 136.5 (C6a), 136.3 (C4’), 131.4 (C5a), 130.2 (C5”), 130.1 (C3’, C5’), 
126.3 (C2’, C6’), 122.1 (C9), 119.3 (C8), 119.1 (C6”), 118.6 (C7), 115.6 (C2”), 115.4 (C4”), 
111.8 (C10), 106.5 (C10b), 53.2 (C11a), 52.1 (C5), 22.9 (C11). LRMS (ES+) m/z (%): 454.24 
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[M+H]+; HRMS (ES+) [M+H]+ m/z cald for C26H20N3O5 454.1403 found 454.1437 [α]20D = 
-114.5 (c = 0.00031, MeOH) 
17-hydroxy-3,6,9,12,15-pentaoxaheptadecyl 4-methylbenzenesulfonate (54)176,211 
 
Hexaethylene glycol (53) (5.32 mL, 21.30 mmol, 1.0 eq) was dissolved in anhydrous DCM 
(200mL) stirred at 0°C for 1hour, then Ag2O (7.39g, 31.91 mmol, 1.5 eq), TsCl (4.46g, 23.40 
mmol, 1.1 eq), KI (0.71 g, 4.25 mmol, 0.2 eq), were added in to the solution stirred for 
another 20 mins. The mixture was filtered through celite, washed with ethyl acetate (150 mL 
x 3), all fractions were combined, and solvent was reduced under vacuum to yield yellow oil. 
Purification by column chromatography (SiO2, MeOH: ethyl acetate 5:95) yielded product 
54 as a yellow oil (7.73g, 17.71 mmol, 84%). 1H NMR (400 MHz, CDCl3) δ 7.81 (d, 2H, 
3J=8.5 Hz, H2’, H6’), 7.36 (d, 2H, 3J=8.5 Hz, H3’, H5’), 4.18 (t, 2H, 3J=4.5 Hz, H1), 
3.59-3.76 (m, 22H, H2, H4, H5, H7, H8, H10, H11, H13, H14, H16, H17), 2.47 (s, 3H, Me),; 
LRMS (ES+) m/z (%): 459.24 (100) [M+Na]+, 437.27 (40) [M+H]+.  
17-azido-3,6,9,12,15-pentaoxaheptadecan-1-ol (55)176,211 
 
To a solution of 54 (4.00 g, 9.20 mmol, 1eq) in DMF, sodium azide (0.89 g, 13.7 mmol, 1.5 
eq) was added. The stirred mixture was reflux at 110 °C. After 6 h, the solution was cooled to 
room temperature, and the DMF was removed by distillation. The residue was purified by 
column chromatography (SiO2, MeOH: ethyl acetate 5:95) to afford 55 as a light yellow oil 
(2.62g, 7.36 mmol, 93%). 1H NMR (300 MHz, CDCl3) δ 3.71 (m, 20H, H2, H4, H5, H7, H8, 
H10, H11, H13, H14, H16), 3.39 (t, 2H, 3J= 8.5 Hz, H1), 1.65 (t, 2H, 3J= 8.5 Hz, H17); 
LRMS (ES+) m/z (%): 30.19 (100) [M+Na]+, 308.23 (40) [M+H]+.  
17-amino-3,6,9,12,15-pentaoxaheptadecan-1-ol (56)176,211 
 
To a chilled solution (0 °C) of 55 (1.2g, 3.90 mmol, 1.0 eq) in anhydrous THF (16 mL) 
triphenylphosphine (1.11 g, 4.22 mmol, 1.1 eq) was added. The solution was stirred for 10 h 
Chapter 4 
                                                                                                     
78
at room temperature. Water (1 mL) was then added, and the solution was stirred for an 
additional 10 h. The solvent was evaporated, and the residue was partitioned between toluene 
and H2O (1: 1, 40mL), then filtered through celite, washed with H2O/toluene (1: 1, 100 mL), 
aqueous layer was extracted with toluene. Solvent of aqueous layer was reduced to yield 56 
as a yellow oil (1.08g, 3.82 mmol, 98%). 1H NMR (300 MHz, CDCl3) δ 3.58-3.67 (m, 20H, 
H2, H4, H5, H7, H8, H10, H11, H13, H14, H16), 3.39 (t, 2H, 3J= 8.5 Hz, H1), 2.87 (t, 2H, 
3J= 8.5 Hz, H17). LRMS (ES+) m/z (%): 282.22 (100) [M+H]+.  
tert-butyl 17-hydroxy-3,6,9,12,15-pentaoxaheptadecylcarbamate(57)211 
 
56 (1.08 g, 3.84 mmol, 1.0 eq) was dissolved in anhydrous DCM and cooled to 0 °C. Boc2O 
(0.88 g, 4.03 mmol, 1.05 eq) was then added to the solution. Mixture was allowed to warm to 
room temperature over night. Solvent was reduced under vacuum to yield yellow oil. 
Purification by column chromatography (SiO2, MeOH: DCM 4: 96) yielded the product 57 
as a yellow oil (1.30g, 3.42 mmol, 89%). 1H NMR (300 MHz, CDCl3) δ 1.45 (s, 9H, H4’), 
3.25 (d, 2H, 3J= 8.5 Hz, H1), 3.40-3.79 (m, 22H, H2, H4, H5, H7, H8, H10, H11, H13, H14, 
H16, H17); LRMS (ES+) m/z (%): 404.26 (100) [M+Na]+.  
2-(2-(tert-butoxycarbonylamino)ethoxy)ethyl 4-methylbenzenesulfonate (58) 
 
57 (0.5g, 1.31 mmol, 1.0 eq) and tosyl chloride (0.375g, 1.97 mmol, 1.5 eq) were dissolved 
in anhydrous pyridine (5 mL), stirred at room temperature over night. Solvent was reduced 
under vacuum, residue was partitioned between EtOAc and HCl (10 mL, 0.3 mol/L), and the 
ethyl acetate layer was extracted with sat. NaCl solution, dried over Na2SO4, filtered and 
solvents reduced to yield yellow oil. Purification by column chromatography (SiO2, ethyl 
acetate) yielded the product 58 as a yellow oil (0.33g, 0.62 mmol, 47%). 1H NMR (300 MHz, 
CDCl3) δ 7.84 (d, 2H, 3J=8.0 Hz, H2’, H6’), 7.36 (d, 2H, 3J=8.0 Hz, H3’, H5’), 3.59-3.76 (m, 
22H, H7, H9, H10, H12, H13, H15, H16, H18, H19, H21, H22), 3.41 (m, 2H, H6), 2.45 (s, 
3H, H1”), 1.45 (s, 9H, H1); 13C NMR (75 MHz CDCl3) δ 155.9 (C4), 143.6 (C1’), 131.9 
(C4’), 130.7 (C2’, C6’), 127.8 (C3’, C5’), 70.6 (C2), 69.5-71.5 (C7, C9, C10, C12, C13, C15, 
C16, C18, C19, C21, C22), 45.3 (C6), 28.7 (C1 x 3), 20.9 (C1”); IR (Nujol): νmax = 2871 (s) 
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(CH2, CH3), 1711 (s) (C=O), 1250 (s) (C-O), 1112 (s) (C-O), 1041 (m) (S=O), 1189, 1391 
(-SO2O-) cm-1. LRMS (ES+) m/z (%): 558.23 (100) [M+Na]+, 536.66 (40) [M+H]+. HRMS 
(ES+): m/z calcd for C24H41NO10SNa [M+Na]+: 558.2451; found 558.2451. 
2-(2-(tert-butoxycarbonylamino)ethoxy)ethyl methanesulfonate (61) 
 
DIPEA (1.10 mL, 6.13 mmol, 2.0 eq) was added to a chilled (0 °C) 57 (1.17 g, 3.07 mmol, 
1.0 eq) anhydrous DCM solution (50 mL), methane sulfonyl chloride (0.31 mL, 3.98 mmol, 
1.3 eq) was then added to the reaction mixture, this solution was stirred at 0 °C for 20 mins, 
then warmed to room temperature overnight. Solvent was reduced, residue was taken up with 
DCM (50 mL), washed with water (50 mL), and saturated NaHCO3 (50 mL), organic layer 
was dried with Na2SO4, solvent was then reduced. The product was purified via column 
chromatography (MeOH: DCM 3:97) to yield a yellow oil 61 (1.18g, 2.30 mmol, 75%). 1H 
NMR (300 MHz, CDCl3) δ 3.59-3.76 (m, 22H, H7, H9, H10, H12, H13, H15, H16, H18, 
H19, H21, H22), 3.4 (t, 2H, 3J= 8.5 Hz, H6), 2.93 (s, 3H, H25), 1.45 (s, 9H, H1); 13C NMR 
(75 MHz CDCl3), δ 157.5 (C4), 72.6 (C2), 62.2-71.5 (C7, C9, C10, C12, C13, C15, C16, 
C18, C19, C21, C22), 45.3 (C6), 33.9 (C25), 28.7 (C1 x 3); IR (NUJOL): νmax = 2873 (s) 
(CH3, CH2), 1700 (s) (C=O), 1517 (m) (-NH-), 1391, 1170 (s) (-SO2O-) cm-1; LRMS (ES+) 
m/z (%): 460.35 (100) [M+H]+, HRMS (ES+): m/z calcd for C18H38NO10S [M+H]+: 460.2183; 
found 460.2172. 
tert-butyl 2-(2-azidoethoxy)ethylcarbamate (59) 
 
61 (0.33 g, 0.61 mmol, 1.0 eq) and sodium azide (0.06 g, 0.92 mmol, 1.5 eq) were dissolved 
in anhydrous DMF (20 mL), heated at 110°C for 4 h, mixture was then cooled to room 
temperature. Solvent was reduced in vacuo (used toluene). Purification by column 
chromatography (SiO2, DCM: MeOH 97: 3) yielded the product 59 as a yellow oil (0.21 g, 
0.54 mmol, 89%). 1H NMR (300 MHz, CDCl3) δ 3.61-3.79 (m, 20H, H2, H4, H5, H7, H8, 
H10, H11, H13, H14, H16, H17), 3.42 (t, 2H, 3J= 7.0, H17), 3.35 (t, 2H, 3J= 8.5 Hz, H1), 
1.45 (s, 9H, H4’). 13C NMR (75 MHz CDCl3) δ 157.5 (C1’), 72.6 (C3’), 70.0-71.4 (C2, C4, 
C5, C7, C8, C10, C11, C13, C14, C16), 50.7 (C17), 40.4 (C1), 28.44 (C4’). IR (Nujol): νmax 
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= 2922 (s) (CH2, CH3), 2113 (s) (N3), 1720 (s) (C=O), 1151 (s) (C-O), 1301 (s) (C-O) cm-1; 
LRMS (ES+) m/z (%): 429.32 (100) [M+Na]+; HRMS (ES+): m/z calcd for C17H34N4O7Na 
[M+Na]+: 429.2427; found 429.2461. 
tert-butyl 2-(2-aminoethoxy)ethylcarbamate (45)211 
 
59 (0.21 g 0.53 mmol) was dissolved in anhydrous THF (5 mL) cooled to 0°C, solid support 
PPh3 (20% loading) (0.75 g, 0.58 mmol, 1.1 eq) was then added and mixture was allowed to 
warm to room temperature over night. H2O (80 μL, 1 mmol, 2.0 eq) was added into mixture 
stirred over night. Solvent was reduced under vacuum; purification by Biotage NH column to 
yield 45 as a yellow oil (0.13g, 0.34 mmol, 65%); 1H NMR (300 MHz, CDCl3) δ 3.61-3.79 
(m, 20H, H2, H4, H5, H7, H8, H10, H11, H13, H14, H16), 3.35 (t, 2H, 3J= 8.5 Hz, H1), 2.84 
(m, 2H, H17), 1.45 (s, 9H, H4’) 13C NMR (75 MHz CDCl3) δ 157.5 (C1’), 70.1-71.4 (C2, C4, 
C5, C7, C8, C10, C11, C13, C14, C16, C3’), 41.78 (C1), 40.33 (C17), 28.41 (C4’ x 3),. 
LRMS (ES+) m/z (%): 381.29 (100) [M+H]+; HRMS (ES+): m/z calcd for C17H37N2O7 
[M+H]+: 381.2523; found 381.2556. 
4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzoic acid (64)170,180 
 
62 (1.65 g, 6.60 mmol, 1.0 eq) and triphenylphosphine dibromide (8.36 g, 19.8 mmol, 3.0 eq) 
were stirred in dry DMA (20 mL) for 24 hours. 4-(methylamino)benzoic acid (1.28 g, 8.5 
mmol, 1.3 eq) and Et3N (3.45 mL, 19.8 mmol, 3.0 eq) were added to the suspension and 
mixture stirred for 4 days. The suspension was diluted with 0.33 M NaOH (15 mL) and 
stirred for 15 mins, resultant solid removed via filtration. The filtrate was acidified to pH 5.5 
with 10% AcOH. The orange solid collected via filtration and dried at 50 ºC under vaccum 
overnight. Product was taken to next step without purification. Mp: 156-158 ºC (lit. 155 ºC). 
1H NMR (400 MHz, (CD3)2SO) δ 8.44 (s, 1H, H7), 7.72 (d, 2H, 3J = 9.1 Hz, H5’, H7’), 3.23 
(s, 3H, H10’), 6.82 (d, 2H, 3J = 9.1 Hz, H4’, H8’), 4.81 (s, 2H, H1’); LRMS (ES-) m/z (%): 
324.13 (100) [M-H]-.  
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(S)-5-tert-butoxy-4-(4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)-5-
oxopentanoic acid (tert-butyl MTX, 47)170,180 
 
64 (645.1 mg, 1.99 mmol, 1.0 eq) and Et3N (554 μL, 3.98 mmol, 2.0 eq) was suspended in 
dry DMF (10 mL), TUTU (591.1 mg, 1.99 mmol, 1.0 eq) was added, mixture stirred 
overnight. α-tButyl-glutamate (451.5 mg, 2.22 mmol, 1.1 eq) and Et3N (554 μL, 3.98 mmol, 
2.0 eq) were suspended in DMF (5mL). The suspension of 64 was cannulated over, stirred 
overnight. The solvent was reduced in vacuo and the residue triturated with ethyl acetate. 
Resultant solid was collected via filtration and washed with ethyl acetate and chloroform. 
Solid dried at 40 ºC under vacuum to give 47 as an orange solid (0.83 g, 1.61 mmol, 81%). 
Mp: 158-159 ºC (lit. 158 ºC); 1H NMR (400 MHz, (CD3)2SO) δ 8.44 (s, 1H, H7), 7.54 (d, 2H, 
3J = 9.1 Hz, H5’, H7’), 6.63 (d, 2H, 3J = 9.1 Hz, H4’, H8’), 4.63 (s, 2H, H1’), 4.09 (m, 1H, 
H12’), 2.10-2.16 (s, 3H, H9’), 1.64-1.89 (m, 2H, H13’), 1.20 (s, 9H, H19’); LRMS (ES-) m/z 
(%): 509.30 (100) [M-H]-.  
N-((3-(dimethylamino)propyl)carbamoyl)-N-ethyl-4-((5R,11aS)-5-(3-hydroxyphenyl)-1,
3-dioxo-11,11a-dihydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indol-2(3H,5H,6H)-yl)benza
mide (68) 
 
52 (0.05 g, 0.11 mmol, 1.0 eq) and Et3N (15.4 μL, 0.11 mmol, 1.0 eq) were taken up with 
anhydrous DCM (10 mL), EDC (66) (0.02 g, 0.11 mmol, 1.0 eq) and a solution of 45 (0.04 g, 
0.11 mmol, 1.0 eq) in dry DCM (2 mL) were then added to the solution. This solution was 
stirred at room temperature under N2 for 18 hrs. The solvent was reduced, residue was taken 
up in ethyl acetate (10 mL) and was washed with sat. NaHCO3 (2 x 5 mL) and brine (5 mL). 
Organic layer was dried over Na2SO4 and then reduced to yield a yellow solid. Purification 
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was via column chromatography (SiO2, DCM:MeOH 85:15) to give 68 as a off-white solid 
(0.04 g, 0.061 mmol, 56%). Mp: 131-132 ºC. 1H NMR (400 MHz, CDCl3) δ 7.86 (d, 2H, 3J 
= 8.7, H3’, H6’), 7.45-7.51 (m, 3H, H10, H2’, H7’), 7.08-7.26 (m, 4H, H8, H9, H5”, H7), 
6.80-6.91 (m, 3H, H4”, H2”, H6”), 6.30 (s, 1H, H5), 4.60 (dd, 1H, 3J= 10.3 5.8 Hz, H11a), 
3.98 (q, 2H, 3J = 6.5, H16’), 3.37-3.41 (m, 3H, H11’, 11syn), 2.93-3.05 (m, 1H, H11anti), 
2.46 (s, 6H, H15’), 2.32 (t, 2H, 3J = 5.5, H13’), 1.33-1.56 (m, 5H, H12’, H17’); 13C NMR 
(100 MHz, CDCl3) δ 171.6 (C1), 167.0 (C5’), 159.6 (C3”), 153.7 (C3), 151.0 (C9’), 140.7 
(C1”), 137.1 (C4’), 137.0 (C1’), 136.5 (C6a), 130.7 (C5”), 130.5 (C5a), 128.4 (C3’, C6’), 
126.5 (C10a), 125.9 (C2’, C7’), 123.4 (C9), 121.1 (C8), 120.6 (C6”), 118.9 (C7), 115.4 
(C2”), 115.3 (C4”), 111.8 (C10), 108.2 (C10b), 58.3 (C13’), 53.6 (C5), 52.6 (C11a), 50.6 
(C11’), 47.0 (C15’ x 2), 33.4 (C16’), 25.9 (C12’), 24.1 (C11), 11.8 (C17’); IR (KBr): νmax = 
3334 (s) (OH), 1720 (s) (C=O), 1650 (s), 1632 (m), 1507 (m) (NH) cm-1. LRMS (ES+) m/z 
(%): 609.27 (100) [M+H]+; HRMS (ES+): m/z calcd for C34H36N6O5 [M+H]+: 609.2747; 
found 609.2781. 
tert-butyl (1-(4-((5R,11aS)-5-(3-hydroxyphenyl)-1,3-dioxo-11,11a-dihydro-1H-imidazo 
[1',5':1,6]pyrido[3,4-b]indol-2(3H,5H,6H)-yl)phenyl)-1-oxo-5,8,11-trioxa-2-azatridecan-
13-yl)carbamate (71) 
 
52 (0.05 g, 0.11 mmol, 1.0 eq) and Et3N (15.4 μL, 0.11 mmol, 1.0 eq) were taken up with 
anhydrous DMF (2 mL), TPTU (65) (0.03 g, 0.11 mmol, 1.0 eq) was then added into solution; 
this solution was stirred at room temperature under N2 for 18 hrs. A solution of Boc-TOTA 
(70) (0.03 g, 0.11 mmol, 1.0 eq) in dry DMF (2 mL) was then added to the solution, this new 
mixture was stirred at room temperature under N2 for 3 days. The solvent was reduced; 
residue was taken up in ethyl acetate (10 mL) and was washed with sat. NaHCO3 (2 x 5 mL) 
and brine (5 mL). Organic layer was dried over Na2SO4 and then reduced to yield a yellow 
solid. Purification was via column chromatography (SiO2, DCM:MeOH 97:3) to give 71 as a 
yellow solid (0.05 g, 0.069 mmol, 63%). Mp: 75.4-76.0 ºC. 1H NMR (400 MHz, CDCl3) δ 
7.86 (d, 2H, 3J = 8.7, H3’, H6’), 7.45-7.51 (m, 3H, H10, H2’, H7’), 7.08-7.26 (m, 4H, H8, 
H9, H5”, H7), 6.80-6.91 (m, 3H, H4”, H2”, H6”), 6.30 (s, 1H, H5), 4.60 (dd, 1H, 3J= 10.3 
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5.8 Hz, H11a), 3.37-3.63 (m, 17H, H9’, H10’ x 6, H11’, 11syn), 2.93-3.05 (m, 1H, H11anti), 
1.35 (s, 9H, H16’). 13C NMR (100 MHz, CDCl3) δ 171.6 (C1), 167.0 (C5’), 159.6 (C3”), 
153.7 (C3), 140.7 (C1”), 137.1 (C4’), 137.0 (C1’), 136.5 (C6a), 134.7 (C13’), 130.7 (C5”), 
130.5 (C5a), 128.4 (C3’, C6’), 126.5 (C10a), 125.9 (C2’, C7’), 123.4 (C9), 121.1 (C8), 120.6 
(C6”), 118.9 (C7), 115.4 (C2”), 115.3 (C4”), 111.8 (C10), 108.2 (C10b), 70.3-70.9 (C10’ x 6), 
53.6 (C5), 52.6 (C11a), 40.8 (C9’), 40.3 (C11’), 30.1 (C15’), 28.8 (C16’), 24.1 (C11). IR 
(KBr): νmax = 3334 (s) (OH), 2872 (s) (CH2, CH3), 1720 (s) (C=O), 1507 (m) (NH), 1247 (m) 
(C-O) cm-1. LRMS (ES+) m/z (%): 728.25 (80) [M+H]+; HRMS (ES+): m/z calcd for 
C39H46N5O9 [M+H]+: 728.3217; found 728.3217; [α]20D = -166.3 (c = 0.00024, DCM). 
tert-butyl (1-(4-((5R,11aS)-5-(3-hydroxyphenyl)-1,3-dioxo-11,11a-dihydro-1H-imidazo 
[1',5':1,6]pyrido[3,4-b]indol-2(3H,5H,6H)-yl)phenyl)-1-oxo-5,8,11,14,17-pentaoxa-2-aza
nonadecan-19-yl)carbamate (72) 
 
52 (0.05 g, 0.11 mmol, 1.0 eq) and Et3N (15.4 uL, 0.11 mmol, 1.0 eq) were taken up with 
anhydrous DMF (2 mL), TPTU (65) (0.03 g, 0.11 mmol, 1.0 eq) was then added into solution; 
this solution was stirred at room temperature under N2 for 18 hrs. A solution of 
Boc-PEG5-Linker (45) (0.04 g, 0.11 mmol, 1.0 eq) in dry DMF (2 mL) was then added to 
the solution, this new mixture was stirred at room temperature under N2 for 3 days. The 
solvent was reduced; residue was taken up in EtOAc (10 mL) and was washed with sat. 
NaHCO3 (2 x 5 mL) and sat. NaCl (5 mL). Organic layer was dried over Na2SO4 and then 
reduced to yield a yellow solid. Purification was via column chromatography (SiO2, 
DCM:MeOH 97:3) to give 72 as a yellow solid (0.04 g, 0.049 mmol, 45%). Mp: 64.1-64.3 
ºC. 1H NMR (400 MHz, CDCl3) δ 7.86 (d, 2H, 3J = 8.7, H3’, H6’), 7.45-7.51 (m, 3H, H10, 
H2’, H7’), 7.08-7.26 (m, 4H, H8, H9, H5”, H7), 6.80-6.91 (m, 3H, H4”, H2”, H6”), 6.30 (s, 
1H, H5), 4.60 (dd, 1H, 3J= 10.3 5.8 Hz, H11a), 3.37-3.63 (m, 17H, H9’, H10’ x 10, H11’, 
11syn), 2.93-3.05 (m, 1H, H11anti), 1.35 (s, 9H, H16’). 13C NMR (100 MHz, CDCl3) δ 
171.6 (C1), 167.0 (C5’), 159.6 (C3”), 153.7 (C3), 140.7 (C1”), 137.1 (C4’), 137.0 (C1’), 
136.5 (C6a), 134.7 (C13’), 130.7 (C5”), 130.5 (C5a), 128.4 (C3’, C6’), 126.5 (C10a), 125.9 
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(C2’, C7’), 123.4 (C9), 121.1 (C8), 120.6 (C6”), 118.9 (C7), 115.4 (C2”), 115.3 (C4”), 111.8 
(C10), 108.2 (C10b), 70.3-70.9 (C10’ x 10), 53.6 (C5), 52.6 (C11a), 40.8 (C9’), 40.3 (C11’), 
30.1 (C15’), 28.8 (C16’), 24.1 (C11); IR (KBr): νmax = 3334 (s) (OH), 2872 (s) (CH2, CH3), 
1720 (s) (C=O), 1507 (m) (NH), 1247 (m) (C-O) cm-1; LRMS (ES+) m/z (%): 816.20 (60) 
[M+H]+; HRMS (ES+): m/z calcd for C43H54N5O11 [M+H]+: 816.3742; found 816.3775; [α]20D 
= -104.3 (c = 0.00015, DCM) 
(1-(4-((5R,11aS)-5-(3-hydroxyphenyl)-1,3-dioxo-11,11a-dihydro-1H-imidazo[1',5':1,6] 
pyrido[3,4-b]indol-2(3H,5H,6H)-yl)phenyl)-1-oxo-5,8,11,14,17-pentaoxa-2-azanonadeca
n-19-yl)carbamate (73) 
 
72 (0.15 g, 0.16 mmol, 1.0 eq) was dissolved in 1 mL TFA and rotated for 5 mins. TFA was 
removed to yield 73 as a dark red oil. 1H NMR (400 MHz, CDCl3) δ 7.86 (d, 2H, 3J = 8.7, 
H3’, H6’), 7.45-7.51 (m, 3H, H10, H2’, H7’), 7.08-7.26 (m, 4H, H8, H9, H5”, H7), 
6.80-6.91 (m, 3H, H4”, H2”, H6”), 6.30 (s, 1H, H5), 4.60 (dd, 1H, 3J= 10.3 5.8 Hz, H11a), 
3.37-3.63 (m, 17H, H9’, H10’ x 10, H11’, 11syn), 2.93-3.05 (m, 1H, H11anti). This product 
was submitted to the next step without purification.  
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Synthesis of tert-butyl CID (74) 
 
73 (0.15 g, 0.16 mmol, 1.0 eq) was taken up in anhydrous DMF (5 mL), TPTU (0.05 g, 0.16 
mmol, 1.0 eq) and DIPEA (1 mL, 6.40 mmol, 40.0 eq) and a solution of 47 (0.10 g, 0.16 
mmol, 1.0 eq) in anhydrous DMF (5 mL) was added. Mixture was stirred at room 
temperature for 3 days. Solvent was reduced to yield a brown solid. The product was purified 
by column chromatography over silica gel (eluent 0-10% MeOH in DCM) to give a bright 
yellow solid (0.15 g, 0.12 mmol, 65%). Mp: 74.1-75.5 ºC; 1H NMR (400 MHz, (CD3)2SO) δ 
10.97 (s, 1H, NH), 9.50 (s, 1H, OH), 8.56 (s, 1H, H34’), 8.24 (d, 1H, 3J = 7.7 Hz, H16’), 
7.77 (d, 2H, 3J = 8.4 Hz, H2’, H7’),7.71 (d, 2H, 3J = 8.4 Hz, H3’, H6’), 7.51-7.58 (m, 3H, H7, 
H19’, H23’), 7.31 (d, 1H, 3J = 7.7 Hz, H10), 7.17 (dd, 1H, 3J = 7.7 7.7 Hz, H5”,), 7.10 (dd, 
1H, 3J = 7.7 7.0 Hz, H9), 7.03 (dd, 1H, 3J = 7.7 7.0 Hz, H8), 6.72-6.84 (m, 5H, H6”, H2”, 
H4”, H20’, H22’), 6.20 (s, 1H, H5), 4.77 (s, 2H, H26’), 4.70 (dd, 1H, 3J = 5.6 10.5 Hz, 
H11a,), 4.16-4.23 (m, 1H, H15’), 3.06-3.66 (m, 26H, H8’, H9’ x 10, H10’, H11anti, H11syn), 
3.20 (s, 3H, H25’), 2.11-2.24 (m, 2H, H13’), 1.82-2.04 (m, 2H, H14’), 1.37 (s, 9H, H38’). 
13C NMR (100 MHz, (CD3)2SO) δ 172.1 (C12’), 171.6 (C1), 171.5 (C17’), 171.3 (C35’), 
166.2 (C5’), 165.5 (C4’), 164.1 (C29’), 162.9 (C31’), 162.6 (C3”), 157.6 (C32a’), 152.8 (C3), 
150.8 (C1’), 149.0 (C34’), 141.05 (C1”), 136.6 (C27’), 134.2 (C6a), 133.5 (C18’), 130.9 
(C5a), 129.7 (C5”), 128.8 (C3’, C6’), 127.5 (C19’, C23’), 126.2 (C2’, C7’), 125.7 (C10a), 
121.7 (C9), 121.1 (C21’), 118.8 (C8), 118.6 (C7), 118.2 (C6”), 115.2 (C28a’), 115.1 (C2”), 
114.9 (C4”), 111.3 (C10), 110.9 (C20’, C22’), 106.0 (C10b), 80.21 (C37’), 68.8-69.7 (C8’ 
C9’ x 10, C10’), 54.8 (C26’), 53.4 (C15’), 52.9 (C11a), 51.6 (C5), 39.5 (C25’), 31.7 (C13’), 
27.6 (C38’), 26.4 (C14’), 22.5 (C11). IR (KBr): νmax = 3449 (s) (OH, NH2), 1715 (s) (C=O), 
1509 (m) (NH), 1364 (s) (OH), 1224 (s) (C-O), 1093 (s) (C-O) cm-1. LRMS (ES+) m/z (%): 
1230.76 (100) [M+Na]+, 1208.87 (80%) [M+H]+; HRMS (ES+): m/z calcd for 
C62H73N13O13Na [M+H]+: 1230.5451; found 1230.5484.   
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Synthesis of CID (44) 
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34 (0.15 g, 0.12 mmol, 1.0 eq) was dissolved in 3 mL DCM, TFA 50 μL was then added. 
Solution was stirred at room temperature for 5 hours, solvent was reduced to yield a yellow 
solid. The product was purified by column chromatography over silica gel (eluent 0-30% 
MeOH in DCM) to give a bright yellow solid (0.07 g, 0.065 mmol, 55%). Mp: 76.5-77.0 ºC. 
1H NMR (400 MHz, (CD3)2SO) δ 10.97 (s, 1H, NH), 9.50 (s, 1H, OH), 8.56 (s, 1H, H34’), 
8.24 (d, 1H, 3J = 7.4, H11’), 7.96 (d, 2H, 3J = 8.8 Hz, H3’, H6’), 7.74 (d, 2H, 3J = 8.8 Hz, 
H2’, H7’), 7.53-7.60 (m, 3H, H7, H19’, H23’), 7.31 (d, 1H, 3J = 8.1 Hz, H10,), 7.17 (dd, 1H, 
3J = 7.7 7.7 Hz, H5”), 7.13 (dd, 1H, 3J = 7.6 8.1 Hz, H9,), 7.03 (dd, 1H, 3J = 7.4 7.6 Hz, H8), 
6.72-6.84 (m, 5H, H6”, H2”, H4”, H20’, H22’), 6.23 (s, 1H, H5), 4.79 (s, 2H, H26’), 4.72 
(dd, 1H, 3J = 5.6 10.5 Hz, H11a), 4.26-4.33 (m, 1H, H15’), 3.26-3.66 (m, 26H, H8’, H9’ x 10, 
H10’, H11syn), 3.22 (s, 3H, H25’), 3.09 (m, 1H, 11anti), 2.18-2.24 (m, 2H, H13’), 1.87-2.09 
(m, 2H, H14’). 13C NMR (100 MHz, (CD3)2SO) δ 173.8 (C12’), 171.8 (C17’), 171.6 (C1), 
171.4 (C35’), 166.2 (C5’), 165.5 (C4’), 164.1 (C29’), 162.9 (C31’), 162.8 (C3”), 157.7 
(C32a’), 155.2 (C28a’), 153.0 (C3), 151.0 (C1’), 149.2 (C34’), 141.2 (C1”), 136.8 (C27’), 
134.4 (C6a), 133.7 (C18’), 131.1 (C5a), 129.8 (C5”), 128.9 (C3’, C6’), 127.7 (C19’, C23’), 
22.6 (C11), 26.6 (C14’), 32.0 (C13’), 38.5 (C25’), 51.7 (C5), 52.3 (C11a), 52.9 (C15’), 54.9 
(C26’), 126.3 (C2’, C7’), 125.8 (C10a), 121.7 (C9), 121.2 (C21’), 118.9 (C6”), 118.6 (C8), 
118.3 (C7), 115.2 (C2”), 115.0 (C4”), 111.5 (C10), 111.1 (C20’, C22’), 106.1 (C10b), 
68.8-69.7 (C8’, C9’ x 10, C10’). IR (KBr): νmax = 3433 (s) (OH, NH2), 2925 (m) (CH2), 1638 
(s) (sec. amide), 1421 (m) (OH), 1204 (s) (C-O), 1099 (s) (C-O) cm-1. LRMS (ES-) m/z (%): 
1150.57 (100) [M-H]-; HRMS (ES-): m/z calcd for C58H64N13O13 [M-H]-: 1150.4825; found 
1150.4858. 
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1-Bromobutane-2,3-dione (89)187 
 
Butane-2,3-dione (88) (5.00 g, 58.1 mmol, 1.0 eq) in CHCl3 (10 mL) was added to copper (II) 
bromide (13.0 g, 58.1 mmol, 1.0 eq) in CHCl3 (10 mL). 18-crown-6 (0.04 g, 0.15 mmol, 
0.002 eq) was then added and the reaction heated at reflux with stirring for 60 h. After 
cooling to room temperature, the reaction was filtered and the filtrate decolourized using 
activated charcoal. After removal of the solvent by distillation, the residue was purified by 
distillation under vacuum giving the desired product 89 as a yellow oil (3.53 g, 21.4 mmol, 
37%); 1H NMR (300 MHz, CDCl3): δ 4.30 (s, 2H, H1), 2.43 (s, 3H, H4); 13C NMR (75 MHz, 
CDCl3): δ 195.7 (C2), 189.2 (C3), 28.7 (C1), 24.3 (C4); LRMS (ES+) m/z (%): 164.94 (100) 
[M+H]+; 
2-(Bromomethyl)-3-methylquinoxaline (90)212 
 
A solution of 1-bromo-2,3-butanedione (89) (3.45 g, 20.9 mmol, 1.0 eq) in anhydrous THF 
(10 mL) was added to a solution of 1,2-phenylene diamine (2.37 g, 22.0 mmol, 1.1 eq) in 
anhydrous THF (35 mL) at 0 °C over 15 mins. The reaction was then warmed to room 
temperature and stirred for a further 17 h. After removal of the solvent in vacuo, the crude 
reaction mixture was partitioned between 10% [wt/vol] sodium hydrogen carbonate solution 
(50 mL) and DCM (100 mL). The organic phase was washed with brine (50 mL), dried 
(MgSO4) and concentrated in vacuo to give a brown solid. Purification by flash column 
chromatography on silica gel (ethyl acetate:PE 40-60, 1:9) gave the desired product 90 as a 
white crystalline solid (1.82 g, 7.83 mmol, 37%); Mp: 120-121 °C (lit. 119-120 °C); 1H 
NMR (300 MHz, CDCl3): δ 7.98-7.91 (m, 2H, H8, H5), 7.69-7.60 (m, 2H, H6, H7), 4.67 (s, 
2H, 1’), 2.80 (s, 3H, H2’); LRMS (ES+) m/z (%): 236.99 (100) [M+H]+; 
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Conoidin B, 2-(Bromomethyl)-3-methylquinoxaline 1,4-dioxide (87)213  
1 2
34N
N
Br
5
6
7
8
O
O  
Purified mCPBA (1.86 g, 10.8 mmol) was added to a solution of 90 (0.50 g, 2.15 mmol) in 
anhydrous DCM (20 mL) at room temperature. After 20 h the reaction mixture was diluted 
with DCM (20 mL) and washed with 10% [wt/vol] aqueous sodium carbonate solution (2 × 
20 mL). The aqueous washings were extracted with DCM (2 × 20 mL) and the organic phase 
dried (MgSO4) and concentrated in vacuo to give a yellow solid.  Purification by flash 
column chromatography on silica gel (ethyl acetate:PE 40-60, 1:1 to 1:0) gave the desired 
product 87 as a bright yellow crystalline solid following recrystallisation from ethyl acetate 
(0.29 g, 1.08 mmol, 50%);  mp 171.0-172.0 ˚C (lit. 172-173 ˚C). 1H NMR (300 MHz, 
CDCl3): δ  8.64-8.61 (m, 2H, H5, H8), 7.89-7.80 (m, 2H, H6, H7), 4.89 (s, 2H, H2), 2.78 (s, 
3H, H3); LRMS (ES+) m/z (%): 293.93 (100) [M+Na]+.  
2-(Bromomethyl)-3-methylquinoxaline 4-oxide (91)  
 
Purified mCPBA (0.15 g, 0.84 mmol, 1.0 eq) was added to a solution of 90 (0.20 g, 0.84 
mmol, 1.0 eq) in anhydrous DCM (5 mL) at room temperature. After 20 h the reaction 
mixture was diluted with DCM (5 mL) and washed with 10% [wt/vol] aqueous sodium 
carbonate solution (2 × 5 mL).  The aqueous washes were extracted with DCM (2 × 5 mL) 
and the combined organic extracts dried (MgSO4) and concentrated in vacuo to give a yellow 
solid.  Purification by flash column chromatography on silica gel (ethyl acetate:PE 40-60, 
1:1 to 1:0) gave an inseparable mixture of the desired compound 6 and 7 in an approximately 
6:1 ratio. Recrystallization from ethyl acetate gave the desired compound 6 as a pale white 
crystalline solid (0.29 g, 1.08 mmol, 50%); Mp: 182.0-183.0 °C. IR (NaCl) νmax= 1506 (w), 
1341 (m) (N–O), 1328 (m) (N–O), 1065 (m), 774 (m) (ArC–H), 629 (m) (C–Br) cm-1; 1H 
NMR (300 MHz, CDCl3): δ 8.64-8.61 (m, 2H, H5, H8), 7.89-7.80 (m, 2H, H6, H7), 4.56 (s, 
2H, H2), 2.78 (s, 3H, C3); 13C NMR (75 MHz, CDCl3): δ 141.2 (C1a), 140.0 (C3a), 137.4 
(C8a), 136.8 (C4a), 132.2 (C5), 131.5 (C8), 120.5 (C6), 120.2 (C7), 31.1 (C2), 14.2 (C3); 
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LRMS (ES+) m/z (%): 274.91 (100) [M + Na]+; HRMS (ES+): calcd for C10H9BrN2O 
[M+Na]+:251.9898, found 251.9898.  
2,3-Bis(methyl)-quinoxaline (93)214 
 
1,2-Phenylenediamine (5.00 g, 46.2 mmol, 1.0 eq) and butane-2,3-dione 88 (4.04 ml, 46.2 
mmol, 1.0 eq) were dissolved in acetic acid (100 mL) and the reaction refluxed for 1.5 hours. 
The reaction mixture was then poured into ice water and partitioned between 10% [wt/vol] 
sodium carbonate (200 mL) and DCM (200 mL). The aqueous layer was extracted with 
DCM (3 x 100 mL) The organic phase was dried (Na2SO4) and concentrated in vacuo to 
yield a brown solid that was recrystallized from hexane to give the desired compound 93 as 
light brown crystals (6.58 g, 41.62 mmol, 90%). Mp: 132-133 °C (lit. 131-133 °C); 1H NMR 
(400 MHz, CDCl3): δ 7.95 (m, 2H, H5, H8), 7.65 (m, 2H, H6, H7), 2.72 (s, 6H, H2, H3); 
LRMS (ES+) m/z (%): 181.20 (100) [M + Na]+;  
2,3-Bis(methyl)-quinoxaline 1-oxide (94) 
 
To a solution of 93 (1.00 g, 6.32 mmol, 1.0 eq) in anhydrous DCM (20.0 mL) was added 
purified mCPBA (1.09 g, 6.32 mmol, 1.0 eq). The reaction was then stirred at room 
temperature for 20 h, diluted with DCM (20 mL) and the organic phase washed with 10% 
[wt/vol] sodium carbonate solution (3 × 20 mL). The organic phase was dried (MgSO4), 
filtered and concentrated in vacuo to give a yellow solid. Purification by flash column 
chromatography on silica gel (ethyl acetate:PE 40-60, 1:19 to 1:9) the desired compound 94 
as a white crystalline solid (0.72 g, 4.10 mmol, 65%); Mp: 100-101 °C: IR (NaCl) νmax= 
1560 (w), 769 (m) (ArC–H) cm-1; 1H NMR (400 MHz, CDCl3): δ 8.56 (d, 3J= 8.0, 1H, H8), 
8.02 (d, 3J= 8.3, 1H, H5), 7.67-7.78 (m, 2H, H6, H7), 2.78 (s, 3H, H3), 2.68 (s, 3H, H2); 13C 
NMR (100 MHz, CDCl3) δ 155.0 (C3a), 142.8 (C1a), 139.6 (C4a), 135.5 (C8a), 130.6 (C7), 
129.2 (C5), 118.8 (C8), 116.3 (C6), 23.9 (C3), 13.9 (C2); LRMS (ES+) m/z (%) 175.20 (100) 
[M+H]+; HRMS (ES+): calcd for C10H11N2O [M+H]+:175.0793, found 175.0812.  
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2,3-Bis(methyl)-quinoxaline 1-oxide (92)  
1 2
34N
N
5
6
7
8
O
Br
 
To a solution of 94 (0.50 g, 2.87 mmol, 1.0 eq) in anhydrous DCM (20.0 mL) was added 
bromine (0.41 g, 2.58 mmol, 0.9 eq). The reaction was then heated at reflux for 2 hrs, cooled 
and washed with 10% [wt/vol] sodium thiolsulfate (3 × 20 mL). The organic phase was dried 
(MgSO4), filtered and concentrated in vacuo to give a pale yellow solid.  Purification by 
flash column chromatography on silica gel (ethyl acetate:PE 40-60, 1:19 to 1:9) gave the 
desired product 92 as a pale yellow solid (0.54 g, 2.15 mmol, 75%). Mp: 117-118 ˚C; IR 
(NaCl) νmax= 1506 (w), 1341 (m) (N–O), 1065 (m), 774 (m) (ArC–H), 629 (m) (C–Br) cm-1; 
1H NMR (400 MHz, CDCl3): δ 8.92 (d, 3J = 8.0, 1H, H8), 8.02 (d, 3J = 8.3, 1H, H5), 
7.67-7.78 (m, 2H, H6, H7,), 4.78 (s, 2H, H2), 2.68 (s, 3H, H3); 13C NMR (100 MHz, CDCl3) 
δ 163.0 (C1a), 142.8 (C8a), 139.6 (C3a), 135.5 (C4a), 130.6 (C7), 129.2 (C6, C5), 118.8 
(C8), 45.8 (C2), 13.9 (C3); LRMS (ES+) m/z (%) 252 (100) [M + H]+; HRMS (ES+): calcd 
for C10H10BrN2O [M+H]+: 252.9898, found 252.9900. 
4.3 Biological experimental.  
The glutamine synthetase (GS) protection assay202 
rTgPrxII was recombinantly expressed in E.coli with a His-tag and purified by Ni affinity 
chromatography (elution buffer: 250 mM imidazole, 50 mM sodium dihydrophosphate, 300 
mM NaCl, protease inhibitors, pH 8.5). 1 μL of commercially available GS (0.5 units), 
varying amount of a rTgPrxII stock solution (prepared by dilution of a 0.37 mM stock to 
7.43 μM using 100 mM Hepes, pH 7.4) and 3 μL of inactivation solution (100 mM DTT, 50 
μM FeCl3, 100 mM Hepes, pH 7.4) were mixed and brought up to a final volume of 20 μL 
using 100 mM Hepes. This mixture was incubated at 30º C for 20 minutes. 150 μL of 
starting solution (100 mM Hepes, 10 mM KAsO4, 20 mM NH2OH, 0.4 mM ADP, 0.5 mM 
MnCl2, 100 mM glutamine, pH 7.0-7.2) was then added and the incubation was continued at 
30ºC for an additional 30 minutes. Reactions were terminated by incubation with 100 μL of 
stopping solution (5.5% [wt/vol] FeCl3•6H2O, 2% [wt/vol] TCA, 2.1% [vol/vol] 
concentrated HCl) for 5 minutes, after which the absorption at 540 nm was measured and 
normalised. These assays determined that the optimum amount of rTgPrxII in the assay is 1.2 
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μg, as this quantity of rTgPrxII protects GS from inactivation to a reasonably high level 
while still resulting in a linear correlation between rTgPrxII activity and GS activity.   
IC50 Determination 
In initial studies, 29 and its analogues and the solvent vector (acetonitrile) were tested to 
determine whether they inhibited GS activity directly. No inhibitory effect on GS was 
observed.  Solutions (0.005 mM, 0.01 mM, 0.05 mM, 0.1 mM, 0.5 mM, 1 mM, 2 mM, 10 
mM, gave the preincubation concentration of 0.312 μM, 0.625μM, 3.125 μM, 6.25 μM, 
31.25 μM, 62.5 μM, 0.312 mM, 0.625 mM, respectively.) of compound were prepared in 
acetonitrile. 3 μL of a rTgPrxII stock solution (15 μM) was added to 12 μL of 100 mM 
Hepes buffer (pH 7.4). 1 μL of the appropriate concentration of compound was added and 
the assay was incubated at room temperature for 5 minutes. 1 μL of GS solution and 3 μL of 
inactivation solution were then added and the mixture was incubated at 30° C for an 
additional 20 minutes. 150 μL of starting solution was added and after further incubation at 
30° C for 30 minutes, the reaction was terminated by incubation with 100 μL of stop solution 
for 5 minutes. The remaining GS activity was determined by measuring the absorbance at 
540 nm and the results were normalized into remaining percentage activity. The IC50 was 
calculated using Prism® software (IC50 curves, see Appendix).  
Electrospray ionisation mass spectrometric time course analysis of the reaction of 
rTgPrxII with 29 
19 μL of 18.6 μM (final concentration of 17.7μM) rTgPrxII and 1 μL of a 1 mM (final 
concentration of 50 μM in assay) stock solution of 2 in acetonitrile were incubated for 
various times from 5 to 30 minutes and analysed by LC-MS.  Samples were desalted 
on-line through a MassPrep On-Line Desalting Cartridge 2.1 x 10 mm, eluting at 50 L/min, 　
with an increasing acetonitrile concentration (from 2% acetonitrile, 98% aqueous 1% formic 
acid to 98% acetonitrile, 2% aqueous 1% formic acid) and delivered to an electrospray 
ionisation mass spectrometer (LCT, Micromass, Manchester, U.K.) that had previously been 
calibrated using myoglobin. Only covalently bound complexes were expected to survive the 
chromatography and ionisation conditions used.  
Mapping the site of rTgPrxII modification by 29 
rTgPrxII and the rTgPrxII:29 complex, generated as described above, were digested with 
trypsin (0.3 μL, 60 ng) at 37 °C overnight. The resultant peptides were acidified prior to 
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desalting and concentrated using a micro C18 column (0.2 L ZipTip, Millipore, 
Gloucestershire, U.K.) according to the manufacturer’s instructions. The peptides were 
eluted directly from the tip onto the target in 1.5 L alpha-cyano-4-hydroxycinnamic acid (10 
mg/mL in 50:50 acetonitrile:0.1% TFA). MALDI-MS and MS/MS was acquired using a 
4800 MALDI-TOF/TOF Analyzer (Applied Biosystems, Foster City, CA) equipped with a 
Nd:YAG 355 nm laser and calibrated using a mixture of peptides. The spot was initially 
analysed in positive MS mode over the range 800 to 4000 m/z by averaging 1000 laser spots.  
MSMS spectra were acquired to a maximum of 3000 laser shots or until the accumulated 
spectrum reached a S/N ratio of 35 for 10 peaks. All MSMS data were acquired using 1keV 
collision energy. 
Construction of the TgPrxII model 
Sequence alignment of T. gondii peroxiredoxin-2 (TgPrxII) and human peroxiredoxin-6 
(human Prx-6) with ClustW215 revealed that the two proteins share 54% sequence identity. 
The secondary structural elements alignment with human Prx-6 crystal structure (Protein 
data bank code: 1PRX) was performed with ESPript 2.2,216 which indicates that both 
proteins present a very similar 3D-structure. The initial model of TgPrxII was built with the 
SWISS-MODEL server using the human Prx-6 as the structural homologue. Refinement of 
the model was performed with the Refmac5 Structure Idealization program in the 
Collaborative Computational Project Number 4 (CCP4) programs suite.217 The final TgPrxII 
model structure was validated with MolProbity218.   
Covalent docking with GOLD  
PDB files of the three compounds (29, 87 and 98) were generated from the PRODRG 
server.219 The genetic algorithm (GA) docking program Cambridge Crystallographic Data 
Centre (CCDC) GOLD v4.01220 was used to dock the three compounds to the proposed 
catalytic cavity of the TgPRxII model structure. The highest scoring poses of the three 
compounds were all found to place the inhibitor in a very similar orientation in the TgPrxII 
binding cavity. All pictures related to the Prx-2 model structures were draw with PyMol. 
General procedure for competition experiment with the model thiol.  
To a solution of two analogues (0.1 mmol, final concentration 1.3 x 10-4 mmol/L each) in 
neutral CHCl3 (0.7 ml) was added a sub-stoichiometric amount of methyl mercaptoacetate 
(0.91 μL, 0.1 mmol, final concentration 1.3 x 10-4 mmol/L) and triethylamine (29.3 l, 0.2　 0 
Chapter 4 
                                                                                                     
93
mmol, 2.6 x 10-4 mmol/L). After stirring at room temperature for 30 minutes, the reaction 
mixture was then submitted for 1H NMR analysis. The rate of the reaction was compared via 
integration of the signals remaining for each starting material. (Spectra see Appendix). 
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Chapter 5: Introduction to Oxidative Fragmentation  
5.0 Introduction 
The aim of this chapter is to provide an overview of oxidative fragmentation methodology, 
with an emphasis on the use of oxidative fragmentation reactions for the synthesis of 
medium-sized ring systems (8-11 ring atoms). Excellent reviews of oxidative fragmentation 
have been published previously,221-223 and the details of these strategies in medium-sized ring 
synthesis have been presented in a PhD thesis from within the group.224 It was therefore 
decided to present here some interesting examples that represent the concept of oxidative 
fragmentation. Asymmetric epoxidation can be considered as a possible means of initiating 
asymmetric oxidative fragmentation reactions as discussed in Chapter 7 of this thesis. 
Therefore, asymmetric epoxidation will also be discussed in detail in this chapter. 
5.1 Medium-sized ring system 
The synthesis of medium-sized ring systems, which often refers to cyclic compounds having 
a ring size in the range of 8 to 11 (however, sometimes, 7 and 12 membered rings are also 
included), remains an important challenge in organic synthesis, especially by cyclisation. 
Attempts to connect the termini of an 8-11 atom chain are complicated by several issues that 
influence the rate of cyclisation such as: 1) torsional effects in single bonds (Pitzer strain) 
due to eclipsing interactions; 2) deformation of ring bond angles from their preferred values 
(Baeyer or I strain); 3) transannular strain (non-bonded interactions) which occurs when 
atoms across the ring are forced into close proximity; and 4) loss of entropy of the system. 
Therefore, chemists are required to develop new and improved methods to overcome these 
problems. There are several excellent reviews on alternative methods for the synthesis of 
medium-sized ring systems.221-223,225-230 However, the focus in part II of this thesis is on the 
use of oxidative fragmentation for the conversion of bicyclic ring systems to medium-sized 
ring containing systems. 
5.2 Oxidative fragmentation approaches for medium-sized ring synthesis 
Oxidative fragmentation is a useful technique in organic synthesis, which can rapidly convert 
one chemical skeleton into another more complex skeleton. In its simplest terms oxidative 
fragmentation oxidises alkene derivatives to obtain two carbonyl containing-fragments 
(Scheme 5.1).  
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Scheme 5.1 Oxidative cleavage of alkenes.  
Oxidative fragmentation reactions can be broadly classified as those involving: (i) in situ 
formation of a 1,2-diol and the resulting oxidative cleavage of the metallate ester (ii) Grob 
fragmentation of peroxyesters and (iii) ozonolysis. 
5.2.1 in situ formation of a 1,2-diol and the resulting oxidative cleavage of the metallate 
ester  
 
Scheme 5.2 Oxidative cleavage of in situ formed 1,2-diols.  
1,2-Diols are cleaved easily under oxidative conditions in good yield. The formation of 
1,2-diols can be achieved in situ using osmium(VIII) tetroxide. The fragmentation of alkene 
groups can also be achieved using sodium periodate or lead tetraacetate with catalytic 
amounts of osmium(VIII) tetroxide to form the 1,2-diol intermediate. The success of this 
reaction is because the osmium(VI) can be re-oxidised from its lower oxidation states back to 
the osmium(VIII) tetroxide, after its addition to the alkene and hydrolysis of the intermediate 
ester. An additional advantage is that this method avoids using large amount of the expensive 
and toxic osmium reagent.231  
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Scheme 5.3 Oxidative fragmentation towards the model study of the synthesis of the AB ring of taxol (107).232 
An interesting example of this type of oxidative fragmentation can be seen in the model 
study of the AB-ring core synthesis of taxol (107) (Scheme 5.3).232 In this study, 102 was 
submitted to a osmium(VIII) oxide catalysed dihydroxylation reaction to yield syn-diol 104, 
followed by treatment with lead tetraacetate to obtain the 8 membered ring intermediate 105 
which is a key intermediate in construction of the model AB ring of taxol (107) excellent 
yield.  
5.2.2 Grob fragmentation (m-CPBA) 
The Grob fragmentation reaction, is a heterolytic fragmentation, which forms three 
fragments as shown in Scheme 5.4. Molecules which contain certain combinations of carbon 
and heteroatoms can undergo this type of fragmentation reaction. Ideally the nucleophilic 
heteroatoms with negative charge or an unshared lone pair and a leaving group are in a 
1,3-relationship to allow the fragmentation occur.233 m-CPBA mediated oxidative 
fragmentations are considered to be one example of the Grob fragmentation. Therefore, for 
m-CPBA mediated oxidative cleavage, a = OH, b = C, c = C, d = O and X = CO2Ar. 
 
Scheme 5.4 The Grob fragmentation employs the concept of fragmentation of a 1,3-diheterofunctionalised 
compound. 
An interesting example of the m-CPBA mediated Grob fragmentation was published by Fink 
et al. (Scheme 5.5).234 Tetrahydrodibenzazocine (110) was identified as a potent 
17β-hydroxysteroid dehydrogenases (17β-HSDs) inhibitor.234 The key step in the synthesis 
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of 110 is the formation of the eight-membered ring. m-CPBA was employed in the oxidative 
fragmentation reaction to furnish 109 in good yield.  
 
Scheme 5.5 m-CPBA mediated Grob fragmentation of 108 to obtain 109 which is a key intermediate in the 
synthesis of 110.  
5.2.3 Ozonolysis 
Ozonolysis is often a clean and effective method for oxidative cleavage of double bond and, 
has been used extensively in both academic and industrial environments. The mechanism of 
ozonolysis reaction has been thoroughly studied and the Criegee mechanism (Scheme 5.6) is 
the most wildly accepted mechanism proposal.235-237  
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Scheme 5.6 Criegee mechanism of ozonolysis. 
As it is shown in Scheme 5.6, ozone adds to alkene C=C double bond to form a very unstable 
primary ozonide which subsequently rearranges to form the relatively stable secondary 
ozonide. On subsequent reductive or oxidative workup, the secondary ozonide can afford a 
wide variety of products. Reductive workups can lead to aldehydes, ketones, or alcohols; 
oxidative workup can afford ketones or carboxylic acids.  
An interesting example of using ozonolysis to afford a medium-sized ring motif has been 
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published by Perez-Sacau and colleagues.238 In order to study the SAR of naphthoquinone 
derivatives as cytotocics against a human Leukemia HL-60 cell line, a large number of 
analogues were required. By using oxidative fragmentation with ozone, it was possible to 
cleave the enolic double bond in 121 to afford 122 which contains medium-sized ring 
functionality in one step with good yield (Scheme 5.7).  
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Scheme 5.7 Ozonolysis of 121 to afford medium-sized ring system 122 in one step.  
5.3 Asymmetric epoxidation 
The asymmetric epoxidation of olefins has raised great interest in the synthetic organic 
chemistry community over the years as the resulting enantiomerically pure epoxides provide 
useful building blocks and intermediates.239-243 The first practical methods for asymmetric 
epoxidation was published by K. B. Sharpless and T. Katsuki in the early 1980s, and this 
work along with pioneer work of asymmetric dihydroxylation has been rewarded by the 
Nobel Prize in chemistry.244 Since then, the area of asymmetric epoxidation has continued to 
be studied extensively and many outstanding reviews have been published previously and the 
reader is directed to these for a more in-depth discussion.239-243,245-248 Therefore, in this 
section of the thesis, a brief overview of the available methods and some interesting 
examples for the most useful methods are provided.  
5.3.1 Metal catalysed asymmetric epoxidation  
The development of chiral metal catalysts which can catalyse the asymmetric epoxidation 
has required considerable research efforts. Among these catalysts, the most well known 
method is the titanium tartrate complexes used in the Sharpless epoxidation of allylic 
alcohols.244 In the early 1990s, both Jacobsen and Katsuki reported the efficient asymmetric 
epoxidation of unfunctionalised alkyl or aryl substituted olefines, especially cis olefins, using 
Mn(salen) complex.249,250 Further development of the asymmetric epoxidation reaction raises 
environmental issues as the existing methods require non-atom efficient reagents as oxidants. 
Therefore, recent studies are more interested in developing catalysts which can perform 
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asymmetric epoxidation using hydrogen peroxide as the oxidant, as hydrogen peroxide only 
generates water as a ‘waste’ product during the reactions. However, due to the instability of 
some transition metal complexes (Ti, Mo, V complex) in the presence of hydrogen peroxide 
and the rapid rate of decomposition of hydrogen peroxide by Ru and Mn, until the early 
2000s the results were rather disappointing.251-254 In the latest 5 years, the Ti254-256 and 
Ru257-259 complexes reported by Kastuki and Beller have significantly improved this 
situation.  
5.3.1.1 Sharpless asymmetric epoxidation  
Ti(IV)-alkoxide catalysed asymmetric epoxidation of allylic alcohols in the presence of 
optically active diethyl tartrate (DET) and tert-butyl hydroperoxide (TBHP) to give 
enantiopure 2,3-epoxy alcohols is known as the Sharpless asymmetric epoxidation (Scheme 
5.8).244 This method shows high enantio selectivity for allylic alcohols and the epoxidation is 
totally reagent controlled. By using (+) or (-) DET, the corresponding enantiomers can be 
prepared. The enantioselectivity can be predicted for all allylic alcohols. The all important 
Ti(IV) complex only shows high catalytic efficiency under anhydrous conditions. In addition, 
in order to achieve high enantiomeric excess, the catalyst has to be freshly prepared for each 
reaction. Except for the presence of free amines, carboxylic acids, thiols and phosphines, this 
reaction tolerates most functional groups.260 
 
Scheme 5.8 Schematic rationalisation of the series of asymmetric approach in the Sharpless asymmetric 
epoxidation reaction.  
 
An interesting application of the Sharpless asymmetric epoxidation (SAE) reaction can be 
found in the total synthesis of (-)-laulimalide (126) (Scheme 5.9).261 The last key step of this 
total synthesis is to form the C16-C17 epoxide selectively. The success of the total synthesis 
is dependent on the efficient kinetic difference between the C15 and C20 allylic alcohols 
during the epoxidation. In the presence of (+)-DIPT (diisopropyltryptamine, used instead of 
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DET) at -27 °C, only the C16-C17 epoxide was formed with excellent regioselectivity and 
e.e..261  
 
Scheme 5.9 Sharpless asymmetric epoxidation used as a key step in the total synthesis of (-)-laulimalide (126).  
5.3.1.2 Jacobsen-Katsuki epoxidation 
Enantioselective epoxidation of unfunctionalised alkyl- and aryl-substituted olefins using 
chiral (salen)Mn(III) complexes as the catalyst is known as the Jacobsen-Katsuki 
epoxidation.249,250,262-268 The chiral salen ligands can be easily prepared by the condensation 
of chiral diamines and a substituted hydroxybenzaldehyde. The enantioselectivity is 
dependent on the structure of the olefins, the nature of the axial donor ligand on the activated 
oxo-manganese species and the reaction temperature. In general, Z olefins are better 
substrates than E olefins, and 1,2-disubstituted olefins are better substrates than terminal 
olefins. Various oxidants can be used in this reaction, however, some of them require lower 
reaction temperatures than others. Addition of a Lewis base to the reaction mixture can 
increase the catalyst turnover rate and number and also increase the yield of the 
reaction.249,250,262-268 The mechanism of the Jacobsen-Katsuki epoxidation is not yet fully 
understood, however, chemists are most likely to believe that a Mn(V) species 129 is the 
reactive intermediate.263,267,268 
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Figure 5.1 A) The Jacobsen-Katsuki epoxidation; B) Jacobsen’s catalysts 131; C) Katsuki’s catalysts 132.  
In the synthesis of the tetrasubstituted dihydroquinoline portion of siomycin D1 (133), the 
Jacobsen oxidation was performed to obtain the epoxide enantioselectively at the C7-C8 
position (Scheme 5.10).269 5 mol% of Jacobsen’s Mn(III)-salen catalyst (131, R= t-Butyl) 
was used with 4% aqueous NaOCl solution as the oxidant. In order to increase the catalyst 
turnover, 4-phenylpyridin-N-oxide was added. This reaction allowed the desired epoxide be 
obtained with excellent e.e. in moderate yield.269 
 
Scheme 5.10 Jacobsen epoxidation was performed in the synthesis of the tetrasubstituted dihydroquinoline 
portion of siomycin D1 (133) 
5.3.1.3 Asymmetric epoxidation catalysed by Ti(salen) complex using hydrogen 
peroxide as oxidant. 
The Ti complex, which uses hydrogen peroxide as an oxidant, is considered to be a 
significant development in the searches for an environmentally friendly asymmetric 
epoxidation reaction.255,256 Catalyst 136 is a chiral di-μ-oxo titanium half reduced salen 
complex, which can be prepared using an in situ Meerwein-Ponndorf-Verley reduction. This 
complex has a homochiral configuration, and is stable as a dimeric structure in methanol 
Chapter 5 
                                                                                                     
103
over 24 hours. In the presence of hydrogen peroxide, the active species for 136 is believed to 
be a monomeric peroxotitanium species 138, and the peroxy-functionality in 138 is likely 
activated by the intramolecular hydrogen bonding with the amine proton (Figure 5.2).255,256  
 
Figure 5.2 Chemical structure of Ti complexes 136, 137, and the proposed active species 138. 
However, due to the complexity of the structure of 136, the synthesis of this catalyst is time 
consuming. In order to improve the situation, catalyst 137 was developed. Catalyst 137 can 
be easily obtained in situ from Ti(OiPr)4 and the salen ligand with comparable 
enantioselectivity to 136, although the catalyst 137 is less robust than 136.255,256 For example, 
in the epoxidation of 139, both 136 and 137 showed excellent e.e. although the yield of the 
reaction using 136 as catalyst was slightly higher than for the reaction using 137 as 
catalyst.255,256  
O
H2O2, catalyst
DCM, r.t. 24 hrs
139 140  
Cat Cat. Loading (mol%) 
Equivalents of 
H2O2 
Yield (%) 
Epoxide 
ee (%) 
Epoxide  
13635 1 1.05 99 99 
137256 1 1.5 87 96 
Table 5.1 Ti complex 136 and 137 in the asymmetric epoxidation reaction of 139.  
5.3.1.4 Asymmetric epoxidation catalysed by [Ru(pybox)(pydic)] complex using 
hydrogen peroxide as oxidant. 
Because of the flexibility of the chemistry of ruthenium, several research groups have 
dedicated their efforts to the development of ruthenium complexes as asymmetric 
epoxidation catalysts.270-272 Non-atom-efficient oxidants were employed in most of the cases. 
A new approach has recently been introduced by Beller and co-workers.257-259 In order to 
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achieve both high yield and high enantioselectivity, ruthenium complexes 141 formed by 
combining two meridional ligands, pybox (red) and pydic ligands (blue), were developed 
based on the previous study by Nishiyama.273 The pydic ligands were considered to be 
responsible for the catalytic activity, and the pybox ligands (pyboxazine ligands in some 
cases), which can be easily synthesised from β-amino acid derivatives, were considered to 
control the observed enantioselectivity.  
 
Figure 5.3 Chemical structure of ruthenium complex 141 and the proposed catalytically active intermediate 
142.  
It was suggested that, during the catalytic process, 141 was oxidised to afford 142 which was 
believed to be the active catalytic complex. In 142, the typical octahedral arrangement of 
ligands about ruthenium has been distorted to allow the oxazoline ring to rotate away from 
the reactive Ru=O group. This conformational change is believed allows the interaction of 
the olefin with Ru=O to occur. It was also proposed that the π-π interaction between the 
ligand and the substrate is the key factor for determining the enantioselectivity.257-259 
 
Scheme 5.11 Ru catalysed asymmetric epoxidation of 144.  
Numerous substrate and Ru catalysts have been scanned in the original studies.257-259 For 
example, 141a was used as the catalyst in the epoxidation of 143. 141a proved promising 
giving 144 in 72% e.e. and 91% yield.  
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5.3.2 Chiral ketone-derived organocatalysts as catalysts for asymmetric epoxidation  
An alternative method of asymmetric epoxidation is to use chiral ketone-derived 
organocatalysts. The treatment of ketones with Oxone (potassium peroxymonosulfate) forms 
dioxiranes, which can transfer an oxygen atom to a wide range of substrates, and regenerate 
the ketone after the oxygen transfer.274 Several chiral ketones have been developed for 
asymmetric epoxidation purposes after the first example was reported by Curci.275-277 The 
most well known reaction of this type is known as the Shi asymmetric epoxidation, which 
uses a fructose-derived ketone catalyst 145 to achieve very high enantioselectivities in 
epoxidation reactions.278 Both enantiomers of the catalyst can be easily accessed by using D- 
or L- fructose. This epoxidation reaction has demanding pH requirements, as side reaction 
can happen in both high and low pH environments. Cis olefins are poorer substrates 
compared to the trans olefins, and substituted olefins are more favoured than terminal 
olefins.277,278  
 
Figure 5.4 Shi fructose-derived ketone 145 and its active species dioxirane 146.  
In the study of the total synthesis of the chiral C2-symmetric pentacyclic oxasqualenoid 
glabrescol (147) by Corey and co-workers, Shi asymmetric epoxidation was employed to 
introduce four epoxides in one step. 145a (R1-4= Me, R5= H) was used in this reaction 
convert 148 to 149 in 66% yield with (R) to (S) ratio of 20: 1.279,280 
 
Scheme 5.12 Application of Shi asymmetric epoxidation in total synthesis of glabrescol (147).  
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5.4 Atropisomerism 
Chirality is one of the most important factors in the pharmaceutical industry as enantiomers 
may have significant differences in both biological activities and toxicities.281,282 However, 
atropisomerism as an alternative source of chirality is often left unstudied or not noticed.283 
Atropisomers are isolable conformers, which interconvert slowly (half-life greater than 1000 
seconds) due to steric or electronic constraints.284,285 For example, polycyclic compound 150 
was shown to exist as a rotamer pair due to the slow rotation about the single bond between 
the sp3 bridge head and the aryl ring, and the half-life of the interconversion between two 
isomers are 21 hours at room temperature.286 
 
Scheme 5.13 Interconversion of two rotamers of 150.  
Due to the hindered rotation about single bond in atropisomers, some apparently achiral 
compounds can be actually exist as racemic mixtures. For example, telenzipine (151), a 
selective muscarinic antagonist, is atropisomeric with a stereogenic C-N axis (two 
atropisomer shown in Scheme 5.14 as 151a and 151b).287 The racemisation half life of 
telenzipine at 20 °C in neutral aqueous solution is 1000 years. The (+)-isomer is 500-fold 
more active against muscarinic receptors in rat cortex than the (-)-isomer.287 Therefore, by 
separating the atropisomers can significantly improve this drug’s efficiency.  
 
Scheme 5.14 Slow interconversion between two atropisomers of telenzipine (151) 
However in some other cases the rotation of the stereogenic axis is relatively fast, therefore 
racemisation is fast. The half lives of these atropisomers are not long enough for them to be 
isolated or meaningless in the concept of biological studies. For example, due to the restrict 
rotation about the C-N bond in compound 152 (Figure 5.5), two conformers can be observed. 
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However, the half life of the racemisation is only 1.6 min at body temperature.288 Although 
these two conformers are separable at lower temperature, it is not relevant in the biological 
process at room temperature. Eight membered ring containing compound 153 exhibited 
promising biological activity, and exists as an atropisomeric pair due to the slow Ar-CO bond 
rotation with the half life of 9.7 hours at 37 °C. By introducing a further stereogenic centre, 
154 was afforded as only one diasteroisomer and showed excellent biological potential.283     
 
Figure 5.5 Chemical structure of 152, 153, and 154.  
5.4.1 Atropisomerism in medium sized ring systems and macrocycles 
Classically, atropisomers are formed by restrict rotation about biaryl C-C bond and C-N 
bond.288 Some aryl amides also exist as atropisomers, for example, compounds 155-157 are 
all atropisomeric.289-291  
 
Figure 5.6 Selected compounds that are atropisomeric due to the restrict rotation about the aryl amide bond.  
In some cases medium sized ring and macrocycle can also show atropisomeric properties due 
to the slow conformer interconversion. Meadow saffron alkaloid colchicine (158) is known 
to be the best treatment for severe gout and cutaneous and oral lesions in Behçet’s disease. 
Except for the classic stereogenic centre C7, colchicine (158) also contains the C12a-C12b 
stereogenic axis. Both of the two atropisomeric forms of colchicine, 158a and 158b, can 
isolated. Due to the high energy barrier that exists between these two isomers, this 
intercoversion has proved to be impossible.292 
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Figure 5.7 Atropisomeric forms of colchicine (158). 
(+)-O-permethyl tellimagrandin II (159), is one of the several known ellagitannins. This 
group of natural products exhibits a wide range of biological activities, the most well-known 
being their inhibition of both DNA topoisomerases I and II, and also HIV reverse 
transcriptase. This 11-membered ring containing natural product showed interesting 
atropisomeric properties, and has been synthesised in optical pure form.293 The atropisomeric 
properties of 160 was demonstrated in a study by Gibson and co-workers.294 This compound 
has two stereogenic axes, as shown in Figure 5.8. All four diastereoisomeric atropisomers 
can be detected by 1H NMR spectroscopy analysis.294 
 
Figure 5.8 Chemical structure of (+)-O-permethyl tellimagrandin II (159) and 160.  
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5.5 Project aim 1: Development of a novel system to help further understanding of the 
oxidative fragmentation reaction established within the group. 
Previously within the group, an oxidative fragmentation method has been developed to 
convert bicyclic compounds into medium sized ring containing compounds or macrocycles 
using m-CPBA.224 
N N
O
O
N
O
N
O
OO
161a 162a
(i)
 
Scheme 5.15 Oxidative fragmentation of diazabenz[e]aceanthrylene 161a to afford medium-sized ring 
compound 162a. reaction conditions: m-CPBA (2.0 eq), CHCl3, r.t., 16 hrs, 92%.224 
Interestingly, 162a exhibited atropisomerism almost certainly due to restricted rotation about 
the urea N and the ring. The two enantiomers of 162a were separated by chiral HPLC and a 
plausible mechanism for this interesting oxidative fragmentation reaction has been proposed. 
However, there remained some uncertainties about this reaction mechanism due to the nature 
and the product of this reaction. It was therefore decided to study a new system, the oxizino 
carbazolone 163, which has a classic stereogenic centre already in place. The diastereomers 
of 164 which might be obtained through oxidative fragmentation of 163, could then be 
possibly isolated by normal chromatographic methods. In addition, with the help of the 
existing stereogenic centre and have proof of relative stereochemistry of 164 and 164’, the 
aim was to further investigate the mechanism of the oxidative fragmentation reaction.  
 
Scheme 5.16 The new system 163 was employed to further investigate the oxidative fragmentation reactions.   
5.6 Project aim 2: Developing a novel system to help further understanding of the 
oxidative fragmentation reaction of 161a. 
The oxidative fragmentation of 161a using m-CPBA afforded 162a as racemic atropisomeric 
mixture. The two enantio-atropisomers were separable by chiral HPLC and it was considered 
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interesting to attempt to synthesise a single enantio-atropisomer of 162a using a catalytic 
asymmetric oxidative fragmentation method. To the best of our knowledge this would be one 
of the few if not only examples of this reaction in the literature. 
Previously within the group, several approaches had been attempted to achieve the formation 
of single enantio-atropisomer of 162a. For example, asymmetric reduction of 161a was 
attempted in order to introduce a stereogenic centre into the molecule which could direct the 
epoxidation of the double bond to form the epoxide on the same face as the hydroxy group. It 
was then proposed that fragmentation and oxidation of 166 generate the single 
enantio-atropisomer of 162a (Scheme 5.16).224  
 
Scheme 5.17 Proposed asymmetric synthesis of single atropisomer of 162a by the asymmetric reduction 
process.  
However, selective reduction of the C8 carbonyl was not achievable as the C14 carbonyl 
group surprisingly reacts instead.  
Asymmetric epoxidation, as discussed in Section 5.3, was another way forward. If it proved 
possible to epoxidise 161a asymmetrically in the first step, followed by the fragmentation, it 
may be possible to prepare enatio-enriched 162a. Therefore, it was decided to further 
investigate this part of the project by studying the asymmetric epoxidation of 161a in more 
detail.  
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Chapter 6: Oxidative Fragmentation and Rearrangement Reactions of the 
Oxizino Carbazolones 
6.1 Introduction 
Previously within the group, an oxidative fragmentation method has been developed to 
convert bicyclic compounds into medium sized ring containing compounds or macrocycles 
using m-CPBA. Interestingly, the product of these reactions exhibited atropisomerism which 
was due to restricted rotation about the N15-C14a bond in 162a. The two enantiomers of 
162a can be separated by chiral HPLC and one of the two enantiomers has been isolated 
using this method.  
 
Scheme 6.1 Oxidative fragmentation of diazabenz[e]aceanthrylene 161a to afford medium-sized ring 
containing compound 162a. Reaction conditions: m-CPBA (2.0 eq), CHCl3, r.t., 16 hrs, 92%.224 
This chapter focuses on using the established oxidative fragmentation method in a novel 
system 163, which already contains a classic stereogenic centre to investigate several 
interesting issues. First, as in the previous system, the fragmented products have the potential 
to exist as atropisomers, this therefore raises the possibility to investigate diastereoselectivity 
in the synthesis of the new system 164 (i.e. the ratio between 164a and 164b, Scheme 6.2). 
Second, the possible mechanisms involved will be investigated and discussed using both 
chemical and computational methods. An interesting rearrangement reaction has also been 
observed during this study and will be discussed in this chapter.  
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Scheme 6.2 General approach used in this project. 
6.1.1 Oxidative fragmentation of diazabenz[e]aceanthrylene system 
Previous research in the Westwood group demonstrated that 161a underwent oxidative 
fragmentation with m-CPBA to give 162a in good yield (Scheme 6.1).224 This provided an 
efficient method for the synthesis of medium-sized ring containing compounds. It has also 
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been shown that 162a can undergo a series of core switching reactions of use in 
diversity-oriented synthesis.  
Interestingly, the aliphatic region of the 1H NMR spectrum of 162a contained diastereotopic 
multiplets despite the fact that 162a lacked a classic stereocentre. It was therefore speculated 
that 162a exhibited atropisomerism. X-ray crystallographic analysis of 162a supported this 
view due to the presence of two enantiomeric forms of 162a in the unit cell (Figure 6.1).224  
  
Figure 6.1 The two enantiomeric forms of 162a (162a, 162a’) are present in the small molecule X-ray crystal 
structure obtained on analysis of 162a.224 
Analytical chiral HPLC analysis of 162a using a reverse phase chiral column showed two 
peaks corresponding to the two enantiomers of 162a. A single enantiomer of 162a was 
isolated using chiral HPLC. Attempted racemisation of this single enantiomer under forcing 
conditions (refluxing in toluene for 48 hours) demonstrated its stability towards racemisation 
(Figure 6.2), as only a trace amount of the single enantiomer of 162a had racemised to the 
alternative enantiomer after 48 hours. These experiments provided evidence that the half life 
of this single enantiomer of 162a was much greater than 1,000 seconds at room temperature 
and therefore, 162a did exhibit atropisomerism (for a brief review of atropisomerism see 
Chapter 5, Section 5.4 ).  
   
Figure 6.2 Chiral HPLC analysis of 162a. (a) Racemic 162a; (b) One isolated enantiomer; (c) The isolated 
enantiomer from (b) after reflux in toluene for 48 hours.  
(a) 
(b) 
(c) 
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6.1.2 Introduction to the new system selected for oxidative fragmentation.  
A possible mechanism for the interesting oxidative fragmentation of 161a has been proposed 
previous within the group (Scheme 6.3).224 However, there remained some uncertainties 
about this proposal. For example, in this proposal, after the formation of intermediate 170, 
the second equivalent of m-CPBA may attack the molecule from the opposite face to the 
hydroxyl group to form the anti-peroxy ester alcohol (Scheme 6.3 anti-170). This geometry 
was thought to be ideal for the subsequent Grob fragmentation.233,295 However, in other 
studies, it has been suggested that the hydroxyl group which is generated in the reaction can, 
via hydrogen bonding, favour the second equivalent of m-CPBA attacking the molecule from 
the same face as the hydroxyl group to form syn-170 (Scheme 6.3).296 
 
 
Scheme 6.3 A mechanistic rationale for the oxidative fragmentation reaction of 161a.224 
Due to the nature and the product outcome of this reaction, it was implossible to rationalise 
which pathway the reaction proceeded by. Furthermore, previous attempts to obtain an 
optically pure sample of 162a using an asymmetric synthetic approach were unsuccessful. It 
was therefore decided to employ a new system, the oxizino carbazolone 163 (Scheme 6.2), 
which has a classic stereogenic centre already in place. Oxidative fragmentation of 163 
should afford 164 which was expected to exhibit atropisomerism. Two diastereomers of 
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compound 164 could then be isolated by normal chromatography methods. In addition, with 
the existing stereogenic centre, it may be possible to further study the mechanism of this 
reaction and therefore answer the question that remained from the original system, namely 
from which side does m-CPBA approach intermediates such as 169.  
6.1.3 Introduction to the oxizino carbazolone 163 
Oxizino carbazole 171 (Figure 6.3) is an analogue of 172, which is one of the inhibitors in 
the parasite invasion assay (see Chapter 1). 172 is a reversible inhibitor of T. gondii invasion 
and has a minimum effective inhibitory concentration (MIC) of 50 μM.155 172 is also a 
well-known monoamine oxidase A (MAO A) inhibitor as well as its imine-reduced analogue 
pirlindole 173 (Figure 6.3).297 The Ki values of 172 and 173 against MAO A was reported to 
be 0.009 and 0.05 μM, respectively.297  
 
Figure 6.3 Chemical structures of the oxizino carbazole 171, unsaturated pirlindole 172, and pirlindole 173. 
 
Similar to 173, oxizino carbazole 171 which is a novel system, has a classic stereogenic 
centre, and the indole motif in the molecule is a substrate for the oxidative fragmentation 
reactions, it was initially chosen as the core substrate for this project. Oxidation of 171 
would install the required carbonyl functionality to give oxizino carbazolone 163, the 
substrate for the fragmentation reaction.  
6.2 Oxidative fragmentation of oxizino carbazolone 163  
The key starting material in this project is oxizino carbazole 171, which is an analogue of 
pirlindole 173. The synthesis of oxizino carbazole 171 followed a similar route to the 
synthesis of 173,298 and shared the same intermediate 178 formed prior to the cyclisation 
reaction (Scheme 6.4). With the consideration that X-ray crystal structures would help to 
give a better view of the reaction products obtained, the first part of this project focused on 
the synthesis and reactions of the bromo-analogue 171a  
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Scheme 6.4 The synthetic route to oxizino carbazole 171 and pirlindole 173. Reaction conditions: (i) NaH, 
ethyl formate, EtOH, THF, 0 °C to r.t. o/n. (ii) NaOAc, NaNO2, HCl, 0 °C 30 min; yield: 176a, 75%; 176f, 81%; 
176g, 76%; 176h, 57%; 176i, 69%; 176j, 76%; 176k, 73%; 176l, 83%; 176m, 67%; 176n, 79%; (iv) HCl, 
AcOH, 120 °C, 25 min; yield: 177a, 64%; 177f, 67%, 177g, 61%; 177h, 12%; 177i, 55%; 177j, 68%; 177k, 
66%; 177l, 59%; 177m, 67%; 177n, 55%; (v) dibromoethane, TBAB, 9N NaOH (aq), r.t., o/n; yield: 178a, 65%; 
178f, 65%; 178g, 61%; 178h, 65%; 178i, 62%; 178j, 67%; 178k, 66%; 178l, 68%; 178m, 69%; 178n, 64%; 
178o, 64%; (vi)ammonium acetate, tetraethyl orthosilicate, (vii) NaBH4, EtOH, 173, 89%. (vii) NaBH4, EtOH, 
60 °C, 6 hrs; yield: 171a, 68%; 171f, 68%; 171g, 68%; 171h, 69%; 171i, 77%; 171k, 87%; 171l, 81%; 171m, 
89%; 171n, 86%; 171o, 67%.   
Commercially available cyclohexanone (174a) was functionalised with ethyl formate and 
then treated with p-bromo-aniline under Japp-Klingemann299 conditions to afford hydrazone 
176a in good yield.300 Fisher indole synthesis was then performed to obtain carbazol-1-one 
177a in good yield.299,300 Selective alkylation of 177a using a biphasic reaction of 
dibromoethane and 9N NaOH as solvent with tetrabutylammonium bromide (TBAB) as the 
phase transfer catalyst yielded 178a in excellent yield.298,300 The reduction of the ketone 
functional group in 178a was achieved using NaBH4 and cyclisation to generate the 
morpholine ring was completed to give 171a in a one pot manner in 68% yield.  
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1H NMR spectroscopic analysis of 171a showed that the signal corresponding to the C2’ 
methylene protons that were present in the 1H NMR spectrum of the starting material 178a 
(4.77 ppm) had disappeared and two new doublets of triplets corresponding to the hydrogens 
at the C2 position in 178a were present (3.95 and 3.75 ppm). In addition, the multiplet 
(4.60-4.64 ppm) corresponding to the C3a proton which was introduced in the reduction 
reaction was also present in the 1H NMR spectrum of 171a. The IR spectrum further 
confirmed the structure of 171a as there was a signal corresponding to the ether C-O stretch 
(1094 cm-1), but no signal corresponding to a hydroxyl group or ketone present in the 
spectrum.  
171a was then submitted to a DDQ oxidation reaction following a literature method in a 
similar system.301 Under these conditions, 171a was oxidised at the C6 position to form 
carbazole-6-one 171a. The structure of 171a was confirmed by X-ray crystallography 
(Scheme 6.5).  
 
Scheme 6.5 DDQ oxidation reaction of 171a to obtain 163a. Reaction conditions: (i) DDQ, THF/H2O, 0 °C to 
r.t. 2 hrs; 68%; X-ray crystal structure of 163a.  
The oxidative cleavage of 163a with m-CPBA, yielded the nine-membered ring containing 
product 164a in 50% yield (100% conversion based on recovered starting material) (Scheme 
6.6). From previous results from within the group, restrict rotation of the nine-membered 
ring would be expected to provide a non-classical stereogenic axis. Therefore 
diastereoisomers of 164a were expected to be formed in this reaction. Interestingly 1H NMR 
analysis showed that this reaction appeared to be completely diasteroselective (at least 
according to this analytical technique). Instead of two racemic diastereoisomers, the 
formation of only a single pair of enantiomers was observed. 1H NMR spectroscopic analysis 
of 164a showed that all the protons at C1, C2, C4 and C5 position were diastereotopic as 
expected. The 13C NMR spectrum of 164a has three signals at 202.3, 190.3 and 173.3 ppm 
respectively, consistent with this product containing three carbonyl groups, one of which is 
an amide carbonyl (173.3 ppm). The overall structure of 164a was therefore assigned as 
shown in Scheme 6.5, and this assignment was confirmed by X-ray crystallography (Figure 
6.4).  
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Scheme 6.6 Oxidative fragmentation of 163a to yield 164a. Reaction conditions: m-CPBA (2.5 eq), DCM, r.t. 
18 hrs, 50 % with compelet diastereoselectivity.  
As well as the overall structure of 164a, additional interesting facts were also observed in the 
X-ray analysis of 164a. The (C11a-N12-C13-O13) torsion angle is different from the naively 
expected 0 º and showed a 17.9 º twist from planarity. Also the torsion angle (O7-C7-C7a-C8) 
was 35.4 º. However, the most interesting observation is the arrangement of the carbonyl 
groups. As it is shown in Figure 6.4, in the enantiomer 164a the C3a-O and C6=O carbonyls 
are pointing behind the plane of the medium-sized ring as drawn as 164a, C7=O and C13=O 
were observed to be up. The unit cell also contained the enantiomer of 164a, as drawn as 
164c in Figure 6.4, but not the diastereomer 164b or its enantiomer.  
 
Figure 6.4 The two enantiomers 164a, 164c, are observed in the small molecule X-ray crystal structure 
(obtained from the racemic unit cell).  
6.2.1 Mechanistic study on the oxidative cleavage of 163a 
Based on the structural information associated with 164a, at least four possible mechanistic 
pathways can be proposed for this oxidative fragmentation reaction (Scheme 6.7).  
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Scheme 6.7 Four possible mechanism pathways for the oxidative fragmentation reaction of 163a.  
 
Mechanism 1: The treatment of 163a with m-CPBA formed the epoxide intermediate 179a. 
The epoxide formation occurred on the less hindered face of the molecule which is opposite 
to the morpholine ring oxygen. Protonation of 179a resulted in a SN1 type opening to give 
iminium ion intermediate 180a. The free hydroxyl group could form a hydrogen bond with 
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the 2nd equivalent of m-CPBA that would direct the m-CPBA to attack from the top face of 
the molecule. Similar directing effects can be seen in a study which has been carried out by 
Davies and co-workers.296 Subsequent Grob fragmentation of 181a would afford 164a with 
the same stereochemical arrangement as observed in the X-ray crystal structure.  
Mechanism 2 is closely related to mechanism 1. The treatment of 163a with m-CPBA 
formed the epoxide intermediate 179a, followed by SN1 type opening to give iminium ion 
intermediate 180a. The 2nd equivalent of m-CPBA would attack from the bottom face of the 
molecule to obtain the intermediate 181b. Subsequent Grob fragmentation of 181b would 
afford 164b, followed by the C13=O group flipping through the nine-membered ring to 
afford 164a.  
Mechanism 3 is different from mechanisms 1 and 2. The treatment of 163a with m-CPBA 
formed the epoxide intermediate 179b. The epoxide formation occurred on the same face as 
the morpholine oxygen. Protonation of 179b resulted in a SN1 type opening to give iminium 
ion intermediate 180b. The 2nd equivalent of m-CPBA would attack from the top face of the 
molecule to form intermediate 181c. Subsequent Grob fragmentation of 181c would afford 
164d, which after a C6, C7 dicarbonyl flip would give 164a.  
Mechanism 4 is closely related to mechanism 3. The treatment of 163a with m-CPBA 
formed the epoxide intermediate 179b. Protonation of 179b resulted in a SN1 type opening to 
give iminium ion intermediate 180b. The free hydroxyl group could form a hydrogen bond 
with the 2nd equivalent of m-CPBA that would direct the m-CPBA to attack from the bottom 
face of the molecule to form the intermediate 181d. Subsequent Grob fragmentation of 181d 
would afford 164e, which after a C6, C7 dicarbonyl flip and the C13 carbonyl rotation 
through the nine-membered ring would form 164a.  
Based on the discussion above, it is clear that to assign most likely mechanistic explanation 
for this oxidative fragmentation reaction, there are three questions that need to be answered: 
1) can the initial products 164b, 164d, and 164e interconvert to give 164a, i.e., can the three 
carbonyl groups flip; 2) from which face of the molecule does epoxidation occur; 3) whether 
the addition of the 2nd equivalent of m-CPBA is directed by the existing OH group.  
6.2.1.1 The possibility of resulting product interconvertion. 
In the mechanism 2, 3, and 4, the products that could be formed are 164b, 164d, and 164e. 
However, if the C6, C7 dicarbonyl flip and C13 amide carbonyl group could flip through the 
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nine-membered ring, these three products could all convert to 164a. Therefore, to examine 
the possibility of these three carbonyl groups flip, computational studies have been 
preformed in collaboration with Dr Lebl.  
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Figure 6.5 a) Energy profile of conformational pathways driven by C11a-N12-C13-O13 torsion angle at RM1 
level of theory. b) 3D mimium energy structure and chemical structure of 164a.  
Figure 6.5 shows the energy profile for progressive driving of the C11a-N12-C13-O13 
torsion angle calculated at the RM1 level of theory. In this computational model, an attempt 
was made to force the carbonyl group at the C13 position through the middle of the 
nine-membered ring to convert the conformation of 164a to 164b. The rest of the molecule 
was relaxed to achieve the lowest energy at each point. Since the energy profile does not 
suggest the existence of a transition state, it seems to be impossible to force the amide 
carbonyl group through the ring at any practical temperature. This result is in agreement with 
the previously discussed system 162 in which the non-classical stereocentre resulted from 
restricted rotation in the nine-membered ring and in particular the inability of the carbonyl 
group to pass through the ring. On the other hand this result rules out mechanisms 2 and 4, 
which require the C13 carbonyl flip through the ring to deliver 164a. Therefore, these two 
mechanisms are viewed as unlikely to explain the oxidative fragmentation reaction of 163a.  
In the mechanism 3, for 164d to be converted to 164a, it requires a C6/C7 dicarbonyl flip. 
Computational studies at B3LYP/6-31G** level of theory were then carried out to investigate 
whether these two carbonyl groups in the molecule can freely rotate. If this rotation is 
possible, then there will be two different minimum energy structures as shown in Table 6.1, 
and 164d would be expected to be able to convert to 164a via the transition state 164β. The 
possibility of two minimum energy structures interconverting, is dependent on how much 
energy they need to access the transition state 164β. From the computational calculations, it 
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showed that only 56.65 kJ/mol of energy was needed to covert 164a to 164β, and only 39.48 
kJ/mol of energy was needed to convert 164d to 164β. These results suggested that the 
energy of 164d is slightly higher than 164a, and the half life of the conversion of 164d to 
164a is only 1.54 x 10-5 seconds (for a more detailed discussion of the data for the 
computational experiments see Appendix 5). In other words, if there was any of 164d 
produced during the reaction, it will convert into 164a very quickly. The fact that only 164a 
is present in crystal structure does not mean that 164a was generated directly in the reaction. 
These computational calculation results suggested that both mechanism 1 and 3 are possible 
mechanisms for the oxidative fragmentation reaction of 164a.  
 
Energy state rel. E [kJ/mol] Torsion angle of O6=C6-C7=O6 
164a 0.00 109.12° 
164β 56.65 -119.47° 
164d 17.17 15.52° 
Table 6.1 Energy profile of conformational energy states.  
6.2.1.2 Epoxidation of 163a with m-CPBA. 
One of the differences between mechanisms 1 and 3 is which face of 163a the epoxidation 
occurred in the first step of the reaction. In mechanism 1, the epoxidation occurred on the 
opposite face of the morphoine oxygen to give epoxide intermediate 179a. On the other hand, 
in mechanism 3, the epoxidation needs to occur on the same face of the morpholine oxygen 
to obtain epoxide intermediate 179b. This outcome would presumably require a directing 
effect from the morpholine oxygen, which is in contrast with well studied m-CPBA 
epoxidation reactions.302 Based on this argument, it is currently believed that mechanism 1 
should be the most likely mechanistic explanation for this oxidative fragmentation reaction.   
6.2.2 Oxidative fragmentation reaction of 182 
In order to provide further evidence to support mechanism 1 and show that there is not a 
directing effect from the morpholine oxygen in this system, it was decided to change the 
oxygen atom (O3) in 163a to a carbon atom to form analogue 182, as carbon cannot undergo 
hydrogen bonding to direct the m-CPBA molecule. These studies also allow the scope of this 
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reaction to be explored in more detail.  
Carbon analogue 182 was obtained by the following sequence. Bromo carbazole-1-one (177a) 
was selectively alkylated on the indole nitrogen with dibromopropane to afford 183, 
followed by the Wittig reaction conditions to furnish alkene 184. Hydrogenation using Pd/C 
as a catalyst gave a racemic mixture 185. DDQ oxidation furnished enaminone 182 (Scheme 
6.8). The structure of 182 was confirmed by X-ray crystallography.  
 
Scheme 6.8 A) Synthesis of 182. Reaction conditions: (i) dibromopropane, 9N NaOH (aq), r.t. o/n, 68%; (ii) 
Ph3P, toluene, reflux, 2 days, quantitative, then n-BuLi, THF, -78 °C to r.t., o/n, 60%; (iii) H2, 1 atom, Pd/C 
(10%), EtOAc (50 mg/10 mL), r.t. H-Cube, 95%; (iv) DDQ, THF/H2O, 0 °C to r.t., 2 hrs, 65%; B) X-ray crystal 
structure of 182. 
Enaminone 182 was then treated with m-CPBA under exactly the same conditions as the 
reaction of 163a to afford 186 in good yield (Scheme 6.9). The X-ray crystal structure of 186 
(Scheme 6.9) showed that the arrangement of the carbonyl groups in 186 had the same 
geometry as in 164a. This observation supported the view that mechanism 1 is the most 
plausible mechanism for the oxidative fragmentation reaction.  
 
Scheme 6.9 oxidative fragmentation of 182. Reaction conditions: (i) m-CPBA (2.5 eq). DCM, r.t., 18 hrs, 67%. 
X-ray crystal structure of 186.  
6.2.3 Oxidation of 163a with different oxidising reagents led to a new rearrangement 
reaction 
The oxidative fragmentation with m-CPBA of 163a showed a very high level of 
diastereoselectivity. It was therefore decided to use another oxidising reagent which may 
enable us to obtain a sample of diastereomer 164b. The plan was to treat the oxizino 
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carbazolone 163a with dimethyl dioxirane (DMDO). In this reaction, it was hoped that 
DMDO could enable access to the epoxide on either side of the molecule. Therefore it was 
planned that m-CPBA would be added after the DMDO reaction to open the epoxide and 
lead to fragmentation. Surprisingly, instead of forming 164a/b, this reaction gave exclusively 
the spiro product 187a as a single diastereomer (Scheme 6.10). This reaction was repeated 
without the addition of m-CPBA and gave the same outcome, which indicated that the 
rearrangement occurred following the treatment with DMDO.  
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Scheme 6.10 Oxidation reaction of 163a with DMDO to afford the rearranged product 187a. Reaction 
conditions: DMDO, DCM, r.t., 30 min, 95%. X-ray crystal structure of 187a. 
As well as the overall structure of 187a, interesting facts were observed in the crystal 
structure analysis of racemic 187a. As it is shown in Scheme 6.10, in the enantiomer 187a 
the C3a-O3 and C6=O carbonyls are pointing behind the plane while C7=O group was 
observed to be up.  
There are two possible explanations for this rearrangement reaction (Scheme 6.11), one of 
which is similar to a literature documented reaction303 can be described as follows; DMDO 
formed the epoxide on the less hindered face of 163a and subsequently opened by the lone 
pair on the indole nitrogen to give 180a. In the absence of another nucleophile, the C6-C6a 
bond migrated to afford the spiro compound 187a (Scheme 6.11, a)). Another possible 
explanation could be that despite our best effort to dry the DMDO solution with molecular 
sieves, it remains possible that water still present in the reaction mixture. Therefore, the 
iminium ion in 180a could be quenched by water molecule to form diol 188, which then 
went through Pinacol rearrangement to afford 187a (Scheme 6.11, b)). Both of these 
mechanisms suggested that in order to obtain the observed geometry of the new stereocentre 
in 187a, the epoxide formation is on the opposite face to the morpholine oxygen. This piece 
of evidence supported mechanism 1 (see Scheme 6.7 earlier).   
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Scheme 6.11 A possible mechanism of oxidative rearrangement to form the spiro compound 187a.   
6.2.4 Oxidative fragmentation of 188 to afford 164a.  
As well as the synthetic approaches which have been discussed above, there is an alternative 
route to 164a which uses 188 as starting material instead of 163a. The synthesis of starting 
material 188 is shown in Scheme 6.12. The treatment of 171a with sodium meta periodate 
resulted in the cleavage of the indole double bond to give 189 in good yield. Under basic 
conditions, 188 was formed in excellent yield. Under exactly the same conditions as was 
used to cleave 163a, 188 was cleaved to give the fragmented product, an X-ray crystal 
structure of which showed that it has the same arrangement of carbonyl groups as 164a. This 
cleavage reaction proceeded in moderate yield. A possible explanation for why 188 is a 
worse substrate for the oxidative fragmentation reaction than 163a could be that, the double 
bond in 188 is less amenable to epoxidation than in 163a due to a significant contribution 
from the resonance form 188a to the electronic structure of 188.  
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Scheme 6.12 A) Alternative approach to afford 164a. Reaction conditions: (i) NaIO4, IPA/H2O, r.t., o/n, 85%; 
(ii) 1 M NaOH, 95 °C, 30 min, 95%; (iii) m-CPBA (2.5 eq), DCM, r.t., 18 hrs, 19%. B) X-ray crystal structure 
of 189.  
The mechanism of this reaction can be explained using mechanism 1. m-CPBA probably 
epoxidised 188 on the opposite face to the morpholine oxygen to give the epoxide 
intermediate 190. 190 was then protonated on the epoxy oxygen. Similar to the intermediate 
179a, the epoxy ring of 190 was opened in an SN1 type opening to give the iminium 
intermediate 191. Subsequently, the free hydroxyl group in 191 directed the 2nd equivalent 
of m-CPBA attacking the iminium ion to give a syn-192, Grob fragmentation of 192 then 
gives 164d and because of the free rotation of the C6=O and C7=O groups, 164d was 
converted to 164a via a dicarbonyl flip (Scheme 6.13).   
 
Scheme 6.13 Possible mechanistic explanation of the oxidative fragmentation reaction of 188 to afford 164a.  
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In addition to the formation of 164a in this approach, another interesting observation also 
attracted our attention. The oxidative cleavage of 171a using sodium meta periodate gave an 
interesting product 189, the structure of which was confirmed by X-ray crystallography 
(Scheme 6.12). 189 is an analogue of 164a with one less carbonyl group on the C6 position. 
From the previous computational calculation on the C13=O group in 164a, it was clear that 
this carbonyl group cannot pass through a nine-membered ring. Therefore, 189 was also 
expected to exhibit atropisomerism. 1H NMR analysis showed that protons at C1, C2, C4, C5 
and C6 positions are all diastereotopic, and the unit cell of X-ray crystallography analysis 
also contained the enantiomer of 189 but not a diastereomer. 
6.3 Enantioselective synthesis of 164a. 
As was discussed above, the oxidative cleavage reaction of the oxizino carbazolone 163a 
was highly diastereoselectivity, the use of enantio-enriched starting material 193, should lead 
to good yield of a single enantiomer of 164a. In order to achieve this goal, enantio-enriched 
193 had to be obtained. Thus, ketone 178a was reduced asymmetrically to give 198 using the 
Corey-Bakshi-Shibata (CBS) catalyst 194 following a literature method reported for a 
similar system (Scheme 6.15).304,305 Based on the reported mechanism for the CBS reduction, 
(S)-OAB (194) was chelated with BH3•DMS and 178a to form the favoured six-membered 
ring transition state 196 for the hydride transfer. 178a was then reduced to form 198 with R 
configuration at C1(Scheme 6.14).  
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Scheme 6.14 Mechanistic study of asymmetric reduction of 178a.  
Chiral HPLC analysis showed that this reduction gave 198 in 98% e.e. (for HPLC analysis 
trace, see Appendix 6). The cyclisation using potassium tbutoxide furnished the D ring to 
afford 199 in good yield. DDQ oxidation under the same condition as in the racemic system 
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furnished 193 and cleavage of 193 using m-CPBA gave 200 in 53% yield. Chiral HPLC 
analysis of 200 (Appendix 7) showed that the e.e. of 200 was 96% as expected. 200 was then 
recrystallised from acetone and submitted for X-ray crystallography analysis and the 
absolute configuration determined as shown in Scheme 6.15.  
  
Scheme 6.15 Asymmetric synthesis of 200. Reaction conditions: (i) (S)-OAB, BH3•DMS, DCM, -20 °C 3.5 hrs, 
76%; (ii) t-BuOK, t-BuOH, r.t., o/n, 94%; (iii) DDQ, THF/H2O, 0 °C, 2 hrs, 65%; (iv) m-CPBA (2.5 eq), DCM, 
50%. X-ray crystal structure of 200.  
6.4 Exploration of the effect of substituents in the aromatic ring and C-ring size on the 
fragmentation reaction  
In order to study the generality of the reaction, studies related to the substituent effects and 
ring size effects were carried out. The para substituted oxizino carbazoles 171 were 
synthesised in the same manner as the p-bromo-oxizino carbazole (171a) using a range of 
anilines (Scheme 6.4). Unsubsitituted oxizino carbazole 171o was synthesised from 
commercially available tetrahydrocarbazole (201). Tetrahydrocarbazole (201) was oxidised 
to the tetrahydrocarbazolone (177o) following a literature method using diiodine pentoxide 
in good yield (Scheme 6.16).306,307 177o was then reacted with dibromo ethane, cyclised via 
sodium borohydride reduction and oxidised with DDQ to afford 163o in the same manner as 
the other analogoues (Scheme 6.17).  
 
Scheme 6.16 Synthesis of 177o. Reaction conditions: diiodine pentoxide, MeOH/H2O, r.t., 0.5 hrs, 65%. 
In addition to incorporation of substituents in the A ring, different size C-ring analogues were 
also synthesised using similar procedures (Scheme 6.4). Cycloheptanone (174b) and 
cyclooctanone (174c) were used, instead of using cyclohexanone (174a), as starting material 
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in the synthesis of cycloheptaindolone (177k, 177l) and cyclooctaindolone (177m, 177n), 
respectively. Subsequent N-alkylation, reduction, cyclisation and oxidation furnished ketones 
163k, 163l, 163m, and 163n which were ready for oxidative fragmentation (Scheme 6.17).  
 
Scheme 6.17 DDQ oxidation to afford oxizino carbazolone 171. Reaction conditions: (i) DDQ, THF/H2O, 0 °C 
to r.t. 2 hrs; yield: 163f, 68%; 163g, 61%; 163h, 55%; 163i, 66%; 163k, 67%; 163l, 64%; 163m, 61%; 163n, 
59%; 163o, 66%.  
An attempt was also made to synthesis the five-membered C ring analogue 171p via the 
same approach. However, due to the inherent instability of the intermediate obtained after the 
reaction of cyclopentanone with ethyl formate, this approach was unsuccessful. It was 
therefore decided to attempt an alternative approach to 171p using carboxylate 202 as the 
starting material instead of cyclopentanone.304 The resulting hydrazone 176p was then 
submitted to the Fischer-indole synthesis to afford 177p followed by substitution with 
dibromoethane to obtain 178p. The treatment of sodium borohydride did not lead to the 
cyclisation of the D-ring, instead, alcohol 203 was obtained. The attempts to cyclise the 
D-ring to obtain 171p were unsuccessful. This is probably due to the unfavoured ring strain.  
 
Scheme 6.18 Attempted synthesis of 171p. Reaction conditions: (i) NaOH, H2O, r.t. 48 hrs; (ii) NaNO2, HCl, 
H2O; (iii) HCl/AcOH, 120 °C, 25 min, 62%; (iv) dibromoethane, 9N NaOH, TBAB, r.t. o/n, 77%; (v) NaBH4, 
EtOH, 60 °C, 6 hrs, 87%.  
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6.4.1 Substituent effects on the oxidative fragmentation reaction.  
Differently substituted ketones 163 were submitted to the oxidative fragmentation reaction 
under exactly the same conditions. The results of these reactions are listed in Table 6.2.  
N
O
R
O
m-CPBA, 2.5 eq
DCM, rt, 18 hrs N
O
O
O O
R
+
N O
OO
R
163 164 187  
R Recovered starting material 163 
Fragmented 
product 164 
Rearranged 
product 187 
After 
optimisation 164
Br  43% (163a) 50% (164a) -- 87% (164a) 
Cl  15% (163f) 83% (164f) -- -- 
I  66% (163g) 32% (164g) -- 83% (164g) 
H  74% (163o) 19% (164o) -- 87% (164o) 
MeO  63% (163i) 15% (164i) 15% (187i) -- 
NO2 67% (163h) -- (164h) 27% (187h) -- 
Table 6.2 Oxidative fragmentation reactions of carbazolone 163 containing different substituents in the A ring 
of 163. Standard reaction conditions: m-CPBA (2.5 eq), DCM, r.t., 18 hrs; optimised reaction conditions: 
m-CPBA (4 eq), DCM, r.t., 18 hrs  
From Table 6.2, it can be seen that when the standard conditions (based on previous system 
161) were used, the percentage conversion trend decreased on changing from a chloro group 
(163f) to an iodo group (163g) (to give 164f, 164g and 164a in 83%, 32% and 50% yield, 
respectively). A further decrease in conversion was observed for the hydrogen analog (163o) 
to give 164o in 19% yield. This observation is likely due to the fact that electron donation 
(mesomeric) from the chlorine 3p orbital to the π system of the A-ring is better than for 
iodine, where the unpaired electrons are in a 5p orbital. Successful donation of electrons into 
the A-ring presumably localises more electron density on the nitrogen making the indole 
C6a-C11a double bond more electron rich. Furthermore, the H atom has no lone pair 
available, therefore, the electron density of the indole double bond in 163o is poorer than 
other analogues, 163a, 163f and 163g, which is not ideal for epoxidation. Both strong 
electron withdrawing groups and electron donating groups in the A-ring seem to hinder 
epoxidation in this system, as the percentage conversions of 163h and 163i, were only 33% 
and 37%, respectively.  
Optimisation was attempted to increase the yield of these reactions. It was not possible by 
prolonging the reaction time to improve the percentage conversion of the reactions. However, 
increasing the amount of m-CPBA in the reaction mixture (other conditions remained same 
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as standard) did have a positive effect on the reactions yields. From the 1H NMR analysis of 
the crude reaction mixture, it was shown that the reaction went to completion and the 
fragmented products were the only compounds detectable. The isolated yields of these 
reactions were good and are shown in Table 6.2 (column 5).  
Another interesting observation was that under the standard reaction conditions, 
rearrangement products were formed for both the nitro (163h) and methoxy 
(163i)-substituted analogues, whereas they were not observed for carbazolone 163a, 163f, 
163g and 163o. A possible explanation for this observation is that by adding a strong electron 
withdrawing or donating group, it significantly changed the electron density on the C11a 
position of the 163, therefore affect the relative rate between addition of second equivalent of 
m-CPBA and migration of C6-C6a bond. Thus, the rearrangement products were obtained.   
6.4.2 C-ring size effect on the fragmentation reaction.  
The different C-ring sized ketones 163 were submitted to the oxidative fragmentation 
reaction under the standard conditions. The results of these reactions are listed in Table 6.3. 
 
Substrate R n Recovered starting material 3
Fragmented product 
4 
Rearranged product 
24 
163a Br 1 43% 50% (164a) 0% 
163k Br 2 35% 0% (164k) 61% (187k) 
163m Br 3 47% 23% (164m) 21% (187m) 
163o H 1 74% 19% (164o) 0% 
163l H 2 37% 0% (164l) 53% (187l) 
163n H 3 53% 17% (164n) 17% (187n) 
Table 6.3 Oxidative fragmentation reactions of indolone 163 containing different ring size of the C-ring of 163. 
Standard reaction conditions: m-CPBA (2.5 eq), DCM, r.t., 18 hrs. 
From Table 6.3, it can be seen that when the standard conditions (based on previous system 
161) were used, the percentage conversion trend which was observed in the six membered 
ring series (163a, 57% better than 163o, 26%) was absent in the larger ring size system 
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(163k, 65% compared to 163l 63%, and 163m, 53% compared to 163n 47%). This 
observation is likely due to the fact that changing the ring size may affect the orbital 
overlapping between the carbonyl group and the indole double bond therefore reduced 
electron withdrawing effect in the system. Compared to this effect, the electron donation 
(mesomeric), which was the key fact in the six membered ring system, from Br 3p orbital to 
the π system of the A-ring is less pronounced in the seven and eight membered ring system. 
Therefore, the difference between H- and Br- analogues cannot be observed.  
Most interestingly, changing the size of the C-ring had a dramatic effect on the ratio of 
fragmentation to rearrangment. In both the hydrogen and bromo- series, only the 
rearrangement products 187k and 187l were observed when the C-ring size was 
seven-membered. The structure of 187k was proved by X-ray crystallography (Figure 6.6). 
Furthermore, a mixture of fragmentation and rearrangement was observed in both the 
hydrogen and bromo- series when the C-ring size was expanded to eight (Table 6.3, 164m 
and 187m, 164n and 187n). However, in the original six-membered series, only 
fragmentation (Table 6.3, 164o for hydrogen series, 164a for bromo- series) was observed. It 
was challenging to explain these observations, because of the difficultly in viewing the 
transition state of the reaction. One possible explanation is that changing the ring size of the 
C-ring may cause some unfavoured steric effects that may affect the fragmentation reaction 
which requires an intermolecular attack from m-CPBA. Therefore, the intramolecular 
rearrangement reaction could dominate.  
 
Figure 6.6. X-ray crystal structure of 163k and 187k.  
6.5 Conclusion 
Previously within the group, an oxidative fragmentation method was established and applied 
to the diazabenz[e]aceanthrylene system 161 to afford an interesting atropisomeric system 
162. However, the attempted asymmetric synthesis of the atropisomers was unsuccessful. 
Therefore, to further study how this unusual type of atropisomerism arose and the 
mechanism of the oxidative fragmentation, it was decided to employ the oxizino carbazolone 
system 163, which already has a classical stereogenic centre in place. To further investigate 
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the interesting oxidative fragmentation reactions 163 and its analogues were synthesised and 
submitted to the oxidative fragmentation reaction using m-CPBA. These reactions showed 
very high diastereoselectivity. Four possible mechanisms of the oxidative fragmentation 
reaction were proposed in the light of X-ray crystallography studies of the product 164a. 
Amongst these four mechanisms, mechanism 1, was supported by a range of experimental 
results and computational calculations, and therefore was believed to be the most likely 
mechanism for this oxidative fragmentation reaction. Oxidation of 163a with an alternative 
oxidizing reagent, DMDO, afforded the interesting rearrangement product 187a. In addition, 
a single enantiomer 200 was synthesised via an asymmetric CBS reduction. The absolute 
stereochemistry of 200 was assigned by X-ray crystallography. Explanations for the effects 
of different substituents and ring sizes on the fragmentation and rearrangement reactions 
were also discussed. The following Chapter 7 will expand on the results obtained in this 
chapter and provide a route to the atrop-selective synthesis of 162.  
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Chapter 7: Asymmetric Oxidative Fragmentation of the 
Diazabenz[e]aceanthrylenes 
7.1 Introduction 
Previously within the group, it has been established that the oxidative fragmentation of 
diazabenz[e]aceanthrylenes 161a using m-CPBA afforded N-acyl cyclic urea 162a as a 
racemic atropisomeric mixture. The two enantio-atropisomers of 162a were separable by 
chiral HPLC and it was therefore considered interesting to attempt to synthesise a single 
enantio-atropisomer of 162a using a catalytic asymmetric oxidative fragmentation method. 
To the best of our knowledge this would be one of the few if not only examples of this 
reaction in the literature. 
 
Scheme 7.1 Oxidative fragmentation of diazabenz[e]aceanthrylene 161a to afford medium-sized ring 
compound 162a as racemic mixture. reaction conditions: (i) m-CPBA (2.0 eq), CHCl3, r.t., 16 hrs, 92%.224 
This chapter focuses on developing an asymmetric oxidative fragmentation method, in the 
diazabenz[e]aceanthrylenes system 161a. Asymmetric oxidative fragmentation reaction 
using [Ru(pybox)(pydic)] catalysts will be discussed. Attempts to optimise the enantiomeric 
excesses of the reaction by varying reaction conditions and substituent in the substrate will 
also be reported.  
7.1.1 Previous work related to the asymmetric oxidative fragmentation of 
diazabenz[e]aceanthrylenes 161a  
Previously within the group, several approaches have been attempted to achieve the 
formation of the single enantio-atropisomer of 162a. For example, asymmetric reduction of 
161a was explored in order to introduce a stereogenic centre into the molecule which could 
direct the epoxidation of the double bond to form the epoxide on the same face as the 
hydroxyl group. It was then proposed that fragmentation and oxidation of 4 would generate 
162a as a single enantiomer (Scheme 7.2).224  
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Scheme 7.2 Proposed asymmetric synthesis of single enantio-atropisomer of 162a’ by the asymmetric 
reduction process.  
However, selective reduction of the C8 carbonyl in 161a failed as the C14 carbonyl group 
surprisingly reacts instead.  
7.2 Asymmetric epoxidation based oxidative fragmentation of 161a. 
Asymmetric epoxidation, as discussed in Section 5.3, was another possible way forward. If it 
proved possible to epoxidise 161a asymmetrically in the first step, subsequent fragmentation 
may enable the synthesis of enantio-enriched 162a (Scheme 7.3).  
 
Scheme 7.3 Proposed asymmetric epoxidation approach to obtain a single enantio-atropisomer of 162a.  
7.2.1 Attempted Jacobsen asymmetric epoxidation 
Jacobsen-Katsuki epoxidation (see Section 5.3.1.2), which uses chiral (salen)Mn(III) 
complexes as the catalyst, is known to epoxidise simple olefins efficiently.249,250 Readily 
available catalyst 204 (Sigma Aldrich®), which was considered as the most efficient and 
stereo-selectivity catalyst,308 has been used in the preparation of the side chain of taxol 
(Scheme 7.4).309 
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Scheme 7.4 Chemical structure of the commercial available Jacobsen catalyst 204. Synthetic approach of using 
204 as catalyst in the formation of 206.  
In Jacobsen’s taxol side chain synthesis, 204 was used as a catalyst in the epoxidation 
reaction of 205 to obtain 206 in good yield with 97% e.e..309 As 205 has a carbonyl group 
conjugated to the olefin as in the diazabenz[e]aceanthrylenes 161a, this method was thought 
to be promising in our asymmetric approach. 161a was therefore submitted to the 
Jacobsen-Katsuki epoxidation reaction under standard reaction conditions (Scheme 7.5). It 
was thought that as this reaction was performed under aqueous conditions, if intermediate 
168 was formed, the epoxide should be opened to afford iminium ion intermediate 169. 
Iminium ion 169 should then react with water, to give diol 207.  
 
Scheme 7.5 Attempted Jacobsen epoxidation of 161a.  
However, the epoxidation reaction was not successful as only starting material 161a was 
recovered from the reaction mixture. Problem may arise due to the relative insolubility of 
161a under the reaction conditions.   
7.2.2 [Ru(pybox)(pydic)] catalysed asymmetric epoxidation 
The [Ru(pybox)(pydic)] catalysed asymmetric epoxidation reaction is a relatively new 
approach which has been introduced by Beller and co-workers (Section 5.3.1.4).257-259 One of 
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the best conditions used in their studies involves the use of [bis(acetoxy)iodo]benzene as the 
oxidant.310 Previously within the group, it has been shown that [bis(acetoxy)iodo]benzene 
can cleave the racemic diols 207a and 207b, to give urea 162a and its enantiomer 162a’ as a 
racemic mixture(Scheme 7.6). PhI(OAc)2 only had very limited reactivity with 161a itself.  
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Scheme 7.6 Previously established cleavage reaction using [bis(acetoxy)iodo]benzene to cleave syn (207a) and 
anti (207b) diol to afford 162a. Reaction conditions: PhI(OAc)2, toluene, r.t., 1 hr, 32% for syn-diol 207a, and 
37% for anti-diol 205b.  
As was discussed in Section 7.2.1, after the formation of iminium ion intermediate 169, diol 
205 could well be formed in the presence of water. As 207 can react with 
[bis(acetoxy)iodo]benzene, there is the potential for 162a’ to be formed directly in a one pot 
procedure. Therefore, the [Ru(pybox)(pydic)] catalysed asymmetric epoxidation of 161a was 
explored.  
The synthesis of the [Ru(pybox)(pydic)] catalysts followed the literature route.258,259 
Commercial available pybox 208b and sodium pyridine-2,6-dicarboxylate (209) were 
reacted with [Ru(p-cymene)Cl2]2 to obtain the [Ru(pybox)(pydic)] complex 141b in good 
yield (Scheme 7.7).  
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Scheme 7.7 Synthesis of [Ru(pybox)(pydic)] catalyst 141. Reaction conditions: [Ru(p-cymene)Cl2]2, 
MeOH/H2O, Ar, 1 hr, 65 °C; yields: 141b, 82%; 141a, 79%; 141c, 79%; 141d, 86%.  
Catalyst 141b was then used in the planned oxidative cleavage reaction of 161a with 
[bis(acetoxy)iodo]benzene as the oxidant in toluene for 4 days to give 162a in 28% yield 
with 25% e.e.(Scheme 7.8, analytical chiral HPLC analysis using a normal phase chiral 
column (isocratic eluant, 50% IPA, 50% Hexanes) was used to determine the e.e.. For spectra, 
see Appendix). Although this procedure requires long reaction times and only gives moderate 
yield and a low enantiomeric excess ratio, it was considered to be encouraging.  
 
Scheme 7.8 Asymmetric oxidative fragmentation reaction of 161a to afford 162a. Reaction conditions: 
[bis(acetoxy)iodo]benzene (3.0 eq), 141b (5 mol%), toluene, r.t., 96 hrs, 28% yield, 25% e.e..  
Analogues 141a, 141c, 141d of 14b were synthesised in the search for a better catalyst for 
use in this reaction. The corresponding pybox ligands 208a, 208b, 208d were used (Scheme 
7.7).258,259 The catalysts 141a, 141c, 141d were then used in to the oxidative fragmentation 
reactions of 161a in place of 141b to afford enantio-enriched 162a. The results of the 
reactions are shown in Table 7.1.  
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Entry  catalyst Yield  e.e. 
1 141b 28% 25% 
2 141a 30% 25% 
3 141c 29% -20% 
4 141d 25% 14% 
Table 7.1 Results of asymmetric oxidation of 161a to afford 162a using 141 as catalyst. Reaction conditions: 
[bis(acetoxy)iodo]benzene (3.0 eq), 141a-d (5 mol%), toluene, r.t., 96 hrs.  
As can be seen from Table 7.1, all four catalysts gave moderate yields and e.e.s. Interstingly, 
catalyst 141c (Entry 3, Table 7.1) led to a reversal in the sense of enantio-enrichment 
compared to catalysts 141a, 141b and 141d. This observation matched the previous work in 
Beller’s group, as 141c also gave the opposite enantiomer in the asymmetric epoxidation 
reactions of simple substrates compared to catalysts 141a, 141b and 141d.258,259 As all the 
catalyst struggled to convert 161a to 162a, and 206b was the most economic option, it was 
decided to attempt to optimise the asymmetric fragmentation reactions further using 141b as 
the catalyst.  
7.2.3 Attempted optimisation of the asymmetric fragmentation of 161a using catalyst 
141b.  
Since the oxidative fragmentation reaction using 141b as the catalyst required long reaction 
times but only gave moderate yield and e.e., it was decide to optimise this reaction. The 
conditions that were changed in an attempt to improve the reaction outcome are shown in 
Table 7.2.  
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Entry 
Equivalents 
of 
PhI(OAc)2 
Equivalents 
of H2O 
Temperature
Catalyst 
loading 
(mol%) 
Time 
(hrs) e.e. Yield 
1 3 0 r.t. 5 96 25% 28% 
2 6 0 r.t. 5 96 25% 31% 
3 1 1 r.t. 5 16 25% 44% 
4 2 1 r.t. 5 16 24% 67% 
5 2 2 r.t. 5 16 20% 66% 
6 3 1 r.t. 5 16 23% 71% 
7 6 6 r.t. 5 16 10% 76% 
8 2 1 0 °C 5 16 -- No reaction
9 2 1 0 °C to r.t. 5 16 33% 65% 
10 2 1 -78 °C to r.t. 5 16 27% 48% 
11 2 1 60 °C 5 3 20% 70% 
12 2 0 60 °C 5 3 27% 5% 
13 2 1 r.t. 20 16 25% 68% 
Table 7.2 The attempted optimisation of asymmetric fragmentation of 161a to afford 162a, using 141b as 
catalyst.  
There are some interesting observations that can be seen in Table 7.2: a) addition of water 
can increase the reaction rate and yield (Entry 1 vs 6). However, addition of more than one 
equivalent of water to the reaction decreased the e.e. (Entry 4 vs 5). These observation 
suggested that water is essential for the reaction but the amount added is important; b) in the 
absence of water, increasing the amount of PhI(OAc)2 did not improve the reaction (Entry 1 
vs 2). However, in the presence of water, increasing the amount of PhI(OAc)2 led to an 
increase in the yield whilst the e.e. remained similar (Entry 3, 4 and 6); c) increasing the 
reaction temperature to 60 °C meant that the reaction time could be shortened to 3 hours 
(Entry 4 vs 11). However, without addition of water, the catalyst 141b decomposed rapidly 
(Entry 12). On the other hand lowering the temperature to 0 °C, there was only starting 
material recovered from the reaction, this is possibly due to the fact that the water was frozen 
under these conditions. However, if the reaction mixture was allowed to warm up from 0 °C 
to room temperature seems an apparently a positive effect on the enantio-selectivity of the 
reaction was observed (Entry 9); d) increasing the percentage loading of the catalyst led to 
no obvious improvement.  
In addition, different solvent systems were also employed to try and optimised the 
fragmentation reaction. However, the catalyst 141b decomposed rapidly in acetonitrile. In 
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chloroform and dichloromethane, the reaction outcomes were inconsistent. Therefore, it was 
decided to continue to use toluene as solvent and the best reaction outcome so far for this 
reaction is 65% yield and 33% e.e. (Entry 9). Importantly, the e.e. of 162a can be improved 
by recrystallisation (Figure 7.1) as racemic crystals of 162a formed rapidly. This meant that 
the mother liqueur of 162a became enriched as the crystals crashed out. As shown in the 
HPLC trace in Figure 7.1, the mother liqueur of 162a were 91% e.e. (trace C). 
 
Figure 7.1 HPLC trace of the asymmetric oxidative fragmentation of 161a to afford 162a. A) Racemic mixture 
of 162a; B) After the asymmetric reaction; C) Mother liqueur after the recrystalisation. Recrystalisation solvent: 
acetone.  
7.2.4 Determination of absolute stereochemistry of the major enantio-atropisomer.  
Since the mechanism of the [Ru(pybox)(pydic)] catalyst asymmetric epoxidation is not very 
well understood, it was very challenging to predict the outcome of the fragmentation reaction 
of 161a in terms of the sense of the asymmetric induction. Therefore, it was decided to use 
X-ray crystallography to try to determine the absolute stereochemistry of the major 
enantiomer of 162a produced on reaction of 161a in the presence of 141b. In order to 
achieve this goal, a heavy atom has to be introduced into the molecule.  
 
Scheme 7.10 Synthesis of bromine containing analogue 211. Reaction conditions: (i) NaBH4 (0.9 eq), THF, 0 
°C to r.t., 1 hr, 67%, [α]20D = -187.2. (ii) 4-bromobenoyl chloride, DMAP, pyridine, DCM, r.t., o/n, 51%, [α]
20
D = 
-179.2. X-ray crystal structure of 211. 
Enantio-enriched 162a (91% e.e.) was submitted to a sodium borohydride reduction 
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following a route established previously within the group to give the mono-reduced product 
210. The structure of 210 was confirmed by X-ray crystallography using racemic material 
prepared separatly.224 The resulting 210 (prepared from enriched 162a) was then treated with 
4-bromobenzoyl chloride to obtain 211 in good yield. Interestingly, instead of acylating on 
the O10 position, the acylation occurred at the O9 position. This observation can be 
explained by the fact that under the reaction conditions, 210 could exist as the tautomeric 
form 212, of which the O9 is presumably sterically more accessible than O10 (Scheme 7.11). 
Therefore, 211 was the only product isolated from the reaction. In the X-ray crystallographic 
analysis, several crystals of 211 that were analysed appeared to be racemic. However, it was 
possible to find a crystal which contained a single enantiomer. The absolute stereochemistry 
of this single enantiomer of 211 has been solved and is shown in Scheme 7.10.  
N
O
N
O
OHO
210
N
O
N
O
OHHO
212
910 910
 
Scheme 7.11 Proposed resonance form 212 of 210.  
7.2.5 The mechanism of [Ru(pybox)(pydic)] catalysed reactions 
To further improve the enantio-selectivity of this [Ru(pybox)(pydic)] catalysed oxidative 
fragmentation, understanding of the mechanism of this reaction becomes essential. There are 
several possible reaction pathways that need to be considered. 
Pathway 1: [Ru(pybox)(pydic)] catalysed epoxidation followed by fragmentation. As was 
proposed in Beller’s asymmetric epoxidation studies, the [Ru(pybox)(pydic)] may firstly be 
oxidised by the oxidant PhI(OAc)2 to an active oxo-ruthenium species [Ru(pybox)(pydic)O] 
142b, which can then deliver the ruthenium-based oxygen (Ru=O) to 161a to form epoxide 
168.258 The epoxide in 6 may then open helped by the lone pair on N5 to afford the iminium 
ion 169, which if quenched by water will form the diol 207. As was shown previously in this 
chapter, diol 207 can be fragmented by PhI(OAc)2 to give 162a.  
Chapter 7 
                                                                                                     
142
 
Scheme 7.12 Proposed pathway 1 for [Ru(pybox)(pydic)] catalyst oxidative fragmentation of 161a to afford 
162a. 
However, in Beller’s asymmetric epoxidation studies, a [Ru(pybox)(pydic)O2] species was 
also proposed as the possible catalyst,258 which means Ru may be oxidised into the higher 
valent ruthenium complex. Although in Bailey’s epoxidation system, the 
(RuO2(bpy)[IO3(OH)3]) complex has been isolated and proved to be an efficient epoxidation 
catalyst,311,312 it is still possible that [Ru(pybox)(pydic)O2] would follow a similar catalytic 
pathway as RuO4 which is known as a strong oxidant and is useful for directly cleaving 
carbon-carbon double bonds.313,314 Therefore, as shown in Scheme 7.13, pathway 2 can also 
be proposed as the [Ru(pybox)(pydic)] catalyst 141b is over oxidised to 
[Ru(pybox)(pydic)O2], and it is this species subsequently cleaves 161a to give 162a’.  
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Scheme 7.13 Proposed pathway 2 and 3 for [Ru(pybox)(pydic)] catalyst oxidative fragmentation of 161a to 
afford 162a. 
On the other hand, high valent ruthenium complexes similar to RuO4 are also known as 
dihydroxylating reagents in an analogous manner to OsO4.231 A third possible pathway must 
therefore be considered, (pathway 3, Scheme 7.13) involves dihydroxylation of 161a by the 
over oxidised [Ru(pybox)(pydic)O2] to afford 207 which is subsequently fragmented by 
PhI(OAc)2 to give 162a.  
At present, it is very challenging to identify which is the most likely pathway for this 
oxidative fragmentation reaction or whether more than one pathway exists. However, as was 
discussed in the context of Table 7.2, water seems to play an important role in this oxidative 
fragmentation reaction. Of the three pathways, only pathway 1 seems to require the 
assistance of water as the diol formation needs the addition of water. To test this possibility, 
heavy water H218O was used in the fragmentation reaction instead of H216O. The product 
162a was submitted to mass spectrometric analysis and a mass increase of 2 was observed 
(376.95 (addition of one molecule of MeOH and sodium) compared to the situation when 
H216O was used (374.96, Figure 7.2). 162a itself was submitted to the [Ru(pybox)(pydic)] 
catalysed oxidative fragmentation conditions with addition of H218O, but no mass increase 
was observed, suggesting that none of the carbonyl oxygen in 162a cab exchange for 18O 
under the reaction conditions. This observation is consistent with pathway 1.  
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Figure 7.2 ESI-MS spectra for H218O experiment. Peak at 374.96 represents the 162a, peak at 376.95 represents 
the oxidative fragmentation reaction with addition of one molecule of H218O. 
Also the observation that 141c catalysed oxidative fragmentation reaction gave the opposite 
enantiomer of 162a consistent with the observation in Beller’s studies,258 suggested that the 
formation of 162a should go via the similar pathway as Beller’s epoxidation.  
7.3 Asymmetric oxidative fragmentation of analogues of 161. 
To study the effects of different substituents in various positions of the molecule, analogues 
of 161 were synthesised following reported method (Scheme 7.14).315 Commercially 
available anthranilates 213 and N-aryl lactams were subjected to a microwave reaction to 
give 161 in moderate to good yields (Scheme 7.14).  
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R1
R2
R3
CO2Me
NH2
N O
MeO2C
R4
+
(i)
N N
O
O
R1
R2
R3
R4
213 214 161
213a R1=R2=R3= H
213b R1= Me, R2=R3= H
213c R1= Cl, R2=R3= H
213d R2= Me, R1= R3= H
213e R2= Cl, R1= R3= H
213f R3= Me, R1= R2= H
214a R4= H
214b R4= Me
214c R4= OMe
214d R4= Cl
161a R1=R2=R3=R4= H
161b R1= Me, R2=R3=R4= H
161c R1= Cl, R2=R3=R4= H
161d R2= Me, R1=R3=R4= H
161e R2= Cl, R1=R3=R4= H
161f R3= Me, R1=R2=R4= H
161g R4= Me, R1=R2=R3= H
161h R4= OMe, R1=R2=R3= H
161i R4= Cl, R1=R2=R3= H  
Scheme 7.11 Synthesis of analogous of 161a. Reaction conditions: MW, 190 °C, 275 w, 30 mins. Yields: 161a, 
67%; 161b, 79%; 161c, 80%; 161d, 48%; 161e, 55%; 161f, 35%; 161g, 63%; 161h, 90%; 161i, 53%.  
Asymmetric oxidative fragmentation reactions of analogues of 161 using 141b as the catalyst 
under the best reaction conditions discussed above, were performed. The results of these 
reactions are listed in Table 7.3. 
 
Entry R1 R2 R3 R4 Yield e.e. 
162a H H H H 65% 33%a 
162b Me H H H 55% 0%a 
162c Cl H H H 72% 36%a 
162d H Me H H 58% 7%a 
162e H Cl H H 73% 35%b 
162f H H Me H 61% -9%a 
162g H H H Me 57% 4%a 
162h H H H OMe 36% 2%a 
162i H H H Cl 63% 36%b 
Table 7.3 Asymmetric oxidative fragmentation reactions of analogues of 161 to afford 162 using 141b as the 
catalyst. Reaction conditions: PhI(OAc)2 (2 eq), H2O (1 eq), 141b (5 mol%), anhydrous toluene, 0 °C to r.t., 16 
hrs. a e.e. determined by HPLC, b e.e. determined by 1H NMR analysis using chiral shift reagent (spectrum see 
Appendix 7).  
From Table 7.3, it can be seen that under the same conditions, the electron donating groups 
had a negative effect on the enantio-selectivity. However, the electron withdrawing groups 
seems to have a positive (162b vs 162c, 162d vs 162e, 162g vs 162i). Another interesting 
observation is, Ru catalysed fragmentation of 161f using catalyst 141b gave the opposite 
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major enantiomer to the other analogues. This is possibly due to the change of the molecule 
shape of 161f caused by the interaction between the methyl group and the C14 carbonyl 
group, which has been discussed in previous work from within the group.224 The e.e. of 162f 
can be improved by recrystalisation from -9% to -60% (Appendix 7). Additionally, methoxy 
analogue 161h could not be cleaved by m-CPBA in the previous studies.224 Ru catalysed 
oxidative fragmentation reaction of 161h gave 162h, although only in moderate yield and 
poor enantio-selectivity.  
7.4 Conclusion. 
Previously within the group, an oxidative fragmentation method was established and applied 
to the diazabenz[e]aceanthrylene system 161 to afford an interesting atropisomeric system 
162. However, the attempted asymmetric synthesis of the atropisomers was unsuccessful. 
Therefore, this chapter was dedicated to further investigate the asymmetric oxidative 
fragmentation reaction based on asymmetric epoxidation reactions. Jacobsen epoxidation 
reaction was attempted but not successful. [Ru(pybox)(pydic)] catalysed oxidation using 
PhI(OAc)2 as oxidant gave 162a in moderate yield and enantio-selectivity. Optimisation of 
this reaction significantly increased the reaction rate (96 hrs to 16 hrs) and yield (28% to 
65%). Although the enantio-selectivity remained moderate, it can be improved by 
recrystalisation (33% to 91%). The absolute configuration of 162a was determined by 
introducing a heavy atom into a derivative of 162a and analysis by X-ray crystallography. 
Analogues of 161 were also submitted to the [Ru(pybox)(pydic)] catalysed asymmetric 
oxidative fragmentation reaction. Explanations for the effects of the different substituents on 
the fragmentation reactions were also discussed. 
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Chapter 8: Experimental 
8.1 General procedures 
Chemicals and reagents were obtained from either Aldrich or Alfa-Aesar and were used as 
received unless otherwise stated. All reactions involving moisture sensitive reagents were 
performed in oven dried glassware under a positive pressure of argon. Tetrahydrofuran 
(THF), dichloromethane (DCM) and toluene were obtained dry from a solvent purification 
system (MBraun, SPS-800). Dimethyldioxirane (DMDO) was prepared using a literature 
method.316  
Thin-layer chromatography was performed using glassplates coated with silica gel (with 
fluorescent indicator UV254) (Aldrich). Developed plates were air-dried and analysed under a 
UV lamp. Flash column chromatography was performed using silica gel (40-63 μm) 
(Fluorochem). 
Melting points were recorded in open capillaries using an Electrothermal 9100 melting point 
apparatus. Values are quoted to the nearest 1 oC and are uncorrected. 
Elemental microanalyses were performed on a Carlo Erba CHNS analyser within the School 
of Chemistry at the University of St Andrews. 
Infrared spectra were recorded on a Perkin Elmer Spectrum GX FT-IR spectrometer using 
either thin films on NaCl plates (NaCl) or KBr discs (KBr) as stated. Absorption maxima are 
reported as wavenumbers (cm-1) and intensities are quoted as strong (s), medium (m), weak 
(w) and broad (br). 
Low resolution (LR) and high resolution (HR) electrospray mass spectral (ES-MS) analyses 
were acquired by electrospray ionisation (ESI), electron impact (EI) or chemical ionisation 
(CI) within the School of Chemistry, University of St Andrews. Low and high resolution ESI 
MS were carried out on a Micromass LCT spectrometer and low and high resolution CI MS 
were carried out on a Micromass GCT spectrometer recorded on a high performance 
orthogonal acceleration reflecting TOF mass spectrometer, coupled to a Waters 2975 HPLC. 
Only the major peaks are reported and intensities are quoted as percentages of the base peak. 
Nuclear magnetic resonance (NMR) spectra were acquired on either a Bruker Avance 300 
(1H, 300.1 MHz; 13C, 75.5 MHz), Bruker Avance 400 (1H, 400 MHz; 13C, 100.1 MHz) or a 
Bruker Avance 500 (1H, 500 MHz; 13C, 125 MHz) spectrometer and in the deuterated solvent 
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stated. 13C NMR spectra were acquired using the PENDANT or DEPTQ pulse sequences. All 
NMR spectra were acquired using the deuterated solvent as the lock. Coupling constants (J) 
are quoted in Hz and are recorded to the nearest 0.1 Hz. The following abbreviations are 
used; s, singlet; d, doublet; dd, doublet of doublets; ddd, doublet of doublets of doublets; dt, 
doublet of triplets; t, triplet; m, multiplet; q, quartet; qt, quintet; and br, broad.  
Microwave assisted reactions were performed using a CEM Discover microwave operated in 
‘powermax’ mode. 
8.2 General procedure of Japp-Klingemeann reaction: to a cold (0 oC) solution of aniline 
175 (44 mmol, 1 eq) in concentrated hydrochloric acid (5 mL) was added sodium nitrite (3.0 
g, 44 mmol, 1 eq) dissolved in water (10 mL) portionwise over 20 minutes. The mixture was 
stirred at 0 oC for 30 minutes. In a separate flask, a cool solution of 
2-(hydroxymethlene)cyclohexanone, 2-(hydroxymethlene)cycloheptanone or 
2-(hydroxymethlene)cyclooctanone (sodium hydride (8.0 g, 300 mmol, 1.5 eq) in 1 L 
three-neck round bottom flask, anhydrous THF (400 mL) and EtOH (1 mL) were added, and 
the mixture was cooled to 0 oC in an ice-bath. A mixture of cyclohexanone 174 (or 
cycloheptanone/ cyclooctanone) (200 mmol, 1 1eq) and ethyl formate (24 mL, 300 mmol, 
1.5 eq) was added dropwise over 1 hour. The reaction mixture was then left stirred overnight. 
EtOH (1 mL) was added, and the reaction mixture was stirred for a further 1 hour. Water 
(100 mL) was added to the flask. THF was removed in vacuo. The aqueous layer was 
extracted with diethyl ether (100 mL), acidified with hydrochloric acid, and extracted with 
diethyl ether (100 mL x 3). The solvent of the organic layer was removed and the resulting 
oil was purified via flash column chromatography (diethyl ether) over silica, and used 
immediately in the reaction.) in methanol (30 mL) was treated with a solution of sodium 
acetate (8.3 g, 101 mmol, 2.5 eq) in water (25 mL). The mixture was stirred at 0 oC for 20 
minutes and the diazonium salt slurry was added. The combined mixture was stirred for 
10-15 minutes, collected by filtration, triturated with ethanol, and collected by filtration to 
give the product.  
2-(2-(4-bromophenyl)hydrazono)cyclohexanone (176a)317 
 
Title compound was afforded as a yellow solid (7.78 g, 33.0 mmol, 75%). Mp: 235 °C (dec.) 
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(lit.317 232-233 °C); 1H NMR (400 MHz, DMSO-d6): δ 9.87 (s, 1H, H1), 7.40 (d, 2H, 3J= 8.5 
Hz, H3’ H5’), 7.12 (d, 2H, 3J= 8.5 Hz, H2’ H6’), 2.44-2.76 (m, 4H, H5 H8), 1.92-1.80 (m, 
4H, H6 H7). LRMS (ES+): m/z (%) 303.02 (100) [M+Na]+, 304.03 (90) [M+Na]+.  
2-(2-(4-chlorophenyl)hydrazono)cyclohexanone (176f)317 
Cl
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Title compound was afforded as a yellow solid (8.41 g, 35.6 mmol, 81%). Mp: 237 °C (dec.) 
(lit.317 236-237 °C); 1H NMR (400 MHz, DMSO-d6): δ 9.93 (s, 1H, H1), 7.35 (d, 2H, 3J= 8.5 
Hz, H3’ H5’), 7.29 (d, 2H, 3J= 8.5 Hz, H2’ H6’), 2.40-2.55 (m, 4H, H5 H8), 1.84-1.75 (m, 
4H, H6 H7). LRMS (ES+): m/z (%) 259.07 (100) [M+Na]+.   
2-(2-(4-iodophenyl)hydrazono)cyclohexanone (176g)317 
 
Title compound was afforded as a yellow solid (11.0 g, 33.4 mmol, 76%). Mp: 259 °C (dec.) 
(lit.317 254-255 °C); 1H NMR (400 MHz, DMSO-d6): δ 9.67 (s, 1H, H1), 7.46 (d, 2H, 3J= 8.5 
Hz, H3’ H5’), 6.79 (d, 2H, 3J= 8.5 Hz, H2’ H6’), 2.40-2.55 (m, 4H, H5 H8), 1.84-1.75 (m, 
4H, H6 H7). LRMS (ES+): m/z (%) 351.01 (100) [M+Na]+.   
2-(2-(4-nitrophenyl)hydrazono)cyclohexanone (176h)317 
O2N
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Title compound was afforded as a red solid (6.19 g, 25.1 mmol, 57%). Mp: 199-200 °C 
(lit.317 193-194 °C); 1H NMR (400 MHz, DMSO-d6): δ 10.13 (s, 1H, H1), 8.05 (d, 2H, 3J= 
8.5 Hz, H3’ H5’), 7.44 (d, 2H, 3J= 8.5 Hz, H2’ H6’), 2.40-2.55 (m, 4H, H5 H8), 1.84-1.75 (m, 
4H, H6 H7). LRMS (ES+): m/z (%) 270.10 (100) [M+Na]+.   
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2-(2-(4-methoxyphenyl)hydrazono)cyclohexanone (176i)317 
 
Title compound was afforded as a brown solid (7.01 g, 30.3 mmol, 69%). Mp: 201-202 °C 
(lit.317 201-202 °C); 1H NMR (400 MHz, DMSO-d6): δ 8.79 (s, 1H, H1), 7.53 (d, 2H, 3J= 8.5 
Hz, H2’ H6’), 7.02 (d, 2H, 3J= 8.5 Hz, H3’ H5’), 2.40-2.55 (m, 4H, H5 H8), 1.84-1.75 (m, 
4H, H6 H7). LRMS (ES+): m/z (%) 255.12 (100) [M+Na]+.   
2-(2-(4-bromophenyl)hydrazono)cycloheptanone (176k)318 
 
Title compound was afforded as a yellow solid (9.44 g, 32.1 mmol, 73%). Mp: 189-192 °C 
(lit.318 189-192 °C); 1H NMR (400 MHz, DMSO-d6): δ 9.87 (s, 1H, H1), 7.35 (d, 2H, 3J= 8.5 
Hz, H3’ H5’), 6.53 (d, 2H, 3J= 8.5 Hz, H2’ H6’), 3.06 (t, 2H, 3J= 6.5 Hz, H9), 2.40 (t, 2H, 
3J= 6.0 Hz, H5), 2.03-2.10 (m, 2H, H6), 1.84-1.75 (m, 4H, H8 H7). LRMS (ES+): m/z (%) 
317.03 (100) [M+Na]+, 319.03 (90) [M+Na]+.  
2-(2-phenylhydrazono)cycloheptanone (176l)318 
 
Title compound was afforded as a yellow solid (7.89 g, 36.5 mmol, 83%). Mp: 166-167 °C 
(lit.318 166-167 °C); 1H NMR (400 MHz, DMSO-d6): δ 9.43 (s, 1H, H1), 7.35 (d, 2H, 3J= 8.5 
Hz, H2’ H6’), 7.20 (dd, 2H, 3J= 8.5 8.0 Hz, H3’ H5’), 6.81 (d, 1H, 3J= 8.0 Hz, H4’), 3.06 (t, 
2H, 3J= 6.5 Hz, H9), 2.40 (t, 2H, 3J= 6.0 Hz, H5), 2.03-2.10 (m, 2H, H6), 1.84-1.75 (m, 4H, 
H8 H7). LRMS (ES+): m/z (%) 317.03 (100) [M+Na]+.  
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2-(2-(4-bromophenyl)hydrazono)cyclooctanone (176m)318 
 
Title compound was afforded as a yellow solid (9.08 g, 29.5 mmol, 67%). Mp: 177-178 °C 
(lit.318 177-178 °C); 1H NMR (400 MHz, DMSO-d6): δ 9.87 (s, 1H, H1), 7.35 (d, 2H, 3J= 8.5 
Hz, H3’ H5’), 6.53 (d, 2H, 3J= 8.5 Hz, H2’ H6’), 3.06 (t, 2H, 3J= 6.5 Hz, H10), 2.40 (t, 2H, 
3J= 6.0 Hz, H5), 2.03-2.10 (m, 2H, H6), 1.84-1.75 (m, 6H, H8 H7 H9). LRMS (ES+): m/z (%) 
331.03 (100) [M+Na]+, 333.03 (90) [M+Na]+.  
2-(2-phenylhydrazono) cyclooctanone (176n)318 
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Title compound was afforded as a yellow solid (7.99 g, 34.8 mmol, 79%). Mp: 153-154 °C 
(lit.318 151-152 °C); 1H NMR (400 MHz, DMSO-d6): δ 9.43 (s, 1H, H1), 7.35 (d, 2H, 3J= 8.5 
Hz, H2’ H6’), 7.20 (dd, 2H, 3J= 8.5 8.0 Hz, H3’ H5’), 6.81 (d, 1H, 3J= 8.0 Hz, H4’), 3.06 (t, 
2H, 3J= 6.5 Hz, H10), 2.40 (t, 2H, 3J= 6.0 Hz, H5), 2.03-2.10 (m, 2H, H6), 1.84-1.75 (m, 6H, 
H8 H7 H9). LRMS (ES+): m/z (%) 253.14 (100) [M+Na]+.  
2-(2-(4-bromophenyl)hydrazono)cyclopentanone (176p)318 
 
A three-neck flask was charged with ethyl 2-oxocyclopentanecarboxylate (202) (15.60 g, 
100.0 mmol, 1 eq), water (200 mL) and 5 N NaOH (110 mmol, 1.1 eq), and the resulting 
solution was stirred at room temperature for 48 hours. The mixture was extracted with 
MTBE (2 x 40 mL) to remove any unreacted starting material, and the aqueous phase 
containing the sodium carboxylate was returned to the original three-neck flask. This 
solution was cooled to 0 °C, treated dropwise with concentrated HCl (110 mmol, 1.1 eq) 
over 15 min, and aged at this temperature for 45 minutes. To a mixture of the p-bromo 
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aniline (175a, 17.10 g, 100 mmol, 1 eq) in water (60 mL), at room temperature, was added 
concentrated HCl (300 mmol), and the resulting thick white slurry was cooled to 0 °C. A 
solution of NaNO2 (6.9 g, 100 mmol, 1 eq) in water (70 mL) was added slowly over 25 
minutes, and the reaction mixture was aged for 30 minutes before filteration to remove any 
insoluble precipitate. To the pre-prepared sodium carboxylate solution at 0 °C was added the 
filtered diazonium solution dropwise over 40 minutes at 0 °C. The resulting thick yellow 
slurry was stirred to room temperature, filtered, and dried to give title compound as a yellow 
solid (16.49 g, 62.0 mmol, 62%). Mp: 241 °C (dec.) (lit.318 232-233 °C); 1H NMR (400 MHz, 
DMSO-d6): δ 9.87 (s, 1H, H1), 7.40 (d, 2H, 3J= 8.5, H3’ H5’), 7.12 (d, 2H, 3J= 8.5, H2’ H6’), 
2.44-2.76 (m, 4H, H5 H7), 1.92-1.80 (m, 2H, H6). LRMS (ES+): m/z (%) 289.11 (100) 
[M+Na]+, 292.27 (90) [M+Na]+. 
8.3 General procedure of Fischer indole synthesis: A solution of hydrozone 176 (10.0 
mmol) in hydrochloric acid (2 mL) and acetic acid (8 mL) was heated at 120 °C for 20 
minutes. The mixture was cooled slightly and treated with ice water. The resulting precipitate 
was collected by filtration to give the corresponding carbazolone.  
6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-one (177a)318 
 
Title compound was afforded as a brown solid (1.68 g, 6.4 mmol, 64%). Mp: 256-257 °C 
(lit.318 256 °C) 1H NMR (400 MHz, CDCl3): δ 8.79 (s, 1H, NH), 7.80 (d, 1H, 4J= 2.0 Hz, H5), 
7.44 (dd, 1H, 3J= 9.0 Hz, 4J= 2.0 Hz, H7), 7.30 (d, 1H, 3J= 9.0 Hz, H8), 2.97 (t, 2H, 3J= 6.0 
Hz, H4), 2.66 (t, 2H, 3J= 6.5 Hz, H2), 2.27 (tt, 2H, 3J= 6.0 6.5 Hz, H3); LRMS (ES+): m/z (%) 
263.05 (100) [M+H]+, 265.05 (100) [M+H]+. 
6-chloro-1,2,3,4-tetrahydrocarbazol-1-one (177f)318 
 
Title compound was afforded as a brown solid (1.67 g, 6.7 mmol, 67%). Mp: 224-225 °C 
(lit.318 226 °C); 1H NMR (400 MHz, DMSO-d6): δ 11.78 (s, 1H, NH), 7.75 (d, 1H, 4J= 2.0 
Hz, H5), 7.38 (d, 1H, 3J= 9.0 Hz, H8), 7.28 (dd, 1H, 3J= 9.0 Hz, 4J= 2.0 Hz, H7), 2.92 (t, 2H, 
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3J= 7.0 Hz, H4), 2.55 (t, 2H, 3J= 7.0 Hz, H2), 2.13 (q, 2H, 3J= 7.0 Hz, H3); LRMS (ES+): 
m/z (%) 220.25 (100) [M+H]+. 
6-iodo-1,2,3,4-tetrahydrocarbazol-1-one (177g)318 
 
Title compound was afforded as a brown solid (1.89 g, 6.1 mmol, 61%). Mp: 277-278 °C 
(lit.318 279 °C); 1H NMR (400 MHz, DMSO-d6): δ 11.78 (s, 1H, NH), 8.01 (d, 1H, 4J= 2.0 
Hz, H5), 7.64 (dd, 1H, 3J= 9.0 Hz, 4J= 2.0 Hz, H7), 7.25 (d, 1H, 3J= 9.0 Hz, H8), 2.92 (t, 2H, 
3J= 7.0 Hz, H4), 2.55 (t, 2H, 3J= 7.0 Hz, H2), 2.13 (q, 2H, 3J= 7.0 Hz, H3); LRMS (ES+): 
m/z (%) 311.98 (100) [M+H]+. 
6-nitro-1,2,3,4-tetrahydrocarbazol-1-one (177h)318 
 
Title compound was afforded as a brown solid (0.28 g, 1.2 mmol, 12%). Mp: 221-222 °C (lit 
220 °C); 1H NMR (400 MHz, DMSO-d6): δ 11.78 (s, 1H, NH), 8.67 (d, 1H, 4J= 2.0, H5), 
8.29 (dd, 1H, 3J= 9.0, 4J= 2.0, H7), 7.54 (d, 1H, 3J= 9.0, H8), 2.92 (t, 2H, 3J= 7.0, H4), 2.55 
(t, 2H, 3J= 7.0, H2), 2.13 (q, 2H, 3J= 7.0, H3); LRMS (ES+): m/z (%) 231.07 (100) [M+H]+. 
6-methoxy-1,2,3,4-tetrahydrocarbazol-1-one (177i)318 
 
Title compound was afforded as a brown solid (1.18 g, 5.5 mmol, 55%). Mp: 188-189 °C 
(lit.318 188 °C); 1H NMR (400 MHz, DMSO-d6): δ 11.78 (s, 1H, NH), 7.19 (d, 1H, 3J= 9.0 
Hz, H8), 6.98 (d, 1H, 4J= 2.5 Hz, H5), 6.86 (dd, 1H, 3J= 9.0 Hz, 4J= 2.5 Hz, H7), 2.92 (t, 2H, 
3J= 7.0 Hz, H4), 2.55 (t, 2H, 3J= 7.0 Hz, H2), 2.13 (q, 2H, 3J= 7.0 Hz, H3); LRMS (ES+): 
m/z (%) 231.07 (100) [M+H]+. 
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2-bromo-7,8,9,10-tetrahydrocyclohepta[b]indol-6(5H)-one (177k)318 
 
Title compound was afforded as a brown solid (1.83 g, 6.6 mmol, 66%). Mp: 188-189 °C 
(lit.318 188 °C); 1H NMR (400 MHz, CDCl3): δ 9.01 (s, 1H, H5), 7.80 (d, 1H, 4J= 2.0 Hz, 
H1), 7.42 (dd, 1H, 3J= 9.0 Hz, 4J= 2.0 Hz, H3), 7.25 (d, 1H, 3J= 9.0 Hz, H4), 3.10 (t, 2H, 3J= 
6.5 Hz, H10), 2.86 (t, 2H, 3J= 6.0 Hz, H7), 1.95-2.16 (m, 4H, H8, H9); LRMS (ES+): m/z (%) 
278.01 (100) [M+H]+, 280.01 (100) [M+H]+.  
7,8,9,10-tetrahydrocyclohepta[b]indol-6(5H)-one (177l)318 
 
Title compound was afforded as a brown solid (1.83 g, 6.6 mmol, 66%). Mp: 188-189 °C 
(lit.318 188 °C); 1H NMR (400 MHz, CDCl3): δ 9.01 (s, 1H, H5), 7.80 (d, 1H, 4J= 2.0 Hz, 
H1), 7.42 (dd, 1H, 3J= 9.0 Hz, 4J= 2.0 Hz, H3), 7.25 (d, 1H, 3J= 9.0 Hz, H4), 3.10 (t, 2H, 3J= 
6.5 Hz, H10), 2.86 (t, 2H, 3J= 6.0 Hz, H7), 1.95-2.16 (m, 4H, H8, H9); LRMS (ES+): m/z (%) 
200.11 (100) [M+H]+. 
2-bromo-8,9,10,11-tetrahydro-5H-cycloocta[b]indol-6(7H)-one (177m)318 
 
Title compound was afforded as a brown solid (1.99 g, 6.7 mmol, 67%). Mp: 107-108 °C 
(lit.318 107 °C); 1H NMR (400 MHz, CDCl3): δ 7.65 (d, 1H, 4J= 2.0 Hz, H1), 7.25 (dd, 1H, 
3J= 9.0 Hz, 4J= 2.0 Hz, H3), 7.13 (d, 1H, 3J= 9.0 Hz, H4), 2.68-2.95 (m, 2H, H7), 2.00-2.22 
(m, 2H, H11), 1.52-1.86 (m, 6H, H8, H9, H10); LRMS (ES+): m/z (%) 292.01 (100) [M+H]+, 
294.01 (100) [M+H]+. 
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5-8,9,10,11 tetrahydro-5H-cycloocta[b] indol-6(7H) –one (177n)318 
 
Title compound was afforded as a brown solid (1.17 g, 5.5 mmol, 55%). Mp: 98-99 °C (lit.318 
99 °C); 1H NMR (400 MHz, CDCl3): δ 7.64 (d, 1H, 3J= 8.0 Hz, H1), 7.31-7.40 (m, 2H, H2, 
H4), 7.11 (dd, 1H, 3J= 7.5 Hz, 4J= 1.5 Hz, H3), 3.27 (t, 2H, 3J= 7.0 Hz, H11), 2.97 (t, 2H, 
3J= 7.5 Hz, H7), 1.66-1.83 (m, 4H, H10, H8), 1.33-1.41 (m, 2H, H9); LRMS (ES+): m/z (%) 
214.11 (100) [M+H]+. 
Synthesis of 9-(2-bromoethyl)-2,3,4,9 tetrahydro-1H-carbazol-1-one (177o)307 
 
To a stirred solution of 1,2,3,4-tetrahydrocarbazole (201, 5.00 g, 29.2 mmol, 1.0 eq) in 300 
mL THF and 75 mL water was added diiodine pentoxide (11.7 g, 35.1 mmol, 1.2 eq). After 
stirring for 20 min at room temperature, the solvent was removed in vacuo at room 
temperature. The residue was extracted with ethyl acetate. The organic portion was washed 
with water, 5% Na2S2O3, saturated sodium bicarbonate and brine, and dried overMgSO4. 
After removing the solvent, the crude product was purified by recrystalisation 
(EtOAc/hexanes, 1/20) to afford title compound as white solid (3.5 g, 18.98 mmol, 65%); mp 
164– 165 °C (lit.307 164– 165 °C); 1H NMR (CDCl3): δ 8.98 (s, 1H, NH), 7.66 (d, 1H, 3J = 
9.0 Hz, H5), 7.44–7.34 (m, 2H, H6 H8), 7.15 (t, 1H, 3J = 6.0 Hz, H7), 3.02 (t, 2H, 3J = 6.0 
Hz, H2), 2.67 (t, 2H, 3J = 6.0 Hz, H4), 2.27 (m, 2H, H3); LRMS (ES+): m/z (%) 208.1 (100) 
[M+H]+. 
7-bromo-1,2-dihydrocyclopenta[b]indol-3(4H)-one (177p)318 
 
Title compound was afforded as a brown solid (1.54 g, 6.2 mmol, 62%). Mp: 261-262 °C 
(lit.318 256 °C) 1H NMR (400 MHz, CDCl3): δ 8.79 (s, 1H, NH), 7.80 (d, 1H, 4J= 2.0 Hz, H8), 
7.44 (dd, 1H, 3J= 9.0 Hz, 4J= 2.0 Hz, H6), 7.30 (d, 1H, 3J= 9.0 Hz, H5), 2.97 (t, 2H, 3J= 6.0 
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Hz, H1), 2.66 (t, 2H, 3J= 6.5 Hz, H2); LRMS (ES+): m/z (%) 271.98 (100) [M+Na]+, 274.02 
(90) [M+Na]+. 
8.4 General procedure of alkylation: carbazolone 177 (10.0 mmol) was suspended in 
1,2-dibromoethane (10 mL) or 1,3-dibromopropane, 9N aqueous sodium hydroxide solution 
(10 mL) and tetrabutyl ammonium bromide (0.086 g, 3.00 mmol, 0.03 eq) were added. The 
mixture was stirred at room temperature for 18 hours. The reaction mixture was diluted with 
DCM (30 mL) and water (30 mL). Organic layer was separated and the water layer was 
washed with DCM (30 mL x 3). The organic layer was dried with MgSO4, filtered, and 
reduced, the crude product was purified by flash column chromatography via silica gel 
(EtOAc/hexanes, 1:19) to afford product 178.  
6-bromo-9-(2-bromoethyl)-2,3,4,9-tetrahydro-1H-carbazol-1-one (178a)307 
 
Title compound was afford as a light brown solid (2.40 g, 6.50 mmol, 65%). Mp: 155-156 °C 
(lit.307 155 °C); 1H NMR (400 MHz, CDCl3): δ 7.71 (d, 1H, 4J= 2.0 Hz, H5), 7.44 (dd, 1H, 
3J= 9.0 Hz, 4J= 2.0 Hz, H7), 7.26 (d, 1H, 3J= 9.0 Hz, H8), 4.77 (t, 2H, 3J= 6.54 Hz, H2’), 
3.61 (t, 2H, 3J= 6.5 Hz, H1’), 2.90 (t, 2H, 3J= 6.0 Hz, H2), 2.59 (t, 2H, 3J= 6.5 Hz, H4), 2.16 
(tt, 2H, 3J= 6.0, 6.5 Hz, H3); LRMS (ES+): m/z (%) 369.93 (100) [M+H]+, 371.93 (100) 
[M+H]+ 
9-(2-bromoethyl)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-one (178f)307 
 
Title compound was afforded as a light brown solid (2.11 g, 6.50 mmol, 65%). Mp: 119-120 
°C (lit.307 121 °C); 1H NMR (400 MHz, CDCl3): δ 7.65 (d, 1H, 4J= 2.0 Hz, H5), 7.38-7.41 
(m, 2H, H7, H8), 4.86 (t, 2H, 3J= 6.5 Hz, H1’), 3.72 (t, 2H, 3J= 6.5 Hz, H2’), 3.00 (t, 2H, 3J= 
6.0 Hz, H4), 2.69 (t, 2H, 3J= 7.0 Hz, H2), 2.26 (tt, 2H, 3J= 6.0 7.0 Hz, H3); LRMS (ES+): 
m/z (%) 325.93 (100) [M+H]+, 327.93 (100) [M+H]+.  
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9-(2-bromoethyl)-6-iodo-2,3,4,9-tetrahydro-1H-carbazol-1-one (178g)307 
 
Title compound was afforded as a light brown solid (2.54 g, 6.10 mmol, 61%). Mp: 126-127 
°C (lit.307 126 °C). 1H NMR (400 MHz, CDCl3): δ 8.01 (d, 1H, 4J= 2.0 Hz, H5), 7.64 (dd, 1H, 
3J= 9.0 Hz, 4J= 2.0 Hz, H7), 7.25 (d, 1H, 3J= 9.0 Hz, H8), 4.84 (t, 2H, 3J= 7.0 Hz, H1’), 3.69 
(t, 2H, 3J= 7.0 Hz, H2’), 2.98 (t, 2H, 3J= 6.5 Hz, H4), 2.67 (t, 2H, 3J= 6.0 Hz, H2), 2.24 (tt, 
2H, 3J= 6.0 6.5 Hz, H3); LRMS (ES+): m/z (%) 417.93 (100) [M+H]+, 419.93 (100) [M+H]+.  
9-(2-bromoethyl)-6-nitro-2,3,4,9-tetrahydro-1H-carbazol-1-one (178h)307 
 
Title compound was afforded as a red solid (2.18 g, 6.50 mmol, 65%). Mp: 83-84 °C (lit.307 
83 °C); 1H NMR (400 MHz, CDCl3): δ 8.67 (d, 1H, 4J= 2.0 Hz, H5), 8.29 (dd, 1H, 3J= 9.0 
Hz, 4J= 2.0 Hz, H7), 7.54 (d, 1H, 3J= 9.0 Hz, H8), 4.92 (t, 2H, 3J= 6.5 Hz, H1’), 3.76 (t, 2H, 
3J= 6.5 Hz, H2’), 3.10 (t, 2H, 3J= 6.0 Hz, H4), 2.72 (t, 2H, 3J= 7.0 Hz, H2), 2.30 (tt, 2H, 3J= 
6.0, 7.0 Hz, H3); LRMS (ES+): m/z (%) 337.01 (100) [M+H]+, 339.01 (100) [M+H]+. 
6-methoxy-1,2,3,4-tetrahydrocarbazol-1-one (178i)318 
 
Title compound was afforded as a brown solid (1.18 g, 5.50 mmol, 55%). Mp: 108-109 °C 
(lit.318 108 °C); 1H NMR (400 MHz, CDCl3): δ 11.78 (s, 1H, NH), 7.19 (d, 1H, 3J= 9.0 Hz, 
H8), 6.98 (d, 1H, 4J= 2.5 Hz, H5), 6.86 (dd, 1H, 3J= 9.0 Hz, 4J= 2.5 Hz, H7), 4.92 (t, 2H, 3J= 
6.5 Hz, H1’), 3.76 (t, 2H, 3J= 6.5 Hz, H2’), 2.92 (t, 2H, 3J= 7.0 Hz, H4), 2.55 (t, 2H, 3J= 7.0 
Hz, H2), 2.13 (q, 2H, 3J= 7.0 Hz, H3); LRMS (ES+): m/z (%) 322.03 (100) [M+H]+, 324.03 
(100) [M+H]+. 
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9-(2-bromoethyl)-2,3,4,9 tetrahydro-1H-carbazol-1-one (178o)318 
 
Title compound was afforded as a light brown solid (1.86 g, 6.4 mmol, 64%). Mp: 129-130 
°C (lit.318 130 °C); 1H NMR (400 MHz, CDCl3): δ 7.59 (d, 1H, 3J= 8.0 Hz, H5), 7.32-7.39 
(m, 2H, H7, H8), 7.10 (dd, 1H, 3J= 7.0, 8.0 Hz, H6), 4.80 (t, 2H, 3J= 7.0 Hz, H1’), 3.61 (t, 
2H, 3J= 7.0 Hz, H2’), 2.96 (t, 2H, 3J= 6.0 Hz, H4), 2.59 (t, 2H, 3J= 7.0 Hz, H2), 2.16 (tt, 2H, 
3J= 6.0, 7.0 Hz, H3); LRMS (ES+): m/z (%) 292.02 (100) [M+H]+, 294.05 (100) [M+H]+. 
2-bromo-5-(2-bromoethyl)-7,8,9,10-tetrahydrocayclohepta[b]indol-6(5H)-one (178k) 
 
Title compound as a light yellow solid (2.52 g, 6.6 mmol, 66%). Mp: 119-120 °C; 1H NMR 
(400 MHz, CDCl3): δ 7.76 (d, 1H, 4J= 2.0 Hz, H1), 7.39 (dd, 1H, 3J= 9.0 Hz, 4J= 2.0 Hz, H3), 
7.26 (d, 1H, 3J= 9.0 Hz, H4), 4.73 (t, 2H, 3J= 7.0 Hz, H2’), 3.60 (t, 2H, 3J= 7.0 Hz, H1’), 
2.97 (t, 2H, 3J= 6.0 Hz, H7), 2.75 (t, 2H, 3J= 6.0 Hz, H10), 1.82-1.91 (m, 4H, H8, H9); 13C 
NMR (100 MHz, CDCl3): δ 195.9 (C6), 137.3 (C4a), 133.7 (C10b), 129.4 (C3), 127.8 
(C10a), 127.1 (C5a),123.5 (C1), 112.0 (C4), 46.5 (C2’), 42.6 (C10), 30.8 (C1’), 25.0 (C9), 
22.9 (C7), 21.5 (C8). IR (KBr) νmax = 2967 (m), 2855 (m), (Ar-H), 1629 (s) (C=O), 1107 (s) 
(C-O), 819 (m) (C-Br), 730 (Ar-H arom); LRMS (ES+): m/z (%) 383.95 (100) [M+H]+, 
384.95 (100) [M+H]+. HRMS (ES+): m/z calcd for C15H15NO79Br2 [M+H]+:383.9520; found 
383.9519; 
2-bromo-5-(2-bromoethyl)-7,8,9,10-tetrahydrocayclohepta[b]indol-6(5H)-one (178l) 
 
Title compound as a light yellow solid (2.52 g, 6.60 mmol, 66%). Mp: 119-120 °C; 1H NMR 
(400 MHz, CDCl3): δ7.30-7.36 (m, 4H, H1, H2, H3, H4), 4.73 (t, 2H, 3J= 7.0 Hz, H2’), 3.60 
(t, 2H, 3J= 7.0 Hz, H1’), 2.97 (t, 2H, 3J= 6.0 Hz, H7), 2.75 (t, 2H, 3J= 6.0 Hz, H10), 
1.82-1.91 (m, 4H, H8, H9); 13C NMR (100 MHz, CDCl3): δ 195.9 (C6), 137.3 (C4a), 133.7 
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(C10b), 129.4 (C3), 127.8 (C10a), 127.1 (C5a), 123.7 (C2), 123.5 (C1), 112.0 (C4), 46.5 
(C2’), 42.6 (C10), 30.8 (C1’), 25.0 (C9), 22.9 (C7), 21.5 (C8). IR (KBr) νmax = 2967 (m), 
2855 (m), (Ar-H), 1629 (s) (C=O), 819 (m) (C-Br), 730 (Ar-H arom); LRMS (ES+): m/z (%) 
306.04 (100) [M+H]+, 308.04 (100) [M+H]+. HRMS (ES+): m/z calcd for C15H17NO79Br 
[M+H]+:306.0415; found 306.0415; 
5-(2-bromoethyl)-8,9,10,11 tetrahydro-5H-cycloocta[b] indol-6(7H) –one (178n) 
 
Title compound was afforded as a light brown solid (2.04 g, 6.40 mmol, 64%). Mp: 119-120 
°C; 1H NMR (400 MHz, CDCl3): δ 7.64 (d, 1H, 3J= 8.0 Hz, H1), 7.31-7.40 (m, 2H, H2, H4), 
7.11 (dd, 1H, 3J= 7.5 Hz, 4J= 1.5 Hz, H3), 4.82 (t, 2H, 3J= 7.0 Hz, H1’), 3.61 (t, 2H, 3J= 7.0 
Hz, H2’), 3.27 (t, 2H, 3J= 7.0 Hz, H11), 2.97 (t, 2H, 3J= 7.5 Hz, H7), 1.66-1.83 (m, 4H, H10, 
H8), 1.33-1.41 (m, 2H, H9); 13C NMR (100 MHz, CDCl3): δ 195.5 (C6), 138.9 (C4a), 134.3 
(C5a), 126.7 (C2), 126.6 (C11a), 124.6 (C11b), 121.0 (C1), 120.2 (C3), 110.3 (C4), 46.8 
(C1’), 42.2 (C7), 30.6 (C2’), 25.6 (C9), 24.1 (C10), 24.0 (C8), 22.6 (C11); IR (KBr) νmax = 
2967 (m), 2855 (m), (Ar-H), 1629 (s) (C=O), 819 (m) (C-Br), 730 (Ar-H arom); LRMS 
(ES+): m/z (%) 320.04 (100) [M+H]+, 322.05 (100) [M+H]+; HRMS (ES+): m/z calcd for 
C15H19NO79Br [M+H]+:320.0572; found 320.0565. 
2-bromo-5-(2-bromoethyl)-8,9,10,11 tetrahydro-5H-cycloocta[b] indol-6(7H) –one 
(178m) 
 
Title compound was afforded as a light brown solid (2.04 g, 6.40 mmol, 64%). Mp: 119-120 
°C; 1H NMR (400 MHz, CDCl3): δ 7.65 (d, 1H, 4J= 2.0 Hz, H1), 7.25 (dd, 1H, 3J= 9.0 Hz, 
4J= 2.0 Hz, H3), 7.13 (d, 1H, 3J= 9.0 Hz, H4), 4.82 (t, 2H, 3J= 7.0 Hz, H1’), 3.61 (t, 2H, 3J= 
7.0 Hz, H2’), 3.27 (t, 2H, 3J= 7.0 Hz, H11), 2.97 (t, 2H, 3J= 7.5 Hz, H7), 1.66-1.83 (m, 4H, 
H10, H8), 1.33-1.41 (m, 2H, H9); 13C NMR (100 MHz, CDCl3): δ 195.5 (C6), 138.9 (C4a), 
134.3 (C5a), 126.6 (C11a), 124.6 (C11b), 121.0 (C1), 120.2 (C3), 113.2 (C2), 110.3 (C4), 
46.8 (C1’), 42.2 (C7), 30.6 (C2’), 25.6 (C9), 24.1 (C10), 24.0 (C8), 22.6 (C11); IR (KBr) 
νmax = 2967 (m), 2855 (m), (Ar-H), 1629 (s) (C=O), 819 (m) (C-Br), 730 (Ar-H arom); 
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LRMS (ES+): m/z (%) 397.97 (100) [M+H]+, 399.97 (100) [M+H]+; HRMS (ES+): m/z calcd 
for C16H18NO79Br2 [M+H]+:397.9677; found 397.9677. 
7-bromo-4-(2-bromoethyl)-1,2-dihydrocyclopenta[b]indol-3(4H)-one (178p) 
 
Title compound was afforded as a light brown solid (2.73 g, 7.70 mmol, 77%). Mp: 191-192 
°C; 1H NMR (400 MHz, CDCl3): δ 7.65 (d, 1H, 4J= 2.0 Hz, H8), 7.25 (dd, 1H, 3J= 9.0 Hz, 
4J= 2.0 Hz, H3), 7.13 (d, 1H, 3J= 9.0 Hz, H5), 4.82 (t, 2H, 3J= 7.0 Hz, H1’), 3.61 (t, 2H, 3J= 
7.0 Hz, H2’), 3.27 (t, 2H, 3J= 7.0 Hz, H1), 2.97 (t, 2H, 3J= 7.0 Hz, H2); 13C NMR (100 MHz, 
CDCl3): δ 195.5 (C3), 138.9 (C5a), 134.3 (C3a), 126.6 (C8b), 124.6 (C8a), 121.0 (C8), 120.2 
(C6), 113.2 (C7), 110.3 (C5), 46.8 (C1’), 42.2 (C2), 30.6 (C2’), 22.6 (C11); IR (KBr) νmax = 
2967 (m), 2855 (m), (Ar-H), 1629 (s) (C=O), 819 (m) (C-Br), 730 (Ar-H arom); LRMS 
(ES+): m/z (%) 355.92 (100) [M+H]+, 357.01 (100) [M+H]+; HRMS (ES+): m/z calcd for 
C13H11NO79Br2 [M+H]+:354.9207; found 355.0013. 
6-bromo-9-(2-bromopropane)-2,3,4,9-tetrahydro-1H-carbazol-1-one (183)307 
 
Title compound was afford as a light brown solid (2.40 g, 6.50 mmol, 65%). Mp: 140-141 °C 
(lit 140 °C); 1H NMR (400 MHz, CDCl3): δ 7.71 (d, 1H, 4J= 2.0 Hz, H5), 7.44 (dd, 1H, 3J= 
9.0 Hz, 4J= 2.0 Hz, H7), 7.26 (d, 1H, 3J= 9.0 Hz, H8), 4.77 (t, 2H, 3J= 6.54 Hz, H3’), 3.61 (t, 
2H, 3J= 6.5 Hz, H1’), 2.90 (t, 2H, 3J= 6.0 Hz, H2), 2.59 (t, 2H, 3J= 6.5 Hz, H4), 2.27 (m, 2H, 
H2’), 2.16 (tt, 2H, 3J= 6.0, 6.5 Hz, H3); LRMS (ES+): m/z (%) 383.95 (100) [M+H]+, 385.93 
(100) [M+H]+ 
8.5 General procedure of sodium borohydride reduction: carbazolone 178 (5.0 mmol, 1.0 
eq) was dissolved in ethanol (100 mL), and sodium borohydride (0.57 g, 15.0 mmol, 3.0 eq) 
was added. This mixture was then heated at 60 °C for 6 hours. Solvent was removed in 
vacuo, the residue was diluted with DCM (50 mL) and water (50 mL). The aqueous layer 
was extracted with DCM (50 mL x 3). The organic layers were combined, dried (MgSO4), 
and reduced to give light brown solid. The crude mixture was purified via flash column 
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chromatography over silica gel (3: 7 ethyl acetate: hexanes) to afford oxizino carbazole 171.  
8-bromo-1,2,3a,4,5,6-hexahydro-[1,4] oxazino [2,3,4-jk] carbazole (171a) 
 
Title compound was afforded as a pale yellow solid (0.99 g, 3.40 mmol, 68%). Mp: 86-87 °C; 
1H NMR (400 MHz, CDCl3): δ 7.53 (d, 1H, 4J= 2.0 Hz, H7), 7.18 (dd, 1H, 3J= 8.5 Hz, 4J= 
2.0 Hz, H9), 7.05 (d, 1H, 3J= 8.5 Hz, H10), 4.60-4.64 (m, 1H, H3a), 4.26 (dt, 1H, 2J= 12.0 
Hz, 3J= 5.5 Hz, H1a), 4.06 (dt, 1H, 2J= 12.0 Hz, 3J= 4.0 Hz, H1b), 3.95 (dt, 1H, 2J= 11.5 Hz, 
3J= 4.0 Hz, H2a), 3.75 (dt, 1H, 2J= 11.5 Hz, 3J= 5.5 Hz, H2b), 2.63-2.69 (m, 1H, H6a), 
2.51-2.61 (m, 1H, H5a), 2.04-2.23 (m, 2H, H4), 1.72-1.85 (m, 1H, H6b), 1.51-1.61 (m, 1H, 
H5b); 13C NMR (100 MHz, CDCl3): δ 137.1 (C11a), 135.9 (C10a), 129.7 (C6b), 124.0 (C9), 
121.5 (C7), 113.1 (C8), 110.8 (C10), 108.4 (C6a), 72.6 (C3a), 64.6 (C1), 43.0 (C2), 29.2 
(C5), 21.4 (C4), 20.5 (C6). IR (KBr) νmax= 2930 (s), 2855 (s), 1442 (s), 1472 (s), 1094 (s) 
(C-O), 819 (m) (C-Br) cm-1; LRMS (ES+): m/z (%) 291.92 (100) [M+H]+, 293.93 (20) 
[M+H]+; HRMS (ES+): m/z calcd for C14H15NO79Br [M+H]+: 292.0337; found 292.0336. 
8-chloro-1,2,3a,4,5,6-hexahydro-[1,4] oxazino [2,3,4-jk] carbazole (171f) 
 
Title compound was obtained as a pale yellow solid (0.84 g, 3.40 mmol, 68%). Mp: 82-83 °C; 
1H NMR (400 MHz, CDCl3): δ 7.45 (d, 1H, 4J= 2.0 Hz, H7), 7.18 (d, 1H, 3J= 9.0 Hz, H10), 
7.14 (dd, 1H, 3J= 9.0 Hz, 4J= 2.0 Hz, H9), 4.66-4.73 (m, 1H, H3a), 4.34 (dd, 1H, 2J= 13.0 Hz, 
3J= 4.5 Hz, H2a), 4.13 (dt, 1H, 2J= 13.0 Hz, 3J= 4.5 Hz, H2b), 4.01 (dd, 1H, 2J= 11.0 Hz, 3J= 
4.5 Hz, H1a), 3.82 (dt, 1H, 2J= 11.0 Hz, 3J= 4.5 Hz, H1b), 2.60-2.79 (m, 2H, H6), 2.24-2.32 
(m, 1H, H4a), 2.13-2.22 (m, 1H, H5a), 1.81-1.94 (m, 1H, H5b), 1.60-1.70 (m, 1H, H4b); 13C 
NMR (100 MHz, CDCl3): δ 136.8 (C10a), 136.1 (C11a), 129.1 (C6b), 125.5 (C8), 121.4 
(C9), 118.4 (C7), 110.3 (C10), 108.4 (C6a), 72.6 (C3a), 64.6 (C2), 43.0 (C1), 29.2 (C4), 21.4 
(C5), 20.5 (C6); IR (KBr) νmax= 2930 (s), 2855 (s), 1442 (s), 1472 (s), 1095 (s) (C-O), 689 
(m) (C-Cl) cm-1; LRMS (ES+): m/z (%) 248.99 (100) [M+H]+; HRMS (ES+): m/z calcd for 
C14H15NCl [M+H]+: 249.0401; found 249.0411. 
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8-iodo-1,2,3a,4,5,6-hexahydro-[1,4] oxazino [2,3,4-jk] carbazole (171g) 
 
Title compound was obtained as a pale yellow solid (1.15 g, 3.40 mmol, 68%). Mp: 96-98 °C. 
1H NMR (400 MHz, CDCl3): δ 7.82 (d, 1H, 4J= 2.0 Hz, H7), 7.43 (dd, 1H, 3J= 9.0 Hz, 4J= 
2.0 Hz, H9), 7.05 (d, 1H, 3J= 9.0 Hz, H10), 4.67-4.73 (m, 1H, H3a), 4.35 (dd, 1H, 2J= 13.0 
Hz, 3J= 4.5 Hz, H2a), 4.15 (dt, 1H, 2J= 13.0 Hz, 3J= 4.5 Hz, H2b), 4.03 (dd, 1H, 2J= 11.0 Hz, 
3J= 4.5 Hz, H1a), 3.83 (dt, 1H, 2J= 11.0 Hz, 3J= 4.5 Hz, H1b), 2.58-2.77 (m, 2H, H6), 
2.23-2.32 (m, 1H, H4a), 2.12-2.22 (m, 1H, H5a), 1.80-1.94 (m, 1H, H5b), 1.58-1.69 (m, 1H, 
H4b); 13C NMR (100 MHz, CDCl3): δ 137.5 (C10a), 135.5 (C11a), 130.5 (C6b), 129.5 (C9), 
127.8 (C7), 111.4 (C10), 108.1 (C6a), 83.3 (C8), 72.6 (C3a), 64.6 (C2), 42.9 (C1), 29.2 (C4), 
21.4 (C5), 20.5 (C6). IR (KBr) νmax= 2868 (s), 2970 (s), 1102 (s) (C-O), 1456 (s), 483 (m) 
(C-I) cm-1; LRMS (ES+): m/z (%) 340.01 (100) [M+H]+; HRMS (ES+): m/z calcd for 
C14H15NI [M+H]+: 340.0154; found 340.0177. 
8-nitro-1,2,3a,4,5,6-hexahydro-[1,4]oxazino[2,3,4-jk]carbazole (171h) 
 
Title compound was afforded as a pale yellow solid (0.89 g, 3.45 mmol, 69%). Mp: 147-148 
°C. 1H NMR (400 MHz, CDCl3): δ 8.44 (d, 1H, 4J= 2.0 Hz, H7), 8.09 (dd, 1H, 3J= 9.0 Hz, 
4J= 2.0 Hz, H9), 7.27 (d, 1H, 3J= 9.0 Hz, H10), 4.67-4.75 (m, 1H, H3a), 4.40 (dd, 1H, 3J= 
12.0 5.0 Hz, H2a), 4.10-4.21 (m, 2H, H2b, H1a), 3.92-4.00 (m, 1H, H1b), 2.62-2.90 (m, 2H, 
H6), 2.16-2.39 (m, 2H, H4a, H5a), 1.84-1.97 (m, 1H, H5b), 1.60-1.72 (m, 1H, H4b); 13C 
NMR (100 MHz, CDCl3): δ 141.8 (C8), 140.9 (C10a), 137.5 (C11a), 127.3 (C6b), 117.0 (C9), 
116.0 (C7), 110.8 (C6a), 109.0 (C10), 72.6 (C3a), 64.4 (C2), 42.9 (C1), 29.0 (C4), 21.2 (C5), 
20.4 (C6); IR: (KBr) νmax= 2955 (m), 2876 (m), 1340 (s) (NO2), 1557 (m) (NO2), 1102 (s) 
(C-O) cm-1; LRMS (ES+): m/z (%) 281.01 (100) [M+Na]+; HRMS (ES+): m/z calcd for 
C14H14N2O3Na [M+Na]+: 281.0901; found 281.0902.  
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8-methoxy-1,2,3a,4,5,6-hexahydro-[1,4]oxazino[2,3,4-jk]carbazole (171i) 
 
Title compound was obtained as a pale yellow solid (0.94 g, 3.85 mmol, 77%). Mp: 96-98 °C; 
1H NMR (400 MHz, CDCl3): δ 7.19 (d, 1H, 3J= 9.0 Hz, H10), 6.98 (d, 1H, 4J= 2.5 Hz, H7), 
6.86 (dd, 1H, 3J= 9.0 Hz, 4J= 2.5 Hz, H9), 4.67-4.77 (m, 1H, H3a), 4.33 (dd, 1H, 3J= 12.0 
5.0 Hz, H2a), 4.15 (dt, 1H, 3J= 12.0 4.0 Hz, H2b), 4.02 (dd, 1H, 3J= 11.0 4.0 Hz, H1a), 3.88 
(s, 3H, H1’), 3.80 (dt, 1H, 3J= 11.0 5.0 Hz, H1b), 2.60-2.83 (m, 2H, H6), 2.11-2.36 (m, 2H, 
H4a, H5a), 1.79-1.99 (m, 1H, H5b), 1.54-1.73 (m, 1H, H4b); 13C NMR (100 MHz, CDCl3): δ 
154.9 (C8), 136.2 (C11a), 134.3 (C10a), 128.5 (C6b), 111.3 (C10), 110.6 (C9), 109.0 (C6a), 
101.8 (C7), 73.0 (C3a), 65.2 (C2), 56.4 (C1’), 43.7 (C1), 29.8 (C4), 21.9 (C5), 21.1 (C6). IR: 
(KBr) νmax= 2933 (s), 1442 (s), 1474 (s), 1455 (s), 1149 (s) (C-O), 1166 (s) (C-O); LRMS 
(ES+): m/z (%) 266.03 (100) [M+Na]+; HRMS (ES+): m/z calcd for C15H17NO2Na [M+Na]+: 
266.0896; found 266.0889. 
9-bromo-2,3a,4,5,6,7-hexahydro-1H-3-oxa-11b-azacyclohepta[jk]fluorine (171k) 
 
Title compound was afforded as a pale yellow solid (1.36 g, 4.45 mmol, 89%). Mp: 90-91 °C; 
1H NMR (400 MHz, CDCl3): δ 7.66 (d, 1H, 4J= 2.0 Hz, H8), 7.25 (dd, 1H, 3J= 9.0 Hz, 4J= 
2.0 Hz, H10), 7.13 (d, 1H, 3J= 9.0 Hz, H11), 4.74-4.84 (m, 1H, H3a), 4.31-4.38 (m, 1H, H2a), 
3.95-4.11 (m, 3H, H2b, H1), 2.99-3.12 (m, 1H, H7a), 2.46-2.61 (m, 1H, H7b), 2.03-2.20 (m, 
2H, H6), 1.90-2.04 (m, 1H, H4a), 1.54-1.79 (m, 2H, H5), 1.33-1.53 (m, 1H, H4b). 13C NMR 
(100 MHz, CDCl3): δ 135.4 (C12a), 133.6 (C11a), 129.2 (C7b), 123.6 (C10), 121.0 (C8), 
112.5 (C9), 109.9 (C7a), 109.7 (C11), 76.7 (C3a), 64.1 (C2), 41.2 (C1), 34.9 (C4), 28.3 (C5), 
26.8 (C7), 24.8 (C6). IR (KBr) νmax = 2926 (m) (Ar-H), 1103 (s) (C-O), 1606 (m) (C=C 
arom), 819 (m) (C-Br), 739 (m) (C-H arom) cm-1; LRMS (ES+): m/z (%) 328.04 
(100)[M+Na]+, 330.04 (95) [M+Na]+; HRMS (ES+): m/z calcd for C15H16NOBrNa [M+Na]+: 
330.2415; found 330.1999. 
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2,3a,4,5,6,7-hexahydro-1H-3-oxa-11b-azacyclohepta[jk]fluorine (171l) 
N O
1
3
57
9
11
2
3a
4
6
8
10
12
 
Title compound was obtained as a pale yellow solid (0.92 g, 4.05 mmol, 81%). Mp: 66-67 °C; 
1H NMR (400 MHz, CDCl3): δ 7.46 (d, 1H, 3J= 8.0 Hz, H8), 7.19 (d, 1H, 3J= 7.59 Hz, H11), 
7.02-7.13 (m, 2H, H9, H10), 5.06 (dd, 1H, 3J= 5.0, 5.5 Hz, H3a), 4.17-4.25 (m, 1H, H2a), 
3.09-4.02 (m, 3H, H2b, H1a, H1b), 2.68-2.92 (m, 2H, H7), 1.99-2.10 (m, 2H, H4), 1.50-1.75 
(m, 4H, H6, H5); 13C NMR (100 MHz, CDCl3): δ 136.2 (C7b), 132.4 (C12a), 127.8 (C11a), 
120.9 (C9), 119.4 (C10), 118.2 (C8), 109.3 (C7a), 108.5 (C11), 73.8 (C3a), 61.3 (C2), 42.1 
(C1), 35.2 (C4), 27.7 (C6), 26.2 (C5), 22.1 (C7). IR (KBr) νmax = 2933 (m) (Ar-H), 1107 (s) 
(C-O), 1615 (m) (C=C arom), 739 (m) (C-H arom) cm-1;LRMS (ES+): m/z (%) 228.04 (100) 
[M+H]+; HRMS (ES+): m/z calcd for C15H18NO [M+H]+: 228.2341; found 228.2344. 
10-bromo-1,2,3a,4,5,6,7,8-octahydro-3-oxa-12b-azacycloocta[jk]fluorine (171m) 
N O
Br
1
3
5
7
9
11
13
2
3a
4
6
8
10
12
 
Title compound was afforded as a pale yellow solid (1.42 g, 4.45 mmol, 89%). Mp: 107-108 
°C; 1H NMR (400 MHz, CDCl3): δ 7.65 (d, 1H, 4J= 2.0 Hz, H9), 7.25 (dd, 1H, 3J= 9.0 Hz, 
4J= 2.0 Hz, H11), 7.13 (d, 1H, 3J= 9.0 Hz, H12), 5.12 (dd, 1H, 3J= 9.5 5.0 Hz, H3a), 
4.21-4.39 (m, 1H, H2a), 3.91-4.10 (m, 3H, H2b, H1), 2.68-2.95 (m, 2H, H8), 2.00-2.22 (m, 
2H, H4), 1.52-1.86 (m, 6H, H7, H6, H5); 13C NMR (100 MHz, CDCl3): δ 134.9 (C13a), 
133.8 (C12a), 129.5 (C8a), 123.6 (C11), 120.8 (C9), 112.7 (C10), 110.0 (C12), 109.0 (C8a), 
73.7 (C3a), 61.1 (C2), 42.2 (C1), 35.2 (C4), 27.7 (C7), 26.1 (C6), 22.0 (C5), 21.2 (C8). IR 
(KBr) νmax = 2926 (m) (Ar-H), 1103 (s) (C-O), 1606 (m) (C=C arom), 790 (m) (C-Br), 739 
(m) (C-H arom) cm-1; LRMS (ES+): m/z (%) 342.06 (100) [M+Na]+, 344.05 (95) [M+Na]+; 
HRMS (ES+): m/z calcd for C16H18NOBrNa [M+Na]+: 342.0572; found 342.0577. 
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1,2,3a,4,5,6,7,8-octahydro-3-oxa-12b-azacycloocta[jk]fluorine (171n) 
N O
1
3
5
7
9
11
13
2
3a
4
6
8
10
12
 
Title compound was obtained as a pale yellow solid (1.04 g, 4.30 mmol, 86%). Mp: 59-60 °C; 
1H NMR (400 MHz, CDCl3): δ 7.46 (d, 1H, 3J= 8.0 Hz, H9), 7.19 (d, 1H, 3J= 7.59 Hz, H12), 
7.02-7.13 (m, 2H, H10, H11), 5.06 (dd, 1H, 3J= 5.0, 5.5 Hz, H3a), 4.17-4.25 (m, 1H, H2a), 
3.09-4.02 (m, 3H, H2b, H1a, H1b), 2.68-2.92 (m, 2H, H8), 1.99-2.10 (m, 2H, H4), 1.50-1.75 
(m, 4H, H7, H5), 1.15-1.30 (m, 2H, H6); 13C NMR (100 MHz, CDCl3): δ 118.2 (C9), 108.5 
(C12), 120.9 (C10), 119.4 (C11), 73.8 (C3a), 61.3 (C2), 42.1 (C1), 22.1 (C8), 35.2 (C4), 27.7 
(C7), 26.2 (C5), 214 (C6), 109.3 (C8a), 136.2 (C8b), 127.8 (C12a), 132.4 (C13a). IR (KBr) 
νmax = 2933 (m) (Ar-H), 1107 (s) (C-O), 1615 (m) (C=C arom), 739 (m) (C-H arom) cm-1; 
LRMS (ES+): m/z (%) 242.15 (100) [M+H]+; HRMS (ES+): m/z calcd for C16H20NO [M+H]+: 
242.1567; found 242.1567. 
Synthesis of 1,2,3a,4,5,6-hexahydro-[1,4]oxazino[2,3,4-jk]carbazole (171o) 
 
Title compound was obtained as a pale yellow solid (0.71 g, 3.35 mmol, 67%). Mp: 101-102 
°C; 1H NMR (400 MHz, CDCl3): δ 7.52 (d, 1H, 3J= 7.5 Hz, H7), 7.30 (d, 1H, 3J= 8.0 Hz, 
H10), 7.21 (t, 1H, 3J= 8.0 Hz, H9), 7.14 (t, 1H, 3J= 7.5 Hz, H8), 4.71-4.77 (m, 1H, H3a), 
4.35 (dd, 1H, 3J= 12.5 5.0 Hz, H2a), 4.17 (dt, 1H, 3J= 12.5 4.0 Hz, H2b), 4.08 (dd, 1H, 3J= 
11.0 4.0 Hz, H1a), 3.86 (dt, 1H, 3J= 11.0 5.0 Hz, H1b), 2.77-2.85 (m, 1H, H6a), 2.66-2.76 (m, 
1H, H6b), 2.24-2.32 (m, 1H, H4a), 2.14-2.23 (m, 1H, H5a), 1.82-1.98 (m, 1H, H5b), 
1.60-1.72 (m, 1H, H4b); 13C NMR (100 MHz, CDCl3): δ 138.5 (C11a), 134.8 (C10a), 128.0 
(C6b), 121.4 (C9), 119.9 (C8), 118.8 (C7), 109.5 (C10), 108.7 (C6a), 72.7 (C3a), 64.8 (C2), 
43.1 (C1), 29.4 (C4), 21.5 (C6), 20.7 (C5); IR (KBr) νmax = 2933 (m) (Ar-H), 1107 (s) (C-O), 
1615 (m) (C=C arom) cm-1; LRMS (ES+): m/z (%) 214.06 (100) [M+H]+; HRMS (ES+): m/z 
calcd for C14H16NO [M+H]+: 214.1232; found 214.1233. 
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7-bromo-4-(2-bromoethyl)-1,2,3,4-tetrahydrocyclopenta[b]indole-3-ol (203) 
N
Br
OH
Br 1
3
5
7
1' 2'
 
Title compound as a white solid ( 0.905 g, 2.5 mmol, 90%). 1H NMR (400 MHz, CDCl3): δ 
7.55 (d, 1H, 4J= 2.0 Hz, H8), 7.72 (dd, 1H, 3J= 9.0 Hz, 4J= 2.0 Hz, H6), 7.11 (d, 1H, 3J= 9.0 
Hz, H5), 5.26-5.36 (m, 1H, H3), 4.39-4.49 (m, 2H, H1’), 3.56-3.67 (m, 2H, H2’), 2.83-2.97 
(m, 2H, H1), 2.58 (m, 1H, H2a), 2.18-2.34 (m, 1H, H2b); 13C NMR (100 MHz, CDCl3): 
δ139.7 (C8a), 139.6 (C3a), 125.1 (C4a), 125.8 (C6), 122.6 (C8), 120.8 (C8b), 112.5 (C7), 
111.2 (C5), 70.0 (C3), 40.3 (C1), 45.9 (C1’), 29.8 (C2’), 22.3 (C2). IR (KBr): νmax = 2971 
(m), 2924 (s) (O-H), 2869 (m) 2921 (m) (Ar-H), 1639 (s) (C=O), 1102 (s) (C-O), 801 (m) 
(C-Br) cm-1; LRMS (ES+): m/z (%) 379.94 (100) [M+Na]+, 381.91 (100) [M+Na]+; HRMS 
(ES+): m/z calcd for C13H13NONa79Br2 [M+Na]+: 379.9413; found 379.9122. 
8.6 General procedure of DDQ oxidation: To a ice-cooled solution of oxizino carbazole 
171 (1.0 mmol, 1.0 eq) in THF/ H2O (9: 1, 11 mL), a DDQ (0.454 g, 2.00 mmol, 2.0 eq) THF 
(4 mL) solution was added dropwise with stirring under nitrogen atmosphere, the reaction 
mixture was then stirred for a further one hour. The reaction mixture was then concentrated 
in vacuo, the resulting solid was then participated between water and ethyl acetate, and 
extracted with ethyl acetate (3 x 20 mL). The organic layer was dried (MgSO4), filtered and 
concentrated in vacuo to give a red solid which was then purified by flash column 
chromatography over aluminum oxide (ethyl acetate) furnished the title compound.  
8-bromo-1,2,4,5-tetrahydro-[1,4]oxazino[2,3,4,jk]carbazol-6(3aH) –one (163a) 
 
Title compound was obtained as a white solid (0.2 g, 0.65 mmol, 65%). Mp: 259 °C (dec.);  
1H NMR (400 MHz, CDCl3): δ 8.26 (d, 1H, 4J= 2.0 Hz, H7), 7.33 (dd, 1H, 3J= 9.0 Hz, 4J= 
2.0 Hz, H9), 7.11 (d, 1H, 3J= 9.0 Hz, H10), 4.84 (dd, 1H, 2J= 12.0 Hz, 3J= 6.0 Hz, H3a), 
4.38-4.48 (m, 1H, H1a), 4.10-4.22 (m, 1H, H1b), 3.95-4.02 (m, 2H, H2), 2.54-2.63 (m, 2H, 
H5), 2.40-2.51 (m, 1H, H4a), 1.97-2.73 (m, 1H, H4b); 13C NMR (100 MHz, CDCl3): δ191.7 
(C6), 150.14 (C11a), 135.8 (C10a), 129.1 (C6b), 123.8 (C9), 121.6 (C7), 118.6 (C8), 110.4 
(C10), 109.7 (C6a), 71.3 (C3a), 64.2 (C2), 41.5 (C1), 36.9 (C5), 31.2 (C4); IR (KBr): νmax = 
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2971 (m), 2869 (m) 2921 (m) (Ar-H), 1639 (s) (C=O), 1102 (s) (C-O), 801 (m) (C-Br) cm-1; 
LRMS (ES+): m/z (%) 327.87 (100) [M+Na]+, 329.88 (100) [M+Na]+; HRMS (ES+): m/z 
calcd for C14H12NO2Na79Br [M+Na]+: 327.9944; found 327.9949; calcd for 
C14H12NO2Na81Br [M+Na]+: 329.9923; found 329.9929. Anal. calcd for C14H12NO2Br: C, 
54.92; H, 3.95; N, 4.58; found: C, 54.79; H, 3.85; N, 4.54. 
8-chloro-1,2,4,5-tetrahydro-[1,4]oxazino[2,3,4-jk]carbazol-6(3aH)- one (163f) 
 
Title compound was obtained as a white solid (0.18 g, 0.68 mmol, 68%). Mp: 258 °C (dec.); 
1H NMR (400 MHz, CDCl3): δ 8.16 (s, 1H, H7), 7.20-7.29 (m, 2H, H9, H10), 4.91 (dd, 1H, 
3J= 11.5 5.0 Hz, H3a), 4.50 (dd, 1H, 3J= 13.0 5.0 Hz, H2a), 4.18-4.27 (m, 1H, H2b), 
4.00-4.09 (m, 2H, H1), 2.49-2.74 (m, 3H, H5, H4a), 2.05-2.10 (m, 1H, H4b); 13C NMR (100 
MHz, CDCl3): δ 191.7 (C6), 150.14 (C11a), 135.8 (C10a), 129.1 (C6b), 125.6 (C8), 123.8 
(C9), 121.6 (C7), 110.4 (C10), 109.7 (C6a), 71.3 (C3a), 64.2 (C2), 41.5 (C1), 36.9 (C5), 31.2 
(C4); IR (KBr): νmax = 2971 (m), 2869 (m) 2921 (m) (Ar-H), 1639 (s) (C=O), 1102 (s) (C-O), 
728 (s) (C-Cl) cm-1; LRMS (ES+): m/z (%) 283.85 (100) [M+Na]+; HRMS (ES+): m/z calcd 
for C14H12NO2NaCl [M+Na]+: 284.0454; found 284.0455. 
8-iodo-1,2,4,5-tetrahydro-[1,4]oxazino[2,3,4-jk]carbazol-6(3aH)-one (163g) 
 
Title compound was obtained as a white solid (0.22 g, 0.61 mmol, 61%). Mp: 231 °C (dec.); 
1H NMR (400 MHz, CDCl3): δ 8.56 (d, 1H, 4J= 1.5 Hz, H7), 7.61 (dd, 1H, 3J= 8.5 Hz, 4J= 
1.5 Hz, H9), 7.12 (d, 1H, 3J= 8.5 Hz, H10), 4.94 (dd, 1H, 3J= 10.5 6.0 Hz, H3a), 4.53 (dd, 
1H, 3J= 12.5 4.0 Hz, H2a), 4.25 (dt, 1H, 3J= 12.0 2J= 5.0 Hz, H2b), 4.04-4.10 (m, 2H, H1), 
2.49-2.79 (m, 3H, H5, H4a), 2.02-2.26 (m, 1H, H4b); 13C NMR (100 MHz, CDCl3): δ 191.0 
(C6), 149.6 (C11a), 137.5 (C10a), 132.0 (C9), 130.5 (C7), 126.9 (C6b), 110.9 (C10), 107.6 
(C6a), 88.3 (C8), 71.3 (C3a), 64.0 (C2), 41.1 (C1), 36.7 (C5), 30.9 (C4); IR (KBr): νmax = 
2868 (m), 2969 (m), 3088 (m) (Ar-H), 1633 (s) (C=O), 1102 (s) (C-O), 531 (s) (C-I) cm-1 
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LRMS (ES+): m/z (%) 375.86 (100) [M+Na]+; HRMS (ES+): m/z calcd for C14H12NO2NaI 
[M+Na]+: 375.9802; found 375.9811. 
8-nitro-1,2,4,5-tetrahydro-[1,4]oxazino[2,3,4-jk]carbazol-6(3aH)-one (163h) 
 
Title compound was furnished as a yellow solid (0.16 g, 0.57 mmol, 57%). Mp: 229 °C (dec.)  
1H NMR (400 MHz, CDCl3): δ 8.95 (d, 1H, 4J= 2.0 Hz, H7), 8.15 (dd, 1H, 3J= 9.0 Hz, 4J= 
2.0 Hz, H9), 7.35 (d, 1H, 3J= 9.0 Hz, H10), 4.96 (dd, 1H, 3J= 11.0 5.5 Hz, H3a), 4.55 (dd, 
1H, 3J= 13.0 4.5 Hz, H2a), 4.27 (dt, 1H, 3J= 13.0 5.0 Hz, H2b), 4.08-4.20 (m, 2H, H1), 
2.51-2.81 (m, 3H, H5, H4a), 2.10-2.24 (m, 1H, H4b); 13C NMR (100 MHz, CDCl3): δ 191.5 
(C6), 152.4 (C11a), 144.1 (C8), 140.1 (C10a), 124.1 (C6b), 119.0 (C9), 118.3 (C7), 111.2 
(C6a), 109.5 (C10), 71.3 (C3a), 64.1 (C2), 41.7 (C1), 37.0 (C5), 31.1 (C4); IR (KBr) νmax = 
3041 (m), 2955 (m), 2876 (m) (Ar-H), 1650 (s) (C=O), 1557 (s), 1340 (s) (NO2), 1102 (s) 
(C-O); LRMS (ES+): m/z (%) 294.96 (100) [M+Na]+; HRMS (ES+): m/z calcd for 
C14H12N2O4Na [M+Na]+: 295.0699; found 295.0695.  
8-methoxy-1,2,4,5-tetrahydro-[1,4]oxazino[2,3,4-jk]carbazol-6(3aH)- one (163i) 
 
Title compound was furnished as a white solid (0.17 g, 0.66 mmol, 66%). Mp: 227 °C (dec.); 
1H NMR (400 MHz, CDCl3): δ 7.67 (d, 1H, 4J= 2.5 Hz, H7), 7.20 (d, 1H, 3J= 9.0 Hz, H10), 
6.93 (dd, 1H, 3J= 9.0 Hz, 4J= 2.5 Hz, H9), 4.87 (dd, 1H, 3J= 11.5 5.5 Hz, H3a), 4.43-4.50 (m, 
1H, H2a), 4.14-4.24 (m, 1H, H2b), 3.98-4.05 (m, 2H, H1), 3.90 (s, 3H, H1’), 2.43-2.73 (m, 
3H, H5, H4a), 1.98-2.25 (m, 1H, H4b). 13C NMR (100 MHz, CDCl3): δ 192.1 (C6), 156.7 
(C8), 149.5 (C11a), 132.2 (C10a), 125.4 (C6b), 110.2 (C6a), 113.4 (C9), 110.0 (C10), 103.6 
(C7), 71.4 (C3a), 63.2 (C2), 55.9 (C1’), 41.5 (C1), 37.0 (C5), 31.1 (C4). IR (KBr) νmax = 
2929 (m), 2975 (m), 2832 (m) (Ar-H), 1637 (s) (C=O), 1132 (s) (C-O), 1159 (s) (C-O); 
LRMS (ES+): m/z (%) 280.11 (100) [M+Na]+; HRMS (ES+): m/z calcd for C15H15NO3Na 
[M+Na]+: 280.2845; found 280.2823.  
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9-bromo-3a,4,5,6-tetrahydro-1H-3-oxa-11b-azacyclohepta[jk]fluoren-7(2H)-one (163k) 
 
Title compound was obtained as a white solid (0.208 g, 0.67 mmol, 67%). Mp: 195-196 °C; 
1H NMR (400 MHz, CDCl3): δ 8.61 (d, 1H, 4J= 2.0 Hz, H8), 7.40 (dd, 1H, 3J= 8.5 Hz, 4J= 
2.0 Hz, H10), 7.17 (d, 1H, 3J= 8.5 Hz, H11), 4.93-4.99 (m, 1H, H3a), 4.43-4.48 (m, 1H, H2a), 
4.05-4.19 (m, 3H, H2b, H1), 2.73-2.78 (m, 2H, H6), 2.43-2.52 (m, 1H, H4a), 1.95-2.09 (m, 
3H, H4b, H5); 13C NMR (100 MHz, CDCl3): δ 196.3 (C7), 144.5 (C12a), 134.8 (C11a), 
126.3 (C10), 125.9 (C7b), 125.5 (C8), 118.6 (C9), 116.4 (C7a), 110.0 (C11), 75.3 (C3a), 63.5 
(C2), 43.6 (C6), 41.8 (C1), 32.4 (C4), 18.5 (C5). IR (KBr) νmax = 2940 (m), 2851 (m) (Ar-H), 
1625 (s) (C=O), 1106 (s) (C-O), 1433 (m), 1444 (m) (CH2), 796 (m) (C-Br); LRMS (ES+): 
m/z (%) 341.86 (100) [M+Na]+, 343.84 (97) [M+Na]+ HRMS (ES+): m/z calcd for 
C15H14NO279BrNa [M+Na]+: 342.0106; found 342.0099; calcd for C15H14NO281BrNa 
[M+Na]+: 344.0085; found 344.0074; Anal. calcd for C15H14NO2Br: C, 56.27; H, 4.41; N, 
4.37; found: C, 56.38; H, 4.64; N, 4.27. 
3a,4,5,6-tetrahydro-1H-3-oxa-11b-azacyclohepta[jk]fluoren-7(2H)-one (163l) 
 
Title compound was obtained as a white solid (0.15 g, 0.64 mmol, 64%). Mp: 155-156 °C; 
1H NMR (400 MHz, CDCl3): δ 8.42-8.49 (m, 1H, H8), 7.30-7.36 (m, 3H, H9, H10, H11), 
4.93-5.01 (m, 1H, H3a), 4.41-4.48 (m, 1H, H2a), 4.03-4.24 (m, 3H, H2b, H1), 2.76 (t, 2H, 
3J= 6.0 Hz, H6), 2.36-2.57 (m, 1H, H4a), 1.93-2.12 (m, 3H, H4b, H5); 13C NMR (100 MHz, 
CDCl3): δ 196.8 (C7), 144.6 (C12a), 136.2 (C11a), 124.6 (C7b), 123.7 (C9), 123.6 (C10), 
123.0 (C8), 110.0 (C7a), 109.1 (C11), 75.7 (C3a), 64.0 (C2), 43.6 (C6), 41.8 (C1), 33.0 (C4), 
19.6 (C5); IR (KBr) νmax = 2940 (m), 2851 (m) (Ar-H), 1625 (s) (C=O), 1106 (s) (C-O), 1433 
(m), 1444 (m) (CH2); LRMS (ES+): m/z (%) 242.86 (100) [M+H]+; HRMS (ES+): m/z calcd 
for C15H16NO2 [M+H]+: 242.1103; found 242.1127.  
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10-bromo-1,2,4,5,6,7-hexahydro-3-oxa-12b-azacycloocta[jk]fluoren-8(3aH)-one (163m) 
 
Title compound was furnished as a white solid (0.20 g, 0.61 mmol, 61%). Mp: 200-201 °C; 
1H NMR (400 MHz, CDCl3): δ 8.71 (d, 1H, 4J= 2.0 Hz, H9), 7.37 (dd, 1H, 3J= 8.5 Hz, 4J= 
2.4 Hz, H11), 7.17 (d, 1H, 3J= 8.5 Hz, H12), 5.83 (dd, 1H, 3J= 10.5 7.5 Hz, H3a), 4.22-4.32 
(m, 1H, H2a), 4.06-4.16 (m, 3H, H2b, H1), 2.65-2.84 (m, 2H, H7), 1.90-2.19 (m, 3H, H4, 
H5a), 1.50-1.83 (m, 3H, H5b, H6); 13C NMR (100 MHz, CDCl3): δ 195.6 (C8), 141.5 (C13a), 
134.6 (C11a), 127.6 (C8b), 125.9 (C11), 125.2 (C9), 116.8 (C10), 115.2 (C8a), 109.9 (C12), 
73.0 (C3a), 58.8 (C2), 42.1 (C7), 41.9 (C2), 31.6 (C4), 23.8 (C5), 22.5 (C6); IR (KBr) νmax = 
2940 (m), 2851 (m) (Ar-H), 1625 (s) (C=O), 1106 (s) (C-O), 1433 (m), 1444 (m) (CH2), 796 
(m) (C-Br); LRMS (ES+): m/z (%) 355.93 (100) [M+Na]+, 357.94 (80) [M+Na]+; HRMS 
(ES+): m/z calcd for C16H16NO2Na79Br [M+Na]+: 356.0258; found 356.0262; calcd for 
C16H16NO2Na81Br [M+Na]+: 358.0239; found 358.0242. 
1,2,4,5,6,7-hexahydro-3-oxa-12b-azacycloocta[jk]fluoren-8(3aH)-one (163n) 
 
Title compound was obtained as a white solid (0.108 g, 0.65 mmol, 65%). 1H NMR (400 
MHz, CDCl3): δ 8.45 (d, 1H, 3J= 8.0 Hz, H9), 7.20-7.27 (m, 3H, H10, H11, H12), 5.75 (dd, 
1H, 3J= 5.0 Hz, 7.5 Hz, H3a), 3.93-4.28 (m, 4H, H1, H2), 2.56-2.81 (m, 2H, H7), 1.55-2.12 
(m, 6H, H4, H5, H6); 13C NMR (100 MHz, CDCl3): δ 195.9 (C8), 122.7 (C9), 108.5 (C12), 
123.0 (C10), 123.3 (C11), 73.2 (C3a), 42.2 (C1), 59.0 (C2), 41.9 (C7), 31.7 (C4), 23.8 (C6), 
22.5 (C5), 135.9 (C8b), 126.3 (C12a), 115.7 (C13a), 140.8 (C8a). IR (KBr) νmax = 2940 (m), 
2851 (m) (Ar-H), 1625 (s) (C=O), 1106 (s) (C-O), 1433 (m), 1444 (m) (CH2); LRMS (ES+): 
m/z (%) 256.86 (100) [M+H]+; HRMS (ES+): m/z calcd for C16H17NO2 [M+H]+: 256.1103; 
found 256.1127.  
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1,2,4,5-tetrahydro-[1,4]oxazino[2,3,4-jk]carbazol-6(3aH)-one (163o) 
 
Title compound was obtained as a white solid (0.174 g, 0.65 mmol, 65%) Mp: 196-197 °C. 
1H NMR (400 MHz, CDCl3): δ 8.19-8.24 (m, 1H, H7), 7.30-7.38 (m, 3H, H8, H9, H10), 4.87 
(dd, 1H, 3J= 10.5 5.5 Hz, H3a), 4.45-4.52 (m, 1H, H2a), 4.17-4.26 (m, 1H, H2b), 3.99-4.09 
(m, 2H, H1), 2.44-2.79 (m, 3H, H5, H4a), 2.02-2.24 (m, 1H, H4b); 13C NMR (100 MHz, 
CDCl3): δ 192.0 (C6), 149.4 (C11a), 137.4 (C10a), 124.6 (C6b), 123.4 (C8), 123.3 (C9), 
121.9 (C7), 110.0 (C6a), 109.4 (C10), 71.4 (C3a), 64.2 (C2), 41.4 (C1), 37.0 (C5), 31.3 (C4). 
IR (KBr) νmax = 2940 (m), 2851 (m) (Ar-H), 1625 (s) (C=O), 1106 (s) (C-O), 1433 (m), 1444 
(m) (CH2); LRMS (ES+): m/z (%) 250 (100) [M+Na]+; HRMS (ES+): m/z calcd for 
C14H13NO2Na [M+Na]+: 250.0844; found 250.0837. Anal. calcd for C14H13NO2: C, 73.99; H, 
5.77; N, 6.16; found: C, 73.79; H, 5.67; N, 6.30. 
10-bromo-2,3,3a,4,5,6-hexahydro-1H-pyrido[3,2,1-jk]carbazol-1-one (182) 
 
Title compound was obtained as a white solid (0.20 g, 0.65 mmol, 65%). Mp: 235 °C (dec.); 
1H NMR (400 MHz, CDCl3): δ 8.34 (d, 1H, 4J= 2.0 Hz, H11), 7.35 (dd, 1H, 3J= 8.5 Hz, 4J= 
2.0 Hz, H9), 7.14 (d, 1H, 3J= 8.5 Hz, H8), 4.24 (q, 1H, 3J= 6.5 Hz, H6a), 3.80 (dt, 1H, 2J= 
13.0 Hz, 3J= 6.0 Hz, H6b), 2.97-3.01 (m, 1H, H3a), 2.59-2.65 (m, 2H, H2), 2.10-2.41 (m, 4H, 
H5, H4a, H3a), 1.76-1.90 (m, 1H, H3b), 1.35-1.50 (m, 1H, H4b); 13C NMR (100 MHz, 
CDCl3): δ 193.1 (C1), 139.0 (C3b), 136.6 (C7a), 128.7 (C11a), 125.6 (C9), 124.2 (C11), 
116.4 (C10), 110.6 (C8), 109.9 (C11b), 41.9 (C6), 38.8 (C2), 33.6 (C3a), 31.4 (C3), 26.9 
(C4), 22.6 (C5); LRMS (ES+): m/z (%) 326.08 (100) [M+Na]+, 328.08 (100) [M+Na]+; 
HRMS (ES+): m/z calcd for C15H14NONa79Br [M+Na]+: 326.0156; found 326.0154; calcd for 
C15H14NONa81Br [M+Na]+: 328.0136; found 328.0139. 
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(R)-8-bromo-1,2,4,5-tetrahydro-[1,4]oxazino[2,3,4,jk]carbazol-6(3aH) –one (193) 
 
Title compound was obtained as a white solid (0.2 g, 0.65 mmol, 65%). Mp: 259 °C (dec.);  
1H NMR (400 MHz, CDCl3): δ 8.26 (d, 1H, 4J= 2.0 Hz, H7), 7.33 (dd, 1H, 3J= 9.0 Hz, 4J= 
2.0 Hz, H9), 7.11 (d, 1H, 3J= 9.0 Hz, H10), 4.84 (dd, 1H, 2J= 12.0 Hz, 3J= 6.0 Hz, H3a), 
4.38-4.48 (m, 1H, H1a), 4.10-4.22 (m, 1H, H1b), 3.95-4.02 (m, 2H, H2), 2.54-2.63 (m, 2H, 
H5), 2.40-2.51 (m, 1H, H4a), 1.97-2.73 (m, 1H, H4b); 13C NMR (100 MHz, CDCl3): δ191.7 
(C6), 150.14 (C11a), 135.8 (C10a), 129.1 (C6b), 123.8 (C9), 121.6 (C7), 118.6 (C8), 110.4 
(C10), 109.7 (C6a), 71.3 (C3a), 64.2 (C2), 41.5 (C1), 36.9 (C5), 31.2 (C4); IR (KBr): νmax = 
2971 (m), 2869 (m) 2921 (m) (Ar-H), 1639 (s) (C=O), 1102 (s) (C-O), 801 (m) (C-Br) cm-1; 
LRMS (ES+): m/z (%) 327.87 (100) [M+Na]+, 329.88 (100) [M+Na]+; HRMS (ES+): m/z 
calcd for C14H12NO2Na79Br [M+Na]+: 327.9944; found 327.9949; calcd for 
C14H12NO2Na81Br [M+Na]+: 329.9923; found 329.9929. Anal. calcd for C14H12NO2Br: C, 
54.92; H, 3.95; N, 4.58; found: C, 54.79; H, 3.85; N, 4.54. [α]20D = 21.0 (c = 0.004, DCM) 
8.7 General procedure of m-CPBA oxidative fragmentation: carbazolone 163 (0.5 mmol, 
1.0 eq) was dissolved in anhydrous DCM (50 mL), purified mCPBA (0.344 g, 2.0 mmol, 4.0 
eq) was then added to the solution. The reaction mixture was stirred at room temperature 
under N2 for 16 hours. Saturated sodium hydrogen carbonate aqueous solution (20 mL) was 
added to the reaction mixture, and extracted with dichloromethane (3 x 20 mL). The organic 
layer was dried (MgSO4), filtered and concentrated in vacuo to give a brown solid which was 
then purified by flash column chromatography over silica gel (3: 7 ethyl acetate: 
dichloromethane) furnished the title compound. 
11-bromo-6,7-dihydro-2H-1,5-methanobenzo[e][1,4]oxaazacycloundecine-8,9,14(3H, 
5H)-trione (164a) 
 
Title compound was afforded as a pale yellow solid (0.084 g, 0.25 mmol, 50%). 
Recrystallisation from acetone afforded analytically pure title compound. Mp: 205-206 °C; 
1H NMR (400 MHz, CDCl3): δ 7.83 (d, 1H, 4J= 2.5 Hz, H10), 7.71 (dd, 1H, 3J= 8.5 Hz, 4J= 
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2.5 Hz, H12), 7.11 (d, 1H, 3J= 8.5 Hz, H9), 4.50 (d, 1H, 3J= 6.0 Hz, H5), 4.02-4.08 (m, 1H, 
H3a), 3.77-3.86 (m, 1H, H3b), 3.67-3.72 (m, 1H, H2a), 3.28-3.38 (m, 1H, H2b), 3.12-3.20 
(m, 1H, H7a), 2.63-2.73 (m, 1H, H7b), 2.58-2.60 (m, 1H, H6a), 2.26-2.36 (m, 1H, H6b); 13C 
NMR (100 MHz, CDCl3): δ 202.3 (C9), 190.3 (C8), 173.3 (C14), 139.7 (C11), 136.9 (C12), 
135.7 (C9a), 133.3 (C10), 126.1 (C13), 122.0 (C13a), 77.3 (C5), 62.2(C3), 49.4 (C2), 34.2 
(C7), 29.7 (C6); IR (KBr): νmax = 2861 (m), 2920 (m), 1682 (s) (C=O), 1648 (s) (C=O), 1710 
(s) (C=O), 1466 (s), 1429 (s), 1102 (s) (C-O), 836 (m) (C-Br) cm-1; LRMS (ES+): m/z (%) 
359.89 (100) [M+Na]+, 361.89 (90) [M+Na]+; HRMS (ES+): m/z calcd for C14H12NO4Na79Br 
[M+Na]+: 359.9847; found 359.9845; calcd for C14H12NO2Na81Br [M+Na]+: 361.9827; 
found 361.9831; Anal. calcd for C14H12NO4Br: C, 49.73; H, 3.58; N, 4.14; found: C, 49.64; 
H, 3.41; N, 4.19. 
11-chloro-6,7-dihydro-2H-1,5-methanobenzo[e][1,4]oxaazacycloundecine-8,9,14(3H, 
5H)-trione (164f) 
 
Title compound was obtained as a pale yellow solid (0.12 g, 0.42 mmol, 83%). 
Recrystallisation from acetone afforded analytically pure title compound. Mp: 205.5-206 °C; 
1H NMR (400 MHz, CDCl3): δ 7.76 (d, 1H, 4J= 2.5 Hz, H10), 7.63 (dd, 1H, 3J= 8.5 Hz, 4J= 
2.5 Hz, H12), 7.25 (d, 1H, 3J= 8.5 Hz, H13), 4.57 (d, 1H, 3J= 6.0 Hz, H5), 4.14 (dd, 1H, 3J= 
4.5 Hz, 2J= 13.5 Hz, H3a), 3.90 (dt, 1H, 2J= 13.5 Hz, 3J= 3.0 Hz, H3b), 3.73-3.81 (m, 1H, 
H2a), 3.40 (dt, 1H, 2J= 12.0 Hz, 3J= 4.5 Hz, H2b), 3.20-3.28 (m, 1H, H7a), 2.71-2.82 (m, 1H, 
H7b), 2.57-2.69 (m, 1H, H6a), 2.33-2.46 (m, 1H, H6b); 13C NMR (100 MHz, CDCl3): δ 
202.3 (C9), 190.4 (C8), 173.4 (C14), 139.2 (C13a), 135.6 (C11), 134.3 (C9a), 134.0 (C12), 
125.9 (C13), 77.2 (C5), 62.3 (C3), 49.4 (C2), 34.2 (C7), 29.3 (C6); IR (KBr): νmax = 2861 
(m), 2920 (m), 1682 (s) (C=O), 1648 (s) (C=O), 1710 (s) (C=O), 1466 (s), 1429 (s), 1102 (s) 
(C-O), 710 (m) (C-Cl) cm-1; LRMS (ES+): m/z (%) 315.90 (100) [M+Na]+; HRMS (ES+): 
m/z calcd for C14H12NO4NaCl [M+Na]+: 316.0346; found 316.0353. Anal. calcd for 
C14H12NO4Cl: C, 57.25; H, 4.12; N, 4.77; found: C, 57.52; H, 3.88; N, 4.91. 
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11-iodo-6,7-dihydro-2H-1,5-methanobenzo[e][1,4]oxaazacycloundecine-8,9,14(3H, 
5H)-trione (164g) 
N
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O
O O
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2 4
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12 14
 
Title compound was obtained as a pale yellow solid (0.16 g, 0.42 mmol, 83%). 
Recrystallisation from acetone afforded analytically pure title compound. Mp: 179-180 °C; 
1H NMR (400 MHz, CDCl3): δ 8.09 (d, 1H, 4J= 2.0 Hz, H10), 7.98 (dd, 1H, 3J= 8.5 Hz, 4J= 
2.0 Hz, H12), 7.05 (d, 1H, 3J= 8.5 Hz, H13), 4.54-4.60 (m, 1H, H5), 4.13 (dd, 1H, 3J= 12.0 
5.0 Hz, H3a), 3.89 (dt, 1H, 3J= 12.0 2.0 Hz, H3b), 3.74-3.79 (m, 1H, H2a), 3.40 (dt, 1H, 3J= 
12.0 4.5 Hz, H2b), 3.23 (ddd, 1H, 3J= 14.0 6.5 3.0 Hz, H7a), 2.70-2.80 (m, 1H, H7b), 
2.58-2.67 (m, 1H, H6a), 2.34-2.43 (m, 1H, H6b); 13C NMR (100 MHz, CDCl3):δ 202.3 (C8), 
190.3 (C9), 173.3 (C14),142.9 (C12), 140.4 (C13a), 139.1 (C10), 135.8 (C9a), 126.3 (C13), 
93.0 (C11), 77.2 (C5), 62.3 (C3), 49.3 (C2), 34.2 (C7), 29.3 (C6); IR (KBr): νmax = 2861 (m), 
2920 (m), 1682 (s) (C=O), 1648 (s) (C=O), 1750 (s) (C=O), 1466 (s), 1429 (s), 1102 (s) 
(C-O), 510 (m) (C-I) cm-1; LRMS (ES+): m/z (%) 407.74 (100) [M+Na]+; HRMS (ES+): m/z 
calcd for C14H12NO4NaI [M+Na]+: 407.9709; found 407.9703.  
hexahydro-1H-cyclopenta[b](5-nitro indolo)[2,1-c][1,4]oxazine-1,12(2H)-dione (187h) 
 
Title compound was afforded as a bright yellow solid (0.04 g, 0.14 mmol, 27%). Mp: 
115-116 °C; 1H NMR (400 MHz, CDCl3): δ 8.46 (d, 1H, 4J= 2.0 Hz, H2), 8.38 (dd, 1H, 3J= 
9.5 Hz, 4J= 2.0 Hz, H4), 6.90 (d, 1H, 3J= 9.5 Hz, H5), 4.13 (d, 1H, 3J= 4.0 Hz, H9a), 
3.97-4.02 (m, 1H, H8a), 3.70-3.76 (m, 1H, H7a), 3.38-3.54 (m, 2H, H8b, H7b), 2.80-2.92 (m, 
1H, H10a), 2.54-2.79 (m, 2H, H11), 2.22-2.32 (m, 1H, H10b); 13C NMR (100 MHz, CDCl3): 
δ 206.7 (C12), 190.5 (C1), 161.8 (C5a), 139.4 (C3), 132.7 (C4), 122.7 (C2), 119.0 (C1a), 
108.5 (C5), 81.5 (C12a), 78.3 (C9a), 65.4 (C8), 41.7 (C7), 32.9 (C11), 24.5 (C10); IR (KBr) 
νmax = 3041 (m), 2955 (m), 2876 (m) (Ar-H), 1650 (s) (C=O), 1640 (s) (C=O), 1557 (s), 
1340 (s) (NO2), 1102 (s) (C-O) cm-1; LRMS (ES+): m/z (%) 311.26 (100) [M+Na]+; HRMS 
(ES+): m/z calcd for C14H12N2O5Na [M+Na]+: 311.0699; found 311.0695.  
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11-methoxy-6,7-dihydro-2H-1,5-methanobenzo[e][1,4]oxaazacycloundecine-8,9,14(3H, 
5H)-trione (164i) 
 
Title compound was afforded as a pale yellow solid (0.02 g, 0.08 mmol, 15%). Mp: 137-138 
°C; 1H NMR (400 MHz, CDCl3): δ 7.31 (d, 1H, 4J= 2.5 Hz, H10), 7.22 (d, 1H, 3J= 8.5 Hz, 
H13), 7.18 (dd, 1H, 3J= 8.5 Hz, 4J= 2.5 Hz, H12), 4.56-4.60 (m, 1H, H5), 4.08-4.15 (m, 1H, 
H3a), 3.89-3.95 (m, 1H, H3b), 3.87 (s, 3H, H1’), 3.72-3.78 (m, 1H, H2a), 3.34-3.44 (m, 1H, 
H2b), 3.19-3.28 (m, 1H, H6a), 2.70-2.82 (m, 1H, H6b), 2.59-2.70 (m, 1H, H7a), 2.34-2.45 
(m, 1H, H7b); 13C NMR (100 MHz, CDCl3): δ 202.7 (C8), 191.9 (C9), 173.5 (C14), 159.2 
(C11), 135.1 (C9a), 133.7 (C13a), 125.8 (C13), 120.9 (C12), 113.9 (C10), 77.5 (C5), 62.4 
(C3), 55.8 (C1’), 49.7 (C2), 34.2 (C6), 29.6 (C7). IR (KBr): νmax = 2861 (m), 2920 (m), 1682 
(s) (C=O), 1648 (s) (C=O), 1750 (s) (C=O), 1466 (s), 1429 (s), 1132 (s) (C-O), 1102 (s) (C-O) 
cm-1; LRMS (ES+): m/z (%) 290.09 (100) [M+H]+; HRMS (ES+): m/z calcd for C15H16NO5 
[M+H]+: 290.0950; found 290.0951.  
10-methoxy-3,3a,5,6-tetrahydro-1H-cyclopenta[2,3][1,4]oxazino[4,3-a]indole-1,12(2H)- 
dione (187i) 
 
Title compound was obtained as a yellow solid (0.02 g, 0.08 mmol, 15%). Mp: 85-86 °C; 1H 
NMR (400 MHz, CDCl3): δ 7.18 (dd, 1H, 3J= 9.0 Hz, 4J= 2.5 Hz, H9), 6.98 (d, 1H, 4J= 2.5 
Hz, H11), 6.86 (d, 1H, 3J= 9.0 Hz, H8), 4.00-4.03 (m, 1H, H3a), 3.82-3.86 (m, 1H, H5a), 
3.76 (s, 3H, H1’), 3.60-3.65 (m, 1H, H6a), 3.32-3.39 (m, 2H, H2b, H6b), 2.76-2.88 (m, 1H, 
H3a), 2.63-2.74 (m, 1H, H2a), 2.51-2.63 (m, 1H, H2b), 2.12-2.27 (m, 1H, H3b). 13C NMR 
(100 MHz, CDCl3): δ 209.9 (C1), 193.0 (C12), 156.8 (C7a), 152.9 (C10), 128.4 (C9), 119.6 
(C11a), 111.0 (C8), 105.2 (C11), 80.8 (C12a), 78.3 (C3a), 65.0 (C5), 55.9 (C1’), 42.2 (C6), 
33.6 (C2), 24.4 (C3). IR (KBr): νmax = 2861 (m), 2920 (m), 1682 (s) (C=O), 1648 (s) (C=O), 
1466 (s), 1429 (s), 1132 (s) (C-O), 1102 (s) (C-O) cm-1; LRMS (ES+): m/z (%) 274.10 (100) 
[M+H]+; HRMS (ES+): m/z calcd for C15H16NO4 [M+H]+: 274.1001; found 274.1032.  
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6,7-dihydro-2H-1,5-methanobenzo[e][1,4]oxaazacycloundecine-8,9,14(3H, 5H)-trione 
(164o) 
 
Title compound was obtained as a pale yellow solid (0.11 g, 0.44 mmol, 87%). 
Recrystallisation from acetone afforded analytically pure title compound. Mp: 176-177 °C; 
1H NMR (400 MHz, CDCl3): δ 7.81 (d, 1H, 3J= 8.0 Hz, H10), 7.68 (t, 1H, 3J= 8.0 Hz, H12), 
7.47 (t, 1H, 3J= 8.0 Hz, H11), 7.30 (d, 1H, 3J= 8.0 Hz, H13), 4.58 (d, 1H, 3J= 5.5 Hz, H5), 
4.14 (d, 1H, 3J= 12.0 5.0 Hz, H3a), 3.89-3.95 (m, 1H, H3b), 3.81 (d, 1H, 3J= 12.5 Hz, H2a), 
3.42 (dt, 1H, 3J= 12.0 5.0 Hz, H2b), 3.25 (ddd, 1H, 3J= 14.0 6.5 3.0 Hz, H7a), 2.58-2.82 (m, 
2H, H7b, H6a), 2.34-2.45 (m, 1H, H6b); 13C NMR (100 MHz, CDCl3): δ 202.8 (C8), 192.0 
(C9), 173.4 (C14) 140.9 (C13a), 134.2 (C9a), 134.1 (C12), 130.4 (C10), 128.3 (C11), 124.5 
(C13), 77.3 (C5), 62.4 (C3), 49.4 (C2), 34.2 (C7), 29.4 (C6) cm-1; LRMS (ES+): m/z (%) 
281.97 (100) [M+Na]+; HRMS (ES+): m/z calcd for C14H13NO3Na [M+Na]+: 282.0742; 
found 282.0737. Anal. calcd for C14H13NO4: C, 64.86; H, 5.05; N, 5.40; found: C, 64.72; H, 
5.20; N, 5.55. 
11-bromo-2,3,4,4a,6,7-hexahydrobenzo[2,3][1,4]oxazino[4,3-a]indole-1,13-dione (187k) 
 
Title compound was obtained as a pale yellow solid (0.10 g, 0.31 mmol, 61%). Mp: 183-184 
°C; 1H NMR (400 MHz, CDCl3): δ 7.66 (d, 1H, 4J= 2.0 Hz, H12), 7.54 (dd, 1H, 4J= 2.0 Hz, 
3J= 9.0 Hz, H10), 6.76 (d, 1H, 3J= 9.0 Hz, H9), 3.95 (dd, 1H, 3J= 4.0 11.0 Hz, H6a), 3.74 (m, 
1H, H7a), 3.68 (dd, 1H, 3J= 14.0 4.0 Hz, H6b), 3.56 (dt, 1H, 3J= 13.0 4.0 Hz, H6a), 3.43 (dt, 
1H, 3J= 12.0 4.0 Hz, H4a), 3.10 (dt, 1H, 3J= 13.5 7.0 Hz, H2a), 2.46-2.63 (m, 2H, H2b, H4a), 
1.92-2.20 (m, 3H, H4b, H3); 13C NMR (100 MHz, CDCl3): δ 201.1 (C1), 190.7 (C13), 157.8 
(C9a), 140.4 (C10), 127.9 (C12), 120.2 (C12a), 110.3 (C9), 109.6 (C11), 81.2 (C4a), 80.9 
(C13a), 66.4 (C6), 41.2 (C7), 38.7 (C2), 26.2 (C4), 20.9 (C3); IR (KBr): νmax = 2861 (m), 
2920 (m), 1682 (s) (C=O), 1648 (s) (C=O), 1466 (s), 1429 (s), 1132 (s) (C-O) cm-1; LRMS 
(ES+): m/z (%) 357.86 (100) [M+Na]+, 359.86 (95) [M+Na]+ HRMS (ES+): m/z calcd for 
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C15H14NO379BrNa [M+Na]+: 358.0055; found 358.0057; calcd for C15H14NO381BrNa 
[M+Na]+: 360.0034; found 360.0038;  Anal. calcd for C15H14NO3Br: C, 53.59; H, 4.20; N, 
4.17; found: C, 53.76; H, 3.80; N, 4.13. 
2,3,4,4a,6,7-hexahydrobenzo[2,3][1,4]oxazino[4,3-a]indole-1,13-dione (187l) 
 
Title compound was obtained as a bright yellow solid (0.07 g, 0.27 mmol, 53%). Mp: 
117-118 °C 1H NMR (400 MHz, CDCl3): δ 7.48 (d, 1H, 3J= 8.0 Hz, H12), 7.40 (dd, 1H, 3J= 
8.5, 7.5 Hz, H10), 6.77 (d, 1H, 3J= 8.5 Hz, H9), 6.65 (dd, 1H, 3J= 8.0, 7.5 Hz, H11), 
3.81-3.89 (m, 2H, H6a. H4aa), 3.62-3.70 (m, 2H, H7a, H4a), 3.45-3.55 (m, 1H, H7b), 
3.32-3.40 (m, 1H, H6b), 3.00-3.12 (m, 1H, H2a), 2.47-2.59 (m, 1H, H4a), 2.38-2.48 (m, 1H, 
H2b), 1.93-2.11 (m, 2H, H3), 1.82-1.93 (m, 1H, H4b); 13C NMR (100 MHz, CDCl3): δ 201.8 
(C1), 192.0 (C13), 159.2 (C9a), 137.9 (C10), 125.6 (C12), 118.7 (C12a), 117.7 (C11), 108.8 
(C9), 81.0 (C13a), 80.9 (C4aa), 66.5 (C6), 38.9 (C2), 41.1 (C7), 26.3 (C4), 20.9 (C3). IR 
(KBr): νmax = 2861 (m), 2920 (m), 1682 (s) (C=O), 1648 (s) (C=O), 1466 (s), 1429 (s), 1132 
(s) (C-O) cm-1; LRMS (ES+): m/z (%) 272.12 (100) [M+H]+; HRMS (ES+): m/z calcd for 
C16H18NO3 [M+H]+: 272.1208; found 272.0175.  
13-bromo-6,7,8,9-tetrahydro-2H-1,5-methanobenzo[e][1,4]oxaazacyclotridecine-10,11, 
16(3H,5H)-trione (164m) 
 
Title compound was obtained as a off white solid (0.07 g, 0.27 mmol, 53%). Mp: 102-103 °C; 
1H NMR (400 MHz, CDCl3): δ 7.98 (d, 1H, 4J= 2.5 Hz, H12), 7.76 (dd, 1H, 4J= 2.5 Hz, 3J= 
9.0 Hz, H14), 7.07 (d, 1H, 3J= 9.0 Hz, H15), 4.36 (dd, 1H, 3J= 5.0 2.0 Hz, H5), 4.06 (dd, 1H, 
3J= 9.0 4.5 Hz, H3a), 3.87-4.01 (m, 2H, H3b, H2a), 3.75-3.81 (m, 1H, H2b), 3.32-3.42 
(m,1H, H9a), 2.54-2.64 (m, 1H, H9b), 1.89-2.19 (m, 3H, H8, H6a), 1.44-1.82 (m, 3H, H7, 
H6b); 13C NMR (100 MHz, CDCl3): δ 201.33 (C10), 189.7 (C11), 170.2 (C16), 139.4 (C15a), 
137.1 (C14), 133.8 (C12), 133.6 (C11a), 127.0 (C15), 121.6 (C13), 73.0 (C5), 63.3 (C3), 
51.0 (C2), 35.5 (C9), 29.7 (C6), 21.6 (C8), 19.2 (C7); IR (KBr): νmax = 2861 (m), 2920 (m), 
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1682 (s) (C=O), 1648 (s) (C=O), 1710 (s) (C=O), 1466 (s), 1429 (s), 1102 (s) (C-O), 836 (m) 
(C-Br) cm-1; LRMS (ES+): m/z (%) 388.02 (100) [M+Na]+, 390.02 (90) [M+Na]+; HRMS 
(ES+): m/z calcd for C16H16NO4Na79Br [M+Na]+: 388.0235; found 388.0233.  
12-bromo-3,4,5,5a,7,8-hexahydro-1H-cyclohepta[2,3][1,4]oxazino[4,3-a]indole-1,14(2H)
-dione (187m) 
 
Title compound was obtained as a yellow solid (0.06 g, 0.16 mmol, 21%). Mp: 163-164 °C; 
1H NMR (400 MHz, CDCl3): δ 7.68 (d, 1H, 4J= 2.0 Hz, H13), 7.54 (dd, 1H, 3J= 9.0 Hz, 4J= 
2.0 Hz, H11), 6.76 (d, 1H, 3J= 9.0 Hz, H10), 3.94-4.00 (m, 1H, H7a), 3.68-3.74 (m, 2H, H8), 
3.32-3.50 (m, 3H, H7b, H5aa, H2a), 2.36-2.60 (m, 2H, H2b, H5a), 1.72-2.10 (m, 5H, H5b, 
H4, H3); 13C NMR (100 MHz, CDCl3): δ 202.6 (C1), 192.0 (C14), 157.7 (C10a), 140.4 
(C11), 127.9 (C13), 120.8 (C13a), 110.5 (C10), 109.7 (C12), 82.5 (C14a), 77.2 (C5aa), 66.8 
(C7), 42.1 (C8), 38.2 (C2), 25.5 (C5), 20.4 (C3), 19.2 (C4); IR (KBr): νmax = 2861 (m), 2920 
(m), 1682 (s) (C=O), 1648 (s) (C=O), 1466 (s), 1429 (s), 1132 (s) (C-O), 813 (C-Br) cm-1; 
LRMS (ES+): m/z (%) 369.86 (100) [M+Na]+, 371.86 (95) [M+Na]+ HRMS (ES+): m/z calcd 
for C16H16NO379BrNa [M+Na]+: 369.0055; found 369.0057. 
6,7,8,9-tetrahydro-2H-1,5-methanobenzo[e][1,4]oxaazacyclotridecine-10,11,16(3H,5H)- 
trione (164n) 
 
Title compound was obtained as an off white solid (0.03 g, 0.09 mmol, 17%). Mp: 102-103 
°C; 1H NMR (400 MHz, CDCl3): δ 7.98 (d, 1H, 4J= 2.5 Hz, H12), 7.76 (m, 2H, H14, H13), 
7.07 (d, 1H, 3J= 9.0 Hz, H15), 4.36 (dd, 1H, 3J= 5.0 2.0 Hz, H5), 4.06 (dd, 1H, 3J= 9.0 4.5 
Hz, H3a), 3.87-4.01 (m, 2H, H3b, H2a), 3.75-3.81 (m, 1H, H2b), 3.32-3.42 (m,1H, H9a), 
2.54-2.64 (m, 1H, H9b), 1.89-2.19 (m, 3H, H8, H6a), 1.44-1.82 (m, 3H, H7, H6b); 13C NMR 
(100 MHz, CDCl3): δ 201.33 (C10), 189.7 (C11), 170.2 (C16), 139.4 (C15a), 137.1 (C14), 
133.9 (C13),  133.8 (C12), 133.6 (C11a), 127.0 (C15), 73.0 (C5), 63.3 (C3), 51.0 (C2), 35.5 
(C9), 29.7 (C6), 21.6 (C8), 19.2 (C7); IR (KBr): νmax = 2861 (m), 2920 (m), 1682 (s) (C=O), 
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1648 (s) (C=O), 1710 (s) (C=O), 1466 (s), 1429 (s), 1102 (s) (C-O) cm-1; LRMS (ES+): m/z 
(%) 310.02 (100) [M+Na]+; HRMS (ES+): m/z calcd for C16H17NO4Na [M+Na]+: 310.0235; 
found 310.0233.  
3,4,5,5a,7,8-hexahydro-1H-cyclohepta[2,3][1,4]oxazino[4,3-a]indole-1,14(2H)-dione 
(187n) 
 
Title compound was obtained as a yellow solid (0.03 g, 0.09 mmol, 17%). Mp: 163-164 °C; 
1H NMR (400 MHz, CDCl3): δ 7.68 (d, 1H, 4J= 2.0 Hz, H13), 7.54 (m, 2H, H11, H12), 6.76 
(d, 1H, 3J= 9.0 Hz, H10), 3.94-4.00 (m, 1H, H7a), 3.68-3.74 (m, 2H, H8), 3.32-3.50 (m, 3H, 
H7b, H5aa, H2a), 2.36-2.60 (m, 2H, H2b, H5a), 1.72-2.10 (m, 5H, H5b, H4, H3); 13C NMR 
(100 MHz, CDCl3): δ 202.6 (C1), 192.0 (C14), 157.7 (C10a), 140.4 (C11), 127.9 (C13), 
122.7 (C12), 120.8 (C13a), 110.5 (C10), 82.5 (C14a), 77.2 (C5aa), 66.8 (C7), 42.1 (C8), 38.2 
(C2), 25.5 (C5), 20.4 (C3), 19.2 (C4); IR (KBr): νmax = 2861 (m), 2920 (m), 1682 (s) (C=O), 
1648 (s) (C=O), 1466 (s), 1429 (s), 1132 (s) (C-O) cm-1; LRMS (ES+): m/z (%) 272.86 (100) 
[M+H]+; HRMS (ES+): m/z calcd for C16H18NO3 [M+H]+: 272.1208; found 272.1208. 
10-bromo-2,3,4,5,6,7-hexahydro-1,5-methanobenzo[b][1]azacycloundecine-7,8,14-trione 
(186) 
 
Title compound was obtained as a yellow solid (0.11 g, 0.34 mmol, 67%). Mp: 139-140 °C; 
1H NMR (400 MHz, CDCl3): δ 8.01 (d, 1H, 4J= 2.5 Hz, H9), 7.76 (dd, 1H, 3J= 8.5 Hz, 4J= 
2.5 Hz, H11), 7.12 (d, 1H, 3J= 8.5 Hz, H12), 3.82-3.90 (m, 1H, H1a), 3.27-3.36 (m, 2H, H1b, 
H6a), 2.84-2.97 (m, 1H, H4), 2.54-2.63 (m, 1H, H6b), 2.39-2.50 (m, 1H, H3a), 2.05-2.22 (m, 
3H, H3b, H5a, H2a), 1.77-1.94 (m, 2H, H5b, H2b); 13C NMR (100 MHz, CDCl3): δ 204.7 
(C7), 191.2 (C8), 174.7 (C14), 142.0 (C12a), 137.2 (C11), 136.6 (C8a), 132.9 (C9), 124.8 
(C12), 120.7 (C10), 50.0 (C1), 40.7 (C4), 35.3 (C6), 28.9 (C3), 25.4 (C5), 18.7 (C2); IR 
(KBr) νmax = 2861 (m), 2920 (m) (Ar-H), 1682 (s), 1648 (s) (C=O), 1466 (s), 1419 (s) (CH2), 
836 (s) (C-Br) cm-1; LRMS (ES+): m/z (%) 357.85 (100) [M+Na]+, 359.85 (95) [M+Na]+; 
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HRMS (ES+): m/z calcd for C15H14NO3Na79Br [M+Na]+: 358.0057; found 358.0055; calcd 
for C15H14NO3Na81Br [M+Na]+: 360.0041; found 360.0034. Anal. calcd for C14H12NO4Br: C, 
53.59; H, 4.20; N, 4.17; found: C, 53.73; H, 3.99; N, 4.19. 
9-bromo-3,3a,5,6-tetrahydro-1H-cyclopenta[2,3][1,4]oxazino[4,3-a]indole-1,12(2H)- 
dione (187a) 
 
Bromo carbazolone 163a (0.500 g, 1.63 mmol, 1 eq) was dissolved in anhydrous DCM (10 
mL), dimethyl dioxirane acetone solution (0.01M, 81.5 mL, 5 eq) was added slowly to the 
solution. The reaction mixture was stirred at room temperature for 30 min before the solvent 
was reduced in vacuo to give a bright yellow solid which was then purified by flash column 
chromatography over silica gel (3: 7 ethyl acetate: hexane) furnished the title compound as a 
bright yellow solid ( 0.500 g, 1.56 mmol, 95%).Mp: 196-197 °C; 1H NMR (400 MHz, 
CDCl3): δ 7.67 (d, 1H, 4J= 2.0 Hz, H8), 7.56 (dd, 1H, 3J= 9.0 Hz, 4J= 2.0 Hz, H10), 6.79 (d, 
1H, 3J= 9.0 Hz, H11), 4.03 (d, 1H, 3J= 4.5 Hz, H3a), 3.86-3.92 (m, 1H, H2a), 3.60-3.66 (m, 
1H, H1a), 3.30-3.45 (m, 2H, H1b, H2b), 2.75-2.89 (m, 1H, H4a), 2.64-2.75 (m, 1H, H5a), 
2.52-2.64 (m, 1H, H5b), 2.16-2.26 (m, 1H, H4b); 13C NMR (100 MHz, CDCl3): δ 208.6 (C6), 
191.4 (C7), 159.1 (C11a), 140.1 (C10), 127.8 (C8), 121.1 (C7a), 111.0 (C11), 110.4 (C9), 
80.5 (C6a), 78.2 (C3a), 65.2 (C2), 41.7 (C1), 33.3 (C5), 24.4 (C4). IR (KBr): νmax = 2861 
(m), 2920 (m), 1682 (s) (C=O), 1648 (s) (C=O), 1466 (s), 1429 (s), 1132 (s) (C-O), 813 
(C-Br) cm-1; LRMS (ES+): m/z (%) 343.84 (100) [M+Na]+, 345.84 (90) [M+Na]+; HRMS 
(ES+): m/z calcd for C14H12NO3Na79Br [M+Na]+: 343.9885; found 343.9898; calcd for 
C14H12NO3Na81Br [M+Na]+: 345.9892; found 345.9878. Anal. calcd for C14H12NO3Br: C, 
52.20; H, 3.75; N, 4.35; found: C, 52.39; H, 3.56; N, 4.38. 
10-bromo-5,6,7,8-tetrahydro-2H-1,5-methanobenzo[e][1,4]oxaazacycloundecine-8,14 
(3H)-dione (189) 
 
Bromo carbazole 171a was suspended in IPA (54 mL), sodium metaperiodate (4.35 g, 20.34 
mmol, 2.2 eq) water (34.2 mL) solution was then added. The reaction mixture was stirred at 
room temperature for 16 hours. The reaction mixture was then filtered, and solvent was 
Chapter 8 
                                                                                                     
181
reduced in vacou to afford a brown solid. This solid was then participated between water and 
dichloromethane, the aqueous layer was extracted with dichloromethane (3 x 50 mL). The 
organic layers were combined, dried (MgSO4), filtered and reduced in vacou to afford 
off-white solid which was then purified by flash column chromatography over silica gel (3: 7, 
ethyl acetate: hexane) furnished the title compound as a white solid (2.54 g, 7.85 mmol, 
85%). Mp: 199-200 °C; 1H NMR (400 MHz, CDCl3): δ 7.58 (d, 1H, 3J= 8.5 Hz, 4J= 2.5 Hz, 
H11), 7.52 (s, 1H, 4J= 2.5 Hz, H9), 7.12 (d, 1H, 3J= 8.5 Hz, H12), 4.44 (d, 1h, 3J= 5.5 Hz, 
H4), 4.12 (dd, 1H, 3J= 12.5 Hz, 4.5 Hz, H2a), 3.88 (dt, 1H, 3J= 11.5, 3.5 Hz, H2b), 3.65-3.79 
(m, 2H, H1), 2.77-2.90 (m, 2H, H1), 2.40-2.51 (m, 1H, H7b), 1.84-2.25 (m, 4H, H6, H5); 13C 
NMR (100 MHz, CDCl3): δ 202.8 (C8), 173.7 (C14), 141.3 (C12a), 138.8 (C8a), 134.7 
(C11), 131.7 (C9), 127.2 (C12), 121.8 (C10), 78.8 (C4), 62.6 (C2), 50.4 (C1), 37.9 (C5), 30.5 
(C7), 18.7 (C6); IR (KBr): νmax = 2861 (m), 2920 (m), 1682 (s) (C=O), 1648 (s) (C=O), 1466 
(s), 1429 (s), 1132 (s) (C-O), 813 (C-Br) cm-1; LRMS (ES+): m/z (%) 345.86 (100) [M+Na]+, 
347.88 (100) [M+Na]+; HRMS (ES+): m/z calcd for C14H14NO3Na79Br [M+Na]+: 346.0054; 
found 346.0052. Anal. calcd for C14H14NO3Br: C, 51.87; H, 4.35; N, 4.32; found: C, 51.87; 
H, 4.38; N, 4.24. 
8-bromo-1,2,4,5-tetrahydro-3-oxa-10b-azaacephenanthrylen-6(3aH)-one (188) 
N
O
O
Br
1 3
5
7
9
11
 
Bromo dione 189 (0.350 g, 1.07 mmol) was suspended in 1M NaOH (10 mL), stirred at 
room temperature for 30 minutes, then at 95 °C for further 30 minutes. Reaction mixture was 
cooled to room temperature, and then neutralized with acetic acid followed by extraction 
using dichloromethane (20 mL x 3). The organic layers were combined, washed with brine 
(20 mL), dried (MgSO4), filtered and reduced in vacou to afford pale brown solid which was 
then purified by flash column chromatography over silica gel (3: 7, ethyl acetate: hexane) 
furnished the title compound as a white solid (0.314 g, 1.02 mmol, 95%). Mp: 200-202 °C; 
1H NMR (400 MHz, CDCl3): δ 8.57 (d, 1H, 4J= 2.5 Hz, H7), 7.68 (dd, 1H, 3J= 9.0 Hz, 4J= 
2.5 Hz, H9), 7.26 (d, 1H, 3J= 9.0 Hz, H10), 4.85 (dd, 1H, 3J= 10.5 6.0 Hz, H3a), 4.50 (dd, 
1H, 3J= 12.5 6.0 Hz, H2a), 4.21 (dt, 1H, 3J= 12.0 4.5 Hz, H2b), 4.00 (dd, 1H, 3J= 12.0 4.5 
Hz, H1a), 3.81 (dt, 1H, 3J= 12.5 5.5 Hz, H1b), 2.94 (dd, 1H, 3J= 14.5 9.0 Hz, H5b), 
2.52-2.68 (m, 2H, H5b, H4a), 1.88-2.04 (m, 1H, H4b); 13C NMR (100 MHz, CDCl3): δ 173.8 
(C7), 151.5 (C11a), 139.5 (C10a), 134.4 (C9), 129.5 (C7), 129.0 (C6a), 118.7 (C8), 117.4 
(C5a), 115.8 (C10), 79.3 (C3a), 64.4 (C2), 31.5 (C4), 42.2 (C1), 23.6 (C5); IR (KBr) νmax = 
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2967 (m), 2855 (m), (Ar-H), 1629 (s) (C=O), 1107 (s) (C-O), 819 (m) (C-Br), 730 (Ar-H 
arom) cm-1; LRMS (ES+): m/z (%) 327.88 (100) [M+Na]+, 329.88 (100) [M+Na]+; HRMS 
(ES+): m/z calcd for C14H12NO2Na79Br [M+Na]+: 327.9949; found 327.9956. 
Synthesis of (R)-6-bromo-9-(2-bromoethyl)-2,3,4,9-tetrahydro-1H-carbazol-1-ol (198) 
 
To a solution of 178a (0.37 g, 1 mmol, 1.0 eq) in dichloromethane at -20 °C was added 
(S)-oxazaborolidine 195 (0.277 g, 1 mmol, 1.0 eq), the solution was aged for 20 min, and 
BH3•DMS was added dropwise over 10 min. the reaction mixture was stirred for 3.5 hours at 
-20 °C, quenched by addition of iso-propyl alcohol, and warmed to room temperature, 
solvent removed in vacuo and the crude product was concentrated from iso-propyl alcohol 
three times and pass through a plug of silica eluting with dichloromethane. The filterate was 
concentrated in vacuo and the semi pure solid product (0.28 g, 0.76 mmol, 76%, 98% 
e.e.)was recrystalised from ethyl acetate (3 mL) and hexane (10 mL). Mp: 167-168 °C; 1H 
NMR (400 MHz, CDCl3): δ 7.67 (d, 1H, 4J= 2.0 Hz, H5), 7.34 (dd, 1H, 3J= 9.0 Hz, 4J= 2.0 
Hz, H7), 7.22 (d, 1H, 3J= 9.0 Hz, H8), 4.98-5.05 (m, 1H, H1), 4.48-4.70 (m, 2H, H1’), 
3.59-3.78 (m, 2H, H2’), 2.76-2.86 (m, 1H, H2a), 2.53-2.65 (m, 1H, H2b), 2.00-2.18 (m, 2H, 
H4), 1.90-1.99 (m, 2H, H5); 13C NMR (100 MHz, CDCl3): δ 121.9 (C5), 125.3 (C7), 110.5 
(C8), 62.0 (C1), 44.9 (C1’), 29.4 (C2’), 21.0 (C2), 33.4 (C4), 18.4 (C3), 112.7 (C6), 106.2 
(C4a), 134.7 (C9a), 131.2 (C8a), 128.3 (C4b). IR(KBr) νmax = 3325 (br) (O-H), 2927 (m), 
2868 (m), 1478 (m), 1405 (m), 815 (m) (C-Br) cm-1; LRMS (ES+): m/z (%) 373.95 (100) 
[M+H]+, 371.83 (60) [M+H]+; HRMS (ES+): m/z calcd for C14H16NO79Br [M+H]+: 373.9506; 
found 373.9511; [α]20D = 77.0 (c = 0.004, DCM) 
10-bromo-2,3,5,6-tetrahydro-1H-pyrido[3,2,1-jk]carbazole (184) 
 
Bromo carbazolone 183 (1.65 g, 4.20 mmol, 1 eq) and PPh3 (1.12 g, 4.20 mmol, 1 eq) was 
dissolved in toluene. This mixture was then reflux under Ar for 48 hours. The solvent was 
removed in vacuo, and the resulting solid was triturated in anhydrous diethyl ether to give an 
off-white solid. This solid was dissolved in anhydrous THF and cooled to -78 °C. n-BuLi 
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(2.62 mL, 4.62 mmol, 1.1 eq) was then added, and the reaction mixture was stirred at -78 °C  
for 3 hours and then warmed up to room temperature. The reaction mixture was cooled to -78 
°C and quenched with ammonium chloride solution. THF was removed in vacuo, the 
resulting aqueous layer was extracted with DCM (30 mL x 3). The organic layer was dried 
(MgSO4), filtered, reduced to give a yellow solid. The crude product mixture was purified 
via flash column chromatography over silica gel to give the title compound as a yellow solid 
(0.73 g, 2.52 mmol, 60%). Mp: 83-83.5 °C; 1H NMR (400 MHz, CDCl3): δ 7.26 (d, 1H, 4J= 
2.0 Hz, H11), 7.24 (dd, 1H, 3J= 9.0 Hz, 4J= 2.0 Hz, H9), 7.10 (d, 1H, 3J= 9.0 Hz, H8), 
5.53-5.58 (m, 1H, H4), 4.00 (t, 2H, 3J= 7.0 Hz, H6), 2.75 (t, 2H, 3J= 6.0 Hz, H1), 2.63-2.72 
(m, 2H, H5), 2.45-2.65 (m, 2H, H3), 1.90-2.03 (m, 2H, H2); 13C NMR (100 MHz, CDCl3): δ 
136.4 (C7a), 134.8 (C3b), 129.9 (C3a), 129.1 (C11a), 124.6 (C9), 121.8 (C11), 115.1 (C4), 
112.6 (C10), 110.6 (C8), 110.1 (C11b), 40.4 (C6), 28.7 (C3), 25.0 (C2), 24.9 (C5), 21.5 (C1). 
IR: (KBr) νmax = 3025 (m) (C=C), 3041 (m), 2955 (m), 2876 (m), 1617 (C=C); 795 (m) 
(C-Br) cm-1; LRMS (ES+): m/z (%) 310.02 (100) [M+Na]+, 312.02 (95) [M+Na]+; HRMS 
(ES+): m/z calcd for C15H14NNa79Br [M+Na]+: 310.0310; found 310.0322; calcd for 
C15H14NNa81Br [M+Na]+: 312.0289; found 312.0277. 
11-bromo-2,3,4,5,6-hexahydro-1H-pyrido[3,2,1-jk]carbazole (185) 
 
184 (0.4 g, 1.4 mmol, 1 eq) was dissolved in ethyl acetate (80 mL) and passed through 
H-Cube (room temperature, 1 atom H2, Pd/C (10%) flow rate: 1 mL/min). Solvent was 
removed to give a white solid. The crude product mixture was purified via flash column 
chromatography over silica gel to give the title compound as a white solid (0.39 g, 1.33 
mmol, 95%). Mp: 65-66 °C; 1H NMR (400 MHz, CDCl3): δ 7.58 (d, 1H, 4J= 2.0 Hz, H12), 
7.21 (dd, 1H, 3J= 9.0 Hz, 4J= 2.0 Hz, H10), 7.10 (d, 1H, 3J= 9.0 Hz, H9), 4.23 (dd, 1H, 3J= 
12.0 5.0 Hz, H7a), 3.63 (dt, 1H, 3J= 12.0 5.0 Hz, H7b), 2.56-2.87 (m, 3H, H4, H1), 1.99-2.27 
(m, 5H, H6, H2, H3a), 1.73-1.93 (m, 1H, H5a), 1.15-1.43 (m, 2H, H3b, H5b); 13C NMR (100 
MHz, CDCl3): δ 139.8 (C4a), 136.4 (C8a), 130.2 (C12a), 123.3 (C10), 121.0 (C12), 112.9 
(C11), 110.7 (C9), 107.2 (C12b), 43.1 (C7), 34.8 (C4), 30.4 (C5), 28.3 (C3), 23.9 (C2), 23.7 
(C6), 21.1 (C1); IR: (KBr) νmax = 3041 (m), 2955 (m), 2876 (m), 1466 (s), 1419 (s), 795 (m) 
(C-Br) cm-1; LRMS (ES+): m/z (%) 290.05 (100) [M+H]+, 292.04 (95) [M+H]+; HRMS 
(ES+): m/z calcd for C15H17N79Br [M+H]+: 290.0446; found 290.0451; calcd for C15H17N81Br 
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[M+H]+: 292.0448; found 292.0446. 
Synthesis of (2,6-bis-((4S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine)-(pyridine 
-2,6-dicarboxylate)ruthenium (141b)319  
 
Disodium pyridine-2,6-dicarboxylate 209 (141 mg, 0.66 mmol) in MeOH/H2O 1:1 (2 mL) 
was added to a solution of 2,6-bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine 208b 
(201 mg, 0.66 mmol) and ((Ru(p-cymene)Cl2)2) (204 mg, 0.33 mmol) in MeOH (2 mL) 
under Ar. The reaction mixture was heated at 65 °C for 1 hour. The reaction mixture was then 
diluted with DCM (30 mL) and washed with H2O (30 mL). The organic layer was dried over 
MgSO4, filtered, and reduced to give a dark violet solid. The crude product mixture was then 
purified by flash column chromatography over silica gel (DCM/MeOH 95:5) to furnish the 
title compound as a violet solid (309 mg, 0.54 mmol, 82%). Mp: 270 °C (dec.) (lit.319 > 240 
°C (dec.)); 1H NMR (400 MHz, CDCl3): δ 8.30 (d, 2H, 3J= 7.7 Hz, H3”, H5”), 8.08 (t, 1H, 
3J= 7.7 Hz, H4”), 7.85 (d, 2H, 3J= 7.9 Hz, H3, H5), 7.61 (t, 1H, 3J= 7.9 Hz, H4), 4.64-4.68 
(m, 2H, H5’, H12’), 3.66-3.71 (m, 4H, H4’, H11’), 1.03-1.10 (m, 2H, H6’, H13’), 0.59 (d, 
6H, 3J= 7.2 Hz, H7’), 0.44 (d, 6H, 3J= 6.8 Hz, H14’). LRMS (ES+): m/z (%) 568.09 (100) 
[M]+.  
Synthesis of (2,6-bis-((4S)-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine)-(pyridine-2,6- 
dicarboxylate)ruthenium (141a)319 
 
Disodium pyridine-2,6-dicarboxylate 209 (286 mg, 1.35 mmol) in MeOH/H2O 1:1 (4 mL) 
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was added to a solution of 2,6-bis((S)-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine 208a (500 
mg, 1.35 mmol) and ((Ru(p-cymene)Cl2)2) (414 mg, 0.68 mmol) in MeOH (4 mL) under Ar. 
The reaction mixture was heated at 65 °C for 1 hour. The reaction mixture was then diluted 
with DCM (30 mL) and washed with H2O (30 mL). The organic layer was dried over MgSO4, 
filtered, and reduced to give a dark violet solid. The crude product mixture was then purified 
by flash column chromatography over silica gel (DCM/MeOH 95:5) to furnish the title 
compound as a violet solid (665 mg, 1.05 mmol, 78%). Mp: 270 °C (dec.) (lit.319 > 240 °C 
(dec.))319; 1H NMR (400 MHz, CDCl3): δ 7.95 (d, 2H, 3J= 7.7 Hz, H3”, H5”), 7.65 (t, 1H, 
3J= 7.7 Hz, H4”), 7.54 (m, 3H, H3, H4, H5), 7.12-7.16 (m, 2H, H9’ H20’), 7,02-7.05 (m, 4H, 
H8’ H10’ H19’ H21’), 6.68 (d, 4H, 3J= 6.8 Hz, H7’ H11’ H18’ H22’), 5.15-5.21 (m, 2H, H5’ 
H16’), 4.59-4.68 (m, 4H, H4’, H15’); LRMS (ES+): m/z (%) 636.06 (100) [M]+.  
Synthesis of (2,6-bis-((4S,5S)-4-methyl-5-phenyl-4,5-dihydrooxazol-2-yl)pyridine)- 
(pyridine-2,6-dicarboxylate)ruthenium (141c)319 
 
Disodium pyridine-2,6-dicarboxylate 209 (72 mg, 0.34 mmol) in MeOH/H2O 1:1 (2 mL) 
was added to a solution of 2,6-bis((4S,5S)-4-methyl-5-phenyl-4,5-dihydrooxazol-2-yl) 
pyridine 208c (135 mg, 0.34 mmol) and ((Ru(p-cymene)Cl2)2) (104 mg, 0.17 mmol) in 
MeOH (2 mL) under Ar. The reaction mixture was heated at 65 °C for 1 hour. The reaction 
mixture was then diluted with DCM (30 mL) and washed with H2O (30 mL). The organic 
layer was dried over MgSO4, filtered, and reduced to give a dark violet solid. The crude 
product mixture was then purified by flash column chromatography over silica gel 
(DCM/MeOH 95:5) to furnish the title compound as a violet solid (177 mg, 0.27 mmol, 
79%). Mp: 250 °C (dec.) (lit.319 > 240 °C (dec.)); 1H NMR (400 MHz, CDCl3): δ 8.23 (d, 2H, 
3J= 7.5 Hz, H3”, H5”), 8.08 (t, 1H, 3J= 7.5 Hz, H4”), 8.00 (d, 2H, 3J= 7.9 Hz, H3 H5), 7.69 
(t, 1H, 3J= 7.9 Hz, H5), 7.38-7.41 (m, 6H, H9’ H10’ H11’ H21’ H22’ H23’), 7.33-7.37 (m, 
4H, H8’ H12’ H20’ H24’), 5.51 (d, 2H, 3J= 9.7 Hz, H4’ H16’), 3.75 (dd, 2H, 3J= 9.7, 6.7 Hz, 
H5’ H17’), 0.84 (d, 6H, 3J= 6.7 Hz, H6’ H18’); LRMS (ES+): m/z (%) 664.09 (100) [M]+.  
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Synthesis of (2,6-bis-((4S,5R)-8,8a-dihydro-3aH-indeno[1,2-d]oxazolyl)pyridine)- 
(pyridine-2,6-dicarboxylate)ruthenium (141d)319 
 
Disodium pyridine-2,6-dicarboxylate 209 (107 mg, 0.57 mmol) in MeOH/H2O 1:1 (2 mL) 
was added to a solution of 2,6-bis((3aS,8aR)-8,8a-dihydro-3aH-indeno[1,2-d]oxazol-2-yl) 
pyridine 208d (200 mg, 0.51 mmol) and ((Ru(p-cymene)Cl2)2) (156 mg, 0.25 mmol) in 
MeOH (2 mL) under Ar. The reaction mixture was heated at 65 °C for 1 hour. The reaction 
mixture was then diluted with DCM (30 mL) and washed with H2O (30 mL). The organic 
layer was dried over MgSO4, filtered, and reduced to give a dark violet solid. The crude 
product mixture was then purified by flash column chromatography over silica gel 
(DCM/MeOH 95:5) to furnish the title compound as a violet solid (290 mg, 0.44 mmol, 
86%). Mp: 250 °C (dec.) (lit. > 240 °C (dec.))319; 1H NMR (400 MHz, CDCl3): δ 8.57 (d, 2H, 
3J= 7.5 Hz, H3”, H5”), 8.31 (t, 1H, 3J= 7.5 Hz, H4”), 7.86 (d, 2H, 3J= 7.9 Hz, H3 H5), 7.59 
(t, 1H, 3J= 7.9 Hz, H5), 7.12-7.18 (m, 4H, H6’ H7’ H14’ H15’), 7.00-7.03 (m, 4H, H5’ H8’ 
H13’ H16’), 5.95 (d, 2H, 3J= 7.7 Hz, H8b’ H16b’), 4.99 (d, 2H, 3J= 8.1 Hz, H3a’ H11a’), 
3.37-3.50 (m, 4H, H4’ H12’); LRMS (ES+): m/z (%) 660.06 (100) [M]+.  
8,14-Dioxo-6,7-dihydro-8H,14H-5,13-diazabenz[e]aceanthrylene (161a) 315 
 
A mixture of the methyl anthranilate 213a (0.63 g, 4.0 mmol, 4.0 eq.) and N-aryl lactam 
214a (0.22 g, 1.0 mmol, 1.0 eq.) in a sealed glass microwave tube was heated to 190 oC, 
(maximum 275 W), with air flowing through the reaction chamber, for 30 minutes. Upon 
cooling the reaction mixture was added to diethyl ether (30 mL) and the resultant precipitate 
filtered. The precipitate was purified by recrystalisation in acetic acid to afford the title 
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compound (0.88 g, 3.04 mmol, 76%). Mp 296-297 oC (lit.315 295-296 oC); 1H NMR (400 
MHz, CDCl3): δ 9.52 (d, 1H, 3J = 8.5 Hz, H12), 8.49 (dd, 1H,3J = 8.5 Hz, 4J = 1.5 Hz, H9), 
8.29 (dd, 1H, 3J = 8.0 Hz, 4J = 1.5 Hz, H1), 7.75-7.69 (m, 1H, H3), 7.68-7.62 (m, 1H, H11), 
7.53-7.48 (m, 1H, H10), 7.28-7.23 (m, 1H, H2), 6.97 (d, 1H, 3J = 8.5 Hz, H4), 4.31 (t, 2H, 3J 
= 9.0 Hz, 3J = 9.0 Hz, H6), 3.89 (t, 2H, 3J = 9.0 Hz, 3J = 9.0 Hz, H7); LRMS (ES+): m/z (%) 
311.02 (100) [M+Na]+; 
Synthesis of 10-Methyl 8,14-dioxo-6,7-dihydro-8H,14H-5,13-diazabenz[e] aceanthrylene 
(161b)315 
 
A mixture of the methyl anthranilate 213b (0.66 g, 4.0 mmol, 4.0 eq.) and N-aryl lactam 
214a (0.22 g, 1.0 mmol, 1.0 eq.) in a sealed glass microwave tube was heated to 190 oC, 
(maximum 275 W), with air flowing through the reaction chamber, for 30 minutes. Upon 
cooling the reaction mixture was added to diethyl ether (30 mL) and the resultant precipitate 
filtered. The precipitate was purified by recrystalisation in acetic acid to afford the title 
compound (0.24 g, 0.79 mmol, 79%). Mp 295 °C (dec.) (lit.315 299 °C (dec.)); 1H NMR (400 
MHz, CDCl3): δ 9.36 (d, 1H, 3J = 9.0 Hz, H12), 8.25−8.22 (m, 2H, H9 H1), 7.64 (ddd, 1H, 
3J = 7.0 Hz, 3J = 7.0 Hz, 4J = 1.5 Hz, H3), 7.41 (dd, 1H, 3J = 9.0 Hz, 4J = 1.5 Hz, H11), 
7.26-7.20 (m, 1H, H2), 6.90 (dd, 1H, 3J = 7.0 Hz, 4J = 1.5 Hz, H4), 4.30 (t, 2H, 3J = 9.0 Hz, 
H6), 3.34 (t, 2H, 3J = 9.0 Hz, H7), 2.42 (s, 3H, Me); LRMS (ES+): m/z (%) 303.11 (100) 
[M+H]+.  
Synthesis of 10-Chloro 8,14-dioxo-6,7-dihydro-8H,14H-5,13-diazabenz[e] aceanthrylene 
(161c)315 
 
A mixture of the methyl anthranilate 213c (0.74 g, 4.0 mmol, 4.0 eq.) and N-aryl lactam 214a 
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(0.22 g, 1.0 mmol, 1.0 eq.) in a sealed glass microwave tube was heated to 190 oC, 
(maximum 275 W), with air flowing through the reaction chamber, for 30 minutes. Upon 
cooling the reaction mixture was added to diethyl ether (30 mL) and the resultant precipitate 
filtered. The precipitate was purified by recrystalisation in acetic acid to afford the title 
compound (0.26 g, 0.80 mmol, 80%). Mp 299 oC (dec.) (lit.315 301 oC (dec.)); 1H NMR (400 
MHz, CDCl3): δ 9.52 (d, 1H, 3J = 9.5 Hz, H12), 8.45 (d, 1H, 4J = 2.5 Hz, H9), 8.29 (d, 1H, 3J 
= 8.5 Hz, 4J = 1.5 Hz, H1), 7.76 (ddd, 1H, 3J = 8.5, 8.5 Hz, 4J = 1.5 Hz, H3), 7.58 (dd, 1H,  
3J = 9.5 Hz, 4J = 2.5 Hz, H11), 7.30 (d, 1H, 3J = 8.5 Hz, H2), 7.00 (d, 1H, 3J = 8.5 Hz, H4), 
4.34 (t, 2H, 3J = 9.0 Hz, H6), 3.40 (t, 2H, 3J = 9.0 Hz, H7); LRMS (ES+): m/z (%) 345.08 (70) 
[M+Na]+, 667.12 (100) [2M(35Cl35Cl)+Na]+, 669.12 [2M(35Cl37Cl)+Na]+.  
Synthesis of  12-methyl-8,14-dioxo-6,7-dihydro-8H,14H-5,13-diazabenz[e]aceanthryl- 
ene (161e)315 
 
A mixture of the methyl anthranilate 213e (0.66 g, 4.0 mmol, 4.0 eq.) and N-aryl lactam 
214a (0.22 g, 1.0 mmol, 1.0 eq.) in a sealed glass microwave tube was heated to 190 oC, 
(maximum 275 W), with air flowing through the reaction chamber, for 30 minutes. Upon 
cooling the reaction mixture was added to diethyl ether (30 mL) and the resultant precipitate 
filtered. The precipitate was purified by recrystalisation in acetic acid to afford the title 
compound (0.15 g, 0.48 mmol, 48%) as a yellow powder. Mp 286 oC (dec.) (lit.315 286 oC 
(dec.)); 1H NMR (400 MHz, CDCl3): δ 9.26 (s, 1H, H12), 8.26 (d, 1H, 3J = 8.0 Hz, H9), 8.19 
(dd, 1H, 3J = 8.0 Hz, 4J = 1.3 Hz, H1), 7.67 (ddd, 1H, 3J = 7.7, 7.7 Hz, 4J = 1.3 Hz, H3), 
7.22-7.16 (m, 2H, H10 H2), 6.90 (d, 1H, 3J = 8.2 Hz, H4), 4.23 (t, 2H, 3J = 8.8 Hz, H6), 3.31 
(t, 2H, 3J = 8.8 Hz, H7), 2.47 (s, 3H, Me); LRMS (CI+): m/z (%) 303.11 (100) [M+H]+.  
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Synthesis of 11-Chloro 8,14-dioxo-6,7-dihydro-8H,14H-5,13-diazabenz[e]aceanthryl- 
ene (161e)315 
 
A mixture of the methyl anthranilate 213e (0.74 g, 4.0 mmol, 4.0 eq.) and N-aryl lactam 214a 
(0.22 g, 1.0 mmol, 1.0 eq.) in a sealed glass microwave tube was heated to 190 oC, 
(maximum 275 W), with air flowing through the reaction chamber, for 30 minutes. Upon 
cooling the reaction mixture was added to diethyl ether (30 mL) and the resultant precipitate 
filtered. The precipitate was purified by recrystalisation in acetic acid to afford the title 
compound (0.18 g, 0.55 mmol, 55%) was afforded as a pale brown powder. Mp 276 oC (dec.) 
(lit.315 276 oC (dec.)); 1H NMR (400 MHz, CDCl3): δ 9.59 (d, 1H, 4J = 2.0 Hz, H12), 8.37 (d, 
1H, 3J = 8.5 Hz, H9), 8.26 (d, 1H, 3J = 8.0 Hz, 4J = 1.5 Hz, H1), 7.76-7.70 (m, 1H, H3), 7.42 
(dd, 1H, 3J = 8.5 Hz, 4J = 2.0 Hz, H10), 7.30-7.24 (m, 1H, H2), 6.97 (d, 1H, 3J = 8.0 Hz, H4), 
4.30 (t, 2H, 3J = 9.5 Hz, H6), 3.36 (t, 2H, 3J = 9.5 Hz, H7); LRMS (ES+): m/z (%) 323.04 
(100) [M+H]+, 345.03 (20) [M+Na]+, 667.07 [2M+Na]+. 
Synthesis of 12-methyl-8,14-dioxo-6,7-dihydro-8H,14H-5,13-diazabenz[e]aceanthrylene 
(161f) 
 
A mixture of the methyl anthranilate 213f (0.66 g, 4.0 mmol, 4.0 eq.) and N-aryl lactam 214a 
(0.22 g, 1.0 mmol, 1.0 eq.) in a sealed glass microwave tube was heated to 190 oC, 
(maximum 275 W), with air flowing through the reaction chamber, for 30 minutes. Upon 
cooling the reaction mixture was added to diethyl ether (30 mL) and the resultant precipitate 
filtered. The precipitate was purified by recrystalisation in acetic acid to afford the title 
compound (0.10 g, 0.35 mmol, 35%) was afforded as a yellow powder. Mp 236-237 oC 
(lit.315 238-239 oC); 1H NMR (400 MHz, CDCl3): δ 8.27-8.22 (m, 1H, H9), 8.18 (dd, 1H, 3J 
Chapter 8 
                                                                                                     
190
= 8.0 Hz, 4J = 1.5 Hz, H1), 7.73 (ddd, 1H, 3J = 7.5, 7.5 Hz, 4J =1.5 Hz, H3), 7.48-7.45 (m, 
2H, H10 H11), 7.27-7.21 (m, 1H, H2), 6.98 (d, 1H, 3J = 7.5 Hz, H4), 4.30 (t, 2H, 3J = 9.0 Hz, 
H6), 3.33 (t, 2H, 3J = 9.0 Hz, H7), 2.32 (s, 3H, Me); LRMS (ES+): m/z (%) 325.29 (100) 
[M+Na]+, 627.09 (25) [2M+Na]+.  
Synthesis of 2-methyl 8,14-dioxo-6,7-dihydro-8H,14H-5,13-diazabenz[e] aceanthrylene 
(161g) 
 
A mixture of the methyl anthranilate 213a (0.60 g, 4.0 mmol, 4.0 eq.) and N-aryl lactam 
214b (0.23 g, 1.0 mmol, 1.0 eq.) in a sealed glass microwave tube was heated to 190 oC, 
(maximum 275 W), with air flowing through the reaction chamber, for 30 minutes. Upon 
cooling the reaction mixture was added to diethyl ether (30 mL) and the resultant precipitate 
filtered. The precipitate was purified by recrystalisation in acetic acid to afford the title 
compound (0.19 g, 0.63 mmol, 63%) was afforded as a yellow powder. Mp: 199-200 °C;  
1H NMR (400 MHz, CDCl3): δ 9.52 (d, 1H, 3J= 9.0, H12), 8.49 (dd, 1H, 3J= 9.0, 4J= 1.5, 
H9), 8.08 (s, 1H, H1), 7.62-7.70 (m, 1H, H11), 7.48-7.56 (m, 2H, H10, H3), 6.89 (d, 1H,  
3J= 8.5, H4), 4.29 (t, 2H, 3J= 9.5, H6), 3.39 (t, 2H, 3J= 9.5, H7), 2.45 (s, 3H, H1’); 13C NMR 
(100 MHz, CDCl3): δ 172.3 (C8), 160.1 (C14), 137.5 (C3), 137.2 (C5a), 136.6 (C4a), 135.2 
(C13a), 132.5 (C9a), 130.7 (C11), 129.6 (C1), 127.8 (C2), 126.4 (C10), 125.6 (C9), 121.0 
(C12), 114.4 (C15a), 112.2 (C4), 101.9 (C7a), 47.3 (C6), 23.4 (C7), 20.9 (C1’); IR (KBr): 
νmax = 3339 (m) (OH), 1712 (s) (C=O), 1602 (m), 1556 (s), 1492 (s), 1320 (m), 1157 (m) 
(C-O), 747 (m) (Ar-H) cm-1; LRMS (ES+): m/z (%) 325.29 (100) [M+Na]+, 627.09 (25) 
[2M+Na]+; HRMS (ES+): m/z calcd for C19H14N2O2Na [M+Na]+: 325.0953; found 325.0944.  
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Synthesis of 2-methoxy-8,14-dioxo-6,7-dihydro-8H,14H-5,13-diazabenz[e]aceanthryl- 
ene (161h)320 
 
A mixture of the methyl anthranilate 213a (0.60 g, 4.0 mmol, 4.0 eq.) and N-aryl lactam 214c 
(0.25 g, 1.0 mmol, 1.0 eq.) in a sealed glass microwave tube was heated to 190 oC, 
(maximum 275 W), with air flowing through the reaction chamber, for 30 minutes. Upon 
cooling the reaction mixture was added to diethyl ether (30 mL) and the resultant precipitate 
filtered. The precipitate was purified by recrystalisation in acetic acid to afford the title 
compound (0.29 g, 0.90 mmol, 90%) was afforded as a brown powder. Mp 295-296 oC (lit.320 
295-296 oC); 1H NMR (400 MHz, CDCl3): δ 9.52 (d, 1H, 3J = 9.0 Hz, H12), 8.51 (dd, 1H,  
3J = 8.0 Hz, 4J = 2.0 Hz, H9), 7.72 (d, 1H, 4J = 3.0 Hz, H1), 7.68-7.61 (m, 1H, H11), 
7.56-7.50 (m, 1H, H10), 7.33 (dd, 1H, 3J = 9.0 Hz, 4J = 3.0 Hz, H3), 6.94 (d, 1H, 3J = 9.0 Hz, 
H4), 4.30 (t, 2H, 3J = 9.0 Hz, H6), 3.91 (s, 3H, Me), 3.38 (t, 2H, 3J = 9.0 Hz, H7); LRMS 
(ES+): m/z (%) 319.08 (100) [M+H]+.  
Synthesis of 2-chloro 8,14-dioxo-6,7-dihydro-8H,14H-5,13-diazabenz[e] aceanthrylene 
(161i) 
 
A mixture of the methyl anthranilate 213a(0.60 g, 4.0 mmol, 4.0 eq.) and N-aryl lactam 214d 
(0.25 g, 1.0 mmol, 1.0 eq.) in a sealed glass microwave tube was heated to 190 oC, 
(maximum 275 W), with air flowing through the reaction chamber, for 30 minutes. Upon 
cooling the reaction mixture was added to diethyl ether (30 mL) and the resultant precipitate 
filtered. The precipitate was purified by recrystalisation in acetic acid to afford the title 
compound (0.17 g, 0.53 mmol, 53%) was afforded as a brown powder. Mp: 256-257 °C; 1H 
NMR (400 MHz, CDCl3): δ 9.52 (d, 1H, 3J= 9.0, H12), 8.55 (d, 1H, 3J= 9.0, H9), 8.40 (s, 1H, 
H1), 7.67-7.77 (m, 2H, H3, H10), 7.55-7.65 (m, 1H, H11), 6.98 (d, 1H, 3J= 8.5, H4), 4.34 (t, 
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2H, 3J= 9.5, H6), 3.43 (t, 2H, 3J= 9.5, H7); 13C NMR (100 MHz, CDCl3): δ 172.3 (C8), 
160.1 (C14), 137.5 (C3), 137.2 (C5a)136.8 (C2), 136.6 (C4a),  135.2 (C13a), 132.5 (C9a), 
130.7 (C11), 129.6 (C1), 126.4 (C10), 125.6 (C9), 121.0 (C12), 114.4 (C15a), 112.2 (C4), 
101.9 (C7a), 47.3 (C6), 23.4 (C7); IR (KBr): νmax = 1707 (s) (C=O), 1604 (s), 1582 (s), 1498 
(s), 1466 (m), 1425 (w), 1324 (w), 1157 (w) (C-O), 746 (m) (Ar-H) cm-1; LRMS (ES+): m/z 
(%) 323.04 (100) [M+H]+, 345.03 (20) [M+Na]+, 667.07 [2M+Na]+; HRMS (ES+): m/z calcd 
for C18H11N2O2NaCl [M+Na]+: 345.0407; found: 345.0402. 
8.8 General procedure of asymmetric oxidative fragmentation of diazabenz[e] 
aceathrylenes: diazabenz[e] aceathrylene 161 (0.5 mmol, 1.0 eq) was suspended in 
anhydrous toluene (10 mL) at 0 °C, catalyst 141a (0.014 g, 0.025 mmol, 5 mol%), 
PhI(OAc)2 (0.32 g, 1 mmol, 2.0 eq) and H2O (9 μL, 0.5 mmol, 1.0 eq) were added. The 
reaction mixture was warmed up during the night and stirred for 16 hrs. The reaction mixture 
was then diluted with DCM (10 mL) and washed with H2O (10 mL). The organic layer was 
dried over MgSO4, filtered, and reduced to give a dark brown solid. The crude product 
mixture was then purified by flash column chromatography over silica gel (ethyl 
actetate/hexane 2:3) to furnish the title compound as a light yellow solid.  
7,8-dihydro-benzo[d]quinazolo[1,2,3-a,b][1,3]diazonane-1,9,10,16-tetrone (162a) 
N N
O
O
1
2
3
4
5
6 7
8910
11
12
13
14
15
O O
16
 
162a (0.097 g, 0.31 mmol, 65%, 33% e.e. recrystalisation from acetone to obtain 91% e.e.) 
was afforded as pale yellow crystals. Mp 213-214 oC; 1H NMR (400 MHz, CDCl3): δ 8.21 
(dd, 1H, 3J = 8.0 Hz, 4J = 1.5 Hz, H2), 8.08 (dd, 1H,  3J = 8.0 Hz, 4J = 1.5 Hz, H11), 
7.79-7.70 (m, 3H, H4, H12, H14), 7.58-7.52 (m, 1H, H13), 7.35-7.26 (m, 2H, H3, H5), 
4.87-4.77 (m, 1H, H7a), 4.42-4.32 (m, 1H, H7b), 3.86-3.76 (m, 1H, H8a), 2.94-2.84 (m, 1H, 
H8b); 13C NMR (75.5 MHz, CDCl3): δ 198.9 (C9), 190.9 (C10), 160.3 (C1), 155.5 (C16), 
141.2 (C5a), 136.3 (C14a), 135.9 (C4), 133.7 (C12), 131.6 (C11), 130.2 (C10a), 129.7 (C14), 
129.6 (C2), 128.8 (C13), 124.3 (C3), 116.6 (C1a), 115.8 (C5), 44.5 (C7), 35.7 (C8); IR (KBr): 
νmax = 2924 (m) (CH2), 1715 (s) (C=O), 1665 (s) (C=O), 1606 (m), 1475 (m), 1451 (m), 
1276 (m), 1193 (w) (C-O), 985 (m), 775 (m) (Ar-H) cm-1; LRMS (ES+): m/z (%) 343.11 (100) 
[M+Na]+; HRMS (ES+): m/z calcd for C18H12N2O4Na [M+Na]+: 343.0695; found 343.0692; 
[α]20D = -202.2 (c = 0.002, DCM).  
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12-methyl-7,8-dihydro-benzo[d]quinazolo[1,2,3-a,b][1,3]diazonane-1,9,10,16-tetrone 
(162b) 
 
161b (0.092 g, 0.28 mmol, 55%, 0% e.e.). Mp 234 oC (dec.); 1H NMR (400 MHz, CDCl3): δ 
8.21 (dd, 1H, 3J = 7.5 Hz, 4J = 1.5 Hz, H2), 7.88 (d, 1H, 4J = 1.0 Hz, H11), 7.44 (ddd, 1H, 3J 
= 7.5, 7.5 Hz, 4J = 1.5 Hz, H4), 7.60 (d, 1H, 3J = 8.0 Hz, H14), 7.55 (dd, 1H, 3J = 8.0 Hz, 4J 
= 2.0 Hz, H13), 7.32 (ddd, 1H, 3J = 7.5, 7.5 Hz, 4J = 1.0 Hz, H3), 7.28 (d, 1H, 3J = 8.5 Hz, 
H5), 4.86-4.78 (m, 1H, H7a), 4.40-4.33 (m, 1H, H7b), 3.86-3.77 (m, 1H, H8a), 2.93-2.85 (m, 
1H, H8b), 2.47 (s, 3H, Me); 13C NMR (100 MHz, CDCl3): δ 199.2 (C9), 190.8 (C10), 160.5 
(C1), 155.7 (C16), 141.4 (C5a), 139.2 (C12), 136.0 (C4), 134.4 (C13), 134.0 (C14a), 132.1 
(C11), 129.8 (C2), 129.6 (C14), 129.5 (C10a), 124.4 (C3), 116.7 (C1a), 115.9 (C5), 44.7 
(C7), 35.9 (C8), 21.3 (Me); IR (KBr): νmax = 2925 (m), 1705 (s), 1660 (s), 1611 (s), 1479 (s), 
1387 (m), 1279 (w), 766 (m) cm-1; LRMS (ES+): m/z (%) 388.98 (100) [M+MeOH+Na]+; 
HRMS (ES+): m/z calcd for C20H18N2O5Na [M+MeOH+Na]+: 389.1133; found 389.1108.  
12-chloro-7,8-dihydro-benzo[d]quinazolo[1,2,3-a,b][1,3]diazonane-1,9,10,16-tetrone 
(162c) 
 
161c (0.13 g, 0.36 mmol, 72%, 36% e.e.). Mp 211-212 oC; 1H NMR (400 MHz, CDCl3): δ 
8.31 (dd, 1H, 3J = 7.5 Hz, 4J = 1.5 Hz, H2), 8.18 (d, 1H, 4J = 2.5 Hz, C11), 7.76 (ddd, 1H, 3J 
= 7.5, 7.5 Hz, 4J = 1.5 Hz, H4), 7.69 (dd, 1H, 3J = 8.5 Hz, 4J = 2.5 Hz, C13), 7.49 (d, 1H, 3J 
= 8.5 Hz, H14), 7.36 (ddd, 1H, 3J = 7.5, 7.5 Hz, 4J = 1.5 Hz, H3), 7.32 (d, 1H, 3J = 7.5 Hz, 
H5), 4.87 (ddd, 1H, 2J = 13.0 Hz, 3J = 13.0, 2.0 Hz, H7a), 4.13 (dt, 1H, 2J = 15.0 Hz, 3J = 3.0, 
H7b), 3.43 (ddd, 1H, 2J = 13.0 Hz, 3J = 13.0, 2.0 Hz, H8a), 2.61 (ddd, 1H, 2J = 16.0 Hz, 3J = 
6.0, 2.0 Hz, H8b); 13C NMR (100 MHz, CDCl3): δ 201.0 (C9), 189.8 (C10), 161.0 (C1), 
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154.6 (C16), 139.1 (C5a), 136.1 (C4), 135.2 (C12), 134.0 (C13), 133.9 (C14a), 131.7 (C14), 
131.6 (C11), 131.2 (C10a), 130.3 (C2), 124.4 (C3), 116.6 (C1a), 114.3 (C5), 44.6 (C7), 36.9 
(C8); IR (KBr): νmax = 2923 (m), 2854 (m), 2362 (m), 1707 (m), 1654 (m), 1606 (m), 1475 
(m), 1388 (m), 1106 (w), 758 (w) cm-1; LRMS (ES+): m/z (%) 408.93 (100) 
[M35Cl+MeOH+Na]+; HRMS (ES+): m/z calcd for C19H15N2O5NaCl [M35Cl+MeOH+Na]+: 
409.0567; found 409.0558. 
13-methyl-7,8-dihydro-benzo[d]quinazolo[1,2,3-a,b][1,3]diazonane-1,9,10,16-tetrone 
(162d) 
 
161d (0.097 g, 0.29 mmol, 58%, 7% e.e.). Mp 202-203 oC; 1H NMR (400 MHz, CDCl3): δ 
8.21 (dd, 1H, 3J = 7.9 Hz, 4J = 1.4 Hz, H2), 8.01 (d, 1H, 3J = 7.9 Hz, H11), 7.76 (ddd, 1H, 3J 
= 7.9, 7.0 Hz, 4J = 1.5 Hz, H4), 7.54-7.51 (m, 1H, H14), 7.38-7.27 (m, 3H, H12, H3, H5), 
4.85-4.75 (m, 1H, H7a), 4.43-4.32 (m, 1H, H7b), 3.89-3.78 (m, 1H, H8a), 2.95-2.83 (m, 1H, 
H8b), 2.53 (s, 3H, Me); 13C NMR (100 MHz, CDCl3): δ 199.3 (C9), 191.1 (C10), 160.5 (C1), 
155.3 (C16), 145.4 (C14a), 141.6 (C5a), 136.6 (C13), 136.0 (C4), 131.8 (C11), 130.5 (C14), 
129.7 (C2 & C12), 127.5 (C10a), 124.4 (C3), 116.8 (C1a), 115.9 (C5), 44.7 (C7), 35.8 (C8), 
21.9 (Me); IR (KBr): νmax = 1713 (s) (C=O), 1670 (s) (C=O), 1610 (s), 1481 (m), 1390 (m), 
1344 (m), 1278 (m), 1167 (w), 755 (m) cm-1; LCMS (ES+): (purity 98%) m/z (%) 334.82 
(100) [M+H]+; HRMS (ES+): m/z calcd for C19H15N2O4 [M+H]+: 335.0896; found 335.0871.  
13-chloro-7,8-dihydro-benzo[d]quinazolo[1,2,3-a,b][1,3]diazonane-1,9,10,16-tetrone 
(162e) 
 
161e (0.13 g, 0.37 mmol, 73%, 35% e.e.). Mp 221-222 oC; 1H NMR (400 MHz, CDCl3): δ 
8.22 (dd, 1H, 3J = 8.0 Hz, 4J = 1.5 Hz, H2), 8.02 (d, 1H, 3J = 8.5 Hz, H11), 7.77 (ddd, 1H, 3J 
= 7.5, 7.5 Hz, 4J = 1.5 Hz, H4), 7.74 (d, 1H, 4J = 2.0 Hz, H14), 7.53 (dd, 1H, 3J = 8.5 Hz, 4J 
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= 2.0 Hz, H12), 7.35 (ddd, 1H, 3J = 7.5 ,7.5 Hz, 4J = 1.5 Hz, H3), 7.29 (d, 1H, 3J = 7.5 Hz, 
H5), 4.86-4.78 (m, 1H, H7a), 4.42-4.35 (m, 1H, H7b), 3.87-3.79 (m, 1H, H8a), 2.94-2.86 (m, 
1H, H8b); 13C NMR (100 MHz, CDCl3): δ 198.8 (C9), 190.9 (C10), 160.0 (C1), 155.6 (C16), 
141.3 (C5a), 140.0 (C13), 137.3 (C14a), 136.3 (C4), 132.6 (C11), 130.3 (C14), 129.9 (C2), 
129.2 (C12), 128.8 (C10a), 124.6 (C3), 116.5 (C1a), 116.0 (C5), 44.6 (C7), 35.7 (C8); IR 
(KBr): νmax = 2925 (m), 1719 (s), 1655 (s), 1609 (m), 1476 (m), 1388 (m), 1261 (m), 756 (m) 
cm-1; LRMS (ES+): m/z (%) 408.93 (100) [M35Cl+MeOH+Na]+, 410.98 (25) 
[M37Cl+MeOH+Na]+; HRMS (ES+): m/z calcd for C19H15N2O5NaCl [M35Cl+MeOH+Na]+: 
409.0567; found 409.0558.  
14-methyl-7,8-dihydro-benzo[d]quinazolo[1,2,3-a,b][1,3]diazonane-1,9,10,16-tetrone 
(162f) 
N N
O
O
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161f (0.10 g, 0.31 mmol, 61%, -9% e.e.). Mp 134-135 oC; 1H NMR (400 MHz, CDCl3): δ 
8.18 (dd, 1H, 3J = 8.0 Hz, 4J = 1.5 Hz, H2), 7.82 (d, 1H, 3J = 7.6 Hz, H11), 7.73 (ddd, 1H, 3J 
= 8.8, 7.1 Hz, 4J = 1.5 Hz, H4), 7.67-7.57 (m, 1H, H13), 7.45 (dd, 1H, 3J = 7.7, 7.7 Hz, H12), 
7.35-7.28 (m, 2H, H3, H5), 4.88-4.78 (m, 1H, H7a), 4.32 (ddd, 1H, 2J = 13.7 Hz, 3J = 8.6, 
3.8 Hz, H7b), 3.57-3.47 (m, 1H, H8a), 3.02-2.91 (m, 1H, H8b), 2.39 (s, 3H, Me); 13C NMR 
(100 MHz, CDCl3): δ 199.0 (C9), 191.0 (C10), 163.7 (C1), 157.5 (C16), 141.2 (C5a), 138.4 
(C14), 135.8 (C4), 135.3 (C12), 135.2 (C13), 132.1 (C14a), 130.3 (C11), 129.6 (C2), 129.5 
(C10a), 124.5 (C3), 117.6 (C1a), 116.3 (C5), 45.3 (C7), 36.2 (C8), 19.4 (Me); IR (KBr): νmax 
= 2926 (m), 1718 (s), 1671 (s), 1609 (s), 1477 (m), 1383 (m), 1276 (m), 759 (m) cm-1; 
LRMS (ES+): m/z (%) 356.99 (100) [M+Na]+; HRMS (ES+): m/z calcd for C19H14N2O4Na 
[M+Na]+: 357.0851; found 357.0853. 
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3-methyl-7,8-dihydro-benzo[d]quinazolo[1,2,3-a,b][1,3]diazonane-1,9,10,16-tetrone 
(162g) 
 
161g (0.096 g, 0.29 mmol, 57%, 4% e.e.). Mp 134-135 oC; 1H NMR (400 MHz, CDCl3): δ 
8.08 (d, 1H, 3J= 8.0, H11), 8.00 (s, 1H, H2), 7.70-7.79 (m, 2H, H4, H12), 7.51-7.61 (m, 2H, 
H14, H13), 7.20 (d, 1H, 3J= 9.0, H5), 4.78-4.88 (m, 1H, H7a), 4.29-4.30 (m, 1H, H7b), 
3.72-3.88 (m, 1H, H8a), 2.80-2.97 (m, 1H, H8b), 2.33 (s, 3H, H1’); 13C NMR (100 MHz, 
CDCl3): δ 198.9 (C9), 190.9 (C10), 160.3 (C1), 155.6 (C16), 139.0 (C5a), 136.5 (C4), 136.3 
(C14a), 133.4 (C12), 131.5 (C11), 129.8 (C10a), 129.6 (C2), 129.3 (C14), 128.7 (C13), 116.6 
(C1a), 116.4 (C3), 115.8 (C5), 44.4 (C7), 35.7 (C8), 20.7 (C1’); IR (KBr): νmax = 2926 (m), 
1718 (s), 1671 (s), 1609 (s), 1477 (m), 1383 (m), 1276 (m), 759 (m) cm-1; LRMS (ES+): m/z 
(%) 356.99 (100) [M+Na]+; HRMS (ES+): m/z calcd for C19H14N2O4Na [M+Na]+: 357.0851; 
found 357.0853. 
3-chloro-7,8-dihydro-benzo[d]quinazolo[1,2,3-a,b][1,3]diazonane- 1,9,10,16-tetrone 
(162i) 
 
161i (0.11 g, 0.32 mmol, 63%, 36% e.e.). Mp 221-222 oC; 1H NMR (400 MHz, CDCl3): δ 
8.17 (d, 1H, 4J= 2.5, H2), 8.09 (dd, 1H, 3J= 8.0, 4J= 1.5, H11), 7.74-7.80 (m, 1H, H12), 
7.60-7.73 (m, 2H, H4, H14), 7.54-7.60 (m, 1H, H13), 7.24 (d, 1H, 3J= 9.0, H2), 4.77-4.87 (m, 
1H, H7a), 4.23-4.37 (m, 1H, H7b), 3.75-3.90 (m, 1H, H8a), 2.85-2.96 (m, 1H, H8b); 13C 
NMR (100 MHz, CDCl3): δ 198.9 (C9), 190.9 (C10), 159.2 (C1), 155.1 (C16), 139.8 (C5a), 
136.1 (C14a), 136.5 (C3), 136.0 (C4), 133.8 (C12), 131.7 (C11), 130.2 (C10a), 129.7 (C14), 
129.0 (C2), 128.9 (C13), 117.8 (C1a), 117.5 (C5), 44.8 (C7), 35.6 (C8); IR (KBr): νmax = 
2923 (m), 2854 (m), 2362 (m), 1707 (m), 1654 (m), 1606 (m), 1475 (m), 1388 (m), 1106 (w), 
758 (w) cm-1; LRMS (ES+): m/z (%) 408.93 (100) [M35Cl+MeOH+Na]+; HRMS (ES+): m/z 
calcd for C19H15N2O5NaCl [M35Cl+MeOH+Na]+: 409.0567; found 409.0558. 
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3-methoxyl-7,8-dihydro-benzo[d]quinazolo[1,2,3-a,b][1,3]diazonane-1,9,10,16-tetrone 
(162h) 
 
161h (0.063 g, 0.18 mmol, 36%, 2% e.e.). 1H NMR (400 MHz, CDCl3): δ 8.08 (d, 1H, 3J= 
8.0, H11), 7.69-7.80 (m, 2H, H12, H14), 7.63 (d, 1H, 4J= 3.0, H2), 7.56 (dt, 1H, 3J= 8.0, 4J= 
1.5, H13), 7.34 (dd, 1H, 3J= 9.0, 4J= 3.0, H4), 7.23 (d, 1H, 3J= 9.0, H5), 4.78-4.89 (m, 1H, 
H7a), 4.27-4.37 (m, 1H, H7b), 3.89 (s, 3H, H1’), 3.75-3.85 (m, 1H, H8a), 2.83-2.94 (m, 1H, 
H8b); 13C NMR (100 MHz, CDCl3): δ 198.8 (C9), 190.9 (C10), 160.3 (C1), 156.1 (C16), 
155.5 (C3), 139.8 (C5a), 136.5 (C14a), 135.2 (C10a), 133.6 (C12), 131.5 (C11), 129.7 (C14), 
128.8 (C13), 125.1 (C4), 117.5 (C5), 117.3 (C1a), 110.3 (C2), 55.9 (C1’), 44.7 (C7), 35.7 
(C8); IR (KBr): νmax = 1702 (s) (C=O), 1656 (s) (C=O), 1480 (m), 1386 (m), 1290 (w), 760 
(m) cm-1; LRMS (ES+): m/z (%) 405.05 (100) [M+MeOH+Na]+; HRMS (ES+): m/z calcd for 
C20H16N2O6Na [M+MeOH+Na]+: 405.1063; found 405.1063. 
7,8,10-trihydro-10-hydroxy-benzo[d]quinazolo[1,2,3-a,b][1,3]diazonane-1,9,16-trione 
(210) 
 
To a solution of 162a (320 mg, 1.0 mmol, 1.0 eq, 91% e.e.) in anhydrous tetrahydrofuran (30 
mL) was added NaBH4 (30 mg, 0.75 mmol, 0.75 eq.) at 0 oC (ice-water bath) and the 
reaction mixture was stirred for 20 min. 10.0 M Hydrochloric acid (10 mL) was added and 
stirred for 10 min, then NaHCO3(aq.) (to pH 7) and extracted with EtOAc (3 x 50 mL). The 
organic layer was dried (MgSO4), filtered and evaporated to dryness. Column 
chromatography over silica gel eluted: (3:7, ethyl acetate:hexane) 210 (0.24 g, 0.73 mmol, 
73%) as a white powder. Mp 239-240 oC; 1H NMR (300 MHz, d6-DMSO): δ = 8.04 (dd, 3J = 
7.9 Hz, 4J = 1.5 Hz, 1H, C2-H), 7.79 (ddd, 3J = 7.1 Hz, 3J = 7.1 Hz, 4J = 1.5 Hz, 1H, H4), 
7.69-7.65 (m, 1H, H5), 7.48-7.45 (m, 2H, H14, H13), 7.40-7.38 (m, 2H, H11, H12), 7.29 
(ddd, 3J = 7.1 Hz, 3J = 7.1 Hz, 4J = 1.0 Hz, 1H, H3), 6.29 (d, 3J = 5.2 Hz, 1H, OH), 4.83 (d, 
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3J = 5.2 Hz, 1H, H10), 4.71-4.59 (m, 1H, H7a), 4.56-4.46 (m, 1H, H7b), 3.57 (ddd, 2J = 11.7 
Hz, 3J = 11.7 Hz, 3J = 5.2 Hz, 1H, H8a), 1.99 (dt, 2J = 11.7 Hz, 3J = 2.5 Hz, 3J = 2.5 Hz, 1H, 
H8b); 13C NMR (75.5 MHz, d6-DMSO): δ = 211.0 (C9), 162.3 (C1), 155.8 (C16), 141.2 
(C5a), 138.4 (C10a), 135.2 (C4), 133.4 (C14a), 132.8 (C2), 130.6 (C12), 128.4 (C14), 128.2 
(C11), 127.8 (C13), 122.8 (C3), 117.4 (C1a), 115.6 (C5), 81.3 (C10), 45.2 (C7), 36.8 (C8); 
IR (KBr): vmax = 3520 (s), 3459 (s), 2926 (m), 1705 (s) (C=O), 1665 (s) (C=O), 1606 (m), 
1475 (m), 775 (m) cm-1; LRMS (ES+): m/z (%) 345.11 (100) [M+Na]+; HRMS (ES+): m/z 
calcd for C18H14N2O4 [M+Na]+: 345.0851; found: 345.0852; [α]20D = -187.2 (c = 0.00293, 
DCM).  
10-(4-bromobenzoyloxy)-7,8-dihydro-benzo[d]quinazolo[1,2,3-a,b][1,3]diazonane-1,9,10, 
16-tetrone (211) 
N
O
N
O
OO O
Br
H
15 16
910
1
2
3
4
5
6
7
8
11
12
13
14
1' 2'
3'
4'
5'
6'
7'
8'
 
210 (0.08 g, 0.25 mmol, 1.0 eq) was dissolved in anhydrous DCM (10 mL), DMAP (0.015 g, 
0.13 mmol, 0.5 eq), anhydrous pyridine (0.08 mL, 1 mmol, 4.0 eq), and 4-bromobenzoyl 
chloride (0.54 g, 2.5 mmol, 10 eq) were added to the solution. The reaction mixture was 
stirred at room temperature for 18 hrs. Saturated ammonium chloride solution was added to 
the reaction mixture. Organic layer was washed with NaHCO3(aq.) (to pH 7) and extracted 
with DCM (3 x 50 mL). The organic layer was dried (MgSO4), filtered and evaporated to 
dryness. Column chromatography over silica gel eluted (3:7, ethyl acetate:hexane) 211 
(0.064 g, 0.13 mmol, 51%) as a white powder 1H NMR (400 MHz, CDCl3): δ 8.11 (d, 1H, 
3J= 8.5 H2), 7.69-7.77 (m, 2H, H4, H5), 7.56-7.63 (m, 1H, H14), 7.40-7.52 (m, 6H, H4’, H5’, 
H7’, H8’, H13, H11), 7.24-7.32 (m, 2H, H12, H3), 5.93 (s, 1H, H9), 4.87-5.00 (m, 1H, H7a), 
4.18-4.28 (m, 1H, H7b), 2.70-2.84 (m, 1H, H8a), 2.46-2.60 (m, 1H, H8b); 13C NMR (100 
MHz, CDCl3): δ 201.7 (C9), 164.9 (C2’), 162.3 (C1), 155.8 (C16), 141.2 (C5a), 135.6 (C4), 
131.7 (C10a), 131.5 (C2), 131.4 (C14a), 131.1 (C5’, C7’), 130.6 (C14), 129.1 (C5), 128.7 
(C3’), 128.4 (C3), 127.6 (C4’, C8’), 127.5 (C11), 123.6 (C13), 122.2 (C6’), 116.6 (C1a), 
114.0 (C12), 76.7 (C10), 43.5 (C7), 31.6 (C8); IR (KBr): vmax = 3520 (s), 3459 (s), 2926 (m), 
1705 (s) (C=O), 1665 (s) (C=O) cm-1; LRMS (ES+): m/z (%) 527.11 (100) [M+Na]+; HRMS 
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(ES+): m/z calcd for C25H17N2O5BrNa [M+Na]+: 527.0321; found: 527.0319; [α]20D = -179.2 
(c = 0.002, DCM).  
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Conclusions 
The investigations presented in the Part I of this thesis were focused on development of 
bio-active small molecules into useful chemical tools in the target identification and 
validation studies in Toxoplasma gondii via chemical and biological methodologies. 
Development of compound 28 from an active hit in the invasion assay to a chemical tool that 
can be used in target identification studies was investigated. Based on the SAR data that had 
been generated in the group, a suitable site to join the small molecule, linker unit and 
methotrexate was determined. The complicated CID 44 has been synthesised and the 
structure has been confirmed using various spectroscopic techniques. The CID 44 has the 
properties necessary to access the nucleus of yeast cells which is an absolute requirement for 
its use in the Y3H approach.  
Identification of possible protein targets for Conoidin A (29), which was one of the active 
hits from the invasion assay, was attempted. Peroxiredoxin II and another potential target 
57.m00038 were identified in the in vivo blocking process. Although the knockout 
experiment of TgPrxII proved that inhibition of this protein is very unlikely to be responsible 
for inhibition of invasion or conoid extension by the parasite, respecting the important role 
the peroxiredoxin family of protein play in many biological systems, further investigations of 
how 29 inhibits this protein were attempted and proved successful. As a result of developing 
additional SAR data relating to 29, further optimisation of 29 was possible and provided a 
better view of the TgPrxII protein’s active site which is particularly useful for future drug 
design and development.   
The investigations presented in the Part II of this thesis described the development of 
synthesis of medium-sized ring containing compounds using oxidative fragmentation and 
rearrangement strategies.  
To investigate the interesting oxidative fragmentation reactions 163 and its analogues were 
synthesised and submitted to the oxidative fragmentation reaction using m-CPBA. These 
reactions showed very high diastereoselectivity. Four possible mechanisms of the oxidative 
fragmentation reaction were proposed in the light of X-ray crystallography studies of the 
product 164a. Amongst these four mechanisms, mechanism 1, was supported by a range of 
experimental results and computational calculations, and therefore was believed to be the 
most likely mechanism for this oxidative fragmentation reaction. Oxidation of 163a with an 
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alternative oxidizing reagent, DMDO, afforded the interesting rearrangement product 187a. 
In addition, a single enantiomer 200 was synthesised via an asymmetric CBS reduction. The 
absolute stereochemistry of 200 was assigned by X-ray crystallography. Effects of different 
substituents and ring sizes on the fragmentation and rearrangement reactions were also 
investigated.  
Asymmetric oxidative fragmentation reaction based on asymmetric epoxidation reactions 
was investigated. Jacobsen epoxidation reaction was attempted but not successful. 
[Ru(pybox)(pydic)] catalyst oxidation using PhI(OAc)2 as oxidant gave 162a in moderate 
yield and enantio-selectivity. Optimisation of this reaction significantly increased the 
reaction rate (96 hrs to 16 hrs) and yield (28% to 65%), although the enantio-selectivity 
remained moderate, it can be improved by recrystalisation (33% to 91%). The absolute 
configuration of 162a was determined by introducing a heavy atom into the molecule and 
analysed by X-ray crystallography. Analogues of 161 were also submitted to the 
[Ru(pybox)(pydic)] catalysed asymmetric oxidative fragmentation reaction. Explanations for 
the effects of different substituents on the fragmentation reactions were also discussed. 
In conclusion the aim of this research have been achieved.  
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Future work 
The results presented in the Part I of this thesis will enable the development of small 
molecule tools to study Toxoplasma gondii invasion.  
1. CID 44 and 75 will be used in Y3H approach to identify the potential target(s) for the 
small molecule 28. Subsequently the target validation studies will be carried out. 
Optimisation of 28 will be carried out to develop 28 into a useful chemical tool to study 
Toxoplasma gondii invasion.  
2. Using the better view of the TgPrxII protein’s active site which is provided by the studies 
presented in this thesis further optimisation of 29 to develop 29 into a noncovalent 
inhibitor may be possible. Further more, experiments to assess whether Conoidin A (29) 
can inhibit its potential protein target hypothetical protein (ToxoDB 57.m00038, 25.7 
kDa, predicted pI 6.95) in vitro will be investigated.  
The results presented in the Part II of this thesis will enable the development of new 
oxidative fragmentation method to synthesise medium-sized ring.  
3. Oxidative fragmentation of oxizino carbazolone 163 gave medium-sized ring 164. It will 
be important to further explore the reaction scope. Further development to convert 
structure f 164 into more complicated chemical structure to improve the diversity of the 
project will also be investigated.  
4. Asymmetric oxidative fragmentation of 161 was developed in this thesis. It may be 
interesting to further develop the [Ru(pybox)(pydic)] catalysed oxidative fragmentation. 
Other catalysts may also be screened to further develop this reaction.  
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Appendix 
Appendix 1: (1H, 1H)-NOESY NMR spectra of 39b.  
 
 
 
 
Figure A1. NOESY spectrum of cis-39b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
H-5 
5.74 ppm
H-11a 
4.51 ppm
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Appendix 2: Electrospray ionisation mass spectrometric time course analysis of the 
reaction of rTgPrxII with 29 
19 μl of 0.5 mg/ml rTgPrxII and 1 μl of a 1 mM stock solution of 29 in acetonitrile were 
incubated for various times from 5 to 30 minutes and analysed by LCMS.  Samples were 
desalted on-line through a MassPrep On-Line Desalting Cartridge 2.1 x 10 mm, eluting at 50 
l/min, with an increasing acetonitrile concentration (from 2% acetonitrile, 98% aqueous 　
1% formic acid to 98% acetonitrile, 2% aqueous 1% formic acid) and delivered to an 
electrospray ionisation mass spectrometer (LCT, Micromass, Manchester, U.K.) that had 
previously been calibrated using myoglobin. Only covalently bound complexes were 
expected to survive the chromatography and ionisation conditions used. The results (Figs. A2) 
showed that after a 5 minute preincubation of rTgPrxII with 29, two main species, 
corresponding to unreacted rTgPrxII and a complex containing both rTgPrxII and 29, were 
observed. As the incubation time increased, the spectra that were obtained became more 
complicated, probably as a result of the signal being split between many species.  
 
 
Figure A2. ESI MS analysis of the incubation of rTgPrxII with 29 as a function of time. (A) t=0 min, the 
species observed at Mr (26927.5) corresponds to rTgPrxII; * corresponds to an unidentified impurity present in 
the purified rTgPrxII sample; (B) t=5 min, the species observed at Mr (26923.0) corresponds to unreacted 
TgPrxII, the species at Mr (27189.6) corresponds to a rTgPrxII:29 complex resulting from displacement of one 
bromine atom from 1 during the reaction. (C-F) A deterioration in the quality of the spectra was observed as the 
incubation time increased, although the main peaks remained the same as at shorter incubation times (C t=10 
min.; D t=15 min.; E t=20 min.; F t=30 min.) 
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Appendix 3: Model thiol competition experiments 
General procedure for competition experiment with the model thiol.  
To a solution of two analogues (0.1 mmol, final concentration 1.3 x 10-4 mmol/L each) in 
neutral CHCl3 (0.7 ml) was added a sub-stoichiometric amount of methyl mercaptoacetate 
(0.91 μL, 0.1 mmol, final concentration 1.3 x 10-4 mmol/L) and triethylamine (29.3 μl, 0.20 
mmol, 2.6 x 10-4 mmol/L). After stirring at room temperature for 30 minutes, the reaction 
mixture was then submitted for 1H NMR analysis. The rate of the reaction was compared via 
integration of the signals remaining for each starting material. 
 
Competition experiment involving 87 and 90 
 
Figure A3. Model thiol competition experiment of 87 vs 90. a Starting material, the two peaks highlighted 
correspond to the CH2 group in each molecule as labeled. b the reaction mixture after 30 minutes. The peak at 
lower field corresponds to unreacted 87 and the peak at higher field corresponds to unreacted 90, indicating that 
87 reacts more rapidly with the model thiol than 90.  
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Competition experiment involving 87 and 92 
 
 
 
 
Figure A4. Model thiol competition experiment of 87 vs 92. a The starting materials, peaks at 4.84 ppm 
corresponds to the CH2 group in 87 and at 4.79 ppm corresponds to the CH2 group in compound 92 respectively; 
b The reaction mixture after 30 min. The ratio between unreated 87 to 92 is 1:1, indicateing that 87 and 92 have 
approximately the same reactivity with the model thiol nucleophile; c The portion of the 1H NMR spectrum of 
the crude reaction mixture in the ppm range 3.50- 4.90. This spectrum clearly shows that both 87 and 92 react 
with the model thiol to produce two new compounds in approximately equal quantities. The new peaks have 
been assigned as follows: i) 2 peaks at 4.9-5.0 ppm correspond to CH2a in compounds S1 and S2; ii) 2 peaks at 
4.4 ppm correspond to CH2b in compounds S1 and S2; iii) 2 peaks at 3.6-3.7 ppm correspond to the methyl 
groups of the methyl esters in compounds S1 and S2. 
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Competition experiment involving 87 and 91 
 
Figure A5. Model thiol competition experiment of 87 vs 91. a Starting material, the two peaks highlighted 
correspond to the CH2 group in each molecule as labeled. b the reaction mixture after 30 minutes. The peak at 
lower field corresponds to unreacted 87 and the peak at higher field corresponds to unreacted 91, indicating that 
87 reacts more rapidly with the model thiol than 91. 
 
Relative reactivity of 90 and 91. The competition experiments between 87 vs 90 and 87 vs 
91 were done under exactly the same conditions with the same amount of 87, therefore by 
comparing the integration values associated with unreacted 87 and unreacted 90 and 91 in 
the two resulting spectra, we concluded that 91 (ratio of peak corresponding to CH2 of 
87:analogous peak in 91 was 1: 11.1) is slightly more reactive than 90 (ratio of peak 
corresponding to CH2 of 87:analogous peak in 90 was 1: 18.3).    
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Reaction of 29 and its analogs with model thiols 
Initial studies focused on the reaction of 29 with methyl mercaptoacetate as a model for a 
protein-based sulfur nucleophile. When treated with an excess of the thiol in the presence of 
triethylamine, 29 afforded the disulfideS2 in 93% isolated yield after only 30 minutes. In the 
absence of base, no reaction occurred even after 48 hours. These experiments were repeated 
using 97 and 98. As with 29, the corresponding disulfides were the major products when 
excess thiol was used. As the relative rate of reaction of 29 and its analogs with methyl 
mercaptoacetate was fast, it was not possible to perform a kinetic study using 1H NMR 
techniques as we have done previously.S3 In order to gain information about the effect of the 
substituents on the rate of the reaction, a series of competition experiments was performed. 
In these experiments a limiting amount of thiol was reacted with a 1:1 mixture of two 
dibromides and the relative amounts of the remaining starting materials (assessed by 1H 
NMR analysis of the crude reaction mixture) were used as a readout of reactivity (Figure 
A6).  
In a representative competition experiment, a mixture of 29 and 98 (10 mM initial 
concentration of 29) in CDCl3 was treated with methyl mercaptoacetate and triethylamine in 
a 1:1:2:2 molar ratio. After stirring for 1 hour, the reaction was analysed by 1H NMR and the 
signals corresponding to the C9/C10 benzylic protons in 29 (4.93ppm, Figure A6, trace A1) 
and 98 (4.896 and 4.890ppm, Figure A6, trace A2) were used to calculate the amounts of 29 
and 98 remaining. In this case (Figure A6, trace A3, and Figure A6 trace B), the final ratio of 
29:98 was 1.00:0.89 demonstrating that 98 reacts more rapidly with the thiol than does 29. 
The additional signals in Figure A6, trace A3 correspond to products from 29 and 98 in 
which only one of the two bromine atoms have been substituted (for 29 see signal I; for 98 
where 2 isomeric products are formed, see signals II). This procedure was repeated for all 
combinations of 29, 97 and 98. For the competition experiment between 97 and 98 see 
Figure A7. The final order of reactivity was determined to be 98 (Br) > 97(NHBoc) > 29 (H). 
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Figure A6. Use of 1H NMR experiments to assess the outcome of a series of competition experiments. A A 
portion of the 1H NMR spectrum of 29 dibromide 1; 2 dibromide 98; 3 reaction of 29 and 98 with methyl 
mercaptoacetate and triethylamine (molar ratio 1:1:2:2). B Results of the competition reactions, expressed as 
the final ratio of the two starting dibromides. a ratio could not be determined by 1H NMR analysis of the crude 
reaction mixture due to overlapping peaks and this value was calculated using HPLC techniques (data not 
shown).  
 
 
Figure A7. 1H NMRs from the competition experiment of 97 vs 98; A a portion of the 1H NMR of 98 peak 
shown corrresponds to the two CH2 peaks present in 98, B a portion of the 1H NMR of 98 peak shown 
corrresponds to the two CH2 peaks present in 97, C a portion of the 1H NMR obtained in the competition 
experiment. The ratio between unreacted 97 to 98 is 1: 0.74 indicating that 98 is slightly more reactive than 97.   
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Figure A8. 1H NMRs from the competition experiment of 29 vs 95; a) mixture of 29 and 95; b) reaction 
mixture after competition experiment.  
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Appendix 4: IC50 determination.  
IC50 Determination 
In initial studies, 29 and its analogues and the solvent vector (acetonitrile) were tested to 
determine whether they inhibited GS activity directly. No inhibitory effect on GS was 
observed.  Solutions (0.005 mM, 0.01 mM, 0.05 mM, 0.1 mM, 0.5 mM, 1 mM, 2 mM, 10 
mM, gave the preincubation concentration of 0.312 μM, 0.625μM, 3.125 μM, 6.25 μM, 
31.25 μM, 62.5 μM, 0.312 mM, 0.625 mM, respectively.) of compound were prepared in 
acetonitrile. 3 μL of a rTgPrxII stock solution (15 μM) was added to 12 μL of 100 mM 
Hepes buffer (pH 7.4). 1 μL of the appropriate concentration of compound was added and 
the assay was incubated at room temperature for 5 minutes. 1 μL of GS solution and 3 μL of 
inactivation solution were then added and the mixture was incubated at 30° C for an 
additional 20 minutes. 150 μL of starting solution was added and after further incubation at 
30° C for 30 minutes, the reaction was terminated by incubation with 100 μL of stop solution 
for 5 minutes. The remaining GS activity was determined by measuring the absorbance at 
540 nm and the results were normalized into remaining percentage activity. The IC50 was 
calculated using Prism® software. The error bar shows the mean of duplicate data.    
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Figure A9. IC50 curve of 97 
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Figure A10. IC50 curve of 95 
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Figure A11. IC50 curve of 98 
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Figure A12. IC50 curve of 96 
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Figure A13. IC50 curve of 90 
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Figure A14. IC50 curve of 92 
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Figure A15. IC50 curve of 91 
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Appendix 5: Computational experimental data of dicarbonyl flip. 
 
 
Energy state rel. E [kJ/mol] O-C6-C7-O 
164a 0.00 109.12 
164β 56.65 -119.47 
164d 17.17 15.52 
Table 6.1 Energy profile of conformational energy states.  
pathway ΔG‡298 [kJ/mol] ΔH‡ [kJ/mol] ΔS‡ [J/mol] k [Hz] t½ [s] 
164a ?164β 59.19 56.67 -8.43 261.6 ( 2.65x10-3 ) 
164d ?164β 46.43 40.09 -21.23 4.51x104 1.54x10-5 
Table A1 computational calculation of two pathways 164a to 164β and 164d to 164β which are possible to 
happen in the reaction.  
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Appendix 6: HPLC trace of 198. 
 
 
Figure A17 Chiral HPLC analysis showed that CBS reduction gave 198 in 98% e.e. A) Chiral HPLC trace of 
198. B) Chiral HPLC trace of racemic 198.  
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Appendix 7: HPLC trace of 200. 
 
 
Figure A18 Chiral HPLC analysis showed that 200 in 96% e.e. A) Chiral HPLC trace of racemic 164a. B) 
Chiral HPLC trace of 200.  
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Appendix 8: HPLC trace and 1H NMR spectra of 162. 
 
Figure A19 Chiral HPLC analysis showed that 141b catalysed oxidative fragmentation of 161a in 33% e.e.  
 
 
Figure A20 HPLC trace of 162a, 141c was used as catalyst. -20% e.e. 
 
Figure A21 HPLC trace of 162b. 0% e.e. 
 
Figure A22 HPLC trace of 162c. 36% e.e. 
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Figure A23 HPLC trace of 162d. 7% e.e. 
 
Figure A24 1H NMR spectra trace of 162e after the treatment of chiral shift reagent. A) racemic mixture; B) 
after reaction 35% e.e.; C) after recrystalisation.  
 
Figure A25 HPLC trace of 162f. -9% e.e. 
 
Figure A26 HPLC trace of 162f after recrystalisation. -75% e.e. 
A) 
B) 
C) 
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Figure A27 HPLC trace of 162g, 4% e.e. 
 
Figure A28 HPLC trace of 162h, 2% e.e. 
          
Figure A29 1H NMR spectra trace of 162i after the treatment of chiral shift reagent. A) racemic mixture; B) 
after reaction 36% e.e..  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) B) 
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